Medical University of South Carolina

Annual Research Funding Report
For the fiscal year ending June 30, 2009
This page intentionally left blank (Reverse of Cover Page)
ANNUAL REPORT OF GRANT & CONTRACT ACTIVITY
For the fiscal year July 2008 through June 2009

<table>
<thead>
<tr>
<th>Source</th>
<th>Projects</th>
<th>Dollars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal</td>
<td>571</td>
<td>$139,627,803</td>
</tr>
<tr>
<td>Direct Federal</td>
<td>399</td>
<td>$119,163,310</td>
</tr>
<tr>
<td>NIH</td>
<td>301</td>
<td>$103,346,831</td>
</tr>
<tr>
<td>Other Federal</td>
<td>98</td>
<td>$15,816,479</td>
</tr>
<tr>
<td>Federal Flow-Down</td>
<td>172</td>
<td>$20,464,493</td>
</tr>
<tr>
<td>Corporate</td>
<td>359</td>
<td>$45,047,727</td>
</tr>
<tr>
<td>State of South Carolina</td>
<td>49</td>
<td>$17,478,638</td>
</tr>
<tr>
<td>Foundation</td>
<td>118</td>
<td>$13,803,217</td>
</tr>
<tr>
<td>Other Support</td>
<td>14</td>
<td>$1,616,376</td>
</tr>
<tr>
<td>Total</td>
<td>1,111</td>
<td>$217,573,761</td>
</tr>
</tbody>
</table>
Executive Summary

Though Fiscal Year 2009 proved to be financially challenging, it was yet another record breaking year for the Medical University of South Carolina. MUSC’s Office of Research and Sponsored Programs (ORSP) recorded 1,111 awards for an overall extramural funding total of $217,573,761 in FY 2009. This record high funding level represented just over a 15 million dollar increase from the previous year’s mark. In FY 2009, MUSC submitted 1,866 proposals for just over 416 million dollars in funding.

Table 1: College Comparison

Table 1 indicates that overall proposals increased by 24% compared to FY 2008. Almost every unit experienced significant growth in proposal submissions from FY 2008 to FY 2009, and the College of Dental Medicine posted a 100% increase in proposals submitted.

The increase in the total number of awards accepted from FY 2008 to FY 2009 was more modest; the overall total of awards (1,111) in FY 2009 increased by 1.28% over the previous year. However, MUSC’s awarded dollars increased by 7.5% to more than $217.5M in FY 2009. A closer look at MUSC’s total funding by source reveals exactly where the increases occurred as compared to data from last fiscal year.

NOTE: The America Recovery and Reinvestment Act (ARRA) pushed the overall proposal count to record highs at MUSC. In FY 2009 the MUSC research community submitted nearly 300 ARRA related proposals worth over $80M in potential funding for MUSC.
Source and Agency Summary

Federal Funding

The total number of awards received in direct federal funding declined by 2.68% (410 awards in FY 2008 down to 399 in FY 2009). MUSC’s overall federal funding decreased from $126.5M in FY 2008 to $119.1 M in FY 2009. This 5.7% decline reflects large federal construction grants that were received in FY2008 from the National Institute of Standards and Technology (NIST). Gains were recognized in FY 2009 with several of MUSC’s other federal sponsors.

Figure 3

The National Institutes of Health (NIH) continued to be the major source of MUSC’s overall extramural funding in FY 2009. Specifically, NIH funding accounted for 47.5% of all funding and 86.7% of direct federal funding. MUSC garnered 301 NIH awards (down 16 from a year ago), which totaled more than $103.3M in funding, a modest 2% increase. The breakdown of the 301 NIH awards received follows: 63 new, 17 competing continuations, 194 non-competing continuations, 23 supplements and 4 transfers.

The increase in NIH funding over last year is mainly attributed to investigator initiated research projects (R-awards) and cooperative agreements (U-awards). Though the number of R type projects only increased by 1 award, the total amount of awarded dollars emanating from these awards grew by $3.2M over the FY 2008 total (Table 2). The number of cooperative agreements (U-awards) decreased by 3 awards, yet the overall funding amount for this mechanism increased by $1.7M. This
growth, along with some smaller gains in the other NIH funding mechanisms (i.e. training, fellowships, construction/instrumentation and contracts), more than offset any decreases experienced in the program projects/centers (M, P) and career development (K) award mechanisms.

Table 2: National Institutes of Health Funding by Activity Type

<table>
<thead>
<tr>
<th>NIH Award Types</th>
<th>Number FY08</th>
<th>+/- from FY08</th>
<th>Amount FY08</th>
<th>FY08 Net Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Projects (R)</td>
<td>201</td>
<td>200</td>
<td>$56,090,539</td>
<td>$3,282,386</td>
</tr>
<tr>
<td>Research Related (S)</td>
<td>0</td>
<td>2</td>
<td>-</td>
<td>-686,541</td>
</tr>
<tr>
<td>Career Development (K)</td>
<td>28</td>
<td>32</td>
<td>$4,258,967</td>
<td>-740,739</td>
</tr>
<tr>
<td>Program Projects/Centers (M,P)</td>
<td>14</td>
<td>19</td>
<td>$19,520,501</td>
<td>-3,517,666</td>
</tr>
<tr>
<td>Training (T,D)</td>
<td>16</td>
<td>19</td>
<td>$4,511,356</td>
<td>157,047</td>
</tr>
<tr>
<td>Fellowships (F)</td>
<td>19</td>
<td>17</td>
<td>$754,321</td>
<td>125,344</td>
</tr>
<tr>
<td>Cooperative Agreements (U)</td>
<td>14</td>
<td>17</td>
<td>$14,298,912</td>
<td>1,731,655</td>
</tr>
<tr>
<td>Construction/Instrumentation (C,G)</td>
<td>2</td>
<td>1</td>
<td>$630,019</td>
<td>495,261</td>
</tr>
<tr>
<td>Contracts</td>
<td>7</td>
<td>10</td>
<td>$3,282,216</td>
<td>1,322,963</td>
</tr>
<tr>
<td></td>
<td><strong>301</strong></td>
<td><strong>317</strong></td>
<td><strong>$103,346,831</strong></td>
<td><strong>$2,169,710</strong></td>
</tr>
</tbody>
</table>

Figure 4 depicts the percentage breakdown by agency funding source of all FY 2009 direct federal funding awarded to MUSC. In addition to the NIST reduction, MUSC experienced significant decreases in funding from NIH’s National Center for Research Resources (NCRR) and Health Research Services Administration (HRSA) both down $4.66M and $1.33M respectively from last year. Veterans Administration (VA) funding increased by $1.88M from FY 2008. The rest of the direct federal funding garnered by MUSC in FY 2009 remained relatively stable with a few minor increases or decreases.

Table 3: NIH Centers/Institutes with increased funding

<table>
<thead>
<tr>
<th>Institute</th>
<th>FY08 Awards</th>
<th>FY09 Awards</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDCD</td>
<td>$1,248,865</td>
<td>$2,900,265</td>
<td>132.23%</td>
</tr>
<tr>
<td>NIH/NIAMS</td>
<td>1,426,874</td>
<td>2,743,690</td>
<td>92.29%</td>
</tr>
<tr>
<td>NIH/NIDCR</td>
<td>2,115,683</td>
<td>3,116,000</td>
<td>47.28%</td>
</tr>
<tr>
<td>NIH/NIAAA</td>
<td>4,383,133</td>
<td>6,182,142</td>
<td>41.04%</td>
</tr>
<tr>
<td>NIH/NIAID</td>
<td>1,032,572</td>
<td>1,352,496</td>
<td>30.98%</td>
</tr>
<tr>
<td>NIH/NIGMS</td>
<td>3,460,325</td>
<td>4,034,175</td>
<td>16.58%</td>
</tr>
<tr>
<td>NIH/NIDA</td>
<td>14,186,379</td>
<td>16,106,512</td>
<td>13.54%</td>
</tr>
<tr>
<td>NIH/NHLBI</td>
<td>13,174,147</td>
<td>14,692,756</td>
<td>11.53%</td>
</tr>
<tr>
<td>NIH/NIDDK</td>
<td>7,319,856</td>
<td>8,123,375</td>
<td>10.98%</td>
</tr>
<tr>
<td>NIH/NCI</td>
<td>10,355,850</td>
<td>11,196,375</td>
<td>8.12%</td>
</tr>
</tbody>
</table>

ARRA NOTE: The American Recovery and Reinvestment Act (ARRA) grant awards accounted for just under $1M ($941,243) in FY 2009, and all 10 of these awards were from NIH. Thus ARRA funding had a modest affect on MUSC’s overall direct federal funding totals in FY 2009.

Federal Flow-Down Funding

In FY 2009, MUSC’s federal flow-down funding decreased by 3% from the previous year’s record high in this category. Federal flow-down funding dropped from $21.2M in FY 2008 to $20.4M in FY 2009. Even with this slight decline of total funding in this category, MUSC still received 11 more awards than last year, from a total of 85 different organizations.
Foundation Funding

MUSC’s foundation funding grew significantly in FY 2009 up nearly 30% (29.8%) over the previous year. Though the total number of awards decreased from 124 in FY 2008 to 118 in FY 2009, overall funding in this category grew by $3.2M over last year reaching $13.8M, an all time high for MUSC.

State Funding

State funding grew dramatically in FY 2009 to $17.5M, up by 80.7% over last year’s count. Similar to last year in the state funding category, most of the FY 2009 increase can be attributed to MUSC’s success in earning awards from South Carolina’s Research Centers of Economic Excellence program. Funding to MUSC from this important state program nearly doubled from FY 2008 to FY 2009. South Carolina’s economic future will be positively impacted by these strategic investments in MUSC’s research efforts.

Corporate Funding

MUSC’s corporate funding also realized significant growth in FY 2009 setting a new record at MUSC. MUSC earned 359 awards (up 19 from a year ago) reaching just over $45M in research support. The increase in total funding in this particular category recognized a remarkable 35% increase over last year. Astrazeneca, Boston Scientific, Covance, Genentech, Merck, Novartis and Quintiles Pacific are responsible for some of MUSC’s largest funded corporate studies in FY 2009.

Figure 4: Percentage of Funding by Federal Sponsors

Federal Funding By Agency

NIH 86.73%

VAMC 5.50%

CDC 2%

HRSA 1.86%

DOD 0.69%

DOD/ONR 0.58%

Education 0.53%

NSF 0.36%

SAMHSA 0.28%

DOE 0.19%

NOAA 0.15%

EPA 0.09%

NIST 0.08%

DHHS 0.02%

NLM 0.01%

US Army 0.47%

DHHS 0.02%

AHRQ 0.44%

SAMHSA 0.28%

NOAA 0.15%

EPA 0.09%

NIST 0.08%

DHHS 0.02%

NLM 0.01%

NIH 86.73%

VAMC 5.50%

CDC 2%

HRSA 1.86%

DOD 0.69%

DOD/ONR 0.58%

Education 0.53%

NSF 0.36%

SAMHSA 0.28%

DOE 0.19%

NOAA 0.15%

EPA 0.09%

NIST 0.08%

DHHS 0.02%

NLM 0.01%

US Army 0.47%

DHHS 0.02%

AHRQ 0.44%
## Sponsored Project Totals by Source and Agency

<table>
<thead>
<tr>
<th>Corporate</th>
<th># Awards</th>
<th>$ Direct</th>
<th>$ Indirect</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>3F Therapeutics</td>
<td>2</td>
<td>32,400</td>
<td>8,100</td>
<td>40,500</td>
</tr>
<tr>
<td>Abbott Cardiovascular Systems, Inc.</td>
<td>1</td>
<td>782,000</td>
<td>194,250</td>
<td>976,250</td>
</tr>
<tr>
<td>Abbott Labs</td>
<td>6</td>
<td>235,980</td>
<td>58,995</td>
<td>294,975</td>
</tr>
<tr>
<td>Acorn Biomedical, Inc.</td>
<td>1</td>
<td>9,899</td>
<td>4,701</td>
<td>14,600</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals</td>
<td>11</td>
<td>680,329</td>
<td>168,207</td>
<td>848,536</td>
</tr>
<tr>
<td>Advanced Cardiovascular Systems</td>
<td>2</td>
<td>16,280</td>
<td>4,070</td>
<td>20,350</td>
</tr>
<tr>
<td>AF Research</td>
<td>1</td>
<td>4,800</td>
<td>1,200</td>
<td>6,000</td>
</tr>
<tr>
<td>Aga Medical Corp.</td>
<td>4</td>
<td>53,247</td>
<td>12,437</td>
<td>65,684</td>
</tr>
<tr>
<td>Alcon, Inc.</td>
<td>3</td>
<td>235,772</td>
<td>58,328</td>
<td>294,100</td>
</tr>
<tr>
<td>Alimera Sciences</td>
<td>1</td>
<td>23,756</td>
<td>11,284</td>
<td>35,040</td>
</tr>
<tr>
<td>Allergan, Inc.</td>
<td>1</td>
<td>4,175</td>
<td>1,044</td>
<td>5,219</td>
</tr>
<tr>
<td>Allos Therapeutics, Inc.</td>
<td>1</td>
<td>87,996</td>
<td>20,999</td>
<td>108,995</td>
</tr>
<tr>
<td>Amgen</td>
<td>5</td>
<td>324,000</td>
<td>8,100</td>
<td>40,500</td>
</tr>
<tr>
<td>Antigen Laboratories, Inc.</td>
<td>1</td>
<td>23,756</td>
<td>11,284</td>
<td>35,040</td>
</tr>
<tr>
<td>Apatech, Inc.</td>
<td>1</td>
<td>120,900</td>
<td>29,350</td>
<td>150,250</td>
</tr>
<tr>
<td>Arena Pharmaceuticals, Inc.</td>
<td>1</td>
<td>4,800</td>
<td>1,200</td>
<td>6,000</td>
</tr>
<tr>
<td>Argolyn Bioscience, Inc.</td>
<td>2</td>
<td>102,300</td>
<td>47,058</td>
<td>149,358</td>
</tr>
<tr>
<td>Astrazeneca</td>
<td>2</td>
<td>152,416</td>
<td>36,729</td>
<td>189,145</td>
</tr>
<tr>
<td>Bayer Corp.</td>
<td>2</td>
<td>161,400</td>
<td>39,000</td>
<td>200,400</td>
</tr>
<tr>
<td>Bayer Pharmaceuticals</td>
<td>1</td>
<td>122,500</td>
<td>30,000</td>
<td>152,500</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>1</td>
<td>36,100</td>
<td>8,900</td>
<td>45,000</td>
</tr>
<tr>
<td>Blackstone Medical, Inc.</td>
<td>1</td>
<td>366,456</td>
<td>90,739</td>
<td>457,195</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td>5</td>
<td>263,802</td>
<td>65,678</td>
<td>329,480</td>
</tr>
<tr>
<td>Boston Scientific Corp.</td>
<td>11</td>
<td>5,678,970</td>
<td>92,392</td>
<td>5,771,362</td>
</tr>
<tr>
<td>Bracco Diagnostics, Inc.</td>
<td>1</td>
<td>70,755</td>
<td>17,689</td>
<td>88,444</td>
</tr>
<tr>
<td>Brainsway</td>
<td>1</td>
<td>218,000</td>
<td>69,500</td>
<td>305,500</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>4</td>
<td>468,489</td>
<td>115,122</td>
<td>583,611</td>
</tr>
<tr>
<td>Cameron Health, Inc.</td>
<td>1</td>
<td>1,600</td>
<td>400</td>
<td>2,000</td>
</tr>
<tr>
<td>Cardiac Pacemakers, Inc.</td>
<td>1</td>
<td>502,627</td>
<td>125,656</td>
<td>628,283</td>
</tr>
<tr>
<td>Catalyst Pharmaceutical Partners, Inc.</td>
<td>1</td>
<td>293,794</td>
<td>72,574</td>
<td>366,368</td>
</tr>
<tr>
<td>Celgene Corp.</td>
<td>2</td>
<td>80,979</td>
<td>24,941</td>
<td>105,920</td>
</tr>
<tr>
<td>CellzDirect, Inc.</td>
<td>2</td>
<td>37,022</td>
<td>9,256</td>
<td>46,278</td>
</tr>
<tr>
<td>Centocor, Inc.</td>
<td>4</td>
<td>394,635</td>
<td>96,909</td>
<td>491,544</td>
</tr>
<tr>
<td>Cephalon, Inc.</td>
<td>1</td>
<td>3,279</td>
<td>820</td>
<td>4,099</td>
</tr>
<tr>
<td>Cepheid</td>
<td>2</td>
<td>33,834</td>
<td>8,458</td>
<td>42,292</td>
</tr>
<tr>
<td>CerviLenz, Inc.</td>
<td>1</td>
<td>22,900</td>
<td>5,100</td>
<td>28,000</td>
</tr>
<tr>
<td>Cetus Group, LLC</td>
<td>1</td>
<td>4,420</td>
<td>480</td>
<td>4,900</td>
</tr>
<tr>
<td>Charles River Laboratories</td>
<td>1</td>
<td>9,745</td>
<td>1,811</td>
<td>11,556</td>
</tr>
<tr>
<td>Chiron, Inc.</td>
<td>2</td>
<td>8,914</td>
<td>2,228</td>
<td>11,142</td>
</tr>
<tr>
<td>Cleveland Clinic Fdn.</td>
<td>1</td>
<td>1,000</td>
<td>250</td>
<td>1,250</td>
</tr>
<tr>
<td>Colorado Prevention Center</td>
<td>1</td>
<td>132,198</td>
<td>32,175</td>
<td>164,373</td>
</tr>
<tr>
<td>Columbia Univ.</td>
<td>2</td>
<td>8,500</td>
<td>1,500</td>
<td>10,000</td>
</tr>
<tr>
<td>Covance, Inc.</td>
<td>3</td>
<td>823,554</td>
<td>203,639</td>
<td>1,027,193</td>
</tr>
<tr>
<td>CTI Clinical Trial and Consulting Services, Inc.</td>
<td>2</td>
<td>234,388</td>
<td>57,347</td>
<td>291,735</td>
</tr>
<tr>
<td>CV Therapeutics, Inc.</td>
<td>2</td>
<td>7,446</td>
<td>3,424</td>
<td>10,870</td>
</tr>
<tr>
<td>Cytyc Corp.</td>
<td>1</td>
<td>36,300</td>
<td>9,075</td>
<td>45,375</td>
</tr>
<tr>
<td>Corporate</td>
<td># Awards</td>
<td>$ Direct</td>
<td>$ Indirect</td>
<td>$ Total</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Daiichi Sankyo Pharma</td>
<td>1</td>
<td>80,038</td>
<td>20,009</td>
<td>100,047</td>
</tr>
<tr>
<td>DCI Paul Teschan Research Fund</td>
<td>1</td>
<td>41,340</td>
<td>8,268</td>
<td>49,608</td>
</tr>
<tr>
<td>Debiovision, Inc.</td>
<td>1</td>
<td>4,854</td>
<td>1,213</td>
<td>6,067</td>
</tr>
<tr>
<td>Delaware Valley Outcomes Research</td>
<td>3</td>
<td>377,957</td>
<td>93,614</td>
<td>471,571</td>
</tr>
<tr>
<td>Dialysis Clinics, Inc.</td>
<td>7</td>
<td>315,226</td>
<td>2,500</td>
<td>317,726</td>
</tr>
<tr>
<td>Duke Clinical Research Inst.</td>
<td>2</td>
<td>165,577</td>
<td>40,019</td>
<td>205,596</td>
</tr>
<tr>
<td>Duramed Research, Inc.</td>
<td>1</td>
<td>66,737</td>
<td>16,059</td>
<td>82,796</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>1</td>
<td>157,300</td>
<td>38,700</td>
<td>196,000</td>
</tr>
<tr>
<td>Elan Pharmaceuticals</td>
<td>4</td>
<td>330,084</td>
<td>82,396</td>
<td>412,480</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>5</td>
<td>522,843</td>
<td>128,211</td>
<td>651,054</td>
</tr>
<tr>
<td>EMD Serono, Inc.</td>
<td>1</td>
<td>83,510</td>
<td>20,253</td>
<td>103,763</td>
</tr>
<tr>
<td>Epigenomics, Inc.</td>
<td>1</td>
<td>166,000</td>
<td>40,750</td>
<td>206,750</td>
</tr>
<tr>
<td>Ethica Clinical Research, Inc.</td>
<td>1</td>
<td>89,946</td>
<td>21,862</td>
<td>111,808</td>
</tr>
<tr>
<td>ev3 Neurovascular</td>
<td>1</td>
<td>20,500</td>
<td>4,500</td>
<td>25,000</td>
</tr>
<tr>
<td>Evolve, Inc.</td>
<td>1</td>
<td>39,105</td>
<td>8,651</td>
<td>47,756</td>
</tr>
<tr>
<td>Exalenz Bioscience Ltd.</td>
<td>2</td>
<td>35,019</td>
<td>8,005</td>
<td>43,024</td>
</tr>
<tr>
<td>Exelixis, Inc.</td>
<td>1</td>
<td>98,440</td>
<td>23,985</td>
<td>122,425</td>
</tr>
<tr>
<td>Genentech, Inc.</td>
<td>3</td>
<td>3,224,691</td>
<td>804,547</td>
<td>4,029,238</td>
</tr>
<tr>
<td>General Electric</td>
<td>4</td>
<td>232,900</td>
<td>55,850</td>
<td>288,750</td>
</tr>
<tr>
<td>Genzyme Corp.</td>
<td>2</td>
<td>721,504</td>
<td>178,876</td>
<td>900,380</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>4</td>
<td>256,942</td>
<td>62,362</td>
<td>319,304</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>5</td>
<td>466,976</td>
<td>115,120</td>
<td>582,096</td>
</tr>
<tr>
<td>Hammerhead Design, Inc.</td>
<td>1</td>
<td>10,169</td>
<td>4,831</td>
<td>15,000</td>
</tr>
<tr>
<td>Hoffman-Laroche, Inc.</td>
<td>1</td>
<td>1,200</td>
<td>300</td>
<td>1,500</td>
</tr>
<tr>
<td>i3 Research</td>
<td>2</td>
<td>237,866</td>
<td>58,092</td>
<td>295,958</td>
</tr>
<tr>
<td>Icon Clinical Research, Inc.</td>
<td>7</td>
<td>583,653</td>
<td>141,288</td>
<td>724,941</td>
</tr>
<tr>
<td>ikonisys, Inc.</td>
<td>1</td>
<td>166,000</td>
<td>40,750</td>
<td>206,750</td>
</tr>
<tr>
<td>INC Research, Inc.</td>
<td>4</td>
<td>502,957</td>
<td>124,239</td>
<td>627,196</td>
</tr>
<tr>
<td>Inotek Pharmaceuticals</td>
<td>1</td>
<td>72,700</td>
<td>34,533</td>
<td>107,233</td>
</tr>
<tr>
<td>Inspire Pharmaceuticals, Inc.</td>
<td>3</td>
<td>115,050</td>
<td>28,138</td>
<td>143,188</td>
</tr>
<tr>
<td>Isotechnika, Inc.</td>
<td>1</td>
<td>3,216</td>
<td>804</td>
<td>4,020</td>
</tr>
<tr>
<td>Johns Hopkins Univ.</td>
<td>1</td>
<td>404,921</td>
<td>100,605</td>
<td>505,526</td>
</tr>
<tr>
<td>Johnson and Johnson</td>
<td>5</td>
<td>68,550</td>
<td>16,513</td>
<td>85,063</td>
</tr>
<tr>
<td>Kendle Research Assoc.</td>
<td>1</td>
<td>28,592</td>
<td>7,148</td>
<td>35,740</td>
</tr>
<tr>
<td>Life Point</td>
<td>1</td>
<td>28,592</td>
<td>12,343</td>
<td>40,935</td>
</tr>
<tr>
<td>Life Sciences Services</td>
<td>2</td>
<td>19,500</td>
<td>4,785</td>
<td>24,375</td>
</tr>
<tr>
<td>Lilly Research Laboratories</td>
<td>1</td>
<td>531,250</td>
<td>0</td>
<td>531,250</td>
</tr>
<tr>
<td>Lupus Clinical Trials Consortium</td>
<td>3</td>
<td>51,562</td>
<td>5,451</td>
<td>57,013</td>
</tr>
<tr>
<td>Marine Polymer Technologies</td>
<td>1</td>
<td>8,116</td>
<td>0</td>
<td>8,116</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>2</td>
<td>8,765</td>
<td>2,192</td>
<td>10,957</td>
</tr>
<tr>
<td>Medtronic, Inc.</td>
<td>4</td>
<td>235,561</td>
<td>36,499</td>
<td>272,060</td>
</tr>
<tr>
<td>Merck</td>
<td>4</td>
<td>974,837</td>
<td>241,209</td>
<td>1,216,046</td>
</tr>
<tr>
<td>Millennium Pharmaceuticals</td>
<td>3</td>
<td>28,504</td>
<td>7,001</td>
<td>35,505</td>
</tr>
<tr>
<td>MindFrame, Inc.</td>
<td>1</td>
<td>51,173</td>
<td>24,307</td>
<td>75,480</td>
</tr>
<tr>
<td>MITRE Corp.</td>
<td>2</td>
<td>200,057</td>
<td>60,017</td>
<td>260,074</td>
</tr>
<tr>
<td>Morphotek, Inc.</td>
<td>1</td>
<td>184,863</td>
<td>45,013</td>
<td>229,876</td>
</tr>
<tr>
<td>Mpex Pharmaceuticals, Inc.</td>
<td>1</td>
<td>3,000</td>
<td>750</td>
<td>3,750</td>
</tr>
<tr>
<td>MST Group, LLC</td>
<td>2</td>
<td>136,058</td>
<td>34,015</td>
<td>170,073</td>
</tr>
<tr>
<td>Corporate</td>
<td># Awards</td>
<td>$ Direct</td>
<td>$ Indirect</td>
<td>$ Total</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Multiple Sponsors</td>
<td>18</td>
<td>137,019</td>
<td>0</td>
<td>137,019</td>
</tr>
<tr>
<td>NewCardio, Inc.</td>
<td>1</td>
<td>9,916</td>
<td>1,854</td>
<td>11,770</td>
</tr>
<tr>
<td>Nfocus Neuromedical, Inc.</td>
<td>5</td>
<td>231,537</td>
<td>106,507</td>
<td>338,044</td>
</tr>
<tr>
<td>NoNO, Inc.</td>
<td>1</td>
<td>57,600</td>
<td>14,400</td>
<td>72,000</td>
</tr>
<tr>
<td>Novartis Corp.</td>
<td>9</td>
<td>1,831,003</td>
<td>323,482</td>
<td>2,154,485</td>
</tr>
<tr>
<td>Novo Nordisk Pharmaceuticals</td>
<td>1</td>
<td>210,650</td>
<td>52,663</td>
<td>263,313</td>
</tr>
<tr>
<td>Oceras Therapeutics, Inc.</td>
<td>1</td>
<td>39,278</td>
<td>9,194</td>
<td>48,472</td>
</tr>
<tr>
<td>Ortho-Clinical Diagnostics</td>
<td>1</td>
<td>137,376</td>
<td>34,344</td>
<td>171,720</td>
</tr>
<tr>
<td>Ortho-McNeil-Janssen Pharmaceuticals, Inc.</td>
<td>1</td>
<td>48,683</td>
<td>23,125</td>
<td>71,808</td>
</tr>
<tr>
<td>Osiris Therapeutics, Inc.</td>
<td>1</td>
<td>50,258</td>
<td>23,873</td>
<td>74,131</td>
</tr>
<tr>
<td>Parexel Intl. Corp.</td>
<td>1</td>
<td>5,400</td>
<td>1,350</td>
<td>6,750</td>
</tr>
<tr>
<td>Paul Teschan Research Fund</td>
<td>1</td>
<td>40,000</td>
<td>8,000</td>
<td>48,000</td>
</tr>
<tr>
<td>Penumbra, Inc.</td>
<td>1</td>
<td>43,700</td>
<td>10,300</td>
<td>54,000</td>
</tr>
<tr>
<td>Pfizer, Inc.</td>
<td>9</td>
<td>440,849</td>
<td>101,863</td>
<td>542,712</td>
</tr>
<tr>
<td>Pharmaceutical Research Associates</td>
<td>1</td>
<td>97,640</td>
<td>22,660</td>
<td>120,300</td>
</tr>
<tr>
<td>Philips Medical Systems, NA</td>
<td>1</td>
<td>4,100</td>
<td>400</td>
<td>4,500</td>
</tr>
<tr>
<td>PPD Development</td>
<td>6</td>
<td>465,828</td>
<td>115,833</td>
<td>581,661</td>
</tr>
<tr>
<td>Premier Research</td>
<td>1</td>
<td>105,286</td>
<td>25,696</td>
<td>130,982</td>
</tr>
<tr>
<td>QLT, Inc.</td>
<td>2</td>
<td>159,860</td>
<td>39,340</td>
<td>199,200</td>
</tr>
<tr>
<td>Quintiles Pacific, Inc.</td>
<td>9</td>
<td>1,743,181</td>
<td>431,170</td>
<td>2,174,351</td>
</tr>
<tr>
<td>Repligen Corp.</td>
<td>2</td>
<td>121,120</td>
<td>29,031</td>
<td>150,151</td>
</tr>
<tr>
<td>Sanofi Synthelabo, Inc.</td>
<td>1</td>
<td>38,400</td>
<td>9,600</td>
<td>48,000</td>
</tr>
<tr>
<td>Sanofi-Aventis US, Inc.</td>
<td>3</td>
<td>357,656</td>
<td>86,789</td>
<td>444,445</td>
</tr>
<tr>
<td>Schering-Plough Corp.</td>
<td>1</td>
<td>64,600</td>
<td>16,150</td>
<td>80,750</td>
</tr>
<tr>
<td>Schering-Plough Research Institute</td>
<td>5</td>
<td>440,099</td>
<td>107,275</td>
<td>547,374</td>
</tr>
<tr>
<td>Seattle Genetics, Inc.</td>
<td>2</td>
<td>129,327</td>
<td>32,332</td>
<td>161,659</td>
</tr>
<tr>
<td>Sepracor, Inc.</td>
<td>1</td>
<td>21,992</td>
<td>0</td>
<td>21,992</td>
</tr>
<tr>
<td>Siemens Medical Solutions USA</td>
<td>1</td>
<td>30,106</td>
<td>6,902</td>
<td>37,008</td>
</tr>
<tr>
<td>Sirtex Medical</td>
<td>1</td>
<td>10,600</td>
<td>1,900</td>
<td>12,500</td>
</tr>
<tr>
<td>Solstice Neurosciences, Inc.</td>
<td>1</td>
<td>6,400</td>
<td>1,600</td>
<td>8,000</td>
</tr>
<tr>
<td>Southwest Oncology Group</td>
<td>1</td>
<td>43,478</td>
<td>6,522</td>
<td>50,000</td>
</tr>
<tr>
<td>Spaulding Clinical</td>
<td>1</td>
<td>8,000</td>
<td>2,000</td>
<td>10,000</td>
</tr>
<tr>
<td>Spectrum Pharmaceutical Research</td>
<td>1</td>
<td>56,128</td>
<td>13,282</td>
<td>69,410</td>
</tr>
<tr>
<td>St. Jude Medical, Inc.</td>
<td>8</td>
<td>143,188</td>
<td>22,672</td>
<td>165,860</td>
</tr>
<tr>
<td>Stryker Orthopaedics</td>
<td>2</td>
<td>87,092</td>
<td>2,457</td>
<td>89,549</td>
</tr>
<tr>
<td>Sunesis Pharmaceuticals, Inc.</td>
<td>1</td>
<td>148,056</td>
<td>37,014</td>
<td>185,070</td>
</tr>
<tr>
<td>Syndax Pharmaceuticals, Inc.</td>
<td>1</td>
<td>159,460</td>
<td>39,240</td>
<td>198,700</td>
</tr>
<tr>
<td>Synthes (USA)</td>
<td>1</td>
<td>55,000</td>
<td>0</td>
<td>55,000</td>
</tr>
<tr>
<td>Synvista Therapeutics, Inc.</td>
<td>1</td>
<td>67,368</td>
<td>16,092</td>
<td>83,460</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td>4</td>
<td>267,462</td>
<td>85,646</td>
<td>353,108</td>
</tr>
<tr>
<td>Taligen</td>
<td>1</td>
<td>219,178</td>
<td>100,822</td>
<td>320,000</td>
</tr>
<tr>
<td>Targacept, Inc.</td>
<td>1</td>
<td>10,808</td>
<td>5,134</td>
<td>15,942</td>
</tr>
<tr>
<td>Tercica, Inc.</td>
<td>4</td>
<td>12,276</td>
<td>2,320</td>
<td>14,596</td>
</tr>
<tr>
<td>Terumo Medical Corp.</td>
<td>1</td>
<td>26,824</td>
<td>12,742</td>
<td>39,566</td>
</tr>
<tr>
<td>The Medicines Co.</td>
<td>1</td>
<td>71,800</td>
<td>17,200</td>
<td>89,000</td>
</tr>
<tr>
<td>Toler, Inc.</td>
<td>1</td>
<td>162,506</td>
<td>39,752</td>
<td>202,258</td>
</tr>
<tr>
<td>United Therapeutics</td>
<td>2</td>
<td>128,760</td>
<td>30,190</td>
<td>158,950</td>
</tr>
</tbody>
</table>
## Corporate Awards

<table>
<thead>
<tr>
<th>Company</th>
<th># Awards</th>
<th>Direct $</th>
<th>Indirect $</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viropharma, Inc.</td>
<td>1</td>
<td>318,109</td>
<td>51,101</td>
<td>469,210</td>
</tr>
<tr>
<td>Vistakon Pharmaceuticals, LLC</td>
<td>1</td>
<td>9,200</td>
<td>2,300</td>
<td>11,500</td>
</tr>
<tr>
<td>W.L. Gore and Associates, Inc.</td>
<td>4</td>
<td>168,899</td>
<td>40,226</td>
<td>209,125</td>
</tr>
<tr>
<td>Weight Watchers International, Inc.</td>
<td>2</td>
<td>420,500</td>
<td>104,500</td>
<td>525,000</td>
</tr>
<tr>
<td>Wyeth, Inc.</td>
<td>3</td>
<td>359,892</td>
<td>88,348</td>
<td>448,240</td>
</tr>
<tr>
<td>Xanthus Life Sciences</td>
<td>1</td>
<td>118,091</td>
<td>29,523</td>
<td>147,614</td>
</tr>
<tr>
<td>Xdx, Inc.</td>
<td>1</td>
<td>68,916</td>
<td>16,604</td>
<td>85,520</td>
</tr>
</tbody>
</table>

**Total for Corporate (153 Agencies):**

- # Awards: 359
- $ Direct: 37,335,200
- $ Indirect: 7,712,527
- Total: 45,047,727

## Federal Awards

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct $</th>
<th>Indirect $</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHRQ</td>
<td>2</td>
<td>391,668</td>
<td>130,172</td>
<td>521,840</td>
</tr>
<tr>
<td>Augusta VA Medical Center</td>
<td>3</td>
<td>58,582</td>
<td>0</td>
<td>58,582</td>
</tr>
<tr>
<td>CDC</td>
<td>6</td>
<td>1,906,032</td>
<td>534,218</td>
<td>2,440,250</td>
</tr>
<tr>
<td>Department of Veterans Affairs</td>
<td>2</td>
<td>40,558</td>
<td>0</td>
<td>40,558</td>
</tr>
<tr>
<td>Dept. of Education</td>
<td>3</td>
<td>474,887</td>
<td>156,820</td>
<td>631,707</td>
</tr>
<tr>
<td>DHHS</td>
<td>1</td>
<td>12,204</td>
<td>5,796</td>
<td>18,000</td>
</tr>
<tr>
<td>DOD</td>
<td>5</td>
<td>588,534</td>
<td>238,068</td>
<td>826,602</td>
</tr>
<tr>
<td>DOD/ONR</td>
<td>4</td>
<td>123,861</td>
<td>58,315</td>
<td>182,176</td>
</tr>
<tr>
<td>DOD/US Army</td>
<td>2</td>
<td>350,000</td>
<td>161,000</td>
<td>511,000</td>
</tr>
<tr>
<td>DOE</td>
<td>2</td>
<td>153,597</td>
<td>70,155</td>
<td>223,752</td>
</tr>
<tr>
<td>EPA</td>
<td>1</td>
<td>78,375</td>
<td>23,513</td>
<td>101,888</td>
</tr>
<tr>
<td>HRSA</td>
<td>13</td>
<td>2,079,285</td>
<td>132,075</td>
<td>2,211,360</td>
</tr>
<tr>
<td>National Network of Libraries of Medicine</td>
<td>4</td>
<td>4,089</td>
<td>0</td>
<td>4,089</td>
</tr>
<tr>
<td>Natl. Inst. of Standards and Technology (NIST)</td>
<td>1</td>
<td>73,958</td>
<td>19,229</td>
<td>93,187</td>
</tr>
<tr>
<td>National Institutes of Health (NIH)</td>
<td>301</td>
<td>77,386,537</td>
<td>25,960,294</td>
<td>103,346,831</td>
</tr>
</tbody>
</table>

## Inst./Center Awards

<table>
<thead>
<tr>
<th>Inst./Center</th>
<th>#</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NCI</td>
<td>39</td>
<td>11,196,375</td>
</tr>
<tr>
<td>NIH/NCRR</td>
<td>7</td>
<td>9,638,851</td>
</tr>
<tr>
<td>NIH/NEI</td>
<td>7</td>
<td>1,936,826</td>
</tr>
<tr>
<td>NIH/NHLBI</td>
<td>44</td>
<td>14,692,756</td>
</tr>
<tr>
<td>NIH/NIA</td>
<td>6</td>
<td>2,053,308</td>
</tr>
<tr>
<td>NIH/NIAAA</td>
<td>16</td>
<td>6,182,142</td>
</tr>
<tr>
<td>NIH/NIAID</td>
<td>6</td>
<td>1,352,496</td>
</tr>
<tr>
<td>NIH/NIAMS</td>
<td>13</td>
<td>2,743,690</td>
</tr>
<tr>
<td>NIH/NICHD</td>
<td>3</td>
<td>1,147,734</td>
</tr>
<tr>
<td>NIH/NIDA</td>
<td>48</td>
<td>16,106,512</td>
</tr>
<tr>
<td>NIH/NIDCD</td>
<td>6</td>
<td>2,900,265</td>
</tr>
<tr>
<td>NIH/NIDCR</td>
<td>15</td>
<td>3,116,000</td>
</tr>
<tr>
<td>NIH/NIDDK</td>
<td>30</td>
<td>8,123,375</td>
</tr>
<tr>
<td>NIH/NIEHS</td>
<td>5</td>
<td>563,183</td>
</tr>
<tr>
<td>NIH/NIGMS</td>
<td>15</td>
<td>4,034,175</td>
</tr>
<tr>
<td>NIH/NIMH</td>
<td>13</td>
<td>4,218,291</td>
</tr>
<tr>
<td>NIH/NINDS</td>
<td>23</td>
<td>12,495,285</td>
</tr>
<tr>
<td>NIH/NINR</td>
<td>2</td>
<td>242,601</td>
</tr>
<tr>
<td>NIH/NLM</td>
<td>3</td>
<td>602,966</td>
</tr>
<tr>
<td>NOAA</td>
<td>2</td>
<td>163,642</td>
</tr>
<tr>
<td>NSF</td>
<td>5</td>
<td>305,845</td>
</tr>
<tr>
<td>SAMHSA</td>
<td>1</td>
<td>255,006</td>
</tr>
<tr>
<td>US Army/USAMRAA</td>
<td>1</td>
<td>46,296</td>
</tr>
</tbody>
</table>
### Federal Awards

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Indirect</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>US Navy Bureau of Medicine and Surgery</td>
<td>1</td>
<td>370,370</td>
<td>132,962</td>
<td>503,332</td>
</tr>
<tr>
<td>Ralph H. Johnson VAMC</td>
<td>39</td>
<td>6,453,683</td>
<td>0</td>
<td>6,453,683</td>
</tr>
<tr>
<td><strong>Total for Federal (21 Agencies)</strong></td>
<td>399</td>
<td><strong>$91,317,009</strong></td>
<td><strong>27,846,301</strong></td>
<td><strong>$119,163,310</strong></td>
</tr>
</tbody>
</table>

### Federal Flow-Down Awards

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Indirect</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced Technology Institute</td>
<td>2</td>
<td>1,308,031</td>
<td>506,015</td>
<td>1,814,046</td>
</tr>
<tr>
<td>Amer. Acad. of Child Psychiatry</td>
<td>1</td>
<td>151,500</td>
<td>9,160</td>
<td>160,660</td>
</tr>
<tr>
<td>Beth Israel Deaconess Med. Ctr.</td>
<td>1</td>
<td>65,477</td>
<td>30,119</td>
<td>95,596</td>
</tr>
<tr>
<td>Boston Medical Center</td>
<td>1</td>
<td>1,000</td>
<td>0</td>
<td>1,000</td>
</tr>
<tr>
<td>Brigham and Womens Hospital</td>
<td>1</td>
<td>74,486</td>
<td>35,380</td>
<td>109,866</td>
</tr>
<tr>
<td>Case Western Reserve Univ.</td>
<td>1</td>
<td>115,940</td>
<td>0</td>
<td>115,940</td>
</tr>
<tr>
<td>Cell and Tissue Systems, Inc.</td>
<td>2</td>
<td>46,806</td>
<td>21,786</td>
<td>68,592</td>
</tr>
<tr>
<td>Charleston Research Institute</td>
<td>2</td>
<td>157,662</td>
<td>41,336</td>
<td>199,000</td>
</tr>
<tr>
<td>Childrens Hosp. of Philadelphia</td>
<td>2</td>
<td>89,863</td>
<td>0</td>
<td>89,863</td>
</tr>
<tr>
<td>Childrens Hospital Research Fdn.</td>
<td>1</td>
<td>47,512</td>
<td>22,568</td>
<td>70,080</td>
</tr>
<tr>
<td>City College of New York</td>
<td>1</td>
<td>23,387</td>
<td>11,108</td>
<td>34,495</td>
</tr>
<tr>
<td>Clemson Univ.</td>
<td>4</td>
<td>211,721</td>
<td>99,585</td>
<td>311,306</td>
</tr>
<tr>
<td>Clinical Trials and Surveys Corp.</td>
<td>1</td>
<td>146,746</td>
<td>25,503</td>
<td>172,249</td>
</tr>
<tr>
<td>Coll. of Charleston</td>
<td>2</td>
<td>97,555</td>
<td>0</td>
<td>97,555</td>
</tr>
<tr>
<td>Dartmouth Coll.</td>
<td>2</td>
<td>39,240</td>
<td>18,050</td>
<td>57,290</td>
</tr>
<tr>
<td>Duke Univ.</td>
<td>2</td>
<td>1,000</td>
<td>0</td>
<td>1,000</td>
</tr>
<tr>
<td>Emory Univ.</td>
<td>3</td>
<td>28,468</td>
<td>13,095</td>
<td>41,563</td>
</tr>
<tr>
<td>FirstString Research, LLC</td>
<td>1</td>
<td>10,377</td>
<td>0</td>
<td>10,377</td>
</tr>
<tr>
<td>Guild Associates, Inc.</td>
<td>1</td>
<td>10,177</td>
<td>4,681</td>
<td>14,858</td>
</tr>
<tr>
<td>Health Sciences SC</td>
<td>1</td>
<td>23,387</td>
<td>10,666</td>
<td>34,053</td>
</tr>
<tr>
<td>Henry M. Jackson Fdn.</td>
<td>1</td>
<td>59,534</td>
<td>15,918</td>
<td>75,452</td>
</tr>
<tr>
<td>Indiana University</td>
<td>1</td>
<td>1,000</td>
<td>0</td>
<td>1,000</td>
</tr>
<tr>
<td>Jaeb Center for Health Research, Inc.</td>
<td>4</td>
<td>209,441</td>
<td>71,222</td>
<td>280,663</td>
</tr>
<tr>
<td>Johns Hopkins Univ.</td>
<td>4</td>
<td>35,117</td>
<td>9,130</td>
<td>44,247</td>
</tr>
<tr>
<td>Medical Coll. of Georgia</td>
<td>2</td>
<td>35,117</td>
<td>9,130</td>
<td>44,247</td>
</tr>
<tr>
<td>MFC Technologies, LLC</td>
<td>1</td>
<td>97,555</td>
<td>46,338</td>
<td>143,893</td>
</tr>
<tr>
<td>Morehouse School of Medicine, Inc.</td>
<td>1</td>
<td>47,945</td>
<td>22,055</td>
<td>70,000</td>
</tr>
<tr>
<td>National Childhood Cancer Fdn.</td>
<td>5</td>
<td>68,752</td>
<td>13,751</td>
<td>82,503</td>
</tr>
<tr>
<td>National Marrow Donor Program</td>
<td>1</td>
<td>56,572</td>
<td>26,872</td>
<td>83,444</td>
</tr>
<tr>
<td>New England Research Institutes</td>
<td>2</td>
<td>28,468</td>
<td>13,095</td>
<td>41,563</td>
</tr>
<tr>
<td>Optima Neuroscience, Inc.</td>
<td>1</td>
<td>13,723</td>
<td>6,481</td>
<td>20,204</td>
</tr>
<tr>
<td>Princeton Univ.</td>
<td>1</td>
<td>10,177</td>
<td>4,681</td>
<td>14,858</td>
</tr>
<tr>
<td>Rady Childrens Hospital San Diego</td>
<td>2</td>
<td>23,387</td>
<td>10,666</td>
<td>34,053</td>
</tr>
<tr>
<td>Research Fdn. for Mental Hygiene</td>
<td>1</td>
<td>183,123</td>
<td>34,797</td>
<td>217,920</td>
</tr>
<tr>
<td>Rhode Island Hospitals</td>
<td>1</td>
<td>59,534</td>
<td>15,918</td>
<td>75,452</td>
</tr>
<tr>
<td>RTI International</td>
<td>1</td>
<td>35,117</td>
<td>9,130</td>
<td>44,247</td>
</tr>
<tr>
<td>Savannah State</td>
<td>1</td>
<td>69,267</td>
<td>18,010</td>
<td>87,277</td>
</tr>
<tr>
<td>SC Dept. of Education</td>
<td>1</td>
<td>10,177</td>
<td>0</td>
<td>10,177</td>
</tr>
<tr>
<td>SC Dept. of Natural Resources</td>
<td>1</td>
<td>97,555</td>
<td>46,338</td>
<td>143,893</td>
</tr>
<tr>
<td>SC Dept. of Public Safety</td>
<td>3</td>
<td>209,441</td>
<td>71,222</td>
<td>280,663</td>
</tr>
<tr>
<td>SC DHEC</td>
<td>7</td>
<td>1,959,033</td>
<td>24,521</td>
<td>1,983,554</td>
</tr>
<tr>
<td>SC EPSCOR</td>
<td>2</td>
<td>10,177</td>
<td>0</td>
<td>10,177</td>
</tr>
<tr>
<td>SC Forestry Commission</td>
<td>1</td>
<td>10,177</td>
<td>0</td>
<td>10,177</td>
</tr>
</tbody>
</table>
## Federal Flow-Down

<table>
<thead>
<tr>
<th>Federal Flow-Down</th>
<th># Awards</th>
<th>$ Direct</th>
<th>$ Indirect</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC Research Authority</td>
<td>3</td>
<td>703,188</td>
<td>82,752</td>
<td>785,940</td>
</tr>
<tr>
<td>SC Sea Grant Consortium</td>
<td>1</td>
<td>111,600</td>
<td>0</td>
<td>111,600</td>
</tr>
<tr>
<td>SCUREF</td>
<td>10</td>
<td>2,511,066</td>
<td>140,628</td>
<td>2,651,694</td>
</tr>
<tr>
<td>Southwest Fdn. for Biomedical Research</td>
<td>2</td>
<td>7,875</td>
<td>3,740</td>
<td>11,615</td>
</tr>
<tr>
<td>St. Jude Childrens Hospital</td>
<td>3</td>
<td>190,501</td>
<td>82,647</td>
<td>273,148</td>
</tr>
<tr>
<td>Tennessee State Univ.</td>
<td>1</td>
<td>91,270</td>
<td>23,730</td>
<td>115,000</td>
</tr>
<tr>
<td>Texas Southern Univ.</td>
<td>1</td>
<td>22,423</td>
<td>10,315</td>
<td>32,738</td>
</tr>
<tr>
<td>The Feinstein Institute for Medical Research</td>
<td>2</td>
<td>183,565</td>
<td>80,153</td>
<td>263,718</td>
</tr>
<tr>
<td>Univ. of Alabama</td>
<td>1</td>
<td>65,400</td>
<td>0</td>
<td>65,400</td>
</tr>
<tr>
<td>Univ. of Alabama, Birmingham</td>
<td>5</td>
<td>217,769</td>
<td>69,612</td>
<td>287,381</td>
</tr>
<tr>
<td>Univ. of California, Los Angeles</td>
<td>3</td>
<td>227,772</td>
<td>102,136</td>
<td>329,908</td>
</tr>
<tr>
<td>Univ. of California, San Diego</td>
<td>2</td>
<td>69,970</td>
<td>16,555</td>
<td>86,525</td>
</tr>
<tr>
<td>Univ. of Central Florida</td>
<td>1</td>
<td>36,986</td>
<td>17,014</td>
<td>54,000</td>
</tr>
<tr>
<td>Univ. of Chicago</td>
<td>2</td>
<td>34,246</td>
<td>15,754</td>
<td>50,000</td>
</tr>
<tr>
<td>Univ. of Cincinnati</td>
<td>7</td>
<td>239,001</td>
<td>95,365</td>
<td>334,366</td>
</tr>
<tr>
<td>Univ. of Colorado</td>
<td>1</td>
<td>166,575</td>
<td>76,625</td>
<td>243,200</td>
</tr>
<tr>
<td>Univ. of Georgia</td>
<td>1</td>
<td>88,285</td>
<td>41,935</td>
<td>130,220</td>
</tr>
<tr>
<td>Univ. of Illinois, Chicago</td>
<td>3</td>
<td>82,822</td>
<td>39,340</td>
<td>122,162</td>
</tr>
<tr>
<td>Univ. of Kansas Medical Center</td>
<td>1</td>
<td>82,560</td>
<td>37,977</td>
<td>120,537</td>
</tr>
<tr>
<td>Univ. of Louisville</td>
<td>1</td>
<td>33,503</td>
<td>15,411</td>
<td>48,914</td>
</tr>
<tr>
<td>Univ. of Maryland</td>
<td>3</td>
<td>71,831</td>
<td>32,203</td>
<td>104,034</td>
</tr>
<tr>
<td>Univ. of Massachusetts</td>
<td>1</td>
<td>54,110</td>
<td>24,890</td>
<td>79,000</td>
</tr>
<tr>
<td>Univ. of Medicine &amp; Dentistry of NJ</td>
<td>1</td>
<td>21,608</td>
<td>9,940</td>
<td>31,548</td>
</tr>
<tr>
<td>Univ. of Michigan</td>
<td>1</td>
<td>4,291</td>
<td>1,973</td>
<td>6,264</td>
</tr>
<tr>
<td>Univ. of Missouri, Columbia</td>
<td>1</td>
<td>171,233</td>
<td>78,767</td>
<td>250,000</td>
</tr>
<tr>
<td>Univ. of North Carolina</td>
<td>3</td>
<td>66,244</td>
<td>30,748</td>
<td>96,992</td>
</tr>
<tr>
<td>Univ. of Pennsylvania</td>
<td>1</td>
<td>65,426</td>
<td>30,096</td>
<td>95,522</td>
</tr>
<tr>
<td>Univ. of South Carolina</td>
<td>15</td>
<td>830,370</td>
<td>326,641</td>
<td>1,157,011</td>
</tr>
<tr>
<td>Univ. of South Florida</td>
<td>1</td>
<td>130,463</td>
<td>60,012</td>
<td>190,475</td>
</tr>
<tr>
<td>Univ. of Texas</td>
<td>1</td>
<td>108,881</td>
<td>51,719</td>
<td>160,600</td>
</tr>
<tr>
<td>Univ. of Texas Health Science Center/Houston</td>
<td>2</td>
<td>22,564</td>
<td>10,634</td>
<td>33,198</td>
</tr>
<tr>
<td>Univ. of Vermont</td>
<td>1</td>
<td>148,785</td>
<td>70,672</td>
<td>219,457</td>
</tr>
<tr>
<td>Univ. of Wisconsin</td>
<td>1</td>
<td>37,566</td>
<td>17,281</td>
<td>54,847</td>
</tr>
<tr>
<td>University of Minnesota</td>
<td>1</td>
<td>46,797</td>
<td>21,527</td>
<td>68,324</td>
</tr>
<tr>
<td>US Immunodeficiency Network</td>
<td>1</td>
<td>102,740</td>
<td>47,260</td>
<td>150,000</td>
</tr>
<tr>
<td>USC Research Foundation</td>
<td>2</td>
<td>21,432</td>
<td>9,858</td>
<td>31,290</td>
</tr>
<tr>
<td>UT Southwestern Med. Ctr.</td>
<td>2</td>
<td>34,918</td>
<td>16,062</td>
<td>50,980</td>
</tr>
<tr>
<td>Vanderbilt Univ.</td>
<td>1</td>
<td>50,922</td>
<td>22,668</td>
<td>73,590</td>
</tr>
<tr>
<td>Virginia Commonwealth Univ.</td>
<td>1</td>
<td>14,266</td>
<td>6,281</td>
<td>20,547</td>
</tr>
<tr>
<td>Washington Univ.</td>
<td>1</td>
<td>21,798</td>
<td>10,027</td>
<td>31,825</td>
</tr>
<tr>
<td>Wayne State Univ.</td>
<td>2</td>
<td>34,917</td>
<td>16,388</td>
<td>51,305</td>
</tr>
<tr>
<td>Westat</td>
<td>1</td>
<td>84,808</td>
<td>37,612</td>
<td>122,420</td>
</tr>
<tr>
<td><strong>Total for Federal Flow-Down (85 Agencies)</strong></td>
<td><strong>172</strong></td>
<td><strong>$17,050,502</strong></td>
<td><strong>3,413,991</strong></td>
<td><strong>$20,464,493</strong></td>
</tr>
</tbody>
</table>

## Foundation

<table>
<thead>
<tr>
<th>Foundation</th>
<th># Awards</th>
<th>$ Direct</th>
<th>$ Indirect</th>
<th>$ Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAMC</td>
<td>1</td>
<td>4,000</td>
<td>0</td>
<td>4,000</td>
</tr>
<tr>
<td>ACR Research and Education Fdn.</td>
<td>2</td>
<td>186,185</td>
<td>14,815</td>
<td>201,000</td>
</tr>
<tr>
<td>Advocates for Youth</td>
<td>1</td>
<td>5,000</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td>Foundation</td>
<td># Awards</td>
<td>$ Direct</td>
<td>$ Indirect</td>
<td>$ Total</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------</td>
<td>-----------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Alliance for Lupus Research</td>
<td>1</td>
<td>120,605</td>
<td>9,648</td>
<td>130,253</td>
</tr>
<tr>
<td>Alpha-1 Assoc.</td>
<td>1</td>
<td>73,510</td>
<td>0</td>
<td>73,510</td>
</tr>
<tr>
<td>Alpha-1 Fdn.</td>
<td>2</td>
<td>246,670</td>
<td>0</td>
<td>246,670</td>
</tr>
<tr>
<td>Amer. Acad. of Neurology</td>
<td>1</td>
<td>89,290</td>
<td>0</td>
<td>89,290</td>
</tr>
<tr>
<td>Amer. Acad. of Pediatrics</td>
<td>1</td>
<td>6,400</td>
<td>0</td>
<td>6,400</td>
</tr>
<tr>
<td>Amer. Cancer Soc.</td>
<td>1</td>
<td>120,000</td>
<td>0</td>
<td>120,000</td>
</tr>
<tr>
<td>Amer. College of Cardiology</td>
<td>1</td>
<td>65,000</td>
<td>0</td>
<td>65,000</td>
</tr>
<tr>
<td>Amer. College of Gastroenterology</td>
<td>2</td>
<td>84,778</td>
<td>0</td>
<td>84,778</td>
</tr>
<tr>
<td>Amer. College of Ob and Gyn</td>
<td>1</td>
<td>25,000</td>
<td>0</td>
<td>25,000</td>
</tr>
<tr>
<td>Amer. Dental Soc. of Anesthesiology</td>
<td>1</td>
<td>7,819</td>
<td>0</td>
<td>7,819</td>
</tr>
<tr>
<td>Amer. Diabetes Assoc.</td>
<td>1</td>
<td>173,865</td>
<td>26,079</td>
<td>199,944</td>
</tr>
<tr>
<td>Amer. Federation for Aging</td>
<td>1</td>
<td>43,350</td>
<td>0</td>
<td>43,350</td>
</tr>
<tr>
<td>Amer. Health Assistance Fdn.</td>
<td>1</td>
<td>50,000</td>
<td>0</td>
<td>50,000</td>
</tr>
<tr>
<td>Amer. Heart Assoc.</td>
<td>9</td>
<td>533,182</td>
<td>49,818</td>
<td>583,000</td>
</tr>
<tr>
<td>Amer. Heart Assoc./Mid-Atlantic</td>
<td>9</td>
<td>435,000</td>
<td>36,000</td>
<td>471,000</td>
</tr>
<tr>
<td>Amer. Nurses Fdn.</td>
<td>1</td>
<td>3,241</td>
<td>259</td>
<td>3,500</td>
</tr>
<tr>
<td>Amer. Statistical Assoc.</td>
<td>1</td>
<td>3,000</td>
<td>0</td>
<td>3,000</td>
</tr>
<tr>
<td>American Physical Therapy Assoc.</td>
<td>1</td>
<td>8,382</td>
<td>0</td>
<td>8,382</td>
</tr>
<tr>
<td>American Society of Echocardiography</td>
<td>1</td>
<td>45,455</td>
<td>4,545</td>
<td>50,000</td>
</tr>
<tr>
<td>Annie E. Casey Fdn.</td>
<td>2</td>
<td>286,023</td>
<td>0</td>
<td>286,023</td>
</tr>
<tr>
<td>APIRE</td>
<td>1</td>
<td>2,500</td>
<td>0</td>
<td>2,500</td>
</tr>
<tr>
<td>Arthritis Fdn.</td>
<td>1</td>
<td>50,000</td>
<td>0</td>
<td>50,000</td>
</tr>
<tr>
<td>Arthur Vining Davis Fdn.</td>
<td>1</td>
<td>199,543</td>
<td>0</td>
<td>199,543</td>
</tr>
<tr>
<td>Assoc. for Prevention Teaching and Research</td>
<td>1</td>
<td>2,900</td>
<td>0</td>
<td>2,900</td>
</tr>
<tr>
<td>Autism Speaks</td>
<td>1</td>
<td>123,571</td>
<td>12,357</td>
<td>135,928</td>
</tr>
<tr>
<td>Avon Fdn.</td>
<td>1</td>
<td>112,500</td>
<td>12,500</td>
<td>125,000</td>
</tr>
<tr>
<td>Charleston Research Institute</td>
<td>1</td>
<td>300,000</td>
<td>0</td>
<td>300,000</td>
</tr>
<tr>
<td>Charlotte Geyer Fdn.</td>
<td>2</td>
<td>68,182</td>
<td>6,818</td>
<td>75,000</td>
</tr>
<tr>
<td>Coastal Community Fdn. of SC</td>
<td>1</td>
<td>2,500</td>
<td>0</td>
<td>2,500</td>
</tr>
<tr>
<td>Commonwealth Fund</td>
<td>1</td>
<td>15,917</td>
<td>1,592</td>
<td>17,509</td>
</tr>
<tr>
<td>Communities in Schools</td>
<td>1</td>
<td>22,954</td>
<td>0</td>
<td>22,954</td>
</tr>
<tr>
<td>Cystic Fibrosis Fdn.</td>
<td>5</td>
<td>167,497</td>
<td>4,400</td>
<td>171,897</td>
</tr>
<tr>
<td>Cystic Fibrosis Fdn. Therapeutics, Inc.</td>
<td>1</td>
<td>80,000</td>
<td>6,400</td>
<td>86,400</td>
</tr>
<tr>
<td>Dee Norton Lowcountry Childrens Center</td>
<td>1</td>
<td>366,498</td>
<td>29,320</td>
<td>395,818</td>
</tr>
<tr>
<td>Donald W. Reynolds Fdn.</td>
<td>1</td>
<td>424,817</td>
<td>75,183</td>
<td>500,000</td>
</tr>
<tr>
<td>Duke Endowment</td>
<td>5</td>
<td>1,315,338</td>
<td>0</td>
<td>1,315,338</td>
</tr>
<tr>
<td>Epilepsy Fdn.</td>
<td>1</td>
<td>36,626</td>
<td>0</td>
<td>36,626</td>
</tr>
<tr>
<td>Epilepsy Services and Research Inc.</td>
<td>1</td>
<td>20,935</td>
<td>0</td>
<td>20,935</td>
</tr>
<tr>
<td>Fdn. Fighting Blindness</td>
<td>2</td>
<td>284,551</td>
<td>0</td>
<td>284,551</td>
</tr>
<tr>
<td>Gateway for Cancer Research</td>
<td>1</td>
<td>160,164</td>
<td>39,853</td>
<td>200,017</td>
</tr>
<tr>
<td>Health Sciences SC</td>
<td>6</td>
<td>1,875,712</td>
<td>0</td>
<td>1,875,712</td>
</tr>
<tr>
<td>Hope for Depression Research Fdn.</td>
<td>2</td>
<td>76,182</td>
<td>7,618</td>
<td>83,800</td>
</tr>
<tr>
<td>Intl. Association for Dental Research</td>
<td>1</td>
<td>69,445</td>
<td>5,555</td>
<td>75,000</td>
</tr>
<tr>
<td>Komen for the Cure/Lowcountry Affiliate</td>
<td>1</td>
<td>74,914</td>
<td>0</td>
<td>74,914</td>
</tr>
<tr>
<td>Leducq Foundation</td>
<td>1</td>
<td>95,148</td>
<td>9,515</td>
<td>104,663</td>
</tr>
<tr>
<td>Lupus Fdn. of America, Inc.</td>
<td>1</td>
<td>10,000</td>
<td>0</td>
<td>10,000</td>
</tr>
<tr>
<td>March of Dimes/SC Chapter</td>
<td>2</td>
<td>53,672</td>
<td>5,217</td>
<td>58,889</td>
</tr>
<tr>
<td>Movement Disorder Society</td>
<td>1</td>
<td>30,000</td>
<td>0</td>
<td>30,000</td>
</tr>
<tr>
<td>MUSC Fdn.</td>
<td>5</td>
<td>2,907,594</td>
<td>0</td>
<td>2,907,594</td>
</tr>
<tr>
<td>Foundation</td>
<td># Awards</td>
<td>Direct</td>
<td>Indirect</td>
<td>Total</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>Nancy R. Gelman Fdn.</td>
<td>1</td>
<td>1,000</td>
<td>0</td>
<td>1,000</td>
</tr>
<tr>
<td>NARSAD</td>
<td>2</td>
<td>75,128</td>
<td>3,676</td>
<td>78,804</td>
</tr>
<tr>
<td>Natl. Environmental Educ. and Training Fdn.</td>
<td>1</td>
<td>8,333</td>
<td>1,667</td>
<td>10,000</td>
</tr>
<tr>
<td>National Postdoctoral Assoc.</td>
<td>1</td>
<td>1,000</td>
<td>0</td>
<td>1,000</td>
</tr>
<tr>
<td>Nephcure Foundation</td>
<td>1</td>
<td>99,900</td>
<td>0</td>
<td>99,900</td>
</tr>
<tr>
<td>New Morning Fdn.</td>
<td>1</td>
<td>181,181</td>
<td>18,182</td>
<td>200,000</td>
</tr>
<tr>
<td>Pedal with Pete</td>
<td>1</td>
<td>18,000</td>
<td>0</td>
<td>18,000</td>
</tr>
<tr>
<td>PhRMA</td>
<td>1</td>
<td>30,000</td>
<td>0</td>
<td>30,000</td>
</tr>
<tr>
<td>Prevent Cancer Foundation</td>
<td>1</td>
<td>40,000</td>
<td>0</td>
<td>40,000</td>
</tr>
<tr>
<td>Rally Fdn.</td>
<td>1</td>
<td>15,000</td>
<td>0</td>
<td>15,000</td>
</tr>
<tr>
<td>Research to Prevent Blindness</td>
<td>1</td>
<td>110,000</td>
<td>0</td>
<td>110,000</td>
</tr>
<tr>
<td>Robert and Molly Tarr Charitable Fdn.</td>
<td>2</td>
<td>95,000</td>
<td>2,500</td>
<td>97,500</td>
</tr>
<tr>
<td>Robert Wood Johnson Fdn.</td>
<td>3</td>
<td>390,510</td>
<td>18,778</td>
<td>409,288</td>
</tr>
<tr>
<td>SC Hospital Research and Educ. Fdn.</td>
<td>1</td>
<td>400,000</td>
<td>0</td>
<td>400,000</td>
</tr>
<tr>
<td>St. Baldricks Fdn.</td>
<td>1</td>
<td>50,000</td>
<td>0</td>
<td>50,000</td>
</tr>
<tr>
<td>Susan G. Komen Fdn.</td>
<td>1</td>
<td>4,950</td>
<td>0</td>
<td>4,950</td>
</tr>
<tr>
<td>Susan Thompson Buffet Fdn.</td>
<td>1</td>
<td>38,130</td>
<td>0</td>
<td>38,130</td>
</tr>
<tr>
<td>Thrasher Research Fund</td>
<td>1</td>
<td>25,000</td>
<td>1,750</td>
<td>26,750</td>
</tr>
<tr>
<td>Trident United Way</td>
<td>2</td>
<td>175,000</td>
<td>0</td>
<td>175,000</td>
</tr>
<tr>
<td>Whitehall Foundation</td>
<td>1</td>
<td>70,070</td>
<td>4,918</td>
<td>74,988</td>
</tr>
<tr>
<td><strong>Total for Foundation (72 Agencies)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>118</td>
<td>$13,394,254</td>
<td>408,963</td>
<td>$13,803,217</td>
</tr>
<tr>
<td>Other Support</td>
<td># Awards</td>
<td>$ Direct</td>
<td>$ Indirect</td>
<td>$ Total</td>
</tr>
<tr>
<td>Allegheny-Singer Research Inst.</td>
<td>1</td>
<td>20,785</td>
<td>2,079</td>
<td>22,864</td>
</tr>
<tr>
<td>Center for Public Service Communications</td>
<td>1</td>
<td>38,802</td>
<td>3,104</td>
<td>41,906</td>
</tr>
<tr>
<td>Center Hospital - University of Montreal</td>
<td>2</td>
<td>40,542</td>
<td>10,136</td>
<td>50,678</td>
</tr>
<tr>
<td>DC Office of Victim Services</td>
<td>2</td>
<td>428,940</td>
<td>0</td>
<td>428,940</td>
</tr>
<tr>
<td>Georgetown University</td>
<td>1</td>
<td>16,667</td>
<td>1,333</td>
<td>18,000</td>
</tr>
<tr>
<td>Robert J. Sywolski</td>
<td>1</td>
<td>14,868</td>
<td>0</td>
<td>14,868</td>
</tr>
<tr>
<td>Univ. of California</td>
<td>1</td>
<td>35,000</td>
<td>0</td>
<td>35,000</td>
</tr>
<tr>
<td>Univ. of California, San Diego</td>
<td>1</td>
<td>731,132</td>
<td>182,158</td>
<td>913,290</td>
</tr>
<tr>
<td>Univ. of Pennsylvania</td>
<td>1</td>
<td>39,968</td>
<td>4,796</td>
<td>44,764</td>
</tr>
<tr>
<td>Univ. of South Florida</td>
<td>1</td>
<td>11,188</td>
<td>2,747</td>
<td>13,935</td>
</tr>
<tr>
<td>Univ. of Southern Mississippi</td>
<td>1</td>
<td>17,974</td>
<td>2,157</td>
<td>20,131</td>
</tr>
<tr>
<td>Univ. of Texas MD Anderson Cancer Center</td>
<td>1</td>
<td>9,600</td>
<td>2,400</td>
<td>12,000</td>
</tr>
<tr>
<td><strong>Total for Other Support (12 Agencies)</strong></td>
<td></td>
<td>$1,405,466</td>
<td>210,910</td>
<td>$1,616,376</td>
</tr>
<tr>
<td>State of South Carolina</td>
<td># Awards</td>
<td>$ Direct</td>
<td>$ Indirect</td>
<td>$ Total</td>
</tr>
<tr>
<td>Clemson Univ.</td>
<td>9</td>
<td>126,914</td>
<td>31,922</td>
<td>158,836</td>
</tr>
<tr>
<td>Coll. of Charleston</td>
<td>1</td>
<td>45,000</td>
<td>0</td>
<td>45,000</td>
</tr>
<tr>
<td>Eat Smart Move More SC</td>
<td>1</td>
<td>5,000</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td>SC Dept. of Disabilities and Spec. Needs</td>
<td>2</td>
<td>4,630</td>
<td>370</td>
<td>5,000</td>
</tr>
<tr>
<td>SC Dept. of Public Safety</td>
<td>2</td>
<td>33,183</td>
<td>0</td>
<td>33,183</td>
</tr>
<tr>
<td>SC Dept. of Transportation</td>
<td>1</td>
<td>2,590,202</td>
<td>0</td>
<td>2,590,202</td>
</tr>
<tr>
<td>SC Developmental Disabilities Council</td>
<td>1</td>
<td>5,000</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td>SC DHEC</td>
<td>2</td>
<td>261,080</td>
<td>0</td>
<td>261,080</td>
</tr>
<tr>
<td>SC DHHS</td>
<td>1</td>
<td>249,033</td>
<td>0</td>
<td>249,033</td>
</tr>
</tbody>
</table>
The University’s Administration received 35 awards in FY 2009, an increase of seven from the previous year. In addition, funding increased by 38.3%, the majority of which flowed from a $2.5M Research University Infrastructure Act (RUIA) Project awarded to the Provost’s Office and a $2.1M Charleston Area eHealth Alliance grant awarded to Information Services.

The College of Nursing experienced significant growth in FY 2009 posting 27 awards, up four from a year ago. These awards reflect a remarkable 38.1% increase from the previous year for just over a $4.25M total in overall funding for fiscal year 2009. The College also had gains in foundation (up 157.8%), other (up 110.7%), federal (up 25.9%), and federal flow-down (up 12.9%) funding.

The College of Dental Medicine earned 15 awards in FY 2009, an increase of two from last year. Though the records indicated the College dropping in overall funding by 26.2% from last year, this can be explained by the necessity to report two consecutive NIH COBRE grant awards (both accepted and reported) in FY 2008 due to a late award notice. Thus the decrease in overall funding from FY 2008 to FY 2009 should not be of concern. Taking the COBRE
out of the picture, the College has generally maintained a funding level of just over $4M in FY 2008 and FY 2009. The federal category continued to dominate the College’s research funding portfolio in FY 2009.

The College of Medicine demonstrated growth in FY 2009 and increased the total number of awards by 10 to 981, amounting to just under $190M in overall funding. This represented a 7.8% increase in the College’s funding from a year ago. Gains in state (38.7%), other (36.7%), corporate (35.8%), federal flow-down (8.8%), foundation (3.5%) more than made up for the 2.9% decline in the federal sector from last year. In FY 2009 NIH funding grew in the College by more than $5.57M, for a 6.29% increase allowing MUSC to sustain its NIH total over the 100 million dollar mark for the second straight year.

The College of Pharmacy received 7 fewer awards in FY 2009 than in the past year. This resulted in a 20.1% decrease in overall funding in the College during the year.

The College of Health Professions total number of awards in FY 2009 increased by 1 to 27, yet a small decrease of 7.2% was experienced in overall funding from the previous year. The College earned more than $2.67M in total funding during FY 2009. Funding emanating from corporate sponsors (up 149.9%) and foundations (up 87.3%) substantially increased for the College during the past year.
### Summary List of Awards by College/Unit and Department

<table>
<thead>
<tr>
<th>Administration</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic Affairs/Provost</td>
<td>1</td>
<td>1</td>
<td>2,522,456</td>
<td>2,522,456</td>
</tr>
<tr>
<td>Information Services</td>
<td>1</td>
<td>2</td>
<td>5,357,980</td>
<td>5,357,980</td>
</tr>
<tr>
<td>Library Science and Informatics</td>
<td>5</td>
<td>21</td>
<td>430,725</td>
<td>501,538</td>
</tr>
<tr>
<td>Physical Plant</td>
<td>2</td>
<td>2</td>
<td>35,000</td>
<td>35,000</td>
</tr>
<tr>
<td>Presidents Office</td>
<td>1</td>
<td>1</td>
<td>37,800</td>
<td>37,800</td>
</tr>
<tr>
<td>Public Safety</td>
<td>1</td>
<td>1</td>
<td>2,783</td>
<td>2,783</td>
</tr>
<tr>
<td>Risk Management</td>
<td>1</td>
<td>1</td>
<td>5,000</td>
<td>5,000</td>
</tr>
<tr>
<td>SC AHEC</td>
<td>2</td>
<td>5</td>
<td>1,250,420</td>
<td>1,266,375</td>
</tr>
<tr>
<td>VP for Finance and Administration</td>
<td>1</td>
<td>1</td>
<td>2,590,202</td>
<td>2,590,202</td>
</tr>
<tr>
<td><strong>Total for Administration</strong></td>
<td>15</td>
<td>35</td>
<td>12,232,366</td>
<td>12,319,134</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Dental Medicine</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craniofacial Biology</td>
<td>3</td>
<td>10</td>
<td>2,919,115</td>
<td>3,983,514</td>
</tr>
<tr>
<td>Dental Medicine</td>
<td>1</td>
<td>1</td>
<td>2,400</td>
<td>2,400</td>
</tr>
<tr>
<td>Pediatric Dentistry and Orthodontics</td>
<td>1</td>
<td>2</td>
<td>33,016</td>
<td>35,208</td>
</tr>
<tr>
<td>Stomatology</td>
<td>2</td>
<td>2</td>
<td>75,416</td>
<td>75,416</td>
</tr>
<tr>
<td><strong>Total for College of Dental Medicine</strong></td>
<td>7</td>
<td>15</td>
<td>3,029,947</td>
<td>4,096,538</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Graduate Studies</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total for College of Graduate Studies</strong></td>
<td>1</td>
<td>1</td>
<td>191,214</td>
<td>202,385</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Health Professions</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Professions</td>
<td>7</td>
<td>10</td>
<td>709,494</td>
<td>808,187</td>
</tr>
<tr>
<td>Health Sciences and Research</td>
<td>6</td>
<td>17</td>
<td>1,424,011</td>
<td>1,868,870</td>
</tr>
<tr>
<td><strong>Total for College of Health Professions</strong></td>
<td>13</td>
<td>27</td>
<td>2,133,505</td>
<td>2,677,057</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Medicine</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anesthesia and Perioperative Medicine</td>
<td>3</td>
<td>5</td>
<td>4,031,688</td>
<td>4,416,094</td>
</tr>
<tr>
<td>Biochemistry and Molecular Biology</td>
<td>15</td>
<td>38</td>
<td>7,025,971</td>
<td>9,945,094</td>
</tr>
<tr>
<td>Biostatistics, Bioinformatics and Epidemiology</td>
<td>20</td>
<td>47</td>
<td>5,258,859</td>
<td>6,715,148</td>
</tr>
<tr>
<td>Cell Biology and Anatomy</td>
<td>31</td>
<td>63</td>
<td>8,904,432</td>
<td>11,684,580</td>
</tr>
<tr>
<td>Cell and Molecular Pharmacology</td>
<td>10</td>
<td>17</td>
<td>4,868,765</td>
<td>6,409,128</td>
</tr>
<tr>
<td>Comparative Medicine</td>
<td>2</td>
<td>5</td>
<td>875,084</td>
<td>1,052,802</td>
</tr>
<tr>
<td>Dermatology</td>
<td>1</td>
<td>1</td>
<td>5,000</td>
<td>7,300</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>7</td>
<td>13</td>
<td>1,886,240</td>
<td>2,331,133</td>
</tr>
<tr>
<td>Medicine</td>
<td>102</td>
<td>301</td>
<td>39,943,563</td>
<td>47,692,375</td>
</tr>
<tr>
<td>Microbiology and Immunology</td>
<td>12</td>
<td>35</td>
<td>6,465,890</td>
<td>7,859,318</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>46</td>
<td>108</td>
<td>28,015,297</td>
<td>33,427,930</td>
</tr>
<tr>
<td>Obstetrics and Gynecology</td>
<td>9</td>
<td>13</td>
<td>1,803,240</td>
<td>2,142,374</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>12</td>
<td>30</td>
<td>2,410,800</td>
<td>3,166,456</td>
</tr>
<tr>
<td>Orthopaedic Surgery</td>
<td>3</td>
<td>7</td>
<td>219,311</td>
<td>247,936</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>6</td>
<td>13</td>
<td>2,679,582</td>
<td>3,511,738</td>
</tr>
<tr>
<td>College of Medicine</td>
<td># PI's</td>
<td># Awards</td>
<td>Direct Costs</td>
<td>Total Costs</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>--------</td>
<td>----------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Pathology and Laboratory Medicine</td>
<td>15</td>
<td>21</td>
<td>3,294,347</td>
<td>4,525,024</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>38</td>
<td>74</td>
<td>6,277,546</td>
<td>7,822,278</td>
</tr>
<tr>
<td>Psychiatry and Behavioral Sciences</td>
<td>46</td>
<td>118</td>
<td>21,850,202</td>
<td>27,531,137</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>1</td>
<td>1</td>
<td>160,164</td>
<td>200,017</td>
</tr>
<tr>
<td>Radiology</td>
<td>9</td>
<td>27</td>
<td>1,356,002</td>
<td>1,701,602</td>
</tr>
<tr>
<td>Surgery</td>
<td>16</td>
<td>40</td>
<td>5,753,350</td>
<td>7,089,340</td>
</tr>
<tr>
<td>Urology</td>
<td>3</td>
<td>4</td>
<td>346,414</td>
<td>429,943</td>
</tr>
<tr>
<td><strong>Total for College of Medicine</strong></td>
<td>407</td>
<td>981</td>
<td>153,431,747</td>
<td>189,908,747</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Nursing</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total for College of Nursing</strong></td>
<td>14</td>
<td>27</td>
<td>3,744,202</td>
<td>4,253,816</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Pharmacy</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical and Biomedical Sciences</td>
<td>10</td>
<td>19</td>
<td>2,820,369</td>
<td>3,720,523</td>
</tr>
<tr>
<td>Pharmacy and Clinical Sciences</td>
<td>5</td>
<td>6</td>
<td>365,427</td>
<td>395,561</td>
</tr>
<tr>
<td><strong>Total for College of Pharmacy</strong></td>
<td>15</td>
<td>25</td>
<td>3,185,796</td>
<td>4,116,084</td>
</tr>
</tbody>
</table>

**GRAND TOTALS:**

<table>
<thead>
<tr>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>472</td>
<td>1111</td>
<td>177,948,777</td>
<td>217,573,761</td>
</tr>
</tbody>
</table>
### Proposal and Awards Summary List

<table>
<thead>
<tr>
<th>Colleges Departments</th>
<th>Proposals # Submitted</th>
<th>$ Submitted</th>
<th>Awards # Funded</th>
<th>$ Funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Academic Affairs/Provost</td>
<td>1</td>
<td>6,616,774</td>
<td>1</td>
<td>2,522,456</td>
</tr>
<tr>
<td>Information Services</td>
<td>1</td>
<td>2,380,000</td>
<td>2</td>
<td>5,357,980</td>
</tr>
<tr>
<td>Library Science &amp; Informatics</td>
<td>14</td>
<td>1,332,944</td>
<td>21</td>
<td>501,538</td>
</tr>
<tr>
<td>Physical Plant</td>
<td>1</td>
<td>10,000</td>
<td>2</td>
<td>35,000</td>
</tr>
<tr>
<td>President's Office</td>
<td></td>
<td></td>
<td>1</td>
<td>37,800</td>
</tr>
<tr>
<td>Public Safety</td>
<td></td>
<td></td>
<td>1</td>
<td>2,783</td>
</tr>
<tr>
<td>Risk Management</td>
<td>1</td>
<td>5,000</td>
<td>1</td>
<td>5,000</td>
</tr>
<tr>
<td>SC AHEC</td>
<td>7</td>
<td>2,141,103</td>
<td>5</td>
<td>1,266,375</td>
</tr>
<tr>
<td>VP for Finance &amp; Administration</td>
<td>1</td>
<td>141,570</td>
<td>1</td>
<td>2,590,202</td>
</tr>
<tr>
<td>Dental Medicine</td>
<td>40</td>
<td>9,701,356</td>
<td>15</td>
<td>4,096,538</td>
</tr>
<tr>
<td>Craniofacial Biology</td>
<td>19</td>
<td>6,831,021</td>
<td>10</td>
<td>3,983,514</td>
</tr>
<tr>
<td>Dental Medicine</td>
<td>1</td>
<td>2,400</td>
<td>1</td>
<td>2,400</td>
</tr>
<tr>
<td>Materials Science</td>
<td>1</td>
<td>24,000</td>
<td>1</td>
<td>24,000</td>
</tr>
<tr>
<td>Pediatric Dentistry/Orthodontics</td>
<td>2</td>
<td>529,484</td>
<td>2</td>
<td>35,208</td>
</tr>
<tr>
<td>Stomatology</td>
<td>17</td>
<td>2,208,446</td>
<td>2</td>
<td>75,416</td>
</tr>
<tr>
<td>Graduate Studies</td>
<td>3</td>
<td>87,864</td>
<td>1</td>
<td>202,385</td>
</tr>
<tr>
<td>Health Professions</td>
<td>52</td>
<td>7,877,587</td>
<td>27</td>
<td>2,677,057</td>
</tr>
<tr>
<td>Health Admin. &amp; Policy</td>
<td>5</td>
<td>158,996</td>
<td>5</td>
<td>4,416,094</td>
</tr>
<tr>
<td>Health Professions</td>
<td>21</td>
<td>2,884,041</td>
<td>10</td>
<td>808,187</td>
</tr>
<tr>
<td>Health Sciences &amp; Research</td>
<td>22</td>
<td>4,198,013</td>
<td>17</td>
<td>1,868,870</td>
</tr>
<tr>
<td>Rehabilitation Sciences</td>
<td>4</td>
<td>636,537</td>
<td>5</td>
<td>1,052,802</td>
</tr>
<tr>
<td>Dental Medicine</td>
<td>2</td>
<td>1,971,268</td>
<td>3</td>
<td>7,300</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>13</td>
<td>4,993,574</td>
<td>1</td>
<td>2,331,133</td>
</tr>
<tr>
<td>Medicine</td>
<td>365</td>
<td>74,920,564</td>
<td>301</td>
<td>47,692,375</td>
</tr>
<tr>
<td>Microbiology &amp; Immunology</td>
<td>74</td>
<td>14,323,258</td>
<td>35</td>
<td>7,859,318</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>177</td>
<td>48,322,580</td>
<td>108</td>
<td>33,427,930</td>
</tr>
<tr>
<td>Obstetrics &amp; Gynecology</td>
<td>22</td>
<td>3,619,113</td>
<td>13</td>
<td>2,142,374</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>50</td>
<td>7,699,422</td>
<td>30</td>
<td>3,166,456</td>
</tr>
<tr>
<td>Orthopaedic Surgery</td>
<td>8</td>
<td>597,746</td>
<td>7</td>
<td>247,936</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>37</td>
<td>6,147,398</td>
<td>13</td>
<td>3,511,738</td>
</tr>
<tr>
<td>Pathology &amp; Laboratory Med.</td>
<td>65</td>
<td>15,586,286</td>
<td>21</td>
<td>4,525,024</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>109</td>
<td>14,924,940</td>
<td>74</td>
<td>7,822,278</td>
</tr>
<tr>
<td>Psychiatry &amp; Behavioral Sc.</td>
<td>222</td>
<td>62,783,025</td>
<td>118</td>
<td>27,531,137</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>4</td>
<td>603,457</td>
<td>1</td>
<td>200,017</td>
</tr>
<tr>
<td>Radiology</td>
<td>20</td>
<td>2,060,850</td>
<td>27</td>
<td>1,701,602</td>
</tr>
<tr>
<td>Surgery</td>
<td>102</td>
<td>17,633,213</td>
<td>40</td>
<td>7,089,340</td>
</tr>
<tr>
<td>Urology</td>
<td>5</td>
<td>614,958</td>
<td>4</td>
<td>429,943</td>
</tr>
<tr>
<td>Nursing</td>
<td>41</td>
<td>7,106,083</td>
<td>27</td>
<td>4,253,816</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>58</td>
<td>11,526,331</td>
<td>25</td>
<td>4,116,084</td>
</tr>
<tr>
<td>Pharmaceutical &amp; Biomedical Sc.</td>
<td>46</td>
<td>10,370,323</td>
<td>19</td>
<td>3,720,523</td>
</tr>
<tr>
<td>Pharmacy &amp; Clinical Services</td>
<td>12</td>
<td>1,156,008</td>
<td>6</td>
<td>395,561</td>
</tr>
<tr>
<td>Grand Totals</td>
<td>1,866</td>
<td>$ 416,174,680</td>
<td>1,111</td>
<td>$ 217,573,761</td>
</tr>
</tbody>
</table>
Faculty Activity
Academic Affairs/Provost

Raymond, John
Principal Investigator
Research University Infrastructure Act (RUIA) Project
Sponsor: SC Research Centers of Economic Excellence
Award: (09080505)
Budget Dates: 07/01/08 - 06/30/09
Project Dates: 12/12/07 - 11/30/11
Direct: $2,522,456
F & A: 0

Information Services
Clark, Frank
Principal Investigator
Rural Health Care Pilot Program
Sponsor: Health Sciences SC
Award: (08072450)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $3,177,980
F & A: 0

Charleston Area eHealth Alliance
Sponsor: MUSC Fdn.
Award: 6146-C (09010879)
Budget Dates: 11/24/08 - 12/01/10
Project Dates: 11/24/08 - 11/15/11
Direct: $2,180,000
F & A: 0

Library Science and Informatics
Fleming, Glenn
Other
NEPC and Community Leaders Institute, Amendment #6
Pl: David Rivers
Dept: Library Science and Informatics
Sponsor: Tennessee State Univ.
Award: DE-FG02-94EW11428 (08060996-1)
Budget Dates: 11/15/08 - 11/14/09
Project Dates: 11/15/08 - 11/15/10
Direct: $40,000
F & A: 0

Hazard, E.
Co-Investigator
Mechanisms of Regulation of NHE-1
Pl: John Raymond
Dept: Medicine
Sponsor: NIH/NIDDK
Award: 2 R01 DK052448-10A2 (07102984-1)
Budget Dates: 07/01/08 - 06/30/09
Project Dates: 12/12/07 - 11/30/11
Direct: $212,500
F & A: 0

Hoffius, Susan
Principal Investigator
Picture of Health: Digitizing and Preserving South Carolina's Medical Artifacts
Sponsor: MUSC Fdn.
Award: (08122946)
Budget Dates: 11/15/08 - 11/14/09
Project Dates: 11/15/08 - 11/15/10
Direct: $40,000
F & A: 0

Jablonski, Richard
Other
NEPC and Community Leaders Institute, Amendment #6
Pl: David Rivers
Dept: Library Science and Informatics
Sponsor: Tennessee State Univ.
Award: DE-FG02-94EW11428 (08060996-1)
Budget Dates: 11/15/08 - 11/14/09
Project Dates: 11/15/08 - 11/15/10
Direct: $91,270
F & A: 0

Mauldin, Mary
Co-Investigator
National Center for Disaster Mental Health Research-Phase II
Pl: Dean Kilpatrick
Dept: Psychiatry and Behavioral Sciences
Sponsor: Dartmouth Coll.
Award: 496/5P60MH082598-02 (07032710-1)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $62,276
F & A: 0

Web-Based Intervention for Disaster-Affected Adolescents and Families
Pl: Kenneth Ruggiero
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIMH
Award: 1 R01 MH081056-01A1 (07110202-1)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $244,615
F & A: 0

Disseminating Trauma-Focused CBT to Child Welfare Therapists: Web-Based Model
Pl: Benjamin Saunders
Dept: Psychiatry and Behavioral Sciences
Sponsor: Allegheny-Singer Research In
Award: 2 R01 MH081056-01A1 (07110202-1)
Budget Dates: 11/15/08 - 11/14/09
Project Dates: 11/15/08 - 11/15/10
Direct: $20,785
F & A: 0

Charleston County Teen and Family EMPOWER (Ethnic Minority Outreach and Web-Based Education for Risk Reduction) Program
Pl: Carla Danielson
Dept: Psychiatry and Behavioral Sciences
Sponsor: SAMHSA
Award: 1U79SP015156-01 (08032861-1)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $255,006
F & A: 0

Evidence-Based Provider Training Tool for PTSD Patients in Support of Psychological Health
Pl: Connie Best
Dept: Psychiatry and Behavioral Sciences
Sponsor: US Navy Bureau of Medicine
Award: N00189-08-P-ZA85 (08100166-1)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $370,370
F & A: 0

Significant Contributor
Development and Evaluation of a Web-Based Intervention for Disaster Victims
Pl: Kenneth Ruggiero
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIMH
Award: 5 R34 MH077149-03 (08060996-1)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $71,250
F & A: 0

Other
Self-Assessment and Self-Help for Teen Violence Victims
Pl: Dean Kilpatrick
Dept: Psychiatry and Behavioral Sciences
Sponsor: DC Office of Victim Services
Award: 09-MUSC-01 (08082842-1)
Budget Dates: 12/01/08 - 11/30/09
Project Dates: 12/01/07 - 11/30/10
Direct: $278,940

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Research Description</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>May, Janice</td>
<td>American Indian Expo - Exhibiting Award</td>
<td>National Network of Libraries of Medicine</td>
<td>11/01/08 - 12/31/08</td>
<td>$850</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Training Award - Greenville Yr2</td>
<td>Univ. of Maryland</td>
<td>10/01/08 - 12/31/08</td>
<td>$598</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Black Expo-Charleston - Exhibit Award</td>
<td>National Network of Libraries of Medicine</td>
<td>03/11/09 - 04/30/09</td>
<td>$1,590</td>
<td>0</td>
</tr>
<tr>
<td>Moorer, Candace</td>
<td>Express Library Technology Improvement Award</td>
<td>Univ. of Maryland</td>
<td>01/01/09 - 12/31/09</td>
<td>$3,436</td>
<td>0</td>
</tr>
<tr>
<td>Rivers, David</td>
<td>Corp. Support - National Conference on Health Disparities</td>
<td>Multiple Sponsors</td>
<td>02/01/07 - 12/31/09</td>
<td>$95,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Corp. Support - Nuclear Energy Conference</td>
<td>Multiple Sponsors</td>
<td>03/01/08 - 02/28/10</td>
<td>$1,244</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>NEPC and Community Leaders Institute, Amendment #6</td>
<td>Tennessee State Univ.</td>
<td>11/01/03 - 12/31/09</td>
<td>$91,270</td>
<td>23,370</td>
</tr>
<tr>
<td>Sullivan, Joann</td>
<td>Savannah State University SIPI Program</td>
<td>Savannah State</td>
<td>01/01/09 - 03/31/10</td>
<td>$69,267</td>
<td>18,010</td>
</tr>
<tr>
<td>Malmrose, John</td>
<td>FY2009 Collegiate Recycling Grant</td>
<td>SC DHEC</td>
<td>10/01/08 - 06/30/09</td>
<td>$25,000</td>
<td>0</td>
</tr>
<tr>
<td>Thurman, Thomas</td>
<td>Medical University of South Carolina Tree Improvement Program</td>
<td>SC Forestry Commission</td>
<td>07/14/08 - 07/13/09</td>
<td>$10,000</td>
<td>0</td>
</tr>
</tbody>
</table>
### Presidents Office

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Program Administration Core</th>
<th>Sponsor: SC Spinal Cord Injury Fund</th>
<th>Budget Dates: 07/01/08 - 06/30/10</th>
<th>Direct: $37,800</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higerd, Thomas</td>
<td></td>
<td>(02093031)</td>
<td>Project Dates: 07/01/02 - 06/30/10</td>
<td>F &amp; A: 0</td>
</tr>
</tbody>
</table>

### Public Safety

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: SC Dept. of Public Safety</th>
<th>Budget Dates: 01/01/07 - 12/31/07</th>
<th>Direct: $2,783</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dunbar, Anthony</td>
<td>Bulletproof Vest Partnership Grant</td>
<td>(06041041)</td>
<td>Project Dates: 01/01/07 - 12/31/07</td>
<td>F &amp; A: 0</td>
</tr>
</tbody>
</table>

### Risk Management

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: Eat Smart Move More SC</th>
<th>Budget Dates: 09/01/08 - 12/31/09</th>
<th>Direct: $5,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brannan, Wayne</td>
<td>Eat Smart, Move More</td>
<td>(08093058)</td>
<td>Project Dates: 09/01/08 - 12/31/09</td>
<td>F &amp; A: 0</td>
</tr>
</tbody>
</table>

### SC AHEC

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: Duke Endowment</th>
<th>Budget Dates: 11/04/08 - 11/30/09</th>
<th>Direct: $528,346</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garr, David</td>
<td>SC Office Healthcare Workforce Analysis and Planning</td>
<td>6155-SPC (08061639)</td>
<td>Project Dates: 11/04/08 - 11/30/12</td>
<td>F &amp; A: 0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: Duke Endowment</th>
<th>Budget Dates: 07/02/08 - 07/01/10</th>
<th>Direct: $260,587</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brannan, Wayne</td>
<td>Building Coalitions to Increase the Diversity of the South Carolina Health Care Workforce</td>
<td>5914-SP (08080792)</td>
<td>Project Dates: 06/06/06 - 07/01/10</td>
<td>F &amp; A: 0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: HRSA</th>
<th>Budget Dates: 09/01/08 - 08/31/09</th>
<th>Direct: $323,524</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brannan, Wayne</td>
<td>Model State Supported AHEC Program</td>
<td>5 U77 HP03019-15-00 (08082023)</td>
<td>Project Dates: 09/30/09 - 08/31/10</td>
<td>F &amp; A: 4,918</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: Univ. of South Carolina</th>
<th>Budget Dates: 09/01/07 - 06/30/10</th>
<th>Direct: $39,815</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kennedy, D.</td>
<td>Palmetto State Geriatric Education Centers</td>
<td>09-1579/18190-FJ07 (08102371)</td>
<td>Project Dates: 09/01/07 - 06/30/10</td>
<td>F &amp; A: 3,185</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: Univ. of South Carolina</th>
<th>Direct: $39,815</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kennedy, D.</td>
<td>Palmetto State Geriatric Education Centers</td>
<td>Award: 09-1579/18190-FJ07 (08102371-1)</td>
<td></td>
</tr>
</tbody>
</table>

### VP for Finance and Administration

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor: SC Dept. of Transportation</th>
<th>Budget Dates: 10/01/08 - 09/30/09</th>
<th>Direct: $2,590,202</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montgomery, Lisa</td>
<td>MUSC Intermodal Parking Facility-Cannon and Courtney Blvd-Construction</td>
<td>SC-03-0041 (07022253)</td>
<td>Project Dates: 12/05/05 - 09/30/09</td>
<td>F &amp; A: 0</td>
</tr>
</tbody>
</table>

### Co-PI or Project Leader

<table>
<thead>
<tr>
<th>PI: David Garr</th>
<th>Sponsor: Univ. of South Carolina</th>
<th>Direct: $39,815</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: SC AHEC</td>
<td>Award: 09-1579/18190-FJ07 (08102371-1)</td>
<td></td>
</tr>
</tbody>
</table>
### Craniofacial Biology

#### Kirkwood, Keith

**Principal Investigator**

**MUSC Dental Research Training Grant**
- Sponsor: NIH/NIDCR
- Award: 5 T32 DE017551-03 (08041137)

**Negative Regulation of Innate Immune Responses through MAPK Phosphatases**
- Sponsor: NIH/NIDCR
- Award: 7 R01 DE018290-03 (08043012)

**Targeting Post-Transcriptional Signaling for Periodontitis**
- Sponsor: Intl. Association for Dental Research
- Award: (08043017)

**Silencing Post Transcriptional Signaling Mechanisms in Periodontal Inflammation**
- Sponsor: NIH/NIDCR
- Award: 1 R21 DE019272-01 (08081610)

**Altering Cytokine mRNA Stability in Periodontal Bone Loss**
- Sponsor: NIH/NIDCR
- Award: 5 R21 DE017966-03 (08081611)

**Negative Regulation of Innate Responses through MAPK Phosphatases**
- Sponsor: NIH/NIDCR
- Award: 5 R01 DE018290-04 (08120467)

**South Carolina COBRE for Oral Health Grant**
- Sponsor: NIH/NCRR
- Award: 5 P20 RR017696-08 (09033151)

#### Palanisamy, V.

**Principal Investigator**

**Regulation of mRNA Stability in Human Saliva**
- Sponsor: NIH/NIDCR
- Award: 4 R00 DE018165-03 (09062974)

#### Reed, Susan

**Co-Investigator**

**Oral Health in People with Systemic Sclerosis**
- Sponsor: NIH/NIDCR
- Dept: Health Professions
- Award: 5 R21 DE017360-02 (08052830-1)

#### Westwater, Caroline

**Principal Investigator**

**Candida Glabrata Gene Activation During Mucosal Infection**
- Sponsor: NIH/NIAID
- Award: 1 R21 AI076721-01A2 (08031289)

**Phage-Mediated Bioluminescent Detection of Yersinia Pestis**
- Sponsor: Guild Associates, Inc.
- Award: R43 AI082698 (08071490)

### Dental Medicine

#### Hardy, Douglas

**Principal Investigator**

**ATCNow Diabetic Testing in the Emergency Clinic at MUSC**
- Sponsor: Bayer Corp.
- Award: Donation Agreement (09033034)

#### Neville, Brad

**Other**

**Macrophage-Driven Progression of Premalignant Oral Lesions Toward Invasiveness**
- Sponsor: NIH/NIDCR
- Dept: Otolaryngology
- Award: 1 R01 DE018168-01A2 (07102462-1)

**Immunotherapy to Prevent Oral Premalignant Lesion Recurrence and Oral Cancer**
- Sponsor: NIH/NCI
- Dept: Otolaryngology
- Award: 1 R01 CA128837-01A2 (08021972-2)
## Pediatric Dentistry and Orthodontics

### Principal Investigator

**Salinas, Carlos**  
**Dental Treatment for the Diagnosis and Treatment of Special Patients**  
- **Sponsor:** SC Developmental Disabilities Council  
- **Award:** 7-21-0041 (07071083)  
- **Budget Dates:** 09/01/07 - 09/30/07  
- **Direct:** $5,000

**Craniofacial Anomalies and Cleft Lip and Palate Team**  
- **Sponsor:** SC DHEC  
- **Award:** CR-9-135 (08071612)  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $28,016

### Co-PI or Project Leader

**South Carolina COBRE for Oral Health Grant - Core C: Clinical**  
- **PI:** Keith Kirkwood  
- **Dept:** Craniofacial Biology  
- **Budget Dates:** 04/15/00 - 06/30/09  
- **Direct:** $246,288

### Stomatology

### Principal Investigator

**Cannick, Gabrielle**  
**Individual Predoctoral Dental Scientist Fellowship**  
- **Sponsor:** NIH/NIDCR  
- **Award:** 5 F30 DE017046-04 (08042803)  
- **Budget Dates:** 07/01/08 - 05/31/09  
- **Direct:** $33,687

### Co-PI or Project Leader

**Chi, Angela**  
**South Carolina COBRE for Oral Health Grant - Project 2**  
- **PI:** Keith Kirkwood  
- **Dept:** Craniofacial Biology  
- **Budget Dates:** 09/01/08 - 08/31/09  
- **Direct:** $104,371

**Other**  
- **Macrophage-Driven Progression of Premalignant Oral Lesions Toward Invasiveness**  
- **PI:** M. Young  
- **Dept:** Otolaryngology  
- **Sponsor:** NIH/NIDCR  
- **Budget Dates:** 07/01/08 - 05/31/09  
- **Direct:** $250,000

- **Immunotherapy to Prevent Oral Premalignant Lesion Recurrence and Oral Cancer**  
- **PI:** M. Young  
- **Dept:** Otolaryngology  
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 09/01/08 - 05/31/09  
- **Direct:** $207,500

### Embree, Mildred**  
**Individual Predoctoral Dental Scientist Fellowship**  
- **Sponsor:** NIH/NIDCR  
- **Award:** 5 F30 DE018072-03 (08071718)  
- **Budget Dates:** 09/01/08 - 08/31/09  
- **Direct:** $41,729

### Leite, Renata**  
**Co-PI or Project Leader**  
**South Carolina COBRE for Oral Health Grant - Project 6**  
- **PI:** Keith Kirkwood  
- **Dept:** Craniofacial Biology  
- **Sponsor:** NIH/NIDCR  
- **Budget Dates:** 09/01/08 - 08/31/10  
- **Direct:** $95,837

### Sanders, John**  
**Co-Investigator**  
**Diabetes and Periodontal Gene Expression**  
- **PI:** Yan Huang  
- **Dept:** Medicine  
- **Sponsor:** NIH/NIDCR  
- **Budget Dates:** 09/01/08 - 08/31/10  
- **Direct:** $200,445
## College of Graduate Studies

### Graduate Studies

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Training Program for Medical Scientists</th>
<th>Sponsor: NIH/NIGMS</th>
<th>Award: 5 T32 GM008716-10 (07112994)</th>
<th>Budget Dates: 07/01/08 - 06/30/09</th>
<th>Direct: $191,214</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halushka, Perry</td>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 07/01/99 - 06/30/09</td>
<td>F &amp; A: 11,171</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Annan, Dustin</td>
<td>Co-Investigator</td>
<td>Developing Caring Professionals: Infusing Compassion and Humanism in Health Professions Education</td>
<td>Arthur Vining Davis Fdn.</td>
<td>07/01/08 - 06/30/09</td>
<td>199,543</td>
</tr>
<tr>
<td>Bushardt, Reamer</td>
<td>Co-Investigator</td>
<td>Developing Caring Professionals: Infusing Compassion and Humanism in Health Professions Education</td>
<td>Arthur Vining Davis Fdn.</td>
<td>07/01/08 - 06/30/09</td>
<td>259,362</td>
</tr>
<tr>
<td>Chipas, Anthony</td>
<td>Principal Investigator</td>
<td>Nurse Anesthetist Traineeships</td>
<td>HRSA</td>
<td>07/01/08 - 06/30/09</td>
<td>18,179</td>
</tr>
<tr>
<td>Coker, Patricia</td>
<td>Principal Investigator</td>
<td>Camp Hand To Hands</td>
<td>Coastal Community Fdn. of SC</td>
<td>07/01/08 - 06/30/10</td>
<td>2,500</td>
</tr>
<tr>
<td>Hewett, Mary</td>
<td>Co-Investigator</td>
<td>Developing Caring Professionals: Infusing Compassion and Humanism in Health Professions Education</td>
<td>Arthur Vining Davis Fdn.</td>
<td>07/01/08 - 06/30/09</td>
<td>199,543</td>
</tr>
<tr>
<td>Jacques, Paul</td>
<td>Principal Investigator</td>
<td>Physician Assistant Training in Primary Care</td>
<td>HRSA</td>
<td>07/01/08 - 06/30/09</td>
<td>259,362</td>
</tr>
<tr>
<td>Jones, Walter</td>
<td>Principal Investigator</td>
<td>Public Health Finance: Advancing a Field of Study</td>
<td>Univ. of Southern Mississippi</td>
<td>07/01/08 - 06/30/09</td>
<td>17,974</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Book Chapters on Diabetes, Public Health Systems Research, and Health Disparities</td>
<td>DHHS</td>
<td>07/01/08 - 06/30/09</td>
<td>12,204</td>
</tr>
<tr>
<td>Metz, Arnold</td>
<td>Co-Investigator</td>
<td>Physician Assistant Training in Primary Care</td>
<td>HRSA</td>
<td>07/01/08 - 06/30/09</td>
<td>259,362</td>
</tr>
</tbody>
</table>
**Health Professions**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitcham, Maralynne</td>
<td></td>
<td>Arthur Vining Davis Fdn.</td>
<td>199,543</td>
<td>0</td>
</tr>
<tr>
<td><strong>Developing Caring Professionals: Infusing Compassion and Humanism in Health Professions Education</strong></td>
<td></td>
<td>Project Dates: 06/01/09 - 05/31/11</td>
<td>06/01/09 - 05/31/11</td>
<td></td>
</tr>
<tr>
<td>Award: (08071505)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Physician Assistant Training in Primary Care</td>
<td>HRSA</td>
<td>259,362</td>
<td>0</td>
</tr>
<tr>
<td>PI: Paul Jacques</td>
<td>Dept: Health Professions</td>
<td>5 D57HP08309-02-00 (08061904-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Arthur Vining Davis Fdn.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 06/01/09 - 05/31/11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Moreau, Noelle**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In Vivo Assessment of Quadriceps Muscle Plasticity in Children with Cerebral Palsy</strong></td>
<td></td>
<td>Thrasher Research Fund</td>
<td>25,000</td>
<td>0</td>
</tr>
<tr>
<td>Award: NR-0051 (08082843)</td>
<td></td>
<td>Project Dates: 01/01/09 - 12/31/10</td>
<td>01/01/09 - 12/31/10</td>
<td>1,750</td>
</tr>
<tr>
<td><strong>Physical Activity and Muscle Plasticity in Cerebral Palsy</strong></td>
<td>American Physical Therapy Assoc.</td>
<td></td>
<td>8,382</td>
<td>0</td>
</tr>
<tr>
<td>Award: (08082845)</td>
<td></td>
<td>Project Dates: 09/01/09 - 11/30/09</td>
<td>09/01/09 - 11/30/09</td>
<td>0</td>
</tr>
<tr>
<td><strong>In Vivo Assessment of Quadriceps Muscle Plasticity in Children with Cerebral Palsy</strong></td>
<td>Pedal with Pete</td>
<td></td>
<td>18,000</td>
<td>0</td>
</tr>
<tr>
<td>Award: (08121618)</td>
<td></td>
<td>Project Dates: 01/01/09 - 12/31/10</td>
<td>01/01/09 - 12/31/10</td>
<td>0</td>
</tr>
<tr>
<td>Sponsor: Pedal with Pete</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 01/01/09 - 12/31/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**West, Valerie**

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-Doctoral Training in Primary Care: Motivate for Health</strong></td>
<td></td>
<td>HRSA</td>
<td>157,407</td>
<td>0</td>
</tr>
<tr>
<td>PI: Alexander Chessman</td>
<td>Dept: Family Medicine</td>
<td>1 D56HP10309-01-00 (07120623-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Arthur Vining Davis Fdn.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 01/01/09 - 12/31/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**White, Andrea**

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-Doctoral Training in Primary Care: Motivate for Health</strong></td>
<td></td>
<td>HRSA</td>
<td>157,407</td>
<td>0</td>
</tr>
<tr>
<td>PI: Alexander Chessman</td>
<td>Dept: Family Medicine</td>
<td>1 D56HP10309-01-00 (07120623-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Arthur Vining Davis Fdn.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 01/01/09 - 12/31/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Wise, Holly**

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Developing Caring Professionals: Infusing Compassion and Humanism in Health Professions Education</strong></td>
<td></td>
<td>Arthur Vining Davis Fdn.</td>
<td>199,543</td>
<td>0</td>
</tr>
<tr>
<td>PI: Maralynne Mitcham</td>
<td>Dept: Health Professions</td>
<td>(08071505-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Arthur Vining Davis Fdn.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 06/01/09 - 05/31/11</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Yuen, Hon**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Health in People with Systemic Sclerosis</strong></td>
<td></td>
<td>NIH/NIDCR</td>
<td>148,350</td>
<td>68,241</td>
</tr>
<tr>
<td>Award: 5 R21 DE017360-02 (08052830)</td>
<td></td>
<td>Project Dates: 07/01/08 - 06/30/09</td>
<td>07/02/07 - 06/30/10</td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIDCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 07/01/08 - 06/30/09</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Health Sciences and Research**

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Linking Processes of Nursing Care and Patient Safety Outcomes: An Analysis of the Cause and Effect of Safe Practice Implementation</strong></td>
<td></td>
<td>Robert Wood Johnson Fdn.</td>
<td>143,431</td>
<td>0</td>
</tr>
<tr>
<td>PI: Richard Lindrooth</td>
<td>Dept: Health Sciences and Research</td>
<td>62603 (07041272-2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 07/01/08 - 06/30/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Effect on Boxed Warnings and Public Information on Pharmaceutical Use</strong></td>
<td></td>
<td>Univ. of Georgia</td>
<td>88,285</td>
<td>0</td>
</tr>
<tr>
<td>PI: Ruth Jenkins</td>
<td>Dept: Family Medicine</td>
<td>RRS79-050/3503578 (08071496-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Univ. of Georgia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 07/01/08 - 06/30/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Impact of Treatment Profitability on Hospital Responses to Financial Stress</strong></td>
<td></td>
<td>Univ. of Pennsylvania</td>
<td>39,968</td>
<td>0</td>
</tr>
<tr>
<td>PI: Richard Lindrooth</td>
<td>Dept: Health Sciences and Research</td>
<td>549467 (09031779-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Univ. of Pennsylvania</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 07/01/08 - 06/30/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Krause, James**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Research Development Core</strong></td>
<td></td>
<td>SC Spinal Cord Injury Fund</td>
<td>57,750</td>
<td>0</td>
</tr>
<tr>
<td>Award: (02100202)</td>
<td></td>
<td>Project Dates: 07/01/08 - 06/30/10</td>
<td>07/01/08 - 06/30/10</td>
<td></td>
</tr>
<tr>
<td><strong>Risk of Adverse Outcomes after SCI: A Longitudinal Study</strong></td>
<td>NIH/NINDS</td>
<td></td>
<td>54,982</td>
<td>25,292</td>
</tr>
<tr>
<td>Award: 5 R01 NS048117-03 (07110298)</td>
<td></td>
<td>Project Dates: 09/01/08 - 11/30/09</td>
<td>09/01/08 - 11/30/09</td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NINDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 09/01/08 - 11/30/09</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Participation, Subjective Well Being, Health, and Spinal Cord Injury: A 35-Year Longitudinal Study</strong></td>
<td>Dept. of Education</td>
<td></td>
<td>102,703</td>
<td>47,243</td>
</tr>
<tr>
<td>Award: H133G060126-08 (08062590)</td>
<td></td>
<td>Project Dates: 12/01/08 - 11/30/09</td>
<td>12/01/08 - 11/30/09</td>
<td></td>
</tr>
<tr>
<td>Sponsor: Dept. of Education</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Dates: 12/01/08 - 11/30/09</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Krause, James

**Principal Investigator**

**Center on Health Outcomes Research and Capacity Building for Undererved Populations with SCI and TBI**

- **Sponsor:** Dept. of Education
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct:** $243,556
- **Award:** 5 R01 NS048117-04 (08102996)

**Risk of Adverse Outcomes after SCI: A Longitudinal Study**

- **Sponsor:** NIH/NINDS
- **Budget Dates:** 01/01/09 - 12/31/09
- **Direct:** $344,059
- **Award:** 5 R01 NS048117-04 (08102996)

## Leslie, Douglas

**Principal Investigator**

**Women Veterans Cohort Study**

- **Sponsor:** Department of Veterans Affairs
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $35,268
- **Award:** (08072448)

**Mechanisms of Action and Outcome in Peer Support Groups**

- **Sponsor:** Department of Veterans Affairs
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct:** $5,290
- **Award:** (08091602)

## Lindrooth, Richard

**Principal Investigator**

**Linking Processes of Nursing Care and Patient Safety Outcomes: An Analysis of the Cause and Effect of Safe Practice Implementation**

- **Sponsor:** Robert Wood Johnson Fdn.
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct:** $143,431
- **Award:** 549467 (09031779)

**Impact of Treatment Profitability on Hospital Responses to Financial Stress**

- **Sponsor:** Univ. of Pennsylvania
- **Budget Dates:** 12/01/08 - 11/30/09
- **Direct:** $39,968
- **Award:** 549467 (09031779)

## Saladin, Michael

**Principal Investigator**

**Treatment Implications of Beta-Blockade Effects on Memory for Cocaine Craving**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 08/01/08 - 06/30/09
- **Direct:** $150,847
- **Award:** 1 R21 DA025155-01 (07101223)

**The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 08/01/08 - 06/30/09
- **Direct:** $178,500
- **Award:** 5 K23 DA020482-02 (08070869-1)

**Stress and Marijuana Cue-Elicited Craving and Reactivity**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 08/01/08 - 06/30/09
- **Direct:** $124,390
- **Award:** 5 R21 DA022424-02 (08070971-1)

## Saunders, Lee

**Co-Investigator**

**Research Development Core**

- **Sponsor:** SC Spinal Cord Injury Fund
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct:** $57,750
- **Award:** (02100202-7)
Saunders, Lee

Co-Investigator

Center on Health Outcomes Research and Capacity Building for Underserved Populations with SCI and TBI
Pl: James Krause
Dept: Health Sciences and Research
Sponsor: Dept. of Education
Award: H133A080064 (08081919-1)
Risk of Adverse Outcomes after SCI: A Longitudinal Study
Pl: James Krause
Dept: Health Sciences and Research
Sponsor: NIH/NINDS
Award: 5 R01 NS048117-04 (08102996-2)

Simpson, Kit

Principal Investigator

Development of a New Pharmacoeconomic Model for the Tablet Formulation of Kaletra vs. Boosted Atazanavir in Treating Antiretroviral Experienced HIV Patients - Phase II
Sponsor: Abbott Labs
Award: H06-KALETRA-001 (06031561)
Budget Dates: 03/14/06 - 03/31/09
Project Dates: 03/14/06 - 03/31/09
Direct: $2,180
F & A: $545

Economic Model of Kaletra as 2nd Line Regimen in Africa
Sponsor: Abbott Labs
Award: H08.Kaletra.08-01 PO AS51 (08050128)
Budget Dates: 05/15/09 - 06/30/09
Project Dates: 05/15/09 - 06/30/09
Direct: $30,600
F & A: $7,650

HEOR Landscape for Alzheimer's Disease
Sponsor: Abbott Labs
Award: FJ08002-004 / Project H08 (08072451)
Budget Dates: 08/01/08 - 08/31/09
Project Dates: 08/01/08 - 08/31/09
Direct: $41,200
F & A: $10,300

Manuscript Reporting Results of Markov Modeling Study
Sponsor: Abbott Labs
Award: FJ08002-003/H08.Kaletra (08080581)
Budget Dates: 09/01/08 - 08/31/09
Project Dates: 09/01/08 - 08/31/09
Direct: $32,000
F & A: $8,000

Economic Models of Kaletra for Europe
Sponsor: Abbott Labs
Award: FJ08002-005 (09022474)
Budget Dates: 03/18/09 - 03/17/10
Project Dates: 03/18/09 - 03/17/10
Direct: $82,000
F & A: $20,500

Clinical and Economic Benefits of Kaletra’s Clinical, Economic and HRQL Benefits
Sponsor: Abbott Labs
Award: FJ08002006 (09040693)
Budget Dates: 04/15/09 - 04/14/10
Project Dates: 04/15/09 - 04/14/10
Direct: $48,000
F & A: $12,000

Co-Investigator

Physician Assistant Training in Primary Care
Pl: Paul Jacques
Dept: Health Professions
Sponsor: HRSA
Award: 5 D57HP08309-02-00 (08061964-1)
A Program to Increase Living Donations in African Americans
Pl: Prabhakar Baliga
Dept: Surgery
Sponsor: NIH/NIDDK
Award: 5 R01 DK062596-07 (08062489-1)
Statistical and Data Coordinating Center for ALIAS and IMS III Trials
Pl: Yuko Palesch
Dept: Biostatistics, Bioinformatics and Epidemi
Sponsor: NIH/NINDS
Award: 5 U01 NS054630-05 (09032626-1)

Sothmann, Mark

Principal Investigator

Creating an Indiana-Ohio Center for Traumatic Amputation Rehabilitation Research
Sponsor: Indiana University
Budget Dates: 09/01/08 - 07/31/09
Project Dates: 09/01/07 - 07/31/09
Direct: $10,177
F & A: $4,681
### Anesthesia and Perioperative Medicine

**Reeves, Scott**
*Co-Investigator*

**TMS in the Management of Postoperative Pain**
- **Pl:** Jeffrey Borckardt
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NINR
- **Award:** 1 R21 NR010635-01A2 (08031824-1)
- **Direct:** $125,000

**Reves, Joseph**
*Principal Investigator*

**General Clinical Research Center**
- **Sponsor:** NIH/NCCR
- **Budget Dates:** 05/01/07 - 07/31/09
- **Direct:** $1,579,043
- **Award:** 5 M01 RR001070-32 (09042955)
- **Project Dates:** 02/03/97 - 07/31/09
- **F & A:** $384,406

### Biochemistry and Molecular Biology

**Bastia, Deepak**
*Principal Investigator*

**Mechanism of Termination of DNA Replication**
- **Sponsor:** NIH/NIGMS
- **Budget Dates:** 03/01/09 - 02/28/10
- **Direct:** $243,383
- **Award:** 5 R01 GM049264-17 (09011310)
- **Project Dates:** 03/01/94 - 02/28/10
- **F & A:** $111,955

**Bielawska, Alicja**
*Co-PI or Project Leader*

**Sphingolipids in Cancer Biology and Therapy: Core B**
- **Pl:** Yusuf Hannun
- **Dept:** Biochemistry and Molecular Biology
- **Sponsor:** NIH/NCI
- **Award:** 2 P01 CA097132-06 (07101010-3)
- **Direct:** $128,005

**MUSC Cancer Center Support Grant: Lipidomics**
- **Pl:** Andrew Kraft
- **Dept:** Medicine
- **Sponsor:** NIH/NCI
- **Award:** 1 P30 CA138313-01 (08042282-11)
- **Direct:** $41,802

**COBRE in Lipidomics - Core B: Lipidomics Core**
- **Pl:** Lina Obeid
- **Dept:** Biochemistry and Molecular Biology
- **Sponsor:** NIH/NCCR
- **Award:** 5 P20 RR017677-07 (08070866-12)
- **Direct:** $272,492

**Bielawska, Jacek**
*Co-Investigator*

**Sphingolipids in Cancer Biology and Therapy: Core B**
- **Pl:** Yusuf Hannun
- **Dept:** Biochemistry and Molecular Biology
- **Sponsor:** NIH/NCI
- **Award:** 2 P01 CA097132-06 (07101010-3)
- **Direct:** $128,005

**COBRE in Lipidomics - Core B: Lipidomics Core**
- **Pl:** Lina Obeid
- **Dept:** Biochemistry and Molecular Biology
- **Sponsor:** NIH/NCCR
- **Award:** 5 P20 RR017677-07 (08070866-12)
- **Direct:** $272,492

**Bullesbach, Erika**
*Co-Investigator*

**COBRE in Lipidomics - Core D: Protein Core**
- **Pl:** Lina Obeid
- **Dept:** Biochemistry and Molecular Biology
- **Sponsor:** NIH/NCCR
- **Award:** 5 P20 RR017677-07 (08070866-14)
- **Direct:** $135,641

**Chao, Julie**
*Principal Investigator*

**Kallistatin in Hypertension**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 07/01/08 - 06/30/10
- **Direct:** $189,636
- **Award:** 5 R01 HL044083-18 (08051678)
- **Project Dates:** 02/01/90 - 06/30/10
- **F & A:** $87,233

---

**Annual Report for Research FY2009**
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chao, Julie</td>
<td>Regulation and Function of Tissue Kallikrein</td>
<td>NIH/NHLBI</td>
<td>06/01/09 - 10/31/10</td>
<td>$34,829</td>
<td>$16,544</td>
</tr>
<tr>
<td></td>
<td>Regulation and Function of Tissue Kallikrein</td>
<td>NIH/NHLBI</td>
<td>06/01/09 - 05/31/10</td>
<td>$250,000</td>
<td>$118,750</td>
</tr>
<tr>
<td></td>
<td>The Sphingolipid Pathway in Colon Cancer Chemoprevention</td>
<td>NIH/NHLBI</td>
<td>06/01/09 - 05/31/10</td>
<td>$207,500</td>
<td>$0</td>
</tr>
<tr>
<td>Clarke, Christopher</td>
<td>Investigation of the PKC-Mediated Regulation of Neutral Sphingomyelinase 2</td>
<td>NIH/NCI</td>
<td>04/01/09 - 03/31/10</td>
<td>$258,300</td>
<td>$0</td>
</tr>
<tr>
<td>Cowart, Lauren</td>
<td>Sphingolipid-Mediated Skeletal Muscle Pathology in Response to Free Fatty Acids</td>
<td>VAMC</td>
<td>03/01/09 - 02/28/10</td>
<td>$218,400</td>
<td>$73,600</td>
</tr>
<tr>
<td>Davies, Christopher</td>
<td>Molecular Targets in Peptidoglycan Synthesis</td>
<td>NIH/NIGMS</td>
<td>08/18/08 - 07/31/09</td>
<td>$125,000</td>
<td>$59,375</td>
</tr>
<tr>
<td>Del Poeta, Maurizio</td>
<td>New Methods for the Early Diagnosis of Invasive Fungal Infections</td>
<td>NIH/NIAID</td>
<td>08/15/08 - 08/14/09</td>
<td>$128,628</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Role of Phagocytosis in Pathogenesis of Cryptococcus Neoforans</td>
<td>NIH/NIAID</td>
<td>12/01/08 - 11/30/09</td>
<td>$225,000</td>
<td>$103,500</td>
</tr>
<tr>
<td>Duggan, Brendan</td>
<td>Co-Investigator</td>
<td>NIH/NIAID</td>
<td>10/01/07 - 09/30/09</td>
<td>$118,091</td>
<td>$29,523</td>
</tr>
<tr>
<td>Fedarovich, Alena</td>
<td>Co-Investigator</td>
<td>NIH/NIAID</td>
<td>12/06/05 - 12/31/09</td>
<td>$9,000</td>
<td>$0</td>
</tr>
<tr>
<td>Fernandes, Daniel</td>
<td>Principal Investigator</td>
<td>NIH/NIAID</td>
<td>10/01/07 - 09/30/09</td>
<td>$72,243</td>
<td>$0</td>
</tr>
</tbody>
</table>
Fernandes, Daniel

**Principal Investigator**
Award: (09022787)  
Project Dates: 01/23/09 - 01/22/10  
F & A: 22,757

**Co-Investigator**
MUSC Cancer Center Support Grant: Senior Leadership  
PI: Andrew Kraft  
Sponsor: NIH/NCI  
Direct $ 229,094

**Co-Investigator**
Dept: Medicine  
Award: 1 P30 CA138313-01 (08042282-2)

Hama, Hiroko

**Principal Investigator**
Creation of a Fatty Acid 2-Hydroxylase-Knockout Mouse Model  
Sponsor: NIH/NINDS  
Direct $ 50,000

**Project Dates:** 08/01/08 - 07/31/09

**Lipid Hydroxylation in Glial Cell Signaling and Myelination**  
Sponsor: NIH/NINDS  
Direct $ 196,875

**Project Dates:** 04/01/09 - 03/31/10

**Dept:** Medicine

**Award:** 5 R01 NS068072-02 (09021306)

Hannun, Yusuf

**Principal Investigator**
Sphingolipids in Cancer Biology and Therapy  
Sponsor: NIH/NCI  
Direct $ 756,038

**Role and Regulation of Protein Kinase C Isoenzymes**  
Sponsor: NIH/NHLBI  
Direct $ 114,851

**Project Dates:** 04/01/01 - 01/31/10

**Support for the Charleston Ceramide Conference**  
Sponsor: NIH/NIGMS  
Direct $ 5,000

**Project Dates:** 02/01/09 - 01/31/10

**Sphingomyelin Turnover and Cellular Regulation**  
Sponsor: NIH/NIGMS  
Direct $ 248,000

**Project Dates:** 07/01/97 - 12/31/11

**Modeling and Analysis of Roles of Yeast Sphingolipids**  
Sponsor: NIH/NIGMS  
Direct $ 198,888

**Project Dates:** 02/01/09 - 01/31/10

**Ceramide Activated Protein Phosphatases**  
Sponsor: NIH/NCI  
Direct $ 98,354

**Project Dates:** 07/01/09 - 02/28/10

**5th Int'l Charleston Ceramide Conference**  
Sponsor: SC Research Authority  
Direct $ 10,000

**Project Dates:** 02/01/09 - 05/31/09

**5th International Charleston Ceramide Conference**  
Sponsor: Eli Lilly  
Direct $ 4,000

**Project Dates:** 02/01/09 - 04/30/09

**Role and Regulation of Protein Kinase C Isoenzymes**  
Sponsor: NIH/NHLBI  
Direct $ 950

**Project Dates:** 06/01/09 - 08/31/10

**Co-PI or Project Leader**
COBRE in Lipidomics - Administrative Core  
PI: Lina Obeid  
Dept: Biochemistry and Molecular Biology  
Award: 5 P20 RR017677-07 (08070866-2)

**Co-Investigator**
MUSC Cancer Center Support Grant: Senior Leadership  
PI: Andrew Kraft  
Sponsor: NIH/NCI  
Direct $ 229,094

**Co-Investigator**  
Award: 1 P30 CA138313-01 (08042282-2)

Hennig, Mirko

**Principal Investigator**
Characterization of SARS-CoV Frameshift Signal  
Sponsor: Univ. of Maryland  
Direct $ 67,797

**Project Dates:** 07/01/08 - 06/30/09

**CAREER: Structural Requirements for miRNA Processing and Export**  
Sponsor: NSF  
Direct $ 108,474

**Project Dates:** 05/01/09 - 04/30/10

**Co-Investigator**
COBRE in Lipidomics - Core D: Protein Core  
PI: Lina Obeid  
Dept: Biochemistry and Molecular Biology  
Award: 5 P20 RR017677-07 (08070866-14)

**Co-Investigator**
Award: 1 R01 NS068072-02 (09021306)
### Hsu, Yi-Te

**Co-Investigator**

**COBRE in Lipidomics - Core D: Protein Core**  
**PI:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NCRR  
**Award:** 5 P20 RR017677-07  
**Direct $** 135,641

### Jenkins, Russell

**Principal Investigator**

**Role of Protein Kinase C in the Regulation of Secretory Sphingomyelinase**  
**Sponsor:** Amer. Heart Assoc./Mid-Atlantic  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct $** 20,000

### Kitatani, Kazuyuki

**Co-Investigator**

**Sphingolipids in Cancer Biology and Therapy: Project 1**  
**PI:** Yusuf Hannun  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NCI  
**Award:** 2 P01 CA097132-06  
**Direct $** 124,398

### Krupenko, Natalia

**Co-PI or Project Leader**

**COBRE in Lipidomics - Pilot 4**  
**PI:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NCRR  
**Award:** 5 P20 RR017677-07  
**Direct $** 96,500

### Krupenko, Sergey

**Principal Investigator**

**Mechanism of Action of a Major Folate Enzyme**  
**Sponsor:** NIH/NIDDK  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct $** 200,900

**FDH: A Novel Determinant of Tumor Suppression**  
**Sponsor:** NIH/NCI  
**Budget Dates:** 02/01/09 - 01/31/10  
**Direct $** 168,539

**Co-Investigator**

**COBRE in Lipidomics - Core D: Protein Core**  
**PI:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NCRR  
**Award:** 5 P20 RR017677-07  
**Direct $** 135,641

### Lemasters, John

**Principal Investigator**

**Research Training in Bioenergetic, Oxidative Stress and Metabolic Syndromes**  
**Sponsor:** NIH/NIDDK  
**Budget Dates:** 05/01/09 - 04/30/10  
**Direct $** 91,571

**Mitochondrial Dysfunction and Drug Hepatotoxicity**  
**Sponsor:** Univ. of Kansas Medical Center  
**Budget Dates:** 08/01/08 - 07/31/09  
**Direct $** 82,560

**Mechanism of I/R Injury to Hepatocytes**  
**Sponsor:** NIH/NIDDK  
**Budget Dates:** 03/01/09 - 02/28/10  
**Direct $** 200,900

**Liver Preservation for Transplantation**  
**Sponsor:** NIH/NIDDK  
**Budget Dates:** 05/01/09 - 04/30/10  
**Direct $** 402,385

### Luberto, Chiara

**Co-PI or Project Leader**

**COBRE in Lipidomics - Pilot 1**  
**PI:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NCRR  
**Award:** 5 P20 RR017677-07  
**Direct $** 112,314

### Mohanty, Bidyut

**Co-PI or Project Leader**

**American Cancer Society Institutional Research Grant (ACSIRG)**  
**PI:** Carolyn Reed  
**Dept:** Surgery  
**Sponsor:** Amer. Cancer Soc.  
**Award:** IRG-97-219-08  
**Direct $** 24,000

**COBRE in Lipidomics - Pilot 5**  
**PI:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NCRR  
**Award:** 5 P20 RR017677-07  
**Direct $** 110,042

**Co-Investigator**

**Mechanism of Termination of DNA Replication**  
**PI:** Deepak Bastia  
**Dept:** Biochemistry and Molecular Biology  
**Sponsor:** NIH/NIGMS  
**Award:** 5 R01 GM049264-17  
**Direct $** 243,383
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Name</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Obeid, Lina</strong></td>
<td>COBRE in Lipidomics</td>
<td>NIH/NCRR</td>
<td>07/01/08 - 06/30/09</td>
<td>$1,470,001</td>
<td>676,200</td>
</tr>
<tr>
<td></td>
<td>C18-Ceramide in Head and Neck Cancer Growth and Therapy</td>
<td>NIH/NIDCR</td>
<td>04/01/08 - 03/31/09</td>
<td>$52,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regulation of Telomerase by Ceramide in Lung Cancer</td>
<td>NIH/NCI</td>
<td>08/01/08 - 07/31/09</td>
<td>$141,940</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C18-Ceramide in Head and Neck Cancer Growth and Therapy</td>
<td>NIH/NIDCR</td>
<td>04/01/09 - 03/31/10</td>
<td>$181,924</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sphingolipids in Cancer Biology and Therapy: Project 4</td>
<td>NIH/NCI</td>
<td>04/01/05 - 03/31/10</td>
<td>$103,997</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis</td>
<td>NIH/NIA</td>
<td>08/01/08 - 07/31/09</td>
<td>$185,843</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COBRE in Lipidomics - Project 4</td>
<td>NIH/NIDCR</td>
<td>04/01/08 - 03/31/09</td>
<td>$54,601</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sphingogilipids in Cancer Biology and Therapy: Core B</td>
<td>NIH/NCI</td>
<td>04/01/09 - 03/31/10</td>
<td>$128,005</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sphingolipids in Cancer Biology and Therapy: Project 3</td>
<td>NIH/NCI</td>
<td>04/01/09 - 03/31/10</td>
<td>$152,939</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sphingosine Phosphate Role in Inflammation</td>
<td>NIH/NIGMS</td>
<td>08/01/08 - 07/31/09</td>
<td>$180,154</td>
<td></td>
</tr>
<tr>
<td></td>
<td>COBRE in Lipidomics - Core B: Lipidomics Core</td>
<td>NIH/NCRR</td>
<td>04/01/05 - 03/31/10</td>
<td>$272,492</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis</td>
<td>NIH/NIA</td>
<td>08/01/08 - 07/31/09</td>
<td>$185,843</td>
<td></td>
</tr>
</tbody>
</table>

**Biostatistics, Bioinformatics and Epidemiology**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Name</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alberg, Anthony</strong></td>
<td>DNA Repair, Skin Cancer, and Overall Cancer Risk</td>
<td>NIH/NCI</td>
<td>04/01/09 - 03/31/10</td>
<td>$362,331</td>
<td>33,219</td>
</tr>
<tr>
<td></td>
<td>MUSC Cancer Center Support Grant: Senior Leadership</td>
<td>NIH/NCI</td>
<td>08/01/08 - 07/31/09</td>
<td>$229,094</td>
<td></td>
</tr>
</tbody>
</table>

Annual Report for Research FY2009
### Alberg, Anthony

**Co-Investigator**

**Translating an Efficacious HPV Vaccine into the Control of Cervical Cancer**
- **PI:** Sharon Bond
- **Dept:** Nursing
- **Sponsor:** NIH/NCI
- **Award:** 5 R03 CA130724-02 (08062715-1)
- **Direct:** $52,161

**A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers**
- **PI:** Matthew Carpenter
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Award:** 5 R01 DA021619-03 (09032096-1)
- **Direct:** $202,757

### Bandyopadhyay, D.

**Co-PI or Project Leader**

**Modern Semiparametric Methods in Action: SRCOS Summer Research Conference**
- **PI:** Elizabeth Slate
- **Dept:** Biostatistics, Bioinformatics and Epidemi
- **Sponsor:** SC EPSCOR
- **Direct:** $10,000

**South Carolina COBRE for Oral Health Grant - Core B: Biostatistics**
- **PI:** Keith Kirkwood
- **Dept:** Craniofacial Biology
- **Sponsor:** NIH/NCRR
- **Direct:** $269,776

### Carter, Rickey

**Co-Investigator**

**Vitamin D Insufficiency and Cardiovascular Risk in Type 2 Diabetes**
- **PI:** Louis Luttrell
- **Dept:** Medicine
- **Sponsor:** Amer. Heart Assoc./Mid-Atlant
- **Budget Dates:** 12/01/08 - 12/31/09
- **Direct:** $60,000

**Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus**
- **PI:** Maria Lopes-Virella
- **Dept:** Medicine
- **Sponsor:** NIH/NIDDK
- **Direct:** $302,856

**South Carolina Consortium of the Clinical Trials Network**
- **PI:** Kathleen Brady
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Direct:** $989,921

**CSA Prevention Training for Child Care Professionals: Stewards of Children**
- **PI:** Alyssa Rheingold
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** CDC
- **Direct:** $200,635

### DeSantis, Stacia

**Principal Investigator**

**Illustrating Biostatistical Research: An Audiovisual Vignette**
- **Sponsor:** Amer. Statistical Assoc.
- **Budget Dates:** 12/01/08 - 12/31/09
- **Direct:** $3,000

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues</td>
<td></td>
<td>$178,500</td>
<td>0</td>
</tr>
<tr>
<td>Interdisciplinary Women's Health Research at MUSC</td>
<td></td>
<td>$459,990</td>
<td>0</td>
</tr>
<tr>
<td>Drug Abuse Research Training (DART) Program</td>
<td></td>
<td>$256,253</td>
<td>0</td>
</tr>
<tr>
<td>D-Cycloserine Facilitation of Cocaine-Cue Extinction</td>
<td></td>
<td>$251,745</td>
<td>0</td>
</tr>
<tr>
<td>Clinical Investigation of Drug Abuse Disorders</td>
<td></td>
<td>$140,762</td>
<td>0</td>
</tr>
</tbody>
</table>
Durkalski, Valerie

**Principal Investigator**

**Safety and Efficacy of Atorvastatin in Newly Diagnosed Type I Diabetes**

Sponsor: Children's Hosp. of Philadelphia
Award: 950297/RSUB (06031457)

**SERT-GAD Data Management Services (PI Olga Brawman-Mintzer)**

Sponsor: Augusta VA Medical Center
Award: VA247P-2554 (07082951)

**Cadaveric Organ Donor Management Project**

Sponsor: Life Point
Award: Donor Mgmt Project (09022348)

**Safety and Efficacy of Atorvastatin in Newly Diagnosed Type I Diabetes**

Sponsor: Children's Hosp. of Philadelphia
Award: 950384/RSUB (09030305)

**Co-PI or Project Leader**

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) Data

PI: Peter Cotton
Dept: Medicine
Sponsor: NIH/NIDDK
Award: 5 U01 DK074739-02 (08042495-2)

Evaluation of the Efficacy and Tolerability of Duloxetine in Patients with Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction - SOD)

PI: Christopher Lawrence
Dept: Medicine
Sponsor: Lilly Research Laboratories
Award: F13-MC-X038 (06053118-2)

Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM

PI: Leonhard Egebe
Dept: Medicine
Sponsor: NIH/NIDDK
Award: 1 R01 DK081152-01A1 (07110552-1)

Feeding in Elderly Late-Stage Dementia: the FIELD Trial

PI: Mark Delegge
Dept: Medicine
Sponsor: NIH/NIA
Award: 1 R21 AG032083-01A1 (08031073-1)

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD)

PI: Peter Cotton
Dept: Medicine
Sponsor: NIH/NIDDK
Award: 5 U01 DK074739-02 (08042495-1)

Neurological Emergencies Treatment Trials Network Statistical and Data Management

PI: Yuko Palesch
Dept: Biostatistics, Bioinformatics and Epidemiology
Sponsor: NIH/NINDS
Award: 5 U01 NS059041-03 (08069040-1)

Fuguson, Pamela

**Other**

Statewide Investigation of Traumatic Brain Injury in Prisons

PI: E. Pickelsimer
Dept: Biostatistics, Bioinformatics and Epidemiology
Sponsor: CDC
Award: 5 U49 CE001318-02 (08040175-1)

Ford, Marvella

**Principal Investigator**

**The Impact of PTSD and Race on Medication Adherence in Demented Veterans**

Sponsor: Texas Southern Univ.
Award: FA8500-08-1-0026 (07083160)

**Collaborative Undergraduate HBCU Student Summer Prostate Cancer Training Program**

Sponsor: DOD
Award: W81XWH-09-1-0157 (08061014)

**Southeastern US Collaborative CEED**

Sponsor: Morehouse School of Medicine, Inc.
Award: 1U50-DE-000964-01 (09012891)

**Co-Investigator**

MUSC Cancer Center Support Grant: Senior Leadership

PI: Andrew Kraft
Dept: Medicine
Sponsor: NIH/NCI
Award: 1 P30 CA133813-01 (08042262-2)

Translating an Efficacious HPV Vaccine into the Control of Cervical Cancer

PI: Sharon Bond
Dept: Nursing
Sponsor: NIH/NCI
Award: 5 R03 CA130724-02 (08062715-1)

Parkinson's Disease Clinical Trial: Statistical Center

PI: Barbara Tilley
Dept: Biostatistics, Bioinformatics and Epidemiology
Sponsor: NIH/NINDS
Award: 5 U01 NS043127-08 (08100806-2)

**Other**

Increasing Minority Participation in Clinical Research

PI: Arch Mainous
Dept: Family Medicine
Sponsor: Duke Endowment
Award: 6098-SP (08091605-2)
<table>
<thead>
<tr>
<th>Garrett-Mayer, E.</th>
<th>Co-PI or Project Leader</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUSC Cancer Center Support Grant: Biostatistics Shared Resources</td>
<td></td>
</tr>
<tr>
<td>PI: Andrew Kraft</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: 1 P30 CA138313-01 (08042282-12)</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
</tr>
<tr>
<td>Sphingolipids in Cancer Biology and Therapy: Project 4</td>
<td></td>
</tr>
<tr>
<td>PI: Yusuf Hannun</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Biochemistry and Molecular Biology</td>
<td>Award: 2 P01 CA097132-06 (07101010-8)</td>
</tr>
<tr>
<td>The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer</td>
<td></td>
</tr>
<tr>
<td>PI: Omar Moussa</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Pathology and Laboratory Medicine</td>
<td>Award: 1 R01 CA127905-01A1 (08030449-1)</td>
</tr>
<tr>
<td>Role of Ets Genes in Transformation and Differentiation - Core A</td>
<td></td>
</tr>
<tr>
<td>PI: Dennis Watson</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Pathology and Laboratory Medicine</td>
<td>Award: 5 P01 CA078582-05 (09022682-1)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>The Mechanism of Action of Unique Small Molecules That Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth</td>
<td></td>
</tr>
<tr>
<td>PI: Andrew Kraft</td>
<td>Sponsor: DOD</td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: W81XWH-09-1-0300 (08060478-1)</td>
</tr>
<tr>
<td>Stimulus Control and Trajectories of Adolescent Smoking</td>
<td></td>
</tr>
<tr>
<td>PI: Matthew Carpenter</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 6 K23 DA020482-02 (08070869-1)</td>
</tr>
<tr>
<td>Gilbert, Gregory</td>
<td>Co-Investigator</td>
</tr>
<tr>
<td>Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus</td>
<td></td>
</tr>
<tr>
<td>PI: Maria Lopes-Virella</td>
<td>Sponsor: NIH/NIDDK</td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: 1 R01 DK081352-01 (07092852-1)</td>
</tr>
<tr>
<td>Herrin, Amy</td>
<td>Other</td>
</tr>
<tr>
<td>New Methods for the Early Diagnosis of Invasive Fungal Infections</td>
<td></td>
</tr>
<tr>
<td>PI: Maurizio Del Poeta</td>
<td>Sponsor: NIH/NIAID</td>
</tr>
<tr>
<td>Dept: Biochemistry and Molecular Biology</td>
<td>Award: 1 R21 AI078493-01 (07062920-1)</td>
</tr>
<tr>
<td>General Clinical Research Center</td>
<td></td>
</tr>
<tr>
<td>PI: Joseph Reves</td>
<td>Sponsor: NIH/NCRR</td>
</tr>
<tr>
<td>Dept: Anesthesia and Perioperative Medicine</td>
<td>Award: 5 M01 RR001070-32 (09042955-1)</td>
</tr>
<tr>
<td>Hill, Elizabeth</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Statistical Methods for Head and Neck Cancer Proteomics</td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIDCR</td>
<td>Budget Dates: 09/01/08 - 08/31/09</td>
</tr>
<tr>
<td>Award: 5 K25 DE016863-04 (08070243)</td>
<td>Project Dates: 09/20/05 - 08/31/10</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
</tr>
<tr>
<td>Logic Forest: A Statistical Method for Biomarker Discovery</td>
<td></td>
</tr>
<tr>
<td>PI: Elizabeth Slate</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Biostatistics, Bioinformatics and Epidemiology</td>
<td>Award: 1 R03 CA137805-01 (08031822-1)</td>
</tr>
<tr>
<td>Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases</td>
<td></td>
</tr>
<tr>
<td>PI: Scott Eblen</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Cell and Molecular Pharmacology</td>
<td>Award: 1 R01 CA131200-01A1 (08110557-1)</td>
</tr>
<tr>
<td>Prognostic Markers in Postoperative Acute Kidney Injury</td>
<td></td>
</tr>
<tr>
<td>PI: John Arthur</td>
<td>Sponsor: NIH/NIDDK</td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: 5 R01 DK080234-02 (09050819-1)</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy to Prevent Oral Permalignant Lesion Recurrence and Oral Cancer</td>
<td></td>
</tr>
<tr>
<td>PI: M. Young</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Dept: Otolaryngology</td>
<td>Award: 1 R01 CA128837-01A2 (08021972-2)</td>
</tr>
<tr>
<td>Hoel, David</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Low Dose Radiation Cancer Risks: Epidemiological and Toxicological Models</td>
<td></td>
</tr>
<tr>
<td>Sponsor: DOE</td>
<td>Budget Dates: 07/01/08 - 12/31/09</td>
</tr>
<tr>
<td>Award: DE-FG02-08ER64605 (08032441)</td>
<td>Project Dates: 07/01/08 - 12/31/09</td>
</tr>
<tr>
<td>Savannah River Site Former Production Workers Medical Surveillance Program</td>
<td></td>
</tr>
<tr>
<td>Sponsor: DOE</td>
<td>Budget Dates: 04/01/08 - 03/31/10</td>
</tr>
<tr>
<td>Award: DE-FC01-08HS08035 (09022682)</td>
<td>Project Dates: 03/01/08 - 03/31/10</td>
</tr>
</tbody>
</table>
Hunt, Kelly

**Principal Investigator**

**The Metabolic Syndrome in Mexican American Children**

**Sponsor:** Southwest Fdn. for Biomedical Research  
**Award:** 08-1424.005/5R01HD049051- (07100271)  
**Budget Dates:** 07/01/08 - 02/28/09  
**Direct:** $3,351  
**F & A:** $1,592

**Familial Aggregation of Longevity and Cardiovascular Disease in the Evans County Heart Study**

**Sponsor:** Amer. Heart Assoc./Mid-Atlantic  
**Award:** 0865161E (08011045)  
**Budget Dates:** 07/01/08 - 06/30/10  
**Direct:** $60,000  
**F & A:** $6,000

**The Metabolic Syndrome in Mexican American Children**

**Sponsor:** Southwest Fdn. for Biomedical Research  
**Award:** 5 R01 HD049051-05 (09031040)  
**Budget Dates:** 07/01/08 - 02/28/12  
**Direct:** $4,524  
**F & A:** $2,148

Knapp, Rebecca

**Co-Investigator**

**SEFT-GAD Data Management Services (PI Olga Brawman-Mintzer)**

**Pl:** Valerie Durkalski  
**Dept:** Biostatistics, Bioinformatics and Epidemi  
**Award:** V247P-2554 (07082951-2)  
**Budget Dates:** 07/01/08 - 06/30/10  
**Direct:** $2,148

**Innovative Service Delivery for Secondary Prevention of PTSD in at-Risk OIF- OEF Service Men and Women**

**Pl:** Thomas Uhde  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** W81XWH-08-2-0047 (08052722-1)  
**Budget Dates:** 07/01/08 - 06/30/10  
**Direct:** $157,662

Lackland, Daniel

**Principal Investigator**

**Impact of Nativity on Cardiometabolic Syndrome Factors in the REGARDS Study**

**Sponsor:** Univ. of Alabama, Birmingham  
**Award:** 001/5 U01 NS041588-08 (09010875)  
**Budget Dates:** 07/15/08 - 07/14/09  
**Direct:** $50,641  
**F & A:** $23,294

**Kallikrein and Vascular Disease Risk in Diabetes**

**Pl:** Ayad Jaffa  
**Dept:** Medicine  
**Award:** 1 R01 HL087986-01A2 (07102568-1)  
**Budget Dates:** 07/01/08 - 02/28/09  
**Direct:** $254,608

**Cost Effectiveness Evaluation of the Impact of State Spending on Hypertension Prevention and Control Programs**

**Pl:** Brent Egan  
**Dept:** Medicine  
**Award:** 13-312-0208654 (08091291-1)  
**Budget Dates:** 07/01/08 - 06/30/10  
**Direct:** $6,823

**Individual Predoctoral Dental Scientist Fellowship**

**Pl:** Gabrielle Cannick  
**Dept:** Stomatology  
**Award:** 5 F30 DE017046-04 (08042803-1)  
**Budget Dates:** 07/01/08 - 06/30/10  
**Direct:** $33,687

Lawson, Andrew

**Principal Investigator**

**Spatial Epidemiology of Diabetes in the SEARCH for Diabetes in Youth Study**

**Sponsor:** Univ. of South Carolina  
**Award:** 1 R01 DK077131-01 (08103012)  
**Budget Dates:** 01/01/09 - 12/31/09  
**Direct:** $21,295  
**F & A:** $10,115

**Developing Measures of the Built Nutrition Environment**

**Sponsor:** Univ. of South Carolina  
**Award:** 09-1556/11590 FA26 (08110455)  
**Budget Dates:** 08/16/08 - 05/31/09  
**Direct:** $10,431  
**F & A:** $4,955

**Developing Measures of the Built Nutrition Environment**

**Sponsor:** Univ. of South Carolina  
**Award:** 09-1566/1 R21 CA132133-01 (09060187)  
**Budget Dates:** 08/16/08 - 05/31/10  
**Direct:** $41,508  
**F & A:** $19,416

Lu, Xinghua

**Principal Investigator**

**Training of Toolmakers for Bio-Medical Informatics (TTBMI)**

**Sponsor:** NIH/NLM  
**Award:** 3 T15 LM007438-05S2 (07053063)  
**Budget Dates:** 07/01/08 - 06/30/10  
**Direct:** $183,044  
**F & A:** $11,695

**Automatic Literature-Based Protein Annotation**

**Sponsor:** NIH/NLM  
**Award:** 5 R01 LM009153-02 (08051673)  
**Budget Dates:** 07/01/07 - 07/14/10  
**Direct:** $213,367  
**F & A:** $64,841

**Co-PI or Project Leader**

**COBRE in Lipidomics - Project 3**

**Pl:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Award:** S P20 RR017677-07 (08070866-5)  
**Budget Dates:** 04/01/08 - 11/30/12  
**Direct:** $50,000

Martin, Renee

**Principal Investigator**

**A Phase II, Multi-Center, Randomized, Fasting, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study Evaluating a Single-Dose of Intravenous NA-1 in Male and Female Patients Undergoing Endovascular Repair of Brain Aneurysms**

**Sponsor:** NoNO, Inc.  
**Award:** 3302 (NA-1-002) (08082022)  
**Budget Dates:** 06/01/08 - 12/31/10  
**Direct:** $57,600  
**F & A:** $14,400
Martin, Renee

**Principal Investigator**

**The Significance of Intracranial Hemorrhage after Revascularization Therapy**

Sponsor: Univ. of Cincinnati  
Award: 5 K23 NS059843-03 (09022577)  
Project Dates: 07/01/07 - 07/31/12  
F & A: $1,285

**Co-Investigator**

**Antihypertensive Treatment in Acute Cerebral Hemorrhage**

Pl: Yuko Palesch  
Dept: Biostatistics, Bioinformatics and Epidemiology  
Sponsor: University of Minnesota  
Award: N6376410017R01NS044976-0 (08010102-1)  
Direct: $46,797

**Statistical and Data Coordinating Center for ALIAS and IMS III Trials**

Pl: Yuko Palesch  
Dept: Biostatistics, Bioinformatics and Epidemiology  
Sponsor: NIH/NINDS  
Award: 5 U01 NS054630-05 (09032626-1)  
Direct: $955,523

**PRoFESS - Second Stroke analysis and Chronic Pain analysis**

Pl: Yuko Palesch  
Dept: Biostatistics, Bioinformatics and Epidemiology  
Sponsor: Boehringer Ingelheim Pharma  
Award: 9.159 PO45224983 (09062972-1)  
Direct: $21,293

Nicholas, Joyce

**Co-PI or Project Leader**

**SC Autism and Developmental Disabilities Monitoring Project (ADDM)**

Pl: Jane Charles  
Dept: Pediatrics  
Sponsor: CDC  
Award: 5 UR3 DD000083-04 (09022354-2)  
Direct: $392,803

**A Randomized, Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acid Supplementation in Autism**

Pl: Laura Carpenter  
Dept: Pediatrics  
Sponsor: Autism Speaks  
Award: 2934 (08021555-1)  
Direct: $123,571

Nietert, Paul

**Co-Investigator**

**Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care**

Pl: Peter Miller  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIAAA  
Award: 1 R01 AA016768-01A2 (07102672-1)  
Direct: $337,197

**Oral Health in People with Systemic Sclerosis**

Pl: Hon Yuen  
Dept: Health Professions  
Sponsor: NIH/NIDCR  
Award: 5 R21 DE017360-02 (08052830-1)  
Direct: $148,350

**Medication Safety in Primary Care Practice - Translating Research into Practice (MS-TRIP)**

Pl: Steven Ornstein  
Dept: Family Medicine  
Sponsor: AHRQ  
Award: 5 R18 HS017037-02 (08061965-1)  
Direct: $278,258

**Effect on Boxed Warnings and Public Information on Pharmaceutical Use**

Pl: Ruth Jenkins  
Dept: Family Medicine  
Sponsor: Univ. of Georgia  
Direct: $88,825

**Colorectal Cancer Screening in Primary Care Practice**

Pl: Steven Ornstein  
Dept: Family Medicine  
Sponsor: NIH/NCI  
Direct: $288,701

**Mentor**

**NRSA for Primary Medical Care: Developing Primary Care Researchers Using Research Networks**

Pl: William Basco  
Dept: Pediatrics  
Sponsor: HRSA  
Direct: $127,371

**The Role of Vitamin D in Systemic Lupus Erythematosus**

Pl: Diane Kamen  
Dept: Medicine  
Sponsor: NIH/NIAMS  
Direct: $119,875

Palesch, Yuko

**Principal Investigator**

**Antihypertensive Treatment in Acute Cerebral Hemorrhage**

Sponsor: University of Minnesota  
Budget Dates: 09/01/07 - 08/31/08  
Direct: $46,797

**Biostatistics Training with Application to Neuroscience**

Sponsor: NIH/NINDS  
Budget Dates: 07/01/08 - 06/30/09  
Direct: $135,038

**Neurological Emergencies Treatment Trials Network Statistical and Data Management**

Sponsor: NIH/NINDS  
Budget Dates: 08/01/08 - 07/31/09  
Direct: $467,831

**Statistical and Data Coordinating Center for ALIAS and IMS III Trials**

Sponsor: NIH/NINDS  
Budget Dates: 06/01/09 - 05/31/10  
Direct: $955,523

**PRoFESS - Second Stroke analysis and Chronic Pain analysis**

Sponsor: Boehringer Ingelheim Pharmaceuticals  
Budget Dates: 06/01/09 - 05/31/10  
Direct: $21,293

Palesch, Yuko

**Principal Investigator**

**Antihypertensive Treatment in Acute Cerebral Hemorrhage**

Sponsor: University of Minnesota  
Budget Dates: 09/01/07 - 08/31/08  
Direct: $46,797

**Biostatistics Training with Application to Neuroscience**

Sponsor: NIH/NINDS  
Budget Dates: 07/01/08 - 06/30/09  
Direct: $135,038

**Neurological Emergencies Treatment Trials Network Statistical and Data Management**

Sponsor: NIH/NINDS  
Budget Dates: 08/01/08 - 07/31/09  
Direct: $467,831

**Statistical and Data Coordinating Center for ALIAS and IMS III Trials**

Sponsor: NIH/NINDS  
Budget Dates: 06/01/09 - 05/31/10  
Direct: $955,523

**PRoFESS - Second Stroke analysis and Chronic Pain analysis**

Sponsor: Boehringer Ingelheim Pharmaceuticals  
Budget Dates: 06/01/09 - 05/31/10  
Direct: $21,293
## Palesch, Yuko

**Co-PI or Project Leader**

**Increasing Minority Participation in Clinical Research**
- **PI:** Arch Mainous
- **Dept:** Family Medicine
- **Sponsor:** Duke Endowment
- **Award:** 6098-SP (08091605-2)
- **Direct:** $324,767

**Co-Investigator**

**Parkinson’s Disease Clinical Trial: Statistical Center**
- **PI:** Barbara Tilley
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** NIH/NINDS
- **Award:** N01-HV-28181 (02030610-90)
- **Direct:** $66,513

**Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage**
- **PI:** Sharon Yeatts
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** Beth Israel Deaconess Med.
- **Award:** (08100898-1)
- **Direct:** $65,477

## Pickelsimer, E.

**Principal Investigator**

**Statewide Investigation of Traumatic Brain Injury in Prisons**
- **PI:** CDC
- **Sponsor:** Amer. College of Gastroenter
- **Award:** 5 U49 CE001318-02 (08040175)
- **Direct:** $414,619

## Schwacke, John

**Co-PI or Project Leader**

**Cardiovascular Proteomics Center - Core C**
- **PI:** Daniel Knapp
- **Dept:** Cell and Molecular Pharmacology
- **Sponsor:** NIH/NHLBI
- **Award:** N01-HV-28181 (02030610-90)
- **Direct:** $66,513

**Cardiovascular Proteomics Center - Project 7**
- **PI:** Daniel Knapp
- **Dept:** Cell and Molecular Pharmacology
- **Sponsor:** NIH/NHLBI
- **Award:** N01-HV-28181 (02030610-88)
- **Direct:** $85,095

## Selassie, Anbesaw

**Principal Investigator**

**Analysis of Socioeconomic Determinants of Epilepsy Outcomes in Population-Based Cohort in South Carolina**
- **PI:** CDC
- **Sponsor:** Dept. of Education
- **Award:** H133A080064 (08081919-1)
- **Direct:** $76,981

## Shaftman, Stephanie

**Other**

**Validation Study of the New UPDRS**
- **PI:** Barbara Tilley
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** Movement Disorder Society
- **Award:** (08102053-1)
- **Direct:** $30,000

## Sinha, Debajyoti

**Co-Investigator**

**Epistatic Effects of FcgammaR and Fc (GM) Genes in Breast Cancer**
- **PI:** Janardan Pandey
- **Dept:** Microbiology and Immunology
- **Sponsor:** DOD/US Army
- **Award:** W81XWH-08-1-0373 (07052112-2)
- **Direct:** $100,000

## Slate, Elizabeth

**Principal Investigator**

**Joint Modeling and Analysis of Longitudinal Markers and Recurrent Events**
- **Sponsor:** NSF
- **Award:** DMS-0604666 (05102815)
- **Direct:** $47,314
Slate, Elizabeth

**Principal Investigator**

**Biostatistics Training for Basic Biomedical Research**
- **Sponsor:** NIH/NIGMS
- **Award:** 5 T32 GM074934-04 (07120304)
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $140,508

**Logic Forest: A Statistical Method for Biomarker Discovery**
- **Sponsor:** NIH/NCI
- **Award:** 1 R03 CA137805-01 (08031822)
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct:** $50,000

**Modern Semiparametric Methods in Action: SRCOS Summer Research Conference**
- **Sponsor:** SC EPSCOR
- **Award:** Task Order #0043 (08060366)
- **Budget Dates:** 06/08/08 - 09/07/08
- **Direct:** $10,000

**Joint Modeling and Analysis of Longitudinal Markers and Recurrent Events**
- **Sponsor:** NSF
- **Award:** DMS-0604666 (08080583)
- **Budget Dates:** 07/01/06 - 06/30/10
- **Direct:** $47,315

**Co-PI or Project Leader**

**South Carolina COBRE for Oral Health Grant - Core B: Biostatistics**
- **PI:** Keith Kirkwood
- **Sponsor:** NIH/NCRR
- **Award:** 5 P20 RR017696-08 (09033151-3)
- **Budget Dates:** 06/08/08 - 09/07/08
- **Direct:** $269,776

**Exploring Support in African American Women Facing Breast Cancer Survivorship**
- **PI:** Nancy R. Gelman Fdn.
- **Sponsor:** NIH/NIDCR
- **Award:** 5 R21 DE017360-02 (08052830-1)
- **Budget Dates:** 01/01/09 - 12/31/09
- **Direct:** $148,350

Sterba, Katherine

**Principal Investigator**

**Exploring Support in African American Women Facing Breast Cancer Survivorship**
- **Sponsor:** Nancy R. Gelman Fdn.
- **Budget Dates:** 01/01/09 - 12/31/09
- **Direct:** $1,000

Tilley, Barbara

**Principal Investigator**

**Southeastern Predoctoral Training in Clinical Research (RMI)**
- **Sponsor:** NIH/NCCRR
- **Award:** 5 T32 RR023258-04 (08042806)
- **Budget Dates:** 09/20/05 - 08/31/10
- **Direct:** $614,198

**Parkinson's Disease Clinical Trial: Statistical Center**
- **Sponsor:** NIH/NINDS
- **Award:** 5 U01 NS043127-08 (08100806)
- **Budget Dates:** 09/30/01 - 11/30/11
- **Direct:** $404,457

**Validation Study of the New UPDRS**
- **Sponsor:** Movement Disorder Society
- **Award:** (08102053)
- **Budget Dates:** 05/01/05 - 03/31/09
- **Direct:** $30,000

Woolson, Robert

**Co-Investigator**

**CBT and Modafinil for Cocaine Addiction**
- **PI:** Robert Malcolm, Jr.
- **Sponsor:** NIH/NIDA
- **Award:** 2 R01 DA016368-05 (07062927-1)
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct:** $250,000

**Kallikrein and Vascular Disease Risk in Diabetes**
- **PI:** Ayad Jaffa
- **Sponsor:** NIH/NHLBI
- **Award:** 1 R01 HL087986-01A2 (07102568-1)
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct:** $254,608

**Establishing the Vitamin D Requirements During Lactation**
- **PI:** Bruce Hollis
- **Sponsor:** NIH/NICHD
- **Award:** 5 R01 HD047511-03 (08053050-1)
- **Budget Dates:** 05/01/05 - 03/31/09
- **Direct:** $409,086

**A Controlled Trial of NAC for Cocaine Dependence**
- **PI:** Robert Malcolm, Jr.
- **Sponsor:** NIH/NIDA
- **Award:** 5 R01 DA019903-04 (08093054-2)
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct:** $263,066

**Statistical and Data Coordinating Center for ALIAS and IMS III Trials**
- **PI:** Yuko Palesch
- **Sponsor:** NIH/NINDS
- **Award:** 5 U01 NS054630-05 (09032626-1)
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct:** $955,523

**New Methods for the Early Diagnosis of Invasive Fungal Infections**
- **PI:** Maurizio Del Poeta
- **Sponsor:** NIH/NIAID
- **Award:** 1 R21 AI078493-01 (07062920-1)
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct:** $125,000
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yeatts, Sharon</td>
<td>Safety and Tolerance of Deferoxamine in Acute Cerebral Hemorrhage</td>
<td>Beth Israel Deaconess Med. Ctr.</td>
<td>01/01/09 - 12/31/09</td>
<td>$65,477</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>01/15/08 - 10/31/10</td>
<td>$30,119</td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Treatment Implications of Beta-Blockade Effects on Memory for Cocaine Craving</td>
<td>Sponsored by NIH/NIDA</td>
<td>07/01/23-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Statistical and Data Coordinating Center for ALIAS and IMS III Trials</td>
<td>Sponsored by NIH/NINDS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhao, Wenjin</td>
<td>Multi-Scale Lung Cancer Modeling by an Object-Oriented Software Engineering Approach</td>
<td>PhRMA</td>
<td>01/01/09 - 12/31/09</td>
<td>$30,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>01/01/08 - 12/31/09</td>
<td>$0</td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>South Carolina COBRE for Oral Health Grant - Core B: Biostatistics</td>
<td>Sponsored by NIH/NCRRR</td>
<td>09033151-3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>South Carolina COBRE for Oral Health Grant - Core B: Biostatistics</td>
<td>Sponsored by NIH/NCRRR</td>
<td>09033151-3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>South Carolina COBRE for Oral Health Grant - Core B: Biostatistics</td>
<td>Sponsored by NIH/NCRRR</td>
<td>09033151-3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li, Shulan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu, Wei</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park, Hyohee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith, John</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhang, Wei</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhao, Wenjin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zheng, Wenjin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Cell Biology and Anatomy

#### Argraves, Kelley

**Principal Investigator**

**Sphingosine-1-Phosphosphate Signaling in Vasculogenesis**

- **Sponsor:** NIH/NHLBI
- **Award:** 5 R01 HL080404-05 (09041608)
- **Budget Dates:** 06/01/09 - 05/31/10
- **Direct:** $189,636
- **F & A:** $87,233

#### Argraves, W.

**Principal Investigator**

**Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway**

- **Sponsor:** Amer. Heart Assoc./Mid-Atlantic
- **Award:** 0755346U (06122977)
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $60,000
- **F & A:** $0

**NASA REU in Bioastronautics at MUSC - Summer**

- **Sponsor:** Coll. of Charleston
- **Award:** 520605-B/NNG05G168G (07102565)
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $111,665
- **F & A:** $4,600

**Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway**

- **Sponsor:** NIH/NHLBI
- **Award:** 72000157-01 (09041616)
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $250,000
- **F & A:** $118,750

**Mechanisms and Significance of Cubilin-Mediated HDL Uptake**

- **Sponsor:** NIH/NHLBI
- **Award:** 5 R01 HL061873-07 (08091282)
- **Budget Dates:** 05/01/08 - 04/30/10
- **Direct:** $242,750
- **F & A:** $111,665

**NASA Space Grant REU in Bioastronautics**

- **Sponsor:** Coll. of Charleston
- **Award:** 520605-B/NNG05G168G (08110772)
- **Budget Dates:** 05/01/08 - 04/30/10
- **Direct:** $47,556
- **F & A:** $0

**South Carolina Idea Networks of Biomedical Research Excellence**

- **Sponsor:** Univ. of South Carolina
- **Award:** 5 R01 HL080404-05 (09041608)
- **Budget Dates:** 07/15/05 - 05/31/10
- **Direct:** $87,233
- **F & A:** $0

#### Barth, Jeremy

**Principal Investigator**

**Vibratory Mechanotransduction**

- **Sponsor:** Clemson Univ.
- **Award:** 1 R21 EB099489-01/1320-75 (08061007)
- **Budget Dates:** 04/01/09 - 03/31/10
- **Direct:** $46,457
- **F & A:** $22,067

**Co-Investigator**

**NASA REU in Bioastronautics at MUSC - Summer**

- **Sponsor:** Coll. of Charleston
- **Award:** 520605-B/NNG05G168G (07102565)
- **Budget Dates:** 05/01/09 - 04/30/10
- **Direct:** $45,000

**NASA Space Grant REU in Bioastronautics**

- **Sponsor:** Coll. of Charleston
- **Award:** 520605-B/NNG05G168G (08110772)
- **Budget Dates:** 05/01/09 - 04/30/10
- **Direct:** $47,556

**South Carolina Idea Networks of Biomedical Research Excellence**

- **Sponsor:** Univ. of South Carolina
- **Award:** 5 R01 HL080404-05 (09041608)
- **Budget Dates:** 05/01/09 - 04/30/10
- **Direct:** $100,000
- **F & A:** $46,000

#### Boockfor, Fredric

**Principal Investigator**

**Prolactin Gene Expression Dynamics and Mammatrope Function**

- **Sponsor:** NIH/NIDDK
- **Award:** 5 R01 DK073270-03 (09021940)
- **Budget Dates:** 04/01/09 - 03/31/10
- **Direct:** $200,900
- **F & A:** $92,414
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borg, Thomas</td>
<td><strong>Dynamic Interaction of Cardiac Fibroblasts, Myocytes and the ECM</strong></td>
<td>NIH/NHLBI</td>
<td>04/15/09 - 03/31/10</td>
<td>$365,025</td>
<td>$150,905</td>
</tr>
<tr>
<td>Drake, Christopher</td>
<td><strong>HSC-Derived Fibroblasts in Normal and Diseased Valves</strong></td>
<td>NIH/NHLBI</td>
<td>06/01/09 - 05/31/10</td>
<td>$250,000</td>
<td>$115,000</td>
</tr>
<tr>
<td>Eisenberg, Carol</td>
<td><strong>Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds</strong></td>
<td>FirstString Research, LLC</td>
<td>09/15/07 - 09/29/08</td>
<td>$39,240</td>
<td>$18,050</td>
</tr>
<tr>
<td>Ghatak, Shibnath</td>
<td><strong>SC Cobre for Developmentally Based Cardiovascular Diseases: Project 2</strong></td>
<td>Univ. of South Carolina</td>
<td>09/01/08 - 08/31/09</td>
<td>$147,000</td>
<td>$0</td>
</tr>
<tr>
<td>Gourdie, Robert</td>
<td><strong>Function of CX43-Interacting Proteins in Neural Crest Migration</strong></td>
<td>NIH/NHLBI</td>
<td>01/01/09 - 12/31/09</td>
<td>$242,750</td>
<td>$111,665</td>
</tr>
<tr>
<td>Hammad, Samar</td>
<td><strong>Sphingolipid Signaling Induced by LDL Immune Complexes</strong></td>
<td>NIH/NHLBI</td>
<td>04/01/09 - 03/31/10</td>
<td>$194,200</td>
<td>$89,332</td>
</tr>
<tr>
<td>Hoover, Loretta</td>
<td><strong>Interactions between TGFbeta and Retinoid Signaling in Cardiac Development</strong></td>
<td>NIH/NHLBI</td>
<td>09/01/08 - 08/31/10</td>
<td>$33,432</td>
<td>$0</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct</td>
<td>F &amp; A</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>Kern, Christine</td>
<td>The Role of Matrix Metalloproteinase Cleavage of Versican in Cardiac Outflow Tract Remodeling</td>
<td>Amer. Heart Assoc.</td>
<td>07/01/08 - 02/28/10</td>
<td>$50,000</td>
<td>5,000</td>
</tr>
<tr>
<td>Kern, Michael</td>
<td>Alternative Splicing of the Prx1 Homeobox Gene in VSMC</td>
<td>Amer. Heart Assoc.</td>
<td>07/01/08 - 06/30/09</td>
<td>$60,000</td>
<td>6,000</td>
</tr>
<tr>
<td>Krug, Edward</td>
<td>Expansion of the EPSCoR/INBRE Postdoctoral Teacher Training Program</td>
<td>SC Research Authority</td>
<td>05/01/07 - 04/30/08</td>
<td>$2,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>2007 Bring RCR Home Seed Grant Award Contract</td>
<td>National Postdoctoral Assoc.</td>
<td>09/01/07 - 08/31/08</td>
<td>$1,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>South Carolina IDeA Networks of Biomedical Research Excellence (SC INBRE)</td>
<td>USC Research Foundation</td>
<td>05/01/08 - 04/30/09</td>
<td>$10,716</td>
<td>4,929</td>
</tr>
<tr>
<td></td>
<td>South Carolina IDeA Networks of Biomedical Research Excellence (SC INBRE)</td>
<td>USC Research Foundation</td>
<td>05/01/09 - 04/30/10</td>
<td>$10,716</td>
<td>4,929</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Proteomics Center - Project 2</td>
<td>N01-HV-28181</td>
<td>02030610-84</td>
<td>$70,903</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>MUSC-Cl臨 Cooperative for Postdoctoral Academic Career Development</td>
<td>NIH/NIGMS</td>
<td>08061852-1</td>
<td>$336,537</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>CSPG2 Gene and Cardiac Outlet Morphogenesis</td>
<td>NIH/NHLBI</td>
<td>09020215-1</td>
<td>$250,000</td>
<td>0</td>
</tr>
<tr>
<td>Kubalak, Steven</td>
<td>Signaling Mechanisms Regulating Cardiac Remodeling</td>
<td>NIH/NHLBI</td>
<td>09040271</td>
<td>$218,475</td>
<td>100,499</td>
</tr>
<tr>
<td>Lacy, Eric</td>
<td>Taxonomic Center Subcontract for Rachael King 08</td>
<td>SC Dept. of Natural Resources</td>
<td>08062486</td>
<td>$59,534</td>
<td>15,918</td>
</tr>
<tr>
<td></td>
<td>SROH Speaker Support</td>
<td>SC Sea Grant Consortium</td>
<td>08062606</td>
<td>$1,400</td>
<td>0</td>
</tr>
</tbody>
</table>
Lacy, Eric  
**Principal Investigator**

**NOAA Biotechnology Contract Amendment 4**  
Sponsor: NOAA  
Budget Dates: 10/01/08 - 09/30/09  
Direct: $158,701

**MOA-Students-Yr 2**  
Sponsor: SC Sea Grant Consortium  
Budget Dates: 11/01/08 - 10/31/09  
Direct: $111,600

**SROH 2009 Speaker Support**  
Sponsor: SC Sea Grant Consortium  
Budget Dates: 06/01/09 - 08/31/09  
Direct: $900

Markwald, Roger  
**Principal Investigator**

**Stem Cell/Regenerative Medicine Core Facility**  
Sponsor: Univ. of South Carolina  
Budget Dates: 05/01/09 - 04/30/10  
Direct: $190,299

**SC Cobre for Developmentally Based Cardiovascular Diseases**  
Sponsor: NIH/NCRR  
Budget Dates: 07/01/09 - 06/30/10  
Direct: $1,451,520

**The Role of Fluid Flow in Valvulogenesis**  
Sponsor: Univ. of South Carolina  
Budget Dates: 08/1463/5 R01 HL068565-02 (08090784)  
Direct: $25,000

**Mitral Valve Disease: From Genetic Mechanisms to Improved Repair**  
Sponsor: Leducq Foundation  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $95,148

**CSPG2 Gene and Cardiac Outlet Morphogenesis**  
Sponsor: NIH/NHLBI  
Budget Dates: 02/01/09 - 01/31/10  
Direct: $250,000

Mironov, Vladimir  
**Co-Investigator**

**Mitral Valve Disease: From Genetic Mechanisms to Improved Repair**  
Sponsor: Leducq Foundation  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $95,148

Misra, Suniti  
**Co-PI or Project Leader**

**SC Cobre for Developmentally Based Cardiovascular Diseases: Project 2**  
Sponsor: NIH/NCRR  
Budget Dates: 09/30/05 - 04/30/10  
Direct: $147,000

Mjaatvedt, Corey  
**Principal Investigator**

**The Role of Cspg2/Versican in Cardiac Outlet Development**  
Sponsor: Amer. Heart Assoc.  
Budget Dates: 07/01/08 - 06/30/09  
Direct: $60,000

**CSPG2 Gene and Cardiac Outlet Morphogenesis**  
Sponsor: NIH/NHLBI  
Budget Dates: 12/01/00 - 01/31/13  
Direct: $115,000
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Start</th>
<th>End</th>
<th>Direct Amount</th>
<th>F &amp; A Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mjaatvedt, Corey</td>
<td>Co-Investigator</td>
<td>The Role of Cartilage Link Protein 1 (Crtl 1) in Heart Development</td>
<td>NIH/NHLBI</td>
<td>01/01/09</td>
<td>12/31/11</td>
<td>$250,000</td>
<td></td>
</tr>
<tr>
<td>Morad, Martin</td>
<td>Principal Investigator</td>
<td>BCBS Endowed Chair for Cardiovascular Health</td>
<td>Health Sciences SC</td>
<td>05/01/08</td>
<td>04/30/10</td>
<td>$1,111,110</td>
<td></td>
</tr>
<tr>
<td>Morris, Pamela</td>
<td>Principal Investigator</td>
<td>Kimes NSF Grad Research Fellowship</td>
<td>NSF</td>
<td>08/20/08</td>
<td>08/19/09</td>
<td>$40,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>NOAA Biotechnology Contract Amendment 4</td>
<td>NOAA</td>
<td>01/01/06</td>
<td>12/31/11</td>
<td>$108,861</td>
<td></td>
</tr>
<tr>
<td>Muise-Helmericks, R.</td>
<td>Principal Investigator</td>
<td>The Effect of Taliderm on Infected Wounds in a Mouse Model</td>
<td>Marine Polymer Technologies</td>
<td>08/01/05</td>
<td>07/31/10</td>
<td>$49,600</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Novel VEGF Signaling Pathway Leading to Mitochondrial Biogenesis</td>
<td>NIH/NHLBI</td>
<td>01/01/09</td>
<td>12/31/09</td>
<td>$200,000</td>
<td></td>
</tr>
<tr>
<td>Norris, Russell</td>
<td>Principal Investigator</td>
<td>Cardiac Valve Differentiation, Maturation, and Function is Dependent on the Periostin Gene</td>
<td>Amer. Heart Assoc.</td>
<td>07/01/07</td>
<td>06/30/09</td>
<td>$60,000</td>
<td></td>
</tr>
<tr>
<td>Palatinus, Joseph</td>
<td>Principal Investigator</td>
<td>Connexin 43 Gap Junction Dynamics in the Diabetic Heart</td>
<td>NIH/NHLBI</td>
<td>02/01/09</td>
<td>01/31/10</td>
<td>$36,091</td>
<td></td>
</tr>
<tr>
<td>Ramamurthi, Anand</td>
<td>Co-Investigator</td>
<td>Cues for Cell-Mediated Regeneration of Vascular Elastin to Stabilize Aortic Aneurysms</td>
<td>Clemson Univ.</td>
<td>06/01/09</td>
<td>05/31/10</td>
<td>$99,807</td>
<td></td>
</tr>
<tr>
<td>Reaves, Titus</td>
<td>Principal Investigator</td>
<td>Ernest Everett Just Scientific Symposium</td>
<td>SC EPSCOR</td>
<td>02/01/09</td>
<td>07/31/09</td>
<td>$10,000</td>
<td></td>
</tr>
<tr>
<td>Rhett, Joshua</td>
<td>Principal Investigator</td>
<td>Renewal of Mode of Action of the Anti-Dysrhythmic Peptide ACT-1</td>
<td>SC Space Grant Consortium</td>
<td>06/01/09</td>
<td>05/31/10</td>
<td>$10,000</td>
<td></td>
</tr>
<tr>
<td>Slomiany, Mark</td>
<td>Co-Investigator</td>
<td>Perturbation of Hyaluronan Function in Cancer</td>
<td>NIH/NCI</td>
<td>07/01/08</td>
<td>06/30/09</td>
<td>$172,000</td>
<td></td>
</tr>
<tr>
<td>Sugi, Yukiko</td>
<td>Principal Investigator</td>
<td>Cell Autonomous Signaling by BMP Regulates Post-EMT Valvulogenesis</td>
<td>Amer. Heart Assoc./Mid-Atlantic</td>
<td>07/01/08</td>
<td>06/30/09</td>
<td>$60,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Core D - Molecular Tool Kit</td>
<td>NIH/NCRR</td>
<td>07/01/07</td>
<td>06/30/09</td>
<td>$180,160</td>
<td></td>
</tr>
</tbody>
</table>
Swaja, Richard

**Principal Investigator**

**Tissue Engineering for Spinal Cord Regeneration**
- **Sponsor:** Clemson Univ.
- **Budget Dates:** 11/01/06 - 06/30/09
- **Direct:** $143

**Brain Tissue Regeneration Following Traumatic Brain Injury**
- **Sponsor:** Clemson Univ.
- **Budget Dates:** 06/01/08 - 06/30/09
- **Direct:** $17,200

**Accelerating the Maturation of Regenerating Bone Tissue Using Lysyl Oxidase**
- **Sponsor:** Clemson Univ.
- **Budget Dates:** 05/01/08 - 04/30/09
- **Direct:** $10,000

**Developing Living Tissue-Engineered Cochlear Implants for Hearing Restoration in Deaf and Hard-of-Hearing Infants**
- **Sponsor:** Clemson Univ.
- **Budget Dates:** 06/01/08 - 06/30/09
- **Direct:** $17,200

**Cues for Cell-Mediated Regeneration of Vascular Elastin to Stabilize Aortic Aneurysms**
- **Sponsor:** Clemson Univ.
- **Budget Dates:** 05/01/08 - 04/30/09
- **Direct:** $10,000

**Conditioning of Embryonic Myocardial Tubes in Vitro**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 04/01/09 - 03/31/10
- **Direct:** $150,000

**Role of Ets Genes in Transformation and Differentiation - Core C**
- **Sponsor:** NIH/NCI
- **Budget Dates:** 06/01/09 - 05/31/10
- **Direct:** $1,353,000

**SC Cobre for Developmentally Based Cardiovascular Diseases: Core B - Imaging**
- **Sponsor:** NIH/NCRR
- **Budget Dates:** 09/01/07 - 08/31/09
- **Direct:** $250,000

**Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $60,000

Thompson, Robert

**Principal Investigator**

**Conditioning of Embryonic Myocardial Tubes In Vitro**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 04/01/09 - 03/31/10
- **Direct:** $150,000

**SC Cobre for Developmentally Based Cardiovascular Diseases: Core B - Imaging**
- **Sponsor:** NIH/NCRR
- **Budget Dates:** 09/01/07 - 08/31/09
- **Direct:** $250,000

Toole, Bryan

**Principal Investigator**

**Perturbation of Hyaluronan Function in Cancer**
- **Sponsor:** NIH/NCI
- **Budget Dates:** 06/01/09 - 05/31/10
- **Direct:** $172,000

Trusk, Thompson

**Co-PI or Project Leader**

**SC Cobre for Developmentally Based Cardiovascular Diseases: Core B - Imaging**
- **Sponsor:** NIH/NCRR
- **Budget Dates:** 09/01/09 - 06/30/10
- **Direct:** $157,026

Twal, Walied

**Co-Investigator**

**Fibulin-1 Regulation of the DiGeorge Syndrome Pathogenesis Pathway**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $60,000

Visconti, Richard

**Principal Investigator**

**Effects of Angiotensin II Antagonism on Adult HSC-Derived Cells in Post-Infarction Ventricular Remodeling**
- **Sponsor:** Amer. Heart Assoc./Mid-Atlantic
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $60,000
### Visconti, Richard

**Co-PI or Project Leader**

**SC Cobre for Developmentally Based Cardiovascular Diseases: Project 3**

- **PI:** Roger Markwald
- **Sponsor:** NIH/NCRR
- **Dept:** Cell Biology and Anatomy
- **Award:** 5 P20 RR016434-08 (08081298-4)

**Co-Investigator**

**HSC-Derived Fibroblasts in Normal and Diseased Valves**

- **PI:** Christopher Drake
- **Sponsor:** NIH/NHLBI
- **Dept:** Cell Biology and Anatomy
- **Award:** 5 R01 HL080168-03 (09041614-1)

### Wessels, Arno

**Principal Investigator**

**The Role of Cartilage Link Protein 1 (Crtl 1) in Heart Development**

- **Sponsor:** NIH/NHLBI
- **Dept:** Cell Biology and Anatomy
- **Award:** 5 R01 HL084285-03 (08121093)

**SC Cobre for Developmentally Based Cardiovascular Diseases: Core B - Imaging**

- **PI:** Roger Markwald
- **Sponsor:** NIH/NCRR
- **Dept:** Cell Biology and Anatomy
- **Award:** 5 P20 RR016434-08 (08081298-10)

### Wirrig, Elaine

**Principal Investigator**

**The Role of Cartilage Link Protein 1 (Crtl1) During Heart Development**

- **Sponsor:** Amer. Heart Assoc./Mid-Atlantic
- **Dept:** Cell Biology and Anatomy
- **Award:** 0715280U (07010821)

### Cell and Molecular Pharmacology

**Ball, Lauren**

**Co-PI or Project Leader**

**South Carolina COBRE for Oral Health Grant - Project 3**

- **PI:** Keith Kirkwood
- **Sponsor:** NIH/NCRR
- **Dept:** Craniofacial Biology
- **Award:** 5 P20 RR017696-08 (09033151-6)

**Co-Investigator**

**Tyrosine Kinases in G Protein Mediated Signaling**

- **PI:** Louis Luttrell
- **Sponsor:** NIH/NIDDK
- **Dept:** Medicine
- **Award:** 2 R01 DK066231-07 (09020215-1)

**Factors That Modify Insulin Action**

- **PI:** Maria Buse
- **Sponsor:** NIH/NIDDK
- **Dept:** Medicine
- **Award:** 2 R01 DA025896-07 (08122236-2)

**Tyrosine Kinases in G Protein Mediated Signaling**

- **PI:** Louis Luttrell
- **Sponsor:** NIH/NIDDK
- **Dept:** Medicine
- **Award:** 2 R01 GM074247-04 (09011294-2)

**Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases**

- **Sponsor:** NIH/NCI
- **Dept:** Cell and Molecular Pharmacology
- **Award:** 1 R01 CA131200-01A1 (08110557)

### Blumer, Joe

**Co-Investigator**

**Accessory Proteins and G-Protein Signaling Mechanisms**

- **PI:** Stephen Lanier
- **Sponsor:** NIH/NIDA
- **Dept:** Cell and Molecular Pharmacology
- **Award:** 5 R01 DA025896-20 (08122236-2)

**AGS1 and Signal Processing by G-Proteins**

- **PI:** Stephen Lanier
- **Sponsor:** NIH/NIAMS
- **Dept:** Cell and Molecular Pharmacology
- **Award:** 5 R01 GM074247-04 (09011294-2)

### Bohonowycz, Jessica

**Other**

**PACD Scholar: Dr. Jessica Bohonowycz**

- **PI:** Jennifer Isaacs
- **Sponsor:** Univ. of South Carolina
- **Dept:** Cell and Molecular Pharmacology
- **Award:** 22050-FA12 (09062344-1)

### Davis, Jr., Warren

**Co-PI or Project Leader**

**COBRE in Lipidomics - Project 2**

- **PI:** Lina Obied
- **Sponsor:** NIH/NCRR
- **Dept:** Biochemistry and Molecular Biology
- **Award:** 5 P20 RR017677-07 (08070866-4)

### Eblen, Scott

**Principal Investigator**

**Regulation of Senescence by p38 MAP Kinase in ErbB-2-Induced Breast Cancer**

- **Sponsor:** DOD/US Army
- **Dept:** Cell and Molecular Pharmacology
- **Award:** W81XWH-07-1-0691 (07021321)

**Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases**

- **Sponsor:** NIH/NCI
- **Dept:** Cell and Molecular Pharmacology
- **Award:** 1 R01 CA131200-01A1 (08110557)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Direct Amount</th>
<th>F &amp; A Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halushka, Perry</td>
<td>Co-Investigator</td>
<td>The Role of Eicosanoids in Shock</td>
<td>NIH/NIHMS</td>
<td>239,933</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer</td>
<td>NIH/NCI</td>
<td>207,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Southeastern Predoctoral Training in Clinical Research (RMI):</td>
<td>NIH/NCRR</td>
<td>72,090</td>
<td></td>
</tr>
<tr>
<td>Hildebrandt, John</td>
<td>Principal Investigator</td>
<td>Generation and Function of Variable Prenyl Protein Processing</td>
<td>NIH/NIHMS</td>
<td>200,000</td>
<td></td>
</tr>
<tr>
<td>Isaacs, Jennifer</td>
<td>Principal Investigator</td>
<td>Hsp90 Regulates EphA2 Signaling and Cell Migration in Glioblastoma</td>
<td>NIH/NCI</td>
<td>207,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PACD Scholar: Dr. Jessica Bohonowycz</td>
<td>Univ. of South Carolina</td>
<td>57,586</td>
<td></td>
</tr>
<tr>
<td>Knapp, Daniel</td>
<td>Principal Investigator</td>
<td>Cardiovascular Proteomics Center</td>
<td>NIH/NIH/NIHLBI</td>
<td>1,893,606</td>
<td>654,571</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteomics Research Center: Endowed Professorships</td>
<td>SC Research Centers of</td>
<td>451,545</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Economic Excellence</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cellular Factors Promoting Renal Cell Carcinoma</td>
<td>NIH/NCI</td>
<td>190,000</td>
<td></td>
</tr>
<tr>
<td>Lanier, Stephen</td>
<td>Principal Investigator</td>
<td>Accessory Proteins and G-Protein Signaling Mechanisms</td>
<td>NIH/NIDA</td>
<td>225,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AGS1 and Signal Processing by G-Proteins</td>
<td>NIH/NIHMS</td>
<td>228,850</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NIH/NIHMS</td>
<td>69,065</td>
<td></td>
</tr>
<tr>
<td>Mack, Jody</td>
<td>Principal Investigator</td>
<td>Defining the Cellular and Physiological Role of ABCA2</td>
<td>NIH/NCI</td>
<td>26,024</td>
<td></td>
</tr>
<tr>
<td>Neumann, Carola</td>
<td>Co-PI or Project Leader</td>
<td>Regulation of Senescence by p38 MAP Kinase in ErbB-2-Induced Breast</td>
<td>DOD/US Army</td>
<td>250,000</td>
<td></td>
</tr>
<tr>
<td>Oatis, Jr., John</td>
<td>Co-Investigator</td>
<td>Synthetic Retinal Pigments and Binding Proteins</td>
<td>NIH/NEI</td>
<td>242,750</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Supplement to R01 EY004939</td>
<td>NIH/NEI</td>
<td>156,526</td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct</td>
<td>F &amp; A</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>Rosenzweig, Steven</td>
<td>IGF1R Crosstalk to VEGF Action in AMD and Cancer</td>
<td>Amer. Health Assistance Fdn.</td>
<td>04/01/09 - 03/31/10</td>
<td>$50,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>M209086 (08110343)</td>
<td>Project Dates: 04/01/09 - 03/31/10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>MUSC Cancer Center Support Grant: Senior Leadership</td>
<td>Sponsor: NIH/NCI</td>
<td>Award: 1 P30 CA138313-01 (08042282-2)</td>
<td>Direct $229,094</td>
<td></td>
</tr>
<tr>
<td></td>
<td>South Carolina COBRE for Oral Health Grant - Core A: Administrative</td>
<td>Sponsor: NIH/NCRR</td>
<td>Award: 5 P20 RR017696-08 (09033151-2)</td>
<td>Direct $408,237</td>
<td></td>
</tr>
</tbody>
</table>

| Schey, Kevin          | Co-Investigator | Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas | Sponsor: NIH/NCI | Award: 1 R01 CA129560-01A2 (08030450-2) | Direct $209,586 |

| Tew, Kenneth          | Principal Investigator | Training in Cancer Therapeutics | Sponsor: NIH/NCI | Award: 5 T32 CA119945-03 (08043013) | Direct $299,046 |
|                       |                           | Project Dates: 07/01/06 - 06/30/11 | Direct $23,735 |
|                       | Pharmacology of NOV-002 | Sponsor: Novelos Therapeutics, Inc. | Award: Novelos Year 4 (08072963) | Direct $52,663 |
|                       | Glutathione S-Transferases in Drug and Stress Response | Sponsor: NIH/NCI | Award: 5 R01 CA085660-11 (09011304) | Direct $213,341 |

| Wargovich, Michael    | Principal Investigator | Cancer Prevention by West African Medicinal Plants | Sponsor: NIH/NCI | Award: 7 R21 CA107138-03 (08031720) | Direct $3,429 |
|                       |                           | Project Dates: 06/01/08 - 01/31/09 | Direct $1,629 |
|                       | Nitric Oxide as a Target for Dietary Intervention in Colitis | Sponsor: NIH/NIDDK | Award: 7 R21 DK071541-03 (08072337) | Direct $150,482 |

| Webb, Jerry           | Principal Investigator | Kinin/PGE Interaction in Control of Intraocular Pressure | Sponsor: NIH/NEI | Award: 5 R01 EY014653-05 (09040705) | Direct $194,206 |
|                       |                           | Project Dates: 04/01/06 - 03/31/10 | Direct $89,335 |

| Wen, Xuejun           | Co-Investigator | Accelerating the Maturation of Regenerating Bone Tissue Using Lysyl Oxidase | Sponsor: Clemson Univ. | Award: 1275-7559-248-2006525 (07081399-1) | Direct $10,000 |
|                       |                           | Dept: Cell Biology and Anatomy | Award: 1270-7559-247-2006591 (07091180-1) | Direct $34,552 |
|                       | Developing Living Tissue-Engineered Cochlear Implants for Hearing Restoration in Deaf and Hard-of-Hearing Infants | Sponsor: Clemson Univ. | Award: 1305-7559-201-2006543 (07081301-1) | Direct $17,200 |

| Zemskova, Marina      | Co-Investigator | The Mechanism of Action of Unique Small Molecules That Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth | Sponsor: DOD | Award: W81XWH-09-1-0300 (08060478-1) | Direct $125,000 |

|                      |               |               |               |               |       |
### Comparative Medicine

**Smith, Alison**  
Principal Investigator  

**Feasibility of Hypothermic Liver Perfusion**  
- **Sponsor:** Cell and Tissue Systems, Inc.  
- **Budget Dates:** 01/01/09 - 07/31/09  
- **Direct:** $17,027

**New Solutions to Improve Islet Recovery after Machine Preservation of the Pancreas**  
- **Sponsor:** Cell and Tissue Systems, Inc.  
- **Budget Dates:** 01/01/09 - 08/31/10  
- **Direct:** $29,779

**Co-Investigator**  

**Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Core B**  
- **PI:** Ann-Charlotte Granholm  
- **Sponsor:** NIH/NIA  
- **Budget Dates:** 01/01/09 - 07/31/09  
- **Direct:** $164,824

---

### Swindle, M.**

**Principal Investigator**  

**Research Project**  
- **Sponsor:** Private Funding  
- **Budget Dates:** 05/01/08 - 12/31/09  
- **Direct:** $318,109

**Fixed Equipment for DDB Animal Facility**  
- **Sponsor:** NIH/NCRR  
- **Budget Dates:** 06/19/09 - 06/18/10  
- **Direct:** $500,000

**Exilis Satiety Device**  
- **Sponsor:** Hammerhead Design, Inc.  
- **Budget Dates:** 08/01/08 - 11/15/08  
- **Direct:** $10,169

---

### Dermatology

**Thiers, Bruce**  
Principal Investigator  

**Skin Cancer Detection Using Polarized Light Spectroscopic Methods**  
- **Sponsor:** Clemson Univ.  
- **Budget Dates:** 03/15/09 - 02/28/10  
- **Direct:** $5,000

---

### Family Medicine

**Blue, Amy**  
Co-Investigator  

**Pre-Doctoral Training in Primary Care: Motivate for Health**  
- **PI:** Alexander Chessman  
- **Sponsor:** HRSA  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $157,407

**Mentor**  

**NRSA for Primary Medical Care: Developing Primary Care Researchers Using Research Networks**  
- **PI:** William Basco  
- **Sponsor:** HRSA  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $127,371

---

### Carek, Peter**

**Principal Investigator**  

**Residency Training in Primary Care**  
- **Sponsor:** HRSA  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $159,034

**Funding of HSSC MUSC Extramural Program Officer**  
- **Sponsor:** Health Sciences SC  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $44,625

---

### Chessman, Alexander**

**Principal Investigator**  

**Pre-Doctoral Training in Primary Care: Motivate for Health**  
- **Sponsor:** HRSA  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $157,407

---

### Detar, D.**

**Co-Investigator**  

**Pre-Doctoral Training in Primary Care: Motivate for Health**  
- **PI:** Alexander Chessman  
- **Sponsor:** HRSA  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $157,407
### Diaz, Vanessa

**Co-Investigator**

**Residency Training in Primary Care**
- **PI:** Peter Carek
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 5 D58HP03371-05-00 (08062484-1)
- **Direct $** 159,034

**Nurse Education Practice and Retention**
- **PI:** Deborah Williamson
- **Dept:** Nursing
- **Sponsor:** HRSA
- **Award:** 5 D11HP05206-04-00 (08070756-1)
- **Direct $** 261,049

**Increasing Minority Participation in Clinical Research**
- **PI:** Arch Mainous
- **Dept:** Family Medicine
- **Sponsor:** Duke Endowment
- **Award:** 6098-SP (08091605-2)
- **Direct $** 324,767

**Parkinson's Disease Clinical Trial: Statistical Center**
- **PI:** Barbara Tilley
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** NIH/NINDS
- **Award:** 5 U01 NS043127-08-08 (08100806-2)
- **Direct $** 404,457

### Dickerson, Lori

**Co-Investigator**

**Residency Training in Primary Care**
- **PI:** Peter Carek
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 5 D58HP03371-05-00 (08062484-1)
- **Direct $** 159,034

### Gonsalves, Wanda

**Principal Investigator**

**CARES Clinic**
- **Sponsor:** AAMC
- **Budget Dates:** 06/01/09 - 05/31/10
- **Direct $** 4,000
- **F & A:** 0

**Smiles for Life: An Interprofessional Service-Learning Elective**
- **Sponsor:** Assoc. for Prevention Teaching and Research
- **Budget Dates:** 10/27/08 - 09/29/09
- **Direct $** 2,900
- **F & A:** 0

**Co-Investigator**

**Pre-Doctoral Training in Primary Care: Motivate for Health**
- **PI:** Alexander Chessman
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 1 D56HP10309-01-00 (07120623-1)
- **Direct $** 157,407

### Jenkins, Ruth

**Principal Investigator**

**Effect on Boxed Warnings and Public Information on Pharmaceutical Use**
- **Sponsor:** Univ. of Georgia
- **Budget Dates:** 09/01/08 - 08/31/09
- **Direct $** 88,285
- **F & A:** 41,935

**Co-Investigator**

**Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care**
- **PI:** Peter Miller
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 1 R01 AA016768-01A2 (07102672-1)
- **Direct $** 337,197

**Medication Safety in Primary Care Practice - Translating Research into Practice (MS-TRIP)**
- **PI:** Steven Ornstein
- **Dept:** Family Medicine
- **Sponsor:** AHRQ
- **Award:** 5 R18 HS017037-02 (08061965-1)
- **Direct $** 278,258

### Kern, Donna

**Co-Investigator**

**Pre-Doctoral Training in Primary Care: Motivate for Health**
- **PI:** Alexander Chessman
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 1 D56HP10309-01-00 (07120623-1)
- **Direct $** 157,407

### King, Dana

**Principal Investigator**

**Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients with Diabetes**
- **Sponsor:** Takeda Pharmaceuticals
- **Budget Dates:** 07/21/08 - 07/20/10
- **Direct $** 160,306
- **F & A:** 39,326

**Co-Investigator**

**Using an EMR-Based Intervention to Improve Screening and Diagnosis of Bipolar Disorder in Primary Care**
- **PI:** Arch Mainous
- **Dept:** Family Medicine
- **Sponsor:** Delaware Valley Outcomes Research
- **Award:** Bipolar (08082533-1)
- **Direct $** 116,957

### Lambourne, Carol

**Co-Investigator**

**Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care**
- **PI:** Peter Miller
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 1 R01 AA016768-01A2 (07102672-1)
- **Direct $** 337,197

**A Program to Increase Living Donations in African Americans**
- **PI:** Prabhakar Baliga
- **Dept:** Surgery
- **Sponsor:** NIH/NIDDK
- **Award:** 5 R01 DK062596-07 (08062489-1)
- **Direct $** 139,650
Liszka, Heather

Co-Investigator
Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care
Pl: Peter Miller Sponsor: NIH/NIAAA Direct $ 337,197
Dept: Psychiatry and Behavioral Sciences Award: 1 R01 AA016768-01A2 (07102672-1)

Medication Safety in Primary Care Practice - Translating Research into Practice (MS-TRIP)
Pl: Steven Ornstein Sponsor: AHRQ Direct $ 278,258
Dept: Family Medicine Award: 5 R18 HS017037-02 (08061965-1)

Mainous, Arch

Principal Investigator
Using an EMR-Based Intervention to Improve Screening and Diagnosis of Bipolar Disorder in Primary Care
Sponsor: Delaware Valley Outcomes Research Award: Bipolar (08082533)
Budget Dates: 07/01/08 - 07/31/10 Direct $ 116,957
Dept: Family Medicine

Increasing Minority Participation in Clinical Research
Sponsor: Duke Endowment Award: 6098-SP (08091605)
Budget Dates: 07/01/08 - 06/30/10 Direct $ 324,767
Dept: Family Medicine

Using an Electronic Medical Record-Based Intervention to Improve Quality of Care for Migraine Headache in Primary Care
Sponsor: Delaware Valley Outcomes Research Award: DVOR Migraine (09051889)
Budget Dates: 03/01/09 - 02/28/11 Direct $ 249,240
Dept: Family Medicine

Mallin, Robert

Co-Investigator
Pre-Doctoral Training in Primary Care: Motivate for Health
Pl: Alexander Chessman Sponsor: HRSA Direct $ 157,407
Dept: Family Medicine Award: 1 D56HP10309-01-00 (07120623-1)

Ornstein, Steven

Principal Investigator
Medication Safety in Primary Care Practice - Translating Research into Practice (MS-TRIP)
Sponsor: AHRQ Award: 5 R18 HS017037-02 (08061965)
Budget Dates: 09/30/08 - 09/29/10 Direct $ 278,258
Dept: Biostatistics, Bioinformatics and Epidemiology

Colorectal Cancer Screening in Primary Care Practice
Sponsor: NIH/NCI Award: 5 R01 CA112389-04 (09022679)
Budget Dates: 06/01/06 - 04/30/10 Direct $ 288,701
Dept: Family Medicine

Player, Marty

Co-Investigator
Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients with Diabetes
Pl: Dana King Sponsor: Takeda Pharmaceuticals Direct $ 160,306
Dept: Family Medicine Award: (08062697-1)

Using an EMR-Based Intervention to Improve Quality of Care for Migraine Headache in Primary Care
Pl: Arch Mainous Sponsor: Delaware Valley Outcomes R Direct $ 249,240
Dept: Family Medicine Award: (09051889-1)

Rodden, Ann

Co-Investigator
Comparison of South Carolina Family Practice Physicians and Community Pharmacists’ Knowledge and Attitudes Regarding Emergency Contraception
Pl: Sarah Shrader Sponsor: Advocates for Youth Direct $ 5,000
Dept: Pharmacy and Clinical Sciences Award: (08111812-1)
### Family Medicine

**Steyer, Terrence**  
**Co-Investigator**  
**Residency Training in Primary Care**  
*Pl:* Peter Carek  
*Sponsor:* HRSA  
*Dept:* Family Medicine  
*Award:* S58HP03371-00-00 (08062484-1)  
*Direct $*: 159,034

**Wessell, Andrea**  
**Co-Investigator**  
**Colorectal Cancer Screening in Primary Care Practice**  
*Pl:* Steven Ornstein  
*Sponsor:* NIH/NCI  
*Award:* 5 R01 CA112389-04 (09022679-1)  
*Direct $*: 288,701

### Medicine

**Afrin, Lawrence**  
**Principal Investigator**  
**Oncology Journal Club**  
*Sponsor:* Millennium Pharmaceuticals  
*Award:* Oncology Journal Club (09052873)  
*Direct$: 500

**Arthur, John**  
**Principal Investigator**  
**Hopkins Lupus Cohort**  
*Sponsor:* Johns Hopkins Univ.  
*Award:* 200440341/R01AR043727 (07062067)  
*Direct$: 29,663

**Prognostic Biomarkers in Diabetes**  
*Sponsor:* VAMC  
*Award:* (08042162)  
*Direct$: 7,713

**Prognostic Markers in Postoperative Acute Kidney Injury**  
*Sponsor:* NIH/NIDDK  
*Award:* 5 R01 DK080234-02 (09050819)  
*Direct$: 90,893

**Assey, Valerie**  
**Co-Investigator**  
**Ryan White CARE Act Title II Funds**  
*Pl:* J. Kilby  
*Sponsor:* SC DHEC  
*Award:* 627457 (08031072-2)  
*Direct$: 33,000

**Ryan White Title II Funding**  
*Pl:* J. Kilby  
*Sponsor:* SC DHEC  
*Award:* 627457 (09022356-1)  
*Direct$: 1,588,745

**Awgulewitsch, A.**  
**Principal Investigator**  
**Roles of Hox Genes in Skin and Hair Follicle Development**  
*Sponsor:* NIH/NIAMS  
*Award:* 5 R01 AR047204-06 (08062726)  
*Direct$: 218,285

**Baicu, Catalin**  
**Co-Investigator**  
**mTOR in Growth and Protection of Hypertrophying Myocardium**  
*Pl:* Dhandapani Kuppuswamy  
*Sponsor:* NIH/NHLBI  
*Award:* 1 R01 HL092124-01A1 (08022938-1)  
*Direct$: 250,000
### Baicu, Catalin
**Advanced Glycation End-Products in Human Myocardium**
- **PI:** Michael Zile
- **Sponsor:** Univ. of Vermont
- **Award:** 2 R01 HL089944-01A1 (08032442-1)
- **Role of Protein Acetylation in Ncx1 Expression**
- **PI:** Donald Menick
- **Sponsor:** NIH/NHLBI
- **Direct $:** 250,000

### Balasubramanian, S.
**mTOR in Growth and Protection of Hypertrophying Myocardium**
- **PI:** Dhandapani Kuppuswamy
- **Sponsor:** NIH/NHLBI
- **Direct $:** 250,000

### Baldys, Aleksander
**Role of c-Cbl in Trafficking and Signaling of EGF Receptors Induced by Various Growth Factors**
- **PI:** Gary Gilkeson
- **Sponsor:** NIH/NIAMS
- **Direct $:** 247,699

### Bell, Phillip
**Cellular Mechanisms for Cilia Dependent Cystic Disease**
- **PI:** Gary Gilkeson
- **Sponsor:** VAMC
- **Direct $:** 243,207

### Bogatkevich, Galina
**Inhibition of Thrombin and Thrombin-Induced Signaling Molecules in Pulmonary Fibrosis by Dabigatran**
- **PI:** Richard Silver
- **Sponsor:** Actelion Pharmaceuticals
- **Direct $:** 35,854
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradshaw, Amy</td>
<td>PI</td>
<td>Post Synthetic Collagen Processing in Age-Dependent LV Remodeling</td>
<td>VAMC</td>
<td>10/01/08 - 09/30/09</td>
<td>254,200</td>
<td>0</td>
</tr>
<tr>
<td>Brooks, Deborah</td>
<td>Other</td>
<td>Planned Transition to Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy in Renal</td>
<td>UT Southwestern Med. Ctr.</td>
<td>08/01/08 - 07/31/09</td>
<td>21,918</td>
<td>10,082</td>
</tr>
<tr>
<td>Budisavljevic, M</td>
<td>PI</td>
<td>Matricellular Proteins as Regulators of Tumor Progression</td>
<td>NIH/NCRR</td>
<td>04/01/09 - 02/28/10</td>
<td>216,000</td>
<td>102,600</td>
</tr>
<tr>
<td>Bujor, Andreea</td>
<td>PI</td>
<td>Outcome Trial Evaluating the Efficacy and Safety of Norditropin in Adult Patients on Chronic</td>
<td>Dialysis Clinics, Inc.</td>
<td>06/03/08 - 06/02/10</td>
<td>10,000</td>
<td>2,500</td>
</tr>
<tr>
<td>Buse, Maria</td>
<td>PI</td>
<td>mTOR and the Regulation of Collagen Synthesis</td>
<td>Arthritis Fdn.</td>
<td>07/01/08 - 06/30/09</td>
<td>50,000</td>
<td>0</td>
</tr>
<tr>
<td>Cantey, J.</td>
<td>Co-Investigator</td>
<td>Copper Antimicrobial Research Program (CAP)</td>
<td>Advanced Technology Institut</td>
<td>02/19/07 - 08/18/09</td>
<td>123,028</td>
<td>29,757</td>
</tr>
<tr>
<td>Castell, Donald</td>
<td>PI</td>
<td>Copper Air Quality Program</td>
<td>Advanced Technology Institut</td>
<td>02/19/09 - 02/18/10</td>
<td>123,028</td>
<td>29,757</td>
</tr>
<tr>
<td>Chiaramida, S.</td>
<td>PI</td>
<td>A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable</td>
<td>Quintiles Pacific, Inc.</td>
<td>05/15/09 - 12/31/12</td>
<td>123,028</td>
<td>29,757</td>
</tr>
<tr>
<td>Church, L. W.</td>
<td>PI</td>
<td>A Multi-Center, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and</td>
<td>Merck</td>
<td>02/19/07 - 08/18/09</td>
<td>55,075</td>
<td>13,769</td>
</tr>
</tbody>
</table>
Coxum, Sonya  
**Principal Investigator**  
**Regulation of 5-HT1A Receptor by Calmodulin**  
Sponsor: NIH/NHLBI  
Award: 1 K01 HL092606-01 (07071610)  
Budget Dates: 09/20/08 - 06/30/09  
Direct: $100,784  
F & A: $8,063  

**Targeting of G Protein Coupled 5-HT1A Receptors**  
Sponsor: Dialysis Clinics, Inc.  
Award: C-3053 (East Cooper) (09010984)  
Budget Dates: 03/01/09 - 02/29/12  
Direct: $30,000  
F & A: $0  

Comerford, Lawrence  
**Principal Investigator**  
**A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Investigate the Safety and Efficacy of CP-690,550 in Subjects with Moderate to Severe Crohn’s Disease**  
Sponsor: Pfizer, Inc.  
Award: A3921043 (08103024)  
Project Dates: 10/08/08 - 10/31/09  
Direct: $42,434  
F & A: $9,984  

**A Non-Interventional Long-Term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohn’s Disease**  
Sponsor: Pharmaceutical Research Associates  
Award: C87075 (09031259)  
Project Dates: 01/20/09 - 02/28/19  
Direct: $97,640  
F & A: $22,660  

Cooper, IV, George  
**Principal Investigator**  
**Growth Regulation of Adult Cardiac Muscle Cells**  
Sponsor: VAMC  
Award: (06062402)  
Project Dates: 10/01/08 - 09/30/09  
Direct: $125,000  
F & A: $0  

Costa, Luciano  
**Principal Investigator**  
**A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies**  
Sponsor: National Marrow Donor Program  
Award: PO 17466/Protocol 0603 (08102265)  
Project Dates: 11/01/08 - 09/30/09  
Direct: $56,572  
F & A: $26,872  

**An International, Multi-Center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma**  
Sponsor: Allos Therapeutics, Inc.  
Award: PDX-009 (09021072)  
Project Dates: 01/22/09 - 04/01/14  
Direct: $87,996  
F & A: $20,999  

Cotton, Peter  
**Principal Investigator**  
**Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD)**  
Sponsor: NIH/NIDDK  
Award: 5 U01 DK074739-02 (08042495)  
Project Dates: 07/01/08 - 06/30/09  
Direct: $986,623  
F & A: $248,106  

Dantzler, Todd  
**Principal Investigator**  
**A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Antagonist Therapy**  
Sponsor: Centocor, Inc.  
Award: CO743T26 (09021181)  
Project Dates: 02/18/09 - 02/29/12  
Direct: $96,427  
F & A: $22,982  

Delegge, Mark  
**Principal Investigator**  
**Endoscopic Implantation of Enteryx for the Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)**  
Sponsor: Boston Scientific Corp.  
Award: 302-1001 (03081901)  
Budget Dates: 08/01/03 - 06/30/09  
Direct: $5,401  
F & A: $1,350  

**Feeding in Elderly Late-Stage Dementia: the FIELD Trial**  
Sponsor: NIH/NIA  
Award: 1 R21 AG032083-01A1 (08031073)  
Project Dates: 06/01/09 - 05/31/11  
Direct: $122,941  
F & A: $48,755  

Dowdle, Merriman  
**Co-Investigator**  
**A Phase 3, Randomized, Placebo-Controlled, Blinded, Multi-Center Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn’s Disease**  
Sponsor: Quintiles Pacific, Inc.  
Award: C13007 (08101428-1)  
Direct: $51,146
Dowdle, Merriman

**Co-Investigator**

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Investigate the Safety and Efficacy of CP-690,550 in Subjects with Moderate to Severe Crohn’s Disease  
**PI:** Lawrence Comerford  
**Sponsor:** Pfizer, Inc.  
**Dept:** Medicine  
**Award:** A3921043 (08103024-1)  
**Direct:** $42,434

Drabkin, Harry

**Principal Investigator**

**SPORE in Lung Cancer**  
**Sponsor:** Univ. of Colorado  
**Award:** FY08.046.002 (08010206)  
**Budget Dates:** 05/01/08 - 04/30/09  
**Direct:** $166,575

A Double-Blind, Randomized, Placebo-Controlled, Phase III Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAGE-A3-Positive Non-Small Cell Lung Cancer  
**Sponsor:** GlaxoSmithKline  
**Award:** GSK1572932A (08012422)  
**Budget Dates:** 11/14/07 - 02/26/13  
**F & A:** $2,000

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients with Non-Small Cell Lung Carcinoma Who are Progressing on Erlotinib  
**Sponsor:** Syndax Pharmaceuticals, Inc.  
**Award:** SNDX-275-0403 (08043018)  
**Budget Dates:** 05/08/08 - 06/01/13  
**F & A:** $39,240

A Study Pazopanib Versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma  
**Sponsor:** GlaxoSmithKline  
**Award:** VEG108844 (08090771)  
**Budget Dates:** 07/14/08 - 02/11/11  
**F & A:** $40,880

A Phase I, Safety and Tolerability Study of LBH589 in Combination with Sorafenib in Patients with Advanced Renal Cell Carcinoma and Non-Small Cell Lung Carcinoma (NSCLC) of Non-Squamous Histologies  
**Sponsor:** Novartis Corp.  
**Award:** CLBH589BU516T (08123051)  
**Budget Dates:** 03/01/09 - 03/01/12  
**F & A:** $895,778

**Phase 2, Open-Label, Single-Arm, Multi-Center Study for Subjects with Metastatic Renal Cell Carcinoma**  
**Sponsor:** Amgen  
**Award:** (09032516)  
**Budget Dates:** 03/23/09 - 04/30/14  
**F & A:** $81,447

In Vitro and in vivo Activities of CS-7017 Alone, and in Combination with AMP Kinase Activators, in Lung Cancer Cell Lines  
**Sponsor:** Daiichi Sankyo Pharma  
**Award:** CS-7017 (09033039)  
**Budget Dates:** 05/26/09 - 05/25/10  
**F & A:** $20,009

Egan, Brent

**Principal Investigator**

Cost Effectiveness Evaluation of the Impact of State Spending on Hypertension Prevention and Control Programs  
**Sponsor:** RTI International  
**Award:** 13-312-0208654 (08091291)  
**Budget Dates:** 12/01/07 - 10/31/08  
**F & A:** $6,823

Mechanisms of Hypertension in Chronic Kidney Disease  
**Sponsor:** Univ. of Michigan  
**Award:** F014291/DK071222-03 (08091294)  
**Budget Dates:** 07/01/08 - 06/30/09  
**F & A:** $1,973

**Mentor**

NRSA for Primary Medical Care: Developing Primary Care Researchers Using Research Networks  
**PI:** William Basco  
**Sponsor:** HRSA  
**Award:** 1 T32 HP10255-01-00 (08022939-1)  
**Direct:** $127,371

Egede, Leonard

**Principal Investigator**

Telepsychology-Service Delivery for Depressed Elderly Veterans  
**Sponsor:** VAMC  
**Award:** (07063035)  
**Budget Dates:** 08/01/08 - 07/30/09  
**F & A:** $258,500

Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM  
**Sponsor:** NIH/NIDDK  
**Award:** 1 R01 DK081121-01A1 (07111552)  
**Budget Dates:** 08/01/08 - 06/30/12  
**F & A:** $161,841

Short Term Research Training for Health Professional Students  
**Sponsor:** NIH/NIDDK  
**Award:** 5 T35 DK007431-25 (09031364)  
**Budget Dates:** 05/01/09 - 04/30/10  
**F & A:** $11,507

**Co-Investigator**

Innovative Service Delivery for Secondary Prevention of PTSD in at-Risk OIF-OEF Service Men and Women  
**PI:** Thomas Uhde  
**Sponsor:** Charleston Research Institute  
**Award:** W81XWH-08-2-0047 (08052722-1)  
**Direct:** $157,662

**PI:** Lawrence Comerford  
**Sponsor:** Pfizer, Inc.  
**Direct:** $42,434

**PI:** Harry Drabkin  
**Sponsor:** Daiichi Sankyo Pharma  
**Direct:** $39,240

**PI:** Leonard Egede  
**Sponsor:** Charleston Research Institute  
**Direct:** $157,662
Egede, Leonard

**Co-Investigator**

**DHHS Telemedicine Project (Confidant)**
- PI: Louis Luttrell
- Dept: Medicine
- Sponsor: SC DHHS
- Award: A 9  1558 A (08070136-1)
- Direct $ 249,033

**SCCP Medicaid Academic Detailing Project**
- PI: Patrick Mauldin
- Dept: Pharmacy and Clinical Sciences
- Sponsor: Univ. of South Carolina
- Award: 08-1470 (09050172-1)
- Direct $ 93,793

Egidi, Maria

**Principal Investigator**

**A Randomized, Placebo-Controlled, Double-Blind, Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus**
- Sponsor: Wyeth, Inc.
- PI: Ayad Jaffa
- Dept: Medicine
- Direct $ 254,608

**Planned Transition to Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy in Renal Allograft Recipients**
- Sponsor: Wyeth, Inc.
- PI: Charles Bratton
- Dept: Surgery
- Direct $ 223,244

El-Shewy, Hesham

**Co-Investigator**

**Kallikrein and Vascular Disease Risk in Diabetes**
- PI: Ayad Jaffa
- Sponsor: NIH/NHLBI
- Direct $ 254,608

Fernandes, Jyotika

**Principal Investigator**

**An International, Randomized, Double-Blinded, Phase 3, Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer**
- Sponsor: Exelixis, Inc.
- PI: Kathie Hermayer
- Dept: Medicine
- Award: RESET STUDY (09052653)
- Direct $ 38,400

**Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-Naive Patients with Type 2 Diabetes Treated with Metformin and Not Adequately Controlled**
- Sponsor: Sanofi-Aventis US, Inc.
- PI: William Moran
- Dept: Medicine
- Award: A 9  1558 A (08070136-1)
- Direct $ 249,033

**Somatuline Depot Injection for Acromegaly (SODA): A Post-Marketing Observational Study**
- Sponsor: Tercica, Inc.
- PI: William Moran
- Dept: Medicine
- Award: A 9  1558 A (08070136-1)
- Direct $ 249,033

Fernandes, Valerian

**Principal Investigator**

**Restoration of Chronotropic Competence in Heart Failure Patients with Normal Ejection Fraction (The RESET Study)**
- Sponsor: Boston Scientific Corp.
- PI: William Moran
- Dept: Medicine
- Direct $ 139,320

Feussner, John

**Co-PI or Project Leader**

**Aging Q3 - Quality Education, Quality Care, Quality of Life**
- PI: William Moran
- Dept: Medicine
- Sponsor: Donald W. Reynolds Fdn.
- Direct $ 424,817

Fitzgibbon, Wayne

**Co-PI or Project Leader**

**Role of Angiotensin II in Medullary Solute and Water Reabsorption**
- PI: David Ploth
- Dept: Medicine
- Sponsor: Dialysis Clinics, Inc.
- Direct $ 53,425
# Principal Investigator

**Flume, Patrick**

**A Randomized, Open-Label, Multi-Center, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI in Cystic Fibrosis Subjects**

- **Sponsor:** Chiron, Inc.
- **Award:** TIP 003 (08012649)
- **Budget Dates:** 01/30/06 - 01/31/09
- **Direct:** $8,914
- **F & A:** $2,228

**Clinical Research Facilitation Award**

- **Sponsor:** Cystic Fibrosis Fdn.
- **Award:** C104-CRF06A (09021119)
- **Budget Dates:** 12/01/06 - 12/31/08
- **Direct:** $5,000
- **F & A:** $400

**A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosing Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable Cystic Fibrosis Patients**

- **Sponsor:** Mpex Pharmaceuticals, Inc.
- **Award:** MEP - 204 (08041028)
- **Budget Dates:** 04/03/08 - 05/31/10
- **Direct:** $3,000
- **F & A:** $750

**Care Center - Patient Registry**

- **Sponsor:** Cystic Fibrosis Fdn.
- **Award:** C104-08 (08070245)
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct:** $83,650
- **F & A:** $0

**Therapeutic Development Center**

- **Sponsor:** Cystic Fibrosis Fdn. Therapeutics, Inc.
- **Award:** C104-TDC9Y (08090982)
- **Budget Dates:** 01/01/09 - 12/31/09
- **Direct:** $80,000
- **F & A:** $6,400

**A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 mg and 5 mg) Administered Once Daily via the Respimat Device for 12 Weeks in Patients with Cystic Fibrosis**

- **Sponsor:** Boehringer Ingelheim Pharmaceuticals
- **Budget Dates:** 09/25/08 - 09/30/10
- **Direct:** $178,739
- **F & A:** $43,904

**Inhaled Dry Powder Mannitol Known as IDPM**

- **Sponsor:** Ethica Clinical Research, Inc.
- **Budget Dates:** 10/03/08 - 09/30/10
- **Direct:** $89,946
- **F & A:** $21,862

**An Open-Label, Multi-Center Trial to Validate the Quality of Life Questionnaire-Bronchiectasis and to Evaluate Perception of Symptom Improvement Following One Course of Aztreonam for Inhalation Solution (AZLI) in Subjects with Bronchiectasis and Gram-Negative Bacteria in the Airways**

- **Sponsor:** Gilead Sciences, Inc.
- **Budget Dates:** 02/01/09 - 01/31/10
- **Direct:** $87,420
- **F & A:** $21,231

**A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis and Pseudomonas Aeruginosa**

- **Sponsor:** Gilead Sciences, Inc.
- **Budget Dates:** 02/09/09 - 02/28/10
- **Direct:** $90,820
- **F & A:** $22,080

**Updating Practice Guidelines**

- **Sponsor:** Cystic Fibrosis Fdn.
- **Budget Dates:** 10/01/08 - 12/31/09
- **Direct:** $28,847
- **F & A:** $0

**Co-PI or Project Leader**

**Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects with Cystic Fibrosis**

- **PI:** Antine Stenbit
- **Sponsor:** PPD Development
- **Dept:** Medicine
- **Award:** 12429 (08050129-2)

---

**Garnovskaya, Maria**

**Principal Investigator**

**Early Regulation of the Retinoblastoma Gene Product in Vascular Smooth Muscle Cells**

- **Sponsor:** VAMC
- **Budget Dates:** 04/01/09 - 03/31/10
- **Direct:** $209,300
- **F & A:** $0

**Gault, Christopher**

**Principal Investigator**

**The Role of Sphingosine Kinase 1 in Ras-Initiated Lung Carcinogenesis**

- **Sponsor:** NIH/NHLBI
- **Award:** 1 F30 HL093991-01A1 (08040386)
- **Budget Dates:** 02/01/09 - 01/31/12
- **Direct:** $36,091
- **F & A:** $0

**Gelasco, Andrew**

**Co-Investigator**

**Mechanisms of Regulation of NHE-1**

- **PI:** John Raymond
- **Sponsor:** NIH/NIDDK
- **Dept:** Medicine
- **Award:** 2 R01 DK052448-10A2 (07102984-1)

**Gemmill, Robert**

**Co-PI or Project Leader**

**In Vitro and in Vivo Activities of CS-7017 Alone, and in Combination with AMP Kinase Activators, in Lung Cancer Cell Lines**

- **PI:** Harry Drabkin
- **Sponsor:** Daiichi Sankyo Pharma
- **Dept:** Medicine
- **Award:** CS-7017 (09033039-1)

---

**Medical University of South Carolina College of Medicine**

**Research Faculty Activity**

### Annual Report for Research FY2009

<table>
<thead>
<tr>
<th>Research Faculty</th>
<th>Department</th>
<th>Activity</th>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garnovskaya, Maria</td>
<td>Medicine</td>
<td>Early Regulation of the Retinoblastoma Gene Product in Vascular Smooth Muscle Cells</td>
<td>VAMC</td>
<td>(06062404)</td>
<td>04/01/09 - 03/31/10</td>
<td>$209,300</td>
<td>$0</td>
</tr>
<tr>
<td>Gault, Christopher</td>
<td>Medicine</td>
<td>The Role of Sphingosine Kinase 1 in Ras-Initiated Lung Carcinogenesis</td>
<td>NIH/NHLBI</td>
<td>F30 HL093991-01A1 (08040386)</td>
<td>02/01/09 - 01/31/12</td>
<td>$36,091</td>
<td>$0</td>
</tr>
<tr>
<td>Gelasco, Andrew</td>
<td>Medicine</td>
<td>Co-Investigator</td>
<td>NIH/NIDDK</td>
<td></td>
<td>2 R01 DK052448-10A2 (07102984-1)</td>
<td>$212,500</td>
<td>$0</td>
</tr>
<tr>
<td>Gemmill, Robert</td>
<td>Medicine</td>
<td>Co-PI or Project Leader</td>
<td>Daiichi Sankyo Pharma</td>
<td>CS-7017 (09033039-1)</td>
<td>01/30/06 - 01/31/09</td>
<td>$80,038</td>
<td>$0</td>
</tr>
</tbody>
</table>
Gilkeson, Gary

**Principal Investigator**

**LCTC Participating Center**

Sponsor: Lupus Clinical Trials Consortium  
Award: (03100207)  
Budget Dates: 01/01/08 - 06/30/09  
Direct: $32,500  
F & A: 0

**Role of Estrogen Receptors in Lupus-Modulators of the Inflammatory Response**

Sponsor: VAMC  
Award: (06062405)  
Budget Dates: 10/01/08 - 09/30/09  
Direct: $125,000  
F & A: 0

**Role of Sphingosine Kinase in Inflammatory Arthritis**

Sponsor: ACR Research and Education Fdn.  
Award: (07022358)  
Budget Dates: 01/01/04 - 06/30/09  
Direct: $185,185  
F & A: 14,815

**A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single-and-Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMab IFNalpha in Adults with Mildly Active Systemic Lupus Erythematosus**

Sponsor: Genentech, Inc.  
Award: IFN3958g (07031359)  
Budget Dates: 03/14/07 - 06/30/10  
Direct: $3,450  
F & A: 862

**Role of Reactive Intermediates in Lupus Nephritis**

Sponsor: NIH/NIAMS  
Award: 2 R01 AR045476-09A1 (07110214)  
Budget Dates: 04/23/99 - 05/31/13  
Direct: $243,207  
F & A: 58,957

**Continuation of the Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) Registry**

Sponsor: Univ. of Alabama, Birmingham  
Award: HHSN268200682278C (08090361-1)  
Budget Dates: 08/22/08 - 06/30/10  
Direct: $11,871

**Role of Reactive Intermediates in Lupus Nephritis**

Sponsor: NIH/NIAMS  
Award: 2 R01 AR045476-10 (09040806)  
Budget Dates: 07/01/08 - 05/31/13  
Direct: $247,699  
F & A: 46,200

**A Randomized, Double-Blind, Placebo-Controlled, Single, Dose-Escalation and Multiple Dose Extension Trial of NNC 0152-0000-0001 Administered i.v. or s.c. in Subjects with SLE**

Sponsor: Novo Nordisk Pharmaceuticals  
Award: NN8360-3559 (09043066)  
Budget Dates: 05/13/09 - 03/31/12  
Direct: $167,084  
F & A: 41,146

**Complement Inhibitory Therapy of Lupus**

Co-PI or Project Leader: Stephen Tomlinson  
Dept: Microbiology and Immunology  
Sponsor: DOD  
Award: W81XWH-07-1-0161 (06051858-3)  
Direct: $157,720

**Inflammatory Mediators of Glomerular Disease (REAP)**

Co-Investigator: John Raymond  
Dept: Medicine  
Sponsor: VAMC  
Award: (05060630-5)  
Direct: $250,000

**Altered Somatic Mutation in IgAD/CVID; Association with Deficiency of Msh4/5**

PI: Hedeharu Sekine  
Dept: Medicine  
Sponsor: NIH/NIAID  
Award: 1 R21 AI079800-01 (0711555-1)  
Direct: $150,000

**A Role for the Msh4/5 Heterodimers in IgA Deficiency and CVID**

PI: Hedeharu Sekine  
Dept: Medicine  
Sponsor: US Immunodeficiency Network  
Award: COA #40/N01-AI-30070 (08081921-1)  
Direct: $102,740

**The Role of Vitamin D in Systemic Lupus Erythematosus**

PI: Diane Kamen  
Dept: Medicine  
Sponsor: NIH/NIAMS  
Award: 5 K23 AR052364-02 (08051245-1)  
Direct: $119,875

**Mentor**

**Regulation of Fli1 Gene Expression in Lupus**

PI: Tamara Nowling  
Dept: Medicine  
Sponsor: NIH/NIDDK  
Award: 3 K01 DK072306-03S1 (07071075-2)  
Direct: $1,000

**Collaborator**

**Continuation of the Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) Registry**

PI: Edwin Smith  
Dept: Medicine  
Sponsor: Univ. of Alabama, Birmingham  
Award: HHSN268200682278C (08090361-1)  
Direct: $34,259
Gold, Michael

**Principal Investigator**

**Educational Grant in Support of an EP Fellowship**
Sponsor: Medtronic, Inc.
Award: (02102214)
Budget Dates: 10/01/02 - 06/30/11
Direct: $83,333
F & A: $6,667

**Clinical Partners in Excellence Program**
Sponsor: St. Jude Medical, Inc.
Award: (04100800)
Budget Dates: 09/09/04 - 09/08/09
Direct: $76,500
F & A: $8,500

**Device System Post-Approval Study**
Sponsor: St. Jude Medical, Inc.
Award: 60003864/001 (04101401)
Budget Dates: 10/01/04 - 06/30/09
Direct: $400
F & A: $100

**First Arrhythmia Collection of Tranvenous and Simultaneous Subcutaneous Implantable Defibrillator (S-ICD) Data: The FACTS S-ICD Study**
Sponsor: Cameron Health, Inc.
Award: FACTS S-ICD (05100306)
Budget Dates: 10/01/05 - 12/31/08
Direct: $1,600
F & A: $400

**Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates**
Sponsor: St. Jude Medical, Inc.
Award: 06-08-002 (08052727)
Budget Dates: 08/14/08 - 08/13/10
Direct: $23,608
F & A: $5,152

**AF CRT Study: The Effect of Biventricular Pacing on the Incidence of Atrial Fibrillation**
Sponsor: AF Research
Award: AF_CRT (08102162)
Budget Dates: 10/29/08 - 12/31/09
Direct: $4,800
F & A: $1,200

**Evaluation of Left Ventricular Auto Threshold Study**
Sponsor: Boston Scientific Corp.
Award: ELEVATE (09012997)
Budget Dates: 02/18/09 - 12/31/10
Direct: $22,500
F & A: $5,000

**Development of Visual ECG Ischemia Markers Using Digital ECGs Obtained from Patients Being Evaluated for Acute Chest Pain, Clinical Study Protocol #006**
Sponsor: NewCardio, Inc.
Award: Visual ECG (09042264)
Budget Dates: 05/13/09 - 12/31/09
Direct: $9,916
F & A: $1,854

**Detect Fluid Early from Intra-thoracic Impedance Monitoring**
Sponsor: St. Jude Medical, Inc.
Award: DEFEAT PE (09060204)
Budget Dates: 06/16/09 - 12/31/11
Direct: $22,540
F & A: $4,760

Golshayan, Ali

**Principal Investigator**

**AXITINIB (AG-013738) as Second Line Therapy for Metastatic Renal Cell Cancer: Axis Trial**
Sponsor: Pfizer, Inc.
Award: A4061032 (08120464)
Budget Dates: 10/22/08 - 02/01/14
Direct: $88,918
F & A: $21,604

**Co-Investigator**

**A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of 10mg ZD 4054 in Combination with Docetaxel in Patients with Metastatic Hormone-Resistant Prostate Cancer**
Pl: Thomas Keane
Dept: Urology
Sponsor: Astrazeneca
Direct: $119,100
Award: D4320C00033 (08120464)

**A Phase III, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily, Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients**
Pl: Thomas Keane
Dept: Urology
Sponsor: Astrazeneca
Direct: $100,428
Award: D4320C00015 (09010666-1)

Gooz, Monika

**Principal Investigator**

**Crosstalk among Growth Factors, ADAMs and Integrins**
Sponsor: NIH/NIHHD
Award: 5 K01 DK070054-04 (08032650)
Budget Dates: 06/01/08 - 05/31/09
Direct: $1,000
F & A: $0

**Role of ADAM-17/TACE in the Development of Chronic Kidney Disease: Regulation of Its Activity by Binding Partners**
Sponsor: Dialysis Clinics, Inc.
Award: C-2938 (08051984)
Budget Dates: 07/01/08 - 06/30/09
Direct: $37,896
F & A: $0

**Role of ADAM-17/TACE in the Development of Chronic Kidney Disease: Regulation of Its Activity by Binding Partners**
Sponsor: Paul Teschan Research Fund
Award: (08061119)
Budget Dates: 12/01/08 - 11/30/09
Direct: $40,000
F & A: $8,000

**Crosstalk among Growth Factors, ADAMs and Integrins**
Sponsor: NIH/NIHHD
Award: 5 K01 DK070054-05 (09033154)
Budget Dates: 06/01/09 - 05/31/10
Direct: $102,998
F & A: $8,240
<table>
<thead>
<tr>
<th>Research Faculty Activity</th>
<th>Co-PI or Project Leader</th>
<th>PI or Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gooz, Pal</strong></td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Project 5&lt;br&gt;PI: Roger Markwald&lt;br&gt;Dept: Cell Biology and Anatomy</td>
<td>Sponsor: NIH/NCRR</td>
<td>Budget Dates: 04/01/09 - 03/31/10</td>
<td>92,488</td>
<td>0</td>
</tr>
<tr>
<td><strong>Gupta, Monika</strong></td>
<td>Recovery of Kidney Function after Acute Kidney Failure&lt;br&gt;PI: Roger Markwald&lt;br&gt;Dept: Cell Biology and Anatomy</td>
<td>Sponsor: Robert and Molly Tarr Charitable Fdn.</td>
<td>Budget Dates: 04/01/09 - 03/31/10</td>
<td>47,500</td>
<td>0</td>
</tr>
<tr>
<td><strong>Harris, Brett</strong></td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Project 4&lt;br&gt;PI: Roger Markwald&lt;br&gt;Dept: Cell Biology and Anatomy</td>
<td>Sponsor: NIH/NCRR</td>
<td>Award: 5 P20 RR016434-08 (08081298-6)</td>
<td>127,400</td>
<td>0</td>
</tr>
<tr>
<td><strong>Hawes, Robert</strong></td>
<td>Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD)&lt;br&gt;PI: Peter Cotton&lt;br&gt;Dept: Medicine</td>
<td>Sponsor: NIH/NIDDK</td>
<td>Award: 5 U01 DK074739-02 (08042495-1)</td>
<td>866,102</td>
<td>0</td>
</tr>
<tr>
<td><strong>Haycraft, Courtney</strong></td>
<td>UAB Recessive PKD Research and Translational Core Center&lt;br&gt;PI: Phillip Bell&lt;br&gt;Dept: Medicine</td>
<td>Sponsor: Univ. of Alabama, Birmingham</td>
<td>Award: 003/5P30DK074038-04 (08102911-2)</td>
<td>132,869</td>
<td>0</td>
</tr>
<tr>
<td><strong>Hermayer, Kathie</strong></td>
<td>Randomized, Multi-National, Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group&lt;br&gt;Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering Risk Factors (crescendo)&lt;br&gt;PI: Phillip Bell&lt;br&gt;Dept: Medicine</td>
<td>Sponsor: Sanofi Synthelabo, Inc.</td>
<td>Award: EFC 5826 (06011933)</td>
<td>38,400</td>
<td>9,600</td>
</tr>
<tr>
<td><strong>Highland, Kristin</strong></td>
<td>Intravenous Insulin Protocol in Diabetes and Renal Transplantation&lt;br&gt;PI: Phillip Bell&lt;br&gt;Dept: Medicine</td>
<td>Sponsor: Amer. Diabetes Assoc.</td>
<td>Award: T-07-CR-22 (07011042)</td>
<td>173,865</td>
<td>26,079</td>
</tr>
<tr>
<td></td>
<td>A Two-Stage, Prospective, Observational, Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension&lt;br&gt;PI: Actelion Pharmaceuticals&lt;br&gt;Dept: Medicine</td>
<td>Sponsor: Icon Clinical Research, Inc.</td>
<td>Award: B1321001 (09032412)</td>
<td>49,150</td>
<td>11,663</td>
</tr>
<tr>
<td></td>
<td>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension&lt;br&gt;PI: Actelion Pharmaceuticals&lt;br&gt;Dept: Medicine</td>
<td>Sponsor: Icon Clinical Research, Inc.</td>
<td>Award: B1321002 (09032413)</td>
<td>72,938</td>
<td>17,610</td>
</tr>
</tbody>
</table>

Annual Report for Research FY2009
Highland, Kristin

**Principal Investigator**

**A Randomized, Double-Blind, Efficacy and Safety Study of Monotherapy Sitaxsentan Sodium Versus Combination Therapy with Sitaxsentan Sodium and Sildenafil Citrate in Patients with Pulmonary Arterial Hypertension Who Have Completed Study FPH05**

**Sponsor:** Icon Clinical Research, Inc.  
**Budget Dates:** 03/12/09 - 03/11/10  
**Direct:** $ 102,102

**Award:** B1321003 (09032414)  
**F & A:** $ 24,900

**Other**

**Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease - Scleroderma Lungh Study II (SLSII)**

**Pl:** Richard Silver  
**Dept:** Medicine  
**Sponsor:** Univ. of California, Los Angeles  
**Direct:** $ 57,229  
**Award:** 1460 GKB111/1 R01 HL09990 (07100897-1)

Hoffman, Brenda

**Principal Investigator**

**A Phase 3, Randomized, Placebo-Controlled, Blinded, Multi-Center Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Crohn's Disease**

**Sponsor:** Quintiles Pacific, Inc.  
**Budget Dates:** 10/20/08 - 10/31/11  
**Direct:** $ 51,146

**Award:** C13007 (08101428)  
**F & A:** $ 11,912

**A Phase 3, Open-Label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease**

**Sponsor:** Quintiles Pacific, Inc.  
**Budget Dates:** 10/20/08 - 12/31/11  
**Direct:** $ 60,473

**Award:** C13008 (08101429)  
**F & A:** $ 14,243

Hoffman, Stanley

**Co-Investigator**

**SC Cobre for Developmentally Based Cardiovascular Diseases: Project 5**

**Pl:** Roger Markwald  
**Dept:** Cell Biology and Anatomy  
**Sponsor:** NIH/NCRR  
**Direct:** $ 92,488

**Mentor**

**Hyaluronic Acid is Overexpressed in Fibrotic Lung Tissue and Promotes Collagen Expression**

**Pl:** Elena Tourkina  
**Dept:** Medicine  
**Sponsor:** US Army/USAMRAA  
**Direct:** $ 46,296

**Anti-Fibrotic and Anti-Inflammatory Roles of Caveolin-1 in Lung Disease**

**Pl:** Elena Tourkina  
**Dept:** Medicine  
**Sponsor:** NIH/NIAMS  
**Direct:** $ 106,275

**SC Cobre for Developmentally Based Cardiovascular Diseases: Core A2 - Mentoring**

**Pl:** Roger Markwald  
**Dept:** Cell Biology and Anatomy  
**Sponsor:** NIH/NCRR  
**Direct:** $ 73,695

Huang, Yan

**Principal Investigator**

**Diabetes and the Stability of Atherosclerotic Plaques**

**Sponsor:** VAMC  
**Budget Dates:** 04/01/09 - 03/31/10  
**Direct:** $ 191,900

**Award:** (07063036)  
**F & A:** $ 0

**Molecular Mechanisms Involved in Augmentation of Interferon Gamma-Stimulated Matrix Metalloproteinase (MMP-1) Expression in Macrophages**

**Sponsor:** VAMC  
**Budget Dates:** 08/11/08 - 08/10/09  
**Direct:** $ 24,000

**Award:** 534-D8719 (08100801)  
**F & A:** $ 0

**The Effect of Alogliptin on Vascular Inflammation and Atherosclerosis**

**Sponsor:** Takeda Pharmaceuticals  
**Budget Dates:** 01/23/09 - 12/31/10  
**Direct:** $ 98,956

**Award:** 08-003ALO (08112431)  
**F & A:** $ 45,520

**Diabetes and Periodontal Gene Expression**

**Sponsor:** NIH/NIDCR  
**Budget Dates:** 05/01/09 - 04/30/10  
**Direct:** $ 200,445

**Award:** 5 R01 DE016353-05 (09031670)  
**F & A:** $ 92,205

Huggins, John

**Co-Investigator**

**A Phase 2, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis**
Huggins, John  
**Co-Investigator**

**Pl:** Steven Sahn  
**Dept:** Medicine  
**Sponsor:** Centocor, Inc.  
**Direct $** 249,228  
**Award:** CNT0888PUL2001 (09013004-1)

---

Jaffa, Ayad  
**Principal Investigator**

**Lipoproteins, CTGF and Diabetic Vascular Renal Disease**  
**Budget Dates:** 02/01/09 - 01/31/10  
**Direct:** $ 242,750

**Kallikrein and Vascular Disease Risk in Diabetes**  
**Budget Dates:** 09/29/08 - 07/31/09  
**Direct:** $ 254,608

---

Janech, Michael  
**Principal Investigator**

**Collaborative Research: A Proteomic Approach to Understanding Cytoprotective Biogenic Sulfur Production in Sea-Ice Diatoms**  
**Budget Dates:** 08/01/08 - 07/31/09  
**Direct:** $ 62,242

**Identification and Validation of Plasma Biomarkers in California Sea Lions**  
**Budget Dates:** 01/05/08 - 07/31/09  
**Direct:** $ 15,892

---

Jauh, Edward  
**Principal Investigator**

**Recanalization Therapies and Markers of Stroke Outcome**  
**Budget Dates:** 07/01/07 - 06/30/09  
**Direct:** $ 17,882

**Interventional Management of Stroke Study III**  
**Budget Dates:** 07/01/07 - 06/30/09  
**Direct:** $ 22,578

**Interventional Management of Stroke Study III YR2**  
**Budget Dates:** 07/01/07 - 06/30/09  
**Direct:** $ 25,739

---

Joseph, Kusumam  
**Principal Investigator**

**Regulation of Endothelin 1 Production by Bradykinin in Pulmonary Arterial Hypertension**  
**Budget Dates:** 07/01/07 - 06/30/09  
**Direct:** $ 60,000

---

Judson, Marc  
**Principal Investigator**

**The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoildosis**  
**Budget Dates:** 05/01/07 - 04/30/10  
**Direct:** $ 8,736

---
Judson, Marc

**Principal Investigator**

**Development and Validation of a Questionnaire to Assess Patient-Reported Symptoms and Functional Limitation in Patients with Sarcoidosis: The Sarcoidosis Assessment Tool (SAT)**

Sponsor: Centocor, Inc.  
Award: SAT (07042003)  
Budget Dates: 07/27/07 - 01/26/09  
Direct: $ 48,980  
F & A: 12,245

---

Kamen, Diane

**Principal Investigator**

**Effect of Vitamin D3 on the IFNa Signature in Patients with SLE**

Sponsor: The Feinstein Institute for Medical Research  
Award: U19 AI056362 (08033064)  
Budget Dates: 04/01/08 - 09/30/09  
Direct: $ 146,110  
F & A: 64,317

---

**The Role of Vitamin D in Systemic Lupus Erythematosus**

Sponsor: NIH/NIAMS  
Award: 5 K23 AR052364-02 (08051245)  
Budget Dates: 07/01/08 - 06/30/09  
Direct: $ 119,875  
F & A: 16,604

---

**The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study**

Sponsor: Xdx, Inc.  
Award: (08071499)  
Budget Dates: 07/16/08 - 07/15/10  
Direct: $ 68,916  
F & A: 16,604

---

Kilby, J.

**Principal Investigator**

**Ryan White CARE Act Title II Funds**

Sponsor: SC DHEC  
Award: 627457 (08031072)  
Budget Dates: 04/01/08 - 03/31/09  
Direct: $ 33,000  
F & A: 0

---

**Pfizer Visiting Professor - Infectious Diseases**

Sponsor: Pfizer, Inc.  
Award: Visiting Professorship (09013005)  
Budget Dates: 07/01/09 - 06/30/10  
Direct: $ 7,500  
F & A: 0

---

**Ryan White Title II Funding**

Sponsor: SC DHEC  
Award: 627457 (09022356)  
Budget Dates: 04/01/09 - 03/31/10  
Direct: $ 1,588,745  
F & A: 0

---

Klein, Richard

**Principal Investigator**

**Interactions of Lipoproteins and Cells in Diabetes Mellitus**

Sponsor: VAMC  
Award: (08051248)  
Budget Dates: 04/01/09 - 03/31/10  
Direct: $ 246,500  
F & A: 0

---

**Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus**

Sponsor: NIH/NIDDK  
Award: 1 R01 DK081352-01 (07092852-1)  
Budget Dates: 07/01/06 - 12/31/09  
Direct: $ 302,856  
F & A: 0

---

Komlosi, Peter

**Principal Investigator**

**Paramacular Signaling to the Juxtaglomerular Vasculature**

Sponsor: Amer. Heart Assoc.  
Award: 0630098N (06072506)  
Budget Dates: 07/01/06 - 12/31/09  
Direct: $ 59,091  
F & A: 5,909

---

**UAB Recessive PKD Research and Translational Core Center**

Sponsor: Univ. of Alabama, Birmingham  
Award: 0035P30DK074038-04 (08102911-2)  
Budget Dates: 07/01/06 - 12/31/09  
Direct: $ 132,869  
F & A: 0

---

**Cellular Mechanisms for Tubuloglomerular Feedback**

Sponsor: NIH/NIDDK  
Award: 5 R01 DK032032-24 (09011296-2)  
Budget Dates: 07/01/06 - 12/31/09  
Direct: $ 195,074  
F & A: 0

---

Kraft, Andrew

**Principal Investigator**

**A Multi-Center, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or are Refractory to Standard of Care Treatment**

Sponsor: Quintiles Pacific, Inc.  
Award: ET743-SAR-3002 (05062714)  
Budget Dates: 07/19/05 - 04/19/11  
Direct: $ 1,840  
F & A: 460

---

**A Phase 2, Multi-Center, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)**

Sponsor: Johnson and Johnson  
Budget Dates: 09/27/06 - 11/26/10  
Direct: $ 480
Kraft, Andrew

Principal Investigator

**Award:** C0328T07 (06100393)  
Project Dates: 09/27/06 - 11/26/10  
**F & A:** 120

**Hollings Cancer Center Breast Cancer Patient Navigation Program**

Sponsor: Avon Fdn.  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $112,500

**MUSC Cancer Center Support Grant**

Sponsor: NIH/NCI  
Budget Dates: 04/01/09 - 03/31/10  
Direct: $1,000,000

**The Mechanism of Action of Unique Small Molecules That Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth**

Sponsor: DOD  
Budget Dates: 05/01/09 - 04/30/12  
Direct: $125,000

**Early Therapeutics Development with Phase II Emphasis**

Sponsor: Univ. of Chicago  
Budget Dates: 01/01/08 - 12/31/09  
Direct: $17,123

**Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer**

Sponsor: Sanofi-Aventis US, Inc.  
Budget Dates: 08/13/08 - 10/01/13  
Direct: $129,300

**Tobacco Related Malignancy: COEE**

Sponsor: SC Research Centers of Economic Excellence  
Budget Dates: 06/18/09 - 05/17/14  
Direct: $4,023,530

**American Cancer Society Institutional Research Grant (ACSIRG)**

Pl: Carolyn Reed  
Sponsor: Amer. Cancer Soc.  
Direct: $24,000  
Dept: Surgery  
Award: IRG-97-219-08 (06033010-14)

Kuppachi, Sarat

Co-Investigator

**Planned Transition to Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy in Renal Allograft Recipients**

Pt: Maria Egidi  
Sponsor: Wyeth, Inc.  
Direct: $128,448  
Dept: Medicine  
Award: 0468E8-4500-WW (09031367-1)

Kuppuswamy, D.

Principal Investigator

**mTOR in Growth and Protection of Hypertrophying Myocardium**

Sponsor: NIH/HLBI  
Budget Dates: 12/19/08 - 11/30/09  
Direct: $250,000  
Award: 1 R01 HL092124-01A1 (08022938)  
Project Dates: 12/19/08 - 11/30/12  
**F & A:** 118,750

Lawrence, C.

Principal Investigator

**Pilot Study of the Efficacy and Tolerability of Duloxetine in Patients with Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction - SOD)**

Sponsor: Lilly Research Laboratories  
Budget Dates: 09/01/06 - 08/31/09  
Direct: $19,500  
Award: F13-MC-X038 (06053118)  
Project Dates: 09/01/06 - 08/31/09  
**F & A:** 4,875

**A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)-Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis**

Sponsor: Repligen Corp.  
Budget Dates: 10/07/08 - 10/06/09  
Direct: $38,570  
Award: RG1068-16 (08082228)  
Project Dates: 10/07/08 - 10/06/09  
**F & A:** 9,018

Leman, Robert

Principal Investigator

**Optimum Lead Insulation Material Registry**

Sponsor: St. Jude Medical, Inc.  
Budget Dates: 04/02/07 - 12/31/12  
Direct: $400  
Award: OPTIMUM (07032089)  
Project Dates: 04/02/07 - 12/31/12  
**F & A:** 100

**QuickFlex uModel1258T IDE Study**

Sponsor: St. Jude Medical, Inc.  
Budget Dates: 11/04/08 - 12/31/11  
Direct: $19,740  
Award: QuickFlex (08101430)  
Project Dates: 11/04/08 - 12/31/11  
**F & A:** 4,060
### Lopes-Virella, Maria

**Principal Investigator**

**Lipoprotein Metabolism and Cell Lipoprotein in Diabetes Mellitus**  
**Sponsor:** VAMC  
**Award:** (07063038)  
**Budget Dates:** 10/01/07 - 09/30/11  
**Project Dates:** 10/01/07 - 09/30/11  
**Direct:** $68,341  
**F & A:** 0

**Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus**  
**Sponsor:** NIH/NIDDK  
**Award:** 1 R01 DK081352-01 (07092852)  
**Budget Dates:** 09/01/08 - 07/31/09  
**Project Dates:** 09/01/08 - 07/31/09  
**Direct:** $302,856  
**F & A:** 141,140

**DNA Banking for a Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy**  
**Sponsor:** VAMC  
**Award:** VA CSP #565 (08102372)  
**Budget Dates:** 07/15/08 - 06/30/13  
**Project Dates:** 07/15/08 - 06/30/13  
**Direct:** $80,000  
**F & A:** 0

**A Clinical Outcomes Study of Darapladib vs Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)**  
**Sponsor:** GlaxoSmithKline  
**Award:** LPL100601 (08112649)  
**Budget Dates:** 10/10/08 - 10/12/12  
**Project Dates:** 10/10/08 - 10/12/12  
**Direct:** $292,958  
**F & A:** 72,240

### Luttrell, Deirdre

**Co-Investigator**

**Lipoproteins, CTGF and Diabetic Vascular Renal Disease**  
**Pl:** Ayad Jaffa  
**Dept:** Medicine  
**Sponsor:** NIH/NHLBI  
**Award:** 5 R01 HL077192-04 (06120610-1)  
**Budget Dates:** 07/01/07 - 01/30/09  
**Project Dates:** 07/01/07 - 01/30/09  
**Direct:** $242,750  
**F & A:** 0

**The Effect of Alogliptin on Vascular Inflammation and Atherosclerosis**  
**Pl:** Yan Huang  
**Dept:** Medicine  
**Sponsor:** Takeda Pharmaceuticals  
**Award:** 08-003ALO (08112431-1)  
**Budget Dates:** 05/01/08 - 04/30/09  
**Project Dates:** 05/01/08 - 04/30/09  
**Direct:** $98,956  
**F & A:** 0

### Luttrell, Louis

**Principal Investigator**

**Vitamin D Insufficiency and Cardiovascular Risk in Type 2 Diabetes**  
**Sponsor:** Amer. Heart Assoc./Mid-Atlantic  
**Award:** 0755466U (07010511)  
**Budget Dates:** 07/01/08 - 06/30/09  
**Project Dates:** 07/01/08 - 06/30/09  
**Direct:** $60,000  
**F & A:** 6,000

**Tyrosine Kinases in G Protein Mediated Signaling**  
**Sponsor:** NIH/NIDDK  
**Award:** 2 R56 DK055524-11A1 (0702985)  
**Budget Dates:** 08/15/08 - 08/14/09  
**Project Dates:** 08/15/08 - 08/14/09  
**Direct:** $194,234  
**F & A:** 89,347

**DHHS Telemedicine Project (Confidant)**  
**Sponsor:** SC DHHS  
**Award:** A 9 1558 A (08070136)  
**Budget Dates:** 07/01/07 - 01/30/09  
**Project Dates:** 07/01/07 - 01/30/09  
**Direct:** $249,033  
**F & A:** 0

**Tyrosine Kinases in G Protein Mediated Signaling**  
**Sponsor:** NIH/NIDDK  
**Award:** 2 R01 DK055524-11A2 (08080475)  
**Budget Dates:** 06/05/09 - 05/31/10  
**Project Dates:** 06/05/09 - 05/31/10  
**Direct:** $240,000  
**F & A:** 114,000

**Novo Nordisk Fellows Travel Grant**  
**Sponsor:** Novo Nordisk Pharmaceuticals  
**Award:** Fellowship Training (08112021)  
**Budget Dates:** 11/01/08 - 12/31/09  
**Project Dates:** 11/01/08 - 12/31/09  
**Direct:** $8,368  
**F & A:** 0

**Continuing Medical Education Program, the Coming of the Age of Medical Miracles: from Osler to Insulin**  
**Sponsor:** Multiple Sponsors  
**Award:** Educational Grant (09031146)  
**Budget Dates:** 04/01/09 - 04/30/09  
**Project Dates:** 04/01/09 - 04/30/09  
**Direct:** $7,975  
**F & A:** 0

**Endocrinology, Diabetes and Metabolism Fellowship Training Program**  
**Sponsor:** Takeda Pharmaceuticals  
**Award:** Diabetes-5753 (09040686)  
**Budget Dates:** 07/01/08 - 05/31/09  
**Project Dates:** 07/01/08 - 05/31/09  
**Direct:** $5,000  
**F & A:** 0

**Co-Investigator**

**Lipoproteins, CTGF and Diabetic Vascular Renal Disease**  
**Pl:** Ayad Jaffa  
**Dept:** Medicine  
**Sponsor:** NIH/NHLBI  
**Award:** 5 R01 HL077192-04 (06120610-1)  
**Budget Dates:** 06/05/09 - 05/31/10  
**Project Dates:** 06/05/09 - 05/31/10  
**Direct:** $242,750  
**F & A:** 0
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luttrell, Louis</td>
<td>Co-Investigator</td>
<td>Kallikrein and Vascular Disease Risk in Diabetes</td>
<td>Ayad Jaffa</td>
<td>NIH/NHLBI</td>
<td>10/01/08 - 09/30/09</td>
<td>254,608</td>
<td></td>
</tr>
<tr>
<td>Mao, Cungui</td>
<td>Co-Investigator</td>
<td>Sphingosine Phosphate Role in Inflammation</td>
<td>Lina Obeid</td>
<td>NIH/NIGMS</td>
<td>04/20/09 - 03/31/10</td>
<td>180,154</td>
<td></td>
</tr>
<tr>
<td>Markiewicz, Margaret</td>
<td>Co-Investigator</td>
<td>Role of Ets Genes in Transformation and Differentiation - Project 3</td>
<td>Dennis Watson</td>
<td>NIH/NCI</td>
<td>10/01/08 - 09/30/09</td>
<td>182,546</td>
<td></td>
</tr>
<tr>
<td>McDermott, Paul</td>
<td>Principal Investigator</td>
<td>Contractile Regulation of Cardiocyte Protein Synthesis</td>
<td>VAMC</td>
<td></td>
<td>07/01/08 - 06/30/09</td>
<td>238,500</td>
<td></td>
</tr>
<tr>
<td>McGee, Dawn</td>
<td>Principal Investigator</td>
<td>Family Health History</td>
<td>Alpha-1 Fdn.</td>
<td></td>
<td>08/10/099</td>
<td>3,000</td>
<td></td>
</tr>
<tr>
<td>Menick, Donald</td>
<td>Principal Investigator</td>
<td>Training to Improve Cardiovascular Therapies</td>
<td>NIH/NHLBI</td>
<td></td>
<td>04/20/09 - 03/31/10</td>
<td>485,762</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role of Protein Acetylation in Ncx1 Expression</td>
<td>NIH/NHLBI</td>
<td></td>
<td>04/20/09 - 03/31/13</td>
<td>250,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research Education Program for Minority Medical Students</td>
<td>NIH/NHLBI</td>
<td></td>
<td>04/01/09 - 03/31/10</td>
<td>99,443</td>
<td></td>
</tr>
<tr>
<td>Mohr, Jr., Lawrence</td>
<td>Mentor</td>
<td>NRSA for Primary Medical Care: Developing Primary Care Researchers Using Research Networks</td>
<td>William Basco</td>
<td>HRSA</td>
<td>04/01/09 - 03/31/14</td>
<td>127,371</td>
<td></td>
</tr>
<tr>
<td>Moran, William</td>
<td>Principal Investigator</td>
<td>Aging Q3 - Quality Education, Quality Care, Quality of Life</td>
<td>Donald W. Reynolds Fdn.</td>
<td></td>
<td>08062487</td>
<td>424,817</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM</td>
<td>Leonard Egede</td>
<td>NIH/NIDDK</td>
<td>01/01/09 - 12/31/12</td>
<td>343,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Feeding in Elderly Late-Stage Dementia: the FIELD Trial</td>
<td>Mark Delegge</td>
<td>NIH/NIA</td>
<td>01/01/09 - 12/31/12</td>
<td>122,941</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SCCP Medicaid Academic Detailing Project</td>
<td>Patrick Mauldin</td>
<td>Univ. of South Carolina</td>
<td>08-1470</td>
<td>93,793</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mentor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morinelli, Thomas</td>
<td>Co-PI or Project Leader</td>
<td>Nuclear Trafficking of the Angiotensin II Type 1a Receptor</td>
<td>Michael Ullian</td>
<td>Dialysis Clinics, Inc.</td>
<td>01/01/09 - 12/31/12</td>
<td>141,847</td>
<td></td>
</tr>
</tbody>
</table>
Morinelli, Thomas

Co-Investigator
Role of Reactive Intermediates in Lupus Nephritis
Pl: Gary Gilkeson  
Dept: Medicine  
Sponsor: NIH/NIAMS  
Award: 2 R01 AR045476-09A1 (07110214-1)  
Direct $ 243,207

Role of Reactive Intermediates in Lupus Nephritis
Pl: Gary Gilkeson  
Dept: Medicine  
Sponsor: NIH/NIAMS  
Award: 5 R01 AR045476-10 (09040806-1)  
Direct $ 247,699

Morris, Pamela

Co-Investigator
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2)-TIMI 50
Pl: James Thomas  
Dept: Medicine  
Sponsor: Schering-Plough Research In  
Award: P04737/P05183 (07112882-2)  
Direct $ 180,000

Mullen, Thomas

Principal Investigator
Ceramide Synthases CERS5 and CERS6 Regulate Pathways of Programmed Cell Death
Sponsor: NIH/NIHES  
Budget Dates: 07/01/08 - 06/30/09  
Direct $ 36,182

Award: 1 F30 ES016975-01 (07120519)  
Project Dates: 07/01/08 - 06/30/12  
F & A: 0

Nielsen, Christopher

Principal Investigator
A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with De Novo Native Coronary Artery Lesions
Sponsor: Advanced Cardiovascular Systems  
Budget Dates: 10/20/06 - 05/31/12  
Direct $ 16,280

Award: SPIRIT IV - Protocol 05-3 (06101021)  
Project Dates: 10/20/06 - 05/31/12  
F & A: 4,070

Xience V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study
Sponsor: Abbott Cardiovascular Systems, Inc.  
Budget Dates: 09/25/08 - 12/31/13  
Direct $ 782,000

Award: 06-374 (08092321)  
Project Dates: 09/25/08 - 12/31/13  
F & A: 194,250

A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12-Receptor Inhibitor, vs. Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent Percutaneous Coronary Intervention (INNOVATE-PCI)
Budget Dates: 01/06/09 - 12/31/10  
Direct $ 43,960

Award: 07-116 (INNOVATE-PCI) (08122342)  
Project Dates: 01/06/09 - 12/31/10  
F & A: 10,240

A Clinical Evaluation of the Medtronic Endeavor Resolute Zotarolimus-Elutin Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm RESOLUTE
Sponsor: Medtronic, Inc.  
Budget Dates: 03/10/09 - 12/31/14  
Direct $ 124,328

Award: Resolute (09031780)  
Project Dates: 03/10/09 - 12/31/14  
F & A: 29,832

Novgorodov, Sergei

Co-Investigator
Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis
Pl: Lina Obeid  
Dept: Medicine  
Sponsor: NIH/NIA  
Award: 5 R01 AG016583-11 (08070867-1)  
Direct $ 185,843

Nowling, Tamara

Principal Investigator
Regulation of Fli1 Gene Expression in Lupus
Sponsor: NIH/NIDDK  
Budget Dates: 04/01/07 - 10/15/08  
Direct $ 1,000

Award: 3 K01 DK072360-03S1 (07071075)  
Project Dates: 09/20/05 - 10/15/08  
F & A: 0

The Role of Fli1 in the Pathogenesis of Lupus
Sponsor: NIH/NIAMS  
Budget Dates: 04/01/09 - 03/31/10  
Direct $ 49,000

Award: 5 R03 AR053376-03 (09020208)  
Project Dates: 04/01/07 - 03/31/10  
F & A: 22,540

The Role of Fli1 in T Cell Function and the Pathogenesis of Lupus
Sponsor: VAMC  
Budget Dates: 04/01/09 - 03/31/10  
Direct $ 277,700

Award: (09070112)  
Project Dates: 04/01/09 - 03/31/12  
F & A: 0
O’Brien, Paul

**Principal Investigator**

**A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study in Patients with Advanced Carcinoid Tumor Receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and Placebo**

**Sponsor:** Novartis Corp.  
**Award:** CRAD001C2325 (07030627)  
**Budget Dates:** 11/02/06 - 05/23/11  
**Project Dates:** 11/02/06 - 05/23/11  
**Direct:** $111,833  
**F & A:** $27,958

**A Randomized, Open-Label, Controlled-Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-Line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-Over Second-Line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy Only Arm**

**Sponsor:** PPD Development  
**Award:** 20050236 (07031573)  
**Project Dates:** 11/02/06 - 05/23/11  
**Direct:** $197,672  
**F & A:** $49,419

**Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE)**

**Sponsor:** Bristol Myers Squibb  
**Budget Dates:** 05/15/02 - 05/15/09  
**Direct:** $1,200  
**F & A:** $300

**Conduction System Remodeling after Myocardial Infarction**

**Sponsor:** VAMC  
**Budget Dates:** 04/01/09 - 03/31/10  
**Direct:** $160,000  
**F & A:** $0

O’Brien, Terrence

**Principal Investigator**

**Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE)**

**Sponsor:** Bristol Myers Squibb  
**Budget Dates:** 05/15/02 - 05/15/09  
**Direct:** $1,200  
**F & A:** $300

Oates, James

**Principal Investigator**

**Urine Biomarkers of Lupus Nephritis in Aspreva Management Study**

**Sponsor:** VAMC  
**Budget Dates:** 09/01/08 - 08/31/10  
**Direct:** $180,154  
**F & A:** $85,488

**Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis**

**Sponsor:** NIH/NIA  
**Budget Dates:** 09/01/08 - 08/31/09  
**Direct:** $185,843  
**F & A:** $82,871

**Sphingosine Phosphate Role in Inflammation**

**Sponsor:** NIH/NIGMS  
**Budget Dates:** 09/01/08 - 08/31/10  
**Direct:** $152,939  
**F & A:** $5,000

Obeid, Lina

**Principal Investigator**

**Sphingosine Phosphate Role in Inflammation**

**Sponsor:** NIH/NIGMS  
**Budget Dates:** 09/01/08 - 08/31/10  
**Direct:** $180,154  
**F & A:** $85,488

**Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis**

**Sponsor:** NIH/NIA  
**Budget Dates:** 09/01/08 - 08/31/09  
**Direct:** $185,843  
**F & A:** $82,871

**Sphingolipids in Cancer Biology and Therapy: Project 3**

**Sponsor:** NIH/NCI  
**Budget Dates:** 07/01/98 - 08/31/10  
**Direct:** $152,939  
**F & A:** $5,000

**The Role of Sphingosine Kinase in Systemic Lupus Erythematosus**

**Sponsor:** Alliance for Lupus Research  
**Budget Dates:** 02/01/09 - 01/31/10  
**Direct:** $120,605  
**F & A:** $9,648
<table>
<thead>
<tr>
<th>Mentor</th>
<th>PI: Obeid, Lina</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ceramide Synthases CERS5 and CERS6 Regulate Pathways of Programmed Cell Death</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIEHS</td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td></td>
</tr>
<tr>
<td>Award: 1 F30 ES016975-01 (07120519-2)</td>
<td></td>
</tr>
<tr>
<td>Direct $36,182</td>
<td></td>
</tr>
<tr>
<td><strong>A Systems Biology Approach to Determine the Role of Sphingolipids in Extending the Lifespan of Yeast via Caloric Restriction</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Amer. Federation for Aging</td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td></td>
</tr>
<tr>
<td>Award: 07121257-1</td>
<td></td>
</tr>
<tr>
<td>Direct $43,350</td>
<td></td>
</tr>
<tr>
<td><strong>The Role of Sphingosine Kinase 1 in Ras-Initiated Lung Carcinogenesis</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NHLBI</td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td></td>
</tr>
<tr>
<td>Award: 1 F30 HL093991-01A1 (08040386-2)</td>
<td></td>
</tr>
<tr>
<td>Direct $36,091</td>
<td></td>
</tr>
<tr>
<td><strong>The Sphingolipid Pathway in Colon Cancer Chemoprevention</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NCI</td>
<td></td>
</tr>
<tr>
<td>Dept: Pathology and Laboratory Medicine</td>
<td></td>
</tr>
<tr>
<td>Award: 1 R01 CA124667-01A1 (08030341-2)</td>
<td></td>
</tr>
<tr>
<td>Direct $207,500</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>PI: Pannu, Jaspreet</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TGF-Beta Receptor Signaling in Scleroderma</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIAMS</td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td></td>
</tr>
<tr>
<td>Award: 2 R01 AR044883-10A2 (07111550-1)</td>
<td></td>
</tr>
<tr>
<td>Direct $220,000</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PI: Parsons, Christopher</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>An Animal Model for Kaposis's Sarcoma</strong></td>
</tr>
<tr>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Award: 5 K08 CA103858-05 (08071492)</td>
</tr>
<tr>
<td>Project Dates: 09/27/04 - 08/31/10</td>
</tr>
<tr>
<td>Direct $123,225</td>
</tr>
<tr>
<td><strong>South Carolina COBRE for Oral Health Grant - Project 7</strong></td>
</tr>
<tr>
<td>Sponsor: NIH/NCRR</td>
</tr>
<tr>
<td>Dept: Craniofacial Biology</td>
</tr>
<tr>
<td>Award: 5 P20 RR017696-08 (09033151-10)</td>
</tr>
<tr>
<td>Project Dates: 09/27/04 - 08/31/10</td>
</tr>
<tr>
<td>Direct $150,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PI: Peura, Jennifer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy On Top of Standard Therapy, On Morbidity and Mortality When Initiated Early after Hospitalization for Acute Decompensated Heart Failure</strong></td>
</tr>
<tr>
<td>Sponsor: Novartis Corp.</td>
</tr>
<tr>
<td>Award: Spp100A2368 (09050932)</td>
</tr>
<tr>
<td>Project Dates: 04/01/09 - 06/30/11</td>
</tr>
<tr>
<td>Direct $67,701</td>
</tr>
<tr>
<td><strong>Role of Angiotensin II in Medullary Solute and Water Reabsorption</strong></td>
</tr>
<tr>
<td>Sponsor: Dialysis Clinics, Inc.</td>
</tr>
<tr>
<td>Award: C-3052 (East Cooper) (09010876)</td>
</tr>
<tr>
<td>Project Dates: 03/01/09 - 02/28/10</td>
</tr>
<tr>
<td>Direct $53,425</td>
</tr>
<tr>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using GENZ-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis</strong></td>
</tr>
<tr>
<td>Sponsor: Genzyme Corp.</td>
</tr>
<tr>
<td>Award: APB00108 (09021186)</td>
</tr>
<tr>
<td>Project Dates: 01/29/09 - 02/01/10</td>
</tr>
<tr>
<td>Direct $96,804</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PI: Raymond, John</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammatory Mediators of Glomerular Disease (REAP)</strong></td>
</tr>
<tr>
<td>Sponsor: VAMC</td>
</tr>
<tr>
<td>Award: (0506630)</td>
</tr>
<tr>
<td>Project Dates: 01/01/09 - 12/31/09</td>
</tr>
<tr>
<td>Direct $250,000</td>
</tr>
<tr>
<td><strong>Roles for Calmodulin in 5-HT Receptor Function</strong></td>
</tr>
<tr>
<td>Sponsor: VAMC</td>
</tr>
<tr>
<td>Award: (0506631)</td>
</tr>
<tr>
<td>Project Dates: 07/01/08 - 06/30/09</td>
</tr>
<tr>
<td>Direct $139,500</td>
</tr>
<tr>
<td><strong>Mechanisms of Regulation of NHE-1</strong></td>
</tr>
<tr>
<td>Sponsor: NIH/NIDDK</td>
</tr>
<tr>
<td>Award: 2 R01 DK052448-10A2 (071092984)</td>
</tr>
<tr>
<td>Project Dates: 07/01/08 - 06/30/09</td>
</tr>
<tr>
<td>Direct $212,500</td>
</tr>
<tr>
<td><strong>Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury</strong></td>
</tr>
<tr>
<td>Sponsor: NIH/NIDDK</td>
</tr>
<tr>
<td>Dept: Medicine</td>
</tr>
<tr>
<td>Award: 1 K08 DK080944-01 (07060383-1)</td>
</tr>
<tr>
<td>Direct $138,850</td>
</tr>
<tr>
<td><strong>Regulation of 5-HT1A Receptor by Calmodulin</strong></td>
</tr>
<tr>
<td>Sponsor: NIH/NHLBI</td>
</tr>
<tr>
<td>Dept: Medicine</td>
</tr>
<tr>
<td>Award: 1 K01 HL092606-01 (07071610-1)</td>
</tr>
<tr>
<td>Direct $100,784</td>
</tr>
<tr>
<td><strong>Discovery of Urine Biomarkers in Patients with Glomerular Disease</strong></td>
</tr>
<tr>
<td>Sponsor: Nephcure Foundation</td>
</tr>
<tr>
<td>Dept: Medicine</td>
</tr>
<tr>
<td>Award: Y011 (07120101-1)</td>
</tr>
<tr>
<td>Direct $99,900</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>Raymond, John</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Reuben, Adrian</td>
</tr>
<tr>
<td>Romagnuolo, Joseph</td>
</tr>
<tr>
<td>Sahn, Steven</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Sahn, Steven

**Principal Investigator**

**A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF)**

**Sponsor:** PPD Development  
**Award:** GS-US-231-0101 (09032517)  
**F & A:** Project Dates: 01/30/09 - 12/31/11  
**Budget Dates:** 01/30/09 - 12/31/11  
**Direct:** $210,160  
**F & A:** $51,915

Salgado, Cassandra

**Co-Investigator**

**Copper Antimicrobial Research Program (CAP)**

- **PI:** Michael Schmidt  
- **Dept:** Microbiology and Immunology  
- **Sponsor:** Advanced Technology Institute  
- **Award:** 2007-614/Mod. No. 4 (08052315-1)  
- **Direct:** $1,003,994

Sekine, Hedeharu

**Principal Investigator**

**Altered Somatic Mutation in IgAD/CVID; Association with Deficiency of Msh4/5**

**Sponsor:** NIH/NIAID  
**Award:** 1 R21 AI079800-01 (07111555)  
**Budget Dates:** 07/07/08 - 06/30/09  
**Direct:** $150,000  
**F & A:** $71,250

**A Role for the Msh4/5 Heterodimers in IgA Deficiency and CVID**

**Sponsor:** US Immunodeficiency Network  
**Award:** COA #40/N01-AI-30070 (08081921)  
**Budget Dates:** 10/01/07 - 01/31/10  
**Direct:** $102,740  
**F & A:** $47,260

Shapshak, Dag

**Principal Investigator**

**DHEC HIV Testing in Hospital Emergency Departments**

**Sponsor:** SC DHEC  
**Award:** HV-8-941 (08032033)  
**Budget Dates:** 09/30/08 - 09/29/10  
**Direct:** $74,800  
**F & A:** $0

Sherman, Carol

**Principal Investigator**

**Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology**

**Sponsor:** Eli Lilly  
**Award:** H3E-MC-JMIG (08091295)  
**Budget Dates:** 09/03/08 - 11/01/13  
**Direct:** $167,891  
**F & A:** $41,098

**A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404**

**Sponsor:** Novartis Corp.  
**Award:** ASA404A2302 (08111391)  
**Budget Dates:** 09/30/08 - 03/31/11  
**Direct:** $148,541  
**F & A:** $36,510

**A Phase I, Safety and Tolerability Study of LBH589 in Combination with Sorafenib in Patients with Advanced Renal Cell Carcinoma and Non-Small Cell Lung Carcinoma (NSCLC) of Non-Squamous Histologies**

**Sponsor:** Harry Drabkin  
**Dept:** Medicine  
**Award:** CLBH589BUS16T (08123051-1)  
**Direct:** $895,778

Silver, Richard

**Principal Investigator**

**Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Intestinal Lung Disease - Scleroderma Lung Study II (SLSII)**

**Sponsor:** Univ. of California, Los Angeles  
**Award:** 1460 GKB111/1 R01 HL08990 (07100897)  
**Budget Dates:** 10/01/08 - 07/30/09  
**Direct:** $57,229  
**F & A:** $26,326

**Dose-Dependent Effects of Bosentan on Angiogenesis**

**Sponsor:** Actelion Pharmaceuticals  
**Award:** New Bosentan (08032034)  
**Budget Dates:** 03/01/08 - 06/30/10  
**Direct:** $35,854  
**F & A:** $8,964

**DISTOL1: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine - A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study**

**Sponsor:** United Therapeutics  
**Award:** TDE-DU-201 (08120990)  
**Budget Dates:** 02/11/09 - 06/30/10  
**Direct:** $88,100  
**F & A:** $21,400

**An Open-Label Trial to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis, CA180-267-010**

**Sponsor:** Bristol Myers Squibb  
**Award:** CA180-267-010 (09010881)  
**Budget Dates:** 02/12/09 - 01/31/11  
**Direct:** $74,193  
**F & A:** $17,798

**DISTOL-EXT: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study**

**Sponsor:** United Therapeutics  
**Award:** TDE-DU-202 (09061383)  
**Budget Dates:** 04/30/09 - 10/31/13  
**Direct:** $40,660  
**F & A:** $8,964

**Two Stage Genome-wide Association Study in Systemic Sclerosis**

**Sponsor:** Univ. of Texas Health Science Center at Houston  
**Award:** UTHSC-0000363494 (09070744)  
**Budget Dates:** 06/16/09 - 08/31/11  
**Direct:** $16,949  
**F & A:** $8,051

---

**College of Medicine**

**Medical University of South Carolina**

**Medicine**

**Research Faculty Activity**

---

**Annual Report for Research FY2009**

---

**76**
<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>PI</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>Dept</th>
<th>Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silver, Richard</td>
<td>Hon Yuen</td>
<td>NIH/NIDCR</td>
<td>148,350</td>
<td>Health Professions</td>
<td>5 R21 DE017360-02 (08052830-1)</td>
</tr>
<tr>
<td></td>
<td>Galina Bogatkevich</td>
<td>Boehringer Ingelheim Pharma</td>
<td>25,000</td>
<td>Medicine</td>
<td>43023110 (08100273-1)</td>
</tr>
<tr>
<td></td>
<td>Galina Bogatkevich</td>
<td>NIH/NIAMS</td>
<td>116,151</td>
<td>Medicine</td>
<td>5 K01 AR051052-05 (09030630-1)</td>
</tr>
<tr>
<td></td>
<td>Stacie Vela</td>
<td>Amer. College of Gastroenter</td>
<td>9,778</td>
<td>Medicine</td>
<td>(07120307-1)</td>
</tr>
<tr>
<td></td>
<td>Kathie Hermayer</td>
<td>Sanofi Synthelabo, Inc.</td>
<td>15,759</td>
<td>Medicine</td>
<td>EFC 5826 (06011933-2)</td>
</tr>
<tr>
<td></td>
<td>Kathie Hermayer</td>
<td>Sanofi Synthelabo, Inc.</td>
<td>480</td>
<td>Medicine</td>
<td>EFC 5826 (06011933-2)</td>
</tr>
</tbody>
</table>

### Silver, Richard

- **Co-Investigator**
- **Oral Health in People with Systemic Sclerosis**
  - PI: Hon Yuen
  - Sponsor: NIH/NIDCR
  - Direct $148,350
  - Dept: Health Professions
  - Award: 5 R21 DE017360-02 (08052830-1)

- **Inhibition of Thrombin and Thrombin-Induced Signaling Molecules in Pulmonary Fibrosis by Dabigatran**
  - PI: Galina Bogatkevich
  - Sponsor: Boehringer Ingelheim Pharma
  - Direct $25,000
  - Dept: Medicine
  - Award: 43023110 (08100273-1)

- **CTGF-Interacting Proteins in Scleroderma Lung Fibrosis**
  - PI: Galina Bogatkevich
  - Sponsor: NIH/NIAMS
  - Direct $116,151
  - Dept: Medicine
  - Award: 5 K01 AR051052-05 (09030630-1)

### Silvestri, Gerard

- **Principal Investigator**
- **K24 Mid-Career Investigator Award in Patient-Oriented Research**
  - PI: Hon Yuen
  - Sponsor: NIH/NCI
  - Budget Dates: 07/01/08 - 06/30/09
  - Direct $121,661
  - Award: 5 K24 CA120494-02 (08072336)

### Sims, Kellie

- **Principal Investigator**
- **A Systems Biology Approach to Determine the Role of Sphingolipids in Extending the Lifespan of Yeast via Caloric Restriction**
  - PI: Amer. Federation for Aging
  - Sponsor: NIH/NCI
  - Budget Dates: 07/01/08 - 06/30/12
  - Direct $43,350
  - Award: (07121257)

### Siskind, Leah

- **Principal Investigator**
- **Role of Ceramide in Aging Related Diseases**
  - PI: VAMC
  - Sponsor: Amer. College of Gastroenter
  - Budget Dates: 01/01/09 - 12/31/11
  - Direct $145,300
  - Award: (08061962)

### Smith, Edwin

- **Principal Investigator**
- **Long-Term Bosentan, Open-Label Extension of RAPIDS-2 Study in Systemic Sclerosis Patients with Ischemic Digital Ulcers**
  - PI: Actelion Pharmaceuticals
  - Sponsor: NIH/NCI
  - Budget Dates: 05/27/04 - 12/31/09
  - Direct $5,754
  - Award: PROTOCOL#AC-052-333 (04062111)

- **Continuation of the Consortium for the Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) Registry**
  - PI: Univ. of Alabama, Birmingham
  - Sponsor: VAMC
  - Budget Dates: 09/30/08 - 09/29/11
  - Direct $34,259
  - Award: HHSN268200682278C (08090361)

### Smolka, Adam

- **Co-Investigator**
- **Proteomic Analysis of Intraductal Papillary Mucinous Neoplasm Cyst Aspirate**
  - PI: Stacie Vela
  - Sponsor: Amer. College of Gastroenter
  - Direct $9,778
  - Dept: Medicine
  - Award: (07120307-1)

### Soule, Jeremy

- **Principal Investigator**
- **Epidemiology of Diabetes Intervention and Complications - Clinical Coordinating Center (EDIC) Clinic #8**
  - PI: Case Western Reserve Univ.
  - Sponsor: RES429767/N01-DK-6-2203 (08010942)
  - Budget Dates: 03/01/96 - 02/28/26
  - Direct $115,940
  - Award: RES429767/N01-DK-6-2203 (08010942)

- **DEFEND 1: Durable-Response Therapy Evaluation for Early- or New-Onset Type 1 Diabetes**
  - PI: Tolerex, Inc.
  - Sponsor: Tolerex, Inc.
  - Budget Dates: 07/17/08 - 07/16/11
  - Direct $162,506
  - Award: TRX4_DM_006_NA_08 (08101014)

- **Technology Acceptance and Barriers Study**
  - PI: Cetus Group, LLC
  - Sponsor: Cetus Group, LLC
  - Budget Dates: 02/01/09 - 04/30/09
  - Direct $4,420
  - Award: CTS-MDT-1107 (09012786)

- **Co-Investigator**
- **Randomized, Multi-National, Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering Risk Factors (crescendo)**
  - PI: Kathie Hermayer
  - Sponsor: Sanofi Synthelabo, Inc.
  - Direct $38,400
  - Dept: Medicine
  - Award: EFC 5826 (06011933-2)
Steinberg, Daniel

**Principal Investigator**

**A 104-Week, Randomized, Double-Blind, Parallel-Arm, Multi-Center, Phase IIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Patient with Coronary Artery Disease Who Require Coronary Angiography**

**Sponsor:** AstraZeneca

**Award:** D356C0001 (08112432)

**Budget Dates:** 12/10/08 - 12/31/11

**Direct:** $1,191,940

**Project Dates:** 12/10/08 - 12/31/11

**F & A:** $297,110

**Endovascular Valve Edge-to-Edge Repair Study EVEREST II**

**Sponsor:** Evalve, Inc.

**Award:** (09022044)

**Budget Dates:** 01/13/09 - 12/31/14

**Direct:** $39,105

**Project Dates:** 01/13/09 - 12/31/14

**F & A:** $8,651

Stenbit, Antine

**Principal Investigator**

**Localization and Function of the nNOS/Alpha Syntrophin Complex in the Heart**

**Sponsor:** Amer. Heart Assoc.

**Award:** 0535043N (06041046)

**Budget Dates:** 08/01/08 - 07/31/09

**Direct:** $59,091

**Project Dates:** 08/01/08 - 07/31/09

**F & A:** $5,909

**Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects with Cystic Fibrosis**

**Sponsor:** PPD Development

**Award:** 12429 (08050129)

**Budget Dates:** 04/25/08 - 04/30/10

**Direct:** $4,160

**Project Dates:** 04/25/08 - 04/30/10

**F & A:** $1,040

**Program for Adult Care Excellence (PACE)**

**Sponsor:** Cystic Fibrosis Fdn.

**Award:** STENB08AC0 (08053051)

**Budget Dates:** 07/01/08 - 06/30/09

**Direct:** $25,000

**Project Dates:** 07/01/08 - 06/30/09

**F & A:** $2,000

**Circulating Stem Cells and Cytokine Profile in Better Survivors of ARDS/ALI**

**Sponsor:** Robert and Molly Tarr Charitable Fdn.

**Award:** (09021615)

**Budget Dates:** 03/01/09 - 02/28/10

**Direct:** $47,500

**Project Dates:** 03/01/09 - 02/28/10

**F & A:** $2,500

Stuart, Robert

**Principal Investigator**

**Alpha-1 Association Genetic Counseling Center**

**Sponsor:** Alpha-1 Assoc.

**Award:** (08062605)

**Budget Dates:** 07/01/08 - 06/30/09

**Direct:** $73,510

**Project Dates:** 06/01/07 - 06/30/09

**F & A:** $0

**Registry Program and ACT Study**

**Sponsor:** Alpha-1 Fdn.

**Award:** (08092536)

**Budget Dates:** 07/01/08 - 06/30/09

**Direct:** $243,670

**Project Dates:** 07/01/08 - 06/30/09

**F & A:** $0

**Rare Lung Disease Clinical Research Network**

**Sponsor:** Univ. of Cincinnati

**Award:** 469/3U54RR019498-05S1 (09010257)

**Budget Dates:** 08/01/08 - 07/31/09

**Direct:** $65,923

**Project Dates:** 08/01/05 - 07/31/09

**F & A:** $31,313

**MycopHENolate vs. Oral Cyclophosphamide in Scleroderma Intersitial Lung Disease - Scleroderma Lung Study II (SLSII)**

**Sponsor:** Univ. of California, Los Angeles

**Direct:** $57,229

**Award:** 1460 GKB111/1 R01 HL08990 (07100897-1)

**Mentor**

**Family Health History**

**Sponsor:** Alpha-1 Fdn.

**Direct:** $3,000

**Award:** (08100899-1)

**Medicine**

**PI:** Richard Silver

**Dept:** Medicine

**PI:** Dawn McGee

**Dept:** Medicine

Strange, Charlie

**Principal Investigator**

**Alpha-1 Association Genetic Counseling Center**

**Sponsor:** Alpha-1 Assoc.

**Award:** (08062605)

**Budget Dates:** 07/01/08 - 06/30/09

**Direct:** $73,510

**Project Dates:** 06/01/07 - 06/30/09

**F & A:** $0

**Registry Program and ACT Study**

**Sponsor:** Alpha-1 Fdn.

**Award:** (08092536)

**Budget Dates:** 07/01/08 - 06/30/09

**Direct:** $243,670

**Project Dates:** 07/01/08 - 06/30/09

**F & A:** $0

**Rare Lung Disease Clinical Research Network**

**Sponsor:** Univ. of Cincinnati

**Award:** 469/3U54RR019498-05S1 (09010257)

**Budget Dates:** 08/01/08 - 07/31/09

**Direct:** $65,923

**Project Dates:** 08/01/05 - 07/31/09

**F & A:** $31,313

**Co-PI or Project Leader**

**MycopHENolate vs. Oral Cyclophosphamide in Scleroderma Intersitial Lung Disease - Scleroderma Lung Study II (SLSII)**

**Sponsor:** Univ. of California, Los Angeles

**Direct:** $57,229

**Award:** 1460 GKB111/1 R01 HL08990 (07100897-1)

**Mentor**

**Family Health History**

**Sponsor:** Alpha-1 Fdn.

**Direct:** $3,000

**Award:** (08100899-1)
Stuart, Robert

**Principal Investigator**

A Randomized, Phase Ib, Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

**Sponsor:** Seattle Genetics, Inc.

**Award:** SG040-0005 (07082336)

**Budget Dates:** 07/09/07 - 09/15/15

**Project Dates:** 07/09/07 - 09/15/15

**Direct:** $129,327

**F & A:** $32,332

A Phase 2, Open-Label, Multi-Center, Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients > 60 Years of Age with Previously Untreated Acute Myeloid Leukemia

**Sponsor:** Sunesis Pharmaceuticals, Inc.

**Award:** SPO-0014 (08020603)

**Budget Dates:** 02/04/08 - 03/11/13

**Project Dates:** 02/04/08 - 03/11/13

**Direct:** $148,056

**F & A:** $37,014

Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) Versus VELCADE and Dexamethasone (VD) Versus VELCADE, Melphalan, and Prednisone (VMP)

**Sponsor:** Millennium Pharmaceuticals

**Award:** C05009 (08031825)

**Budget Dates:** 03/18/08 - 03/17/13

**Project Dates:** 03/18/08 - 03/17/13

**Direct:** $28,004

**F & A:** $7,001

Phase 3, Open-Label, Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)

**Sponsor:** INC Research, Inc.

**Award:** 0001A3-300-GL (08092323)

**Budget Dates:** 09/25/08 - 12/01/13

**Project Dates:** 09/25/08 - 12/01/13

**Direct:** $135,988

**F & A:** $33,372

An Open-Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

**Sponsor:** Amgen

**Award:** 20030213-249 (08111074)

**Budget Dates:** 11/18/08 - 12/31/10

**Project Dates:** 11/18/08 - 12/31/10

**Direct:** $200,205

**F & A:** $49,301

**SWOG Clinical Trials Initiative - Multiple Studies - Multiple Sponsors**

**Sponsor:** Southwest Oncology Group

**Award:** SWOG - CTI (09031781)

**Budget Dates:** 03/01/09 - 03/17/20

**Project Dates:** 03/01/09 - 03/17/20

**Direct:** $43,478

**F & A:** $6,522

Sturdivant, Lacy

**Principal Investigator**

SMARTDELAY Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART - AV)

**Sponsor:** Boston Scientific Corp.

**Award:** SMART DELAY - AV (08082126)

**Budget Dates:** 09/16/08 - 06/30/10

**Project Dates:** 09/16/08 - 06/30/10

**Direct:** $33,660

**F & A:** $7,660

Sturdivant, Rachel

**Principal Investigator**

#C-3039: Funding for Clinical Research Coordinator

**Sponsor:** Dialysis Clinics, Inc.

**Award:** C-C-3039 (09011086)

**Budget Dates:** 01/01/09 - 12/31/09

**Project Dates:** 01/01/09 - 12/31/09

**Direct:** $30,000

**F & A:** $0

Taylor, Marian

**Principal Investigator**

An Observational Study of the Occurrence of Serious Adverse Reactions among Patients Who Receive Optison in Routine Medical Practice (Optison Registry Study)

**Sponsor:** General Electric

**Award:** GE191-003 (08071826)

**Budget Dates:** 07/08/08 - 07/01/10

**Project Dates:** 07/08/08 - 07/01/10

**Direct:** $65,000

**F & A:** $15,500

Preventing Heart Disease in Women of South Carolina

**Sponsor:** Duke Endowment

**Award:** 6075-SP (08102267)

**Budget Dates:** 07/01/08 - 06/30/09

**Project Dates:** 07/01/08 - 06/30/09

**Direct:** $100,800

**F & A:** $0

Thomas, James

**Principal Investigator**

A Multi-Center, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMPROVE IT)

**Sponsor:** Schering-Plough Corp.

**Award:** P04103-3139 (05102820)

**Budget Dates:** 11/01/05 - 10/30/10

**Project Dates:** 11/01/05 - 10/30/10

**Direct:** $64,600

**F & A:** $16,150

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2)-TIMI 50

**Sponsor:** Schering-Plough Research Institute

**Award:** P04737/P05183 (07112882)

**Budget Dates:** 09/01/07 - 11/30/10

**Project Dates:** 09/01/07 - 11/30/10

**Direct:** $180,000

**F & A:** $45,000
Thomas, James

**Principal Investigator**

**A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in Stable CHD Patients with a Documented Recent Acute Coronary Syndrome (ACS)**

**Sponsor:** Hoffman-Laroche, Inc.
**Budget Dates:** 03/04/08 - 03/01/11
**Direct:** $1,200

**A Phase IIa, Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication**

**Sponsor:** Colorado Prevention Center
**Budget Dates:** 01/20/09 - 09/30/10
**Direct:** $132,198

**A Phase 2, Double-Blind, Placebo-Controlled, Randomized, International, Multi-Center Study of Oral Tac-101 as Second Line Treatment in Patients with Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy**

**Sponsor:** Quintiles Pacific, Inc.
**Budget Dates:** 12/08/08 - 12/07/13
**Direct:** $345,076

**COEE for Gastrointestinal Cancer Diagnostics - Endowed Chair Medicine**

**Sponsor:** MUSC Fdn.
**Budget Dates:** 07/01/08 - 06/30/09
**Direct:** $150,000

**Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib**

**Sponsor:** Bayer Corp.
**Budget Dates:** 02/24/09 - 04/01/14
**Direct:** $2,835,229

**A Randomized, Open-Label, Multi-Institution, Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)**

**Sponsor:** Genentech, Inc.
**Budget Dates:** 02/10/09 - 03/11/15
**Direct:** $2,835,229

**MUSC Cancer Center Support Grant: Senior Leadership**

**PI:** Andrew Kraft
**Dept:** Pathology and Laboratory Medicine
**Award:** 5 P30 CA138313-01 (08042268-2)

**Tourkina, Eleni**

**Principal Investigator**

**Hyaluronic Acid is Overexpressed in Fibrotic Lung Tissue and Promotes Collagen Expression**

**Sponsor:** US Army/USAMRAA
**Budget Dates:** 03/15/09 - 03/14/10
**Direct:** $46,296

**Anti-Fibrotic and Anti-Inflammatory Roles of Caveolin-1 in Lung Disease**

**Sponsor:** NIH/NIAMS
**Budget Dates:** 07/01/08 - 06/30/09
**Direct:** $106,275

**Trojanowska, Maria**

**Principal Investigator**

**TGF-Beta Receptor Signaling in Scleroderma**

**Sponsor:** NIH/NIAMS
**Budget Dates:** 07/01/08 - 05/31/09
**Direct:** $220,000

**The Molecular Mechanisms of Fibrosis**

**Sponsor:** NIH/NIAMS
**Budget Dates:** 04/01/09 - 03/31/10
**Direct:** $220,000

**mTOR and the Regulation of Collagen Synthesis**

**PI:** Andreea Bujor
**Dept:** Medicine
**Award:** 0 P01 CA138313-01 (08042268-2)

**Role of Ets Genes in Transformation and Differentiation - Project 3**

**PI:** Dennis Watson
**Dept:** Pathology and Laboratory Medicine
**Award:** 5 P01 CA078582-10 (09022680-4)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Dates</th>
<th>Budget Dates</th>
<th>Sponsor</th>
<th>Amount Direct</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ullian</td>
<td>05/10/08 - 08/31/13</td>
<td>Direct: $278,738</td>
<td>General Electric</td>
<td></td>
</tr>
<tr>
<td>Adrian Van Bakel</td>
<td>08/10/07 - 11/30/09</td>
<td>Direct: $41,340</td>
<td>Synvista Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Stacie Vela</td>
<td>07/01/08 - 06/30/09</td>
<td>Direct: $138,850</td>
<td>Amer. College of Gastroenterology</td>
<td></td>
</tr>
<tr>
<td>Juan Carlos Velez</td>
<td>06/06/07 - 08/31/10</td>
<td>Direct: $75,000</td>
<td>NIH/NIDDK</td>
<td></td>
</tr>
<tr>
<td>Patricia Watson</td>
<td>07/01/08 - 06/30/09</td>
<td>Direct: $138,850</td>
<td>NIH/NCI</td>
<td></td>
</tr>
<tr>
<td>Michael Ullian</td>
<td>07/01/08 - 06/30/09</td>
<td>Direct: $75,000</td>
<td>NIH/NCI</td>
<td></td>
</tr>
<tr>
<td>Adrian Van Bakel</td>
<td>07/01/08 - 06/30/09</td>
<td>Direct: $75,000</td>
<td>NIH/NCI</td>
<td></td>
</tr>
<tr>
<td>Stacie Vela</td>
<td>07/01/08 - 06/30/09</td>
<td>Direct: $9,778</td>
<td>NIH/NCI</td>
<td></td>
</tr>
<tr>
<td>Juan Carlos Velez</td>
<td>07/01/08 - 06/30/09</td>
<td>Direct: $9,778</td>
<td>NIH/NCI</td>
<td></td>
</tr>
</tbody>
</table>

**Research Faculty Activity**

**Medical University of South Carolina College of Medicine**

**Research Faculty Activity**

**Vela Aquino, Marcelo**

**Principal Investigator**

**Nuclear Trafficking of the Angiotensin II Type 1a Receptor**

- **Sponsor**: Dialysis Clinics, Inc.
- **Budget Dates**: 07/01/08 - 06/30/10
- **Direct**: $141,847

**Van Bakel, Adrian**

**Principal Investigator**

**A 24-Month, Multi-Center, Randomized, Open-Label, Non-Inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-Controlled Study Drug in De Novo Heart Transplant Recipients**

- **Sponsor**: Novartis Corp.
- **Budget Dates**: 09/01/05 - 04/30/10
- **Direct**: $45,965

**A Double-Blind, Placebo-Controlled, Multi-Center Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND HF)**

- **Sponsor**: Cleveland Clinic Fdn.
- **Budget Dates**: 06/06/07 - 08/31/10
- **Direct**: $1,000

**Vela, Stacie**

**Principal Investigator**

**Impedance pH and Electron Microscopy to Evaluate Endoscopy-Negative Reflux Disease**

- **Sponsor**: Amer. College of Gastroenterology
- **Budget Dates**: 07/01/08 - 06/30/09
- **Direct**: $75,000

**Proteomic Analysis of Intraductal Papillary Mucinous Neoplasm Cyst Aspirate**

- **Sponsor**: Amer. College of Gastroenterology
- **Budget Dates**: 07/01/08 - 06/30/09
- **Direct**: $9,778

**Velez, Juan Carlos**

**Principal Investigator**

**Angiotensin Metabolite Formation by Podocytes: Implications in Glomerular Injury**

- **Sponsor**: NIH/NIDDK
- **Budget Dates**: 07/01/08 - 06/30/09
- **Direct**: $138,850

**Non-Ace Pathways for Angiotensin II and Angiotensin-Derived Peptides Generation in Kidney Cells**

- **Sponsor**: DCI Paul Teschan Research Fund
- **Budget Dates**: 12/01/08 - 11/30/09
- **Direct**: $41,340

**A Multi-Center, Randomized, Double-Blind, Active-Controlled, Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment with Vildagliptin (50 mg od or 100 mg od) Versus Sitagliptin (25 mg od) in Patients with Type 2 Diabetes and Severe Renal Insufficiency**

- **Sponsor**: Novartis Corp.
- **Budget Dates**: 08/10/07 - 07/31/11
- **Direct**: $12,133

**Watson, Patricia**

**Co-Investigator**

**Role of Ets Genes in Transformation and Differentiation - Project 1**

- **PI**: Dennis Watson
- **Sponsor**: NIH/NCI
- **Direct**: $278,738
### Wiley, Maria

**Co-Investigator**
- **Institution:** Palmetto State Geriatric Education Centers
- **PI:** Ann-Charlotte Granholm
- **Sponsor:** Univ. of South Carolina
- **Direct:** $39,815
- **Award:** 09-1611/18190-FJ07/D31HP0 (08070862-1)

### Willner, Ira

**Principal Investigator**
- **Project Title:** A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy
- **Sponsor:** Ocera Therapeutics, Inc.
- **Budget Dates:** 04/15/09 - 05/11/10
- **Direct:** $39,278
- **Award:** AST-MHE201 (09031675)

### Wray, Dannah

**Principal Investigator**
- **Project Title:** An International, Multi-Center, Prospective, Observational Study of the Safety of Maraviroc Used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients
- **Sponsor:** Icon Clinical Research, Inc.
- **Budget Dates:** 09/03/08 - 08/31/13
- **Direct:** $163,530
- **Award:** A4001067 (08092426)

### Zhang, Xian

**Principal Investigator**
- **Project Title:** Role of Fli-1 Gene in Pathogenic B Cell Development
- **Sponsor:** VAMC
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct:** $261,300
- **Award:** 5 R03 AR054546-03 (09032411)

### Zhang, Zhi-Ren

**Co-Investigator**
- **Institution:** UAB Recessive PKD Research and Translational Core Center
- **PI:** Phillip Bell
- **Sponsor:** Univ. of Alabama, Birmingham
- **Direct:** $132,869
- **Award:** 03/5P30DK074038-04 (08102911-2)

### Zile, Michael

**Principal Investigator**
- **Project Title:** Diastolic Heart Failure: Role of the Extracellular Matrix
- **Sponsor:** VAMC
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct:** $125,000
- **Award:** CARD-009-00F (03063026)

**Co-PI or Project Leader**
- **Institution:** Cardiovascular Proteomics Center - Project 1
- **PI:** Daniel Knapp
- **Sponsor:** NIH/NHLBI
- **Direct:** $72,564
- **Award:** N01-HV-28181 (02030610-83)
Zile, Michael
Co-Investigator
mTOR in Growth and Protection of Hypertrophying Myocardium
PI: Dhandapani Kuppuswamy
Sponsor: NIH/NHLBI
Direct $250,000
Dept: Medicine
Award: 1 R01 HL092124-01A1 (08022938-1)

Role of Protein Acetylation in Ncx1 Expression
PI: Donald Menick
Sponsor: NIH/NHLBI
Direct $250,000
Dept: Medicine
Award: 1 R01 HL095696-01 (08053152-1)

Zwerner, Peter
Principal Investigator
CV185030 - A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Sponsor: Bristol Myers Squibb
Budget Dates: 01/13/09 - 12/31/14
Direct: $283,051
Project Dates: 01/13/09 - 12/31/14
F & A: 69,513
Award: ARISTOTLE CV185-030 (08122947)

RELY-ABLE: Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomized Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes
Sponsor: Boehringer Ingelheim Pharmaceuticals
Budget Dates: 01/20/09 - 12/31/11
Direct: $26,840
Project Dates: 01/20/09 - 12/31/11
F & A: 5,835
Award: RELY-ABLE 1160.71 (08122948)

Microbiology and Immunology
Atkinson, Carl
Principal Investigator
The Role of Complement in Brain Death and Ischemia Reperfusion Injury in a Mouse Heterotopic Heart Transplant Model
Sponsor: Amer. Heart Assoc.
Budget Dates: 07/01/08 - 06/30/09
Direct: $59,091
Project Dates: 07/01/06 - 06/30/10
F & A: 5,909
Award: 0635131N (07061116)

Haque, Azizul
Principal Investigator
Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas
Sponsor: NIH/NCI
Budget Dates: 03/01/09 - 12/31/09
Direct: $209,586
Project Dates: 03/01/09 - 12/31/09
F & A: 90,957
Award: 1 R01 CA129560-01A2 (08030450)

Disruption of HLA Class II-Mediated Immune Recognition of B-Cell Lymphomas
Sponsor: NIH/NCI
Budget Dates: 06/01/09 - 10/31/10
Direct: $10,256
Project Dates: 06/01/09 - 10/31/10
F & A: 4,872
Award: 3 R01 CA129560-01A2S1 (09041580)

Kasman, Laura
Principal Investigator
Ethanologenic / Electricigenic Consolidated Bioprocessing of Cellulosic Biomass: Phase II
Sponsor: MFC Technologies, LLC
Budget Dates: 08/15/08 - 08/14/09
Direct: $97,555
Project Dates: 08/15/08 - 08/14/09
F & A: 46,338
Award: DE-FG02-07ER86319 (08041755)

Liu, Xiang
Co-Investigator
Sphingolipids in Cancer Biology and Therapy: Project 2
PI: Yusuf Hannun
Sponsor: NIH/NCI
Direct $142,415
Dept: Biochemistry and Molecular Biology
Award: 2 P01 CA097132-06 (07101010-6)

May, Harold
Principal Investigator
Kinetics and Threshold Levels of Microbial PCB Dechlorination: N00014-06-1-0091 Expansion
Sponsor: DOD/ONR
Budget Dates: 10/17/05 - 09/30/09
Direct: $89,312
Project Dates: 10/17/05 - 09/30/09
F & A: 42,423
Award: N00014-06-1-0091/P00003 (08070758)

Integrating Microbial Biostimulation and Electrolytic Aeration to Degrade POPs
Sponsor: NIH/NIAMS
Budget Dates: 02/01/02 - 01/31/10
Direct: $247,023
Project Dates: 02/01/02 - 01/31/10
F & A: 48,864
Award: 5 R01 ES016197-02 (09013982)

Co-PI or Project Leader
Ethanologenic / Electricogenic Consolidated Bioprocessing of Cellulosic Biomass: Phase II
PI: Laura Kasman
Sponsor: MFC Technologies, LLC
Direct $97,555
Dept: Microbiology and Immunology
Award: DE-FG02-07ER86319 (08041755-1)
### Norris, James

**Co-PI or Project Leader**

**Modulating Complement to Enhance Apoptosis-Based Therapy of Breast Cancer**

**PI:** Stephen Tomlinson  
**Dept:** Microbiology and Immunology  
**Award:** W81XWH-07-1-0332 (06052484-2)  
**Direct:** $221,840

**Sphingolipids in Cancer Biology and Therapy: Project 2**

**PI:** Yusuf Hannun  
**Dept:** Biochemistry and Molecular Biology  
**Award:** 2 P01 CA097132-06 (07101010-6)  
**Direct:** $142,415

**Mentor**  
**An Animal Model for Kaposi’s Sarcoma**

**PI:** Christopher Parsons  
**Dept:** Medicine  
**Award:** 5 K08 CA103858-05 (08071492-1)  
**Direct:** $123,225

### Pandey, Janardan

**Principal Investigator**

**Epistatic Effects of Fc gammaR and Fc (GM) Genes in Breast Cancer**

**Sponsor:** DOD/US Army  
**Budget Dates:** 06/01/09 - 05/31/10  
**Direct:** $100,000

**Complement and Immunotherapy of Breast Cancer**

**Sponsor:** NIH/NCI  
**Budget Dates:** 10/16/08 - 10/15/09  
**Direct:** $30,000

### Rapisardo, Michelle

**Principal Investigator**

**Radiochemistry Education Award and Junior Faculty Programs (REAP)**

**Sponsor:** SCUREF  
**Budget Dates:** 09/15/05 - 09/14/10  
**Direct:** $271,171

**Copper Antimicrobial Research Program (CAP)**

**Sponsor:** Advanced Technology Institute  
**Budget Dates:** 07/18/08 - 07/17/09  
**Direct:** $1,003,994

### Rubinchik, Semyon

**Co-Investigator**

**Development of Human Monoclonal Antibodies for Neutralization of Avian Influenza Virus (H5N1) and for Use in Diagnosis**

**PI:** Natalie Sutkowski  
**Dept:** Microbiology and Immunology  
**Award:** 67568 (07092645-3)  
**Direct:** $200,057

### Schmidt, Michael

**Principal Investigator**

**Management of the Nuclear Energy Research Advisory Committee (NERAC)**

**Sponsor:** SCUREF  
**Budget Dates:** 09/15/05 - 09/14/10  
**Direct:** $49,537

**Copper Air Quality Program**

**Sponsor:** Advanced Technology Institute  
**Budget Dates:** 07/18/08 - 07/17/09  
**Direct:** $304,037

**Nuclear Forensics Graduate Fellowship Program**

**Sponsor:** SCUREF  
**Budget Dates:** 09/15/05 - 09/14/10  
**Direct:** $387,074

**Clinical Evaluation of the Charles River Laboratories LAL Test for the Presence of (1,3)Beta-D-Glucan Present in Human Serum**

**Sponsor:** Charles River Laboratories  
**Budget Dates:** 12/01/08 - 06/30/10  
**Direct:** $9,745

**Nuclear Forensics Education Award Program**

**Sponsor:** SCUREF  
**Budget Dates:** 06/30/09 - 09/14/10  
**Direct:** $348,450

**Nuclear Forensics Graduate Fellowship Program**

**Sponsor:** SCUREF  
**Budget Dates:** 09/15/05 - 09/14/10  
**Direct:** $176,288
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomlinson, Stephen</td>
<td>Complement Inhibitory Therapy of Lupus</td>
<td>DOD</td>
<td>04/01/09 - 04/30/10</td>
<td>$157,720</td>
<td>$72,551</td>
</tr>
<tr>
<td></td>
<td>Modulating Complement to Enhance Apoptosis-Based Therapy of Breast Cancer</td>
<td>DOD</td>
<td>07/01/08 - 06/30/09</td>
<td>$221,840</td>
<td>$102,046</td>
</tr>
<tr>
<td></td>
<td>Role of Complement in Brain Death Induced Injury to Donor Hearts</td>
<td>NIH/NHLBI</td>
<td>08/01/08 - 07/31/09</td>
<td>$272,318</td>
<td>$101,312</td>
</tr>
<tr>
<td></td>
<td>Therapeutic Intervention in Cervical Spinal Cord Injury</td>
<td>VAMC</td>
<td>10/01/08 - 09/30/09</td>
<td>$48,887</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Controlling Complement in Cerebral Ischemic Injury</td>
<td>NIH/NHLBI</td>
<td>12/01/08 - 11/30/09</td>
<td>$218,475</td>
<td>$100,499</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Minority Predoctoral Fellowship Program</td>
<td>NIH/NCI</td>
<td>09/30/08 - 09/29/09</td>
<td>$34,291</td>
<td>0</td>
</tr>
<tr>
<td>Virella, Gabriel</td>
<td>Medical University of South Carolina AIDS Symposium</td>
<td>Multiple Sponsors</td>
<td>04/01/05 - 03/31/09</td>
<td>$17,000</td>
<td>0</td>
</tr>
<tr>
<td>Voelkel-Johnson, C.</td>
<td>Isolation and Characterization of Prostate Antigen Specific High Affinity TCR</td>
<td>NIH/NCI</td>
<td>03/01/05 - 04/30/13</td>
<td>$110,000</td>
<td>0</td>
</tr>
<tr>
<td>Wright, Cynthia</td>
<td>MUSC-Claffin Cooperative for Postdoctoral Academic Career Development</td>
<td>NIH/NIGMS</td>
<td>08/01/08 - 07/31/09</td>
<td>$336,537</td>
<td>$23,490</td>
</tr>
<tr>
<td></td>
<td>MUSC Minority Student Development Program</td>
<td>NIH/NIGMS</td>
<td>05/01/05 - 04/30/10</td>
<td>$296,521</td>
<td>$18,455</td>
</tr>
<tr>
<td></td>
<td>MUSC Short-Term Research Education Program to Increase Diversity</td>
<td>NIH/NHLBI</td>
<td>05/01/05 - 04/30/10</td>
<td>$102,400</td>
<td>$8,192</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>Calpain Activation of T Cells in Demyelinating Disease</td>
<td>NIH/NINDS</td>
<td>08/01/07 - 03/31/10</td>
<td>$218,475</td>
<td>0</td>
</tr>
<tr>
<td>Adams, Robert</td>
<td>Pediatric Hydroxyurea Phase II Clinical Trial (Baby Hug)</td>
<td>Clinical Trials and Surveys Corp.</td>
<td>08/01/07 - 06/30/12</td>
<td>$146,746</td>
<td>$25,503</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Project Description</td>
<td>Sponsor</td>
<td>Project Dates</td>
<td>Budget Dates</td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>--------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Adams, Robert</td>
<td>Principal Investigator</td>
<td>Stroke with Transfusions Changing to Hydroxyurea (SWITCH)</td>
<td>NIH/NIDA</td>
<td>01/15/01 - 02/28/10</td>
<td>08/01/01 - 07/31/09</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stroke Center for Economic Excellence</td>
<td>SC Research Centers of Economic Excellence</td>
<td>09/01/01 - 08/31/10</td>
<td>06/18/09 - 05/17/10</td>
</tr>
<tr>
<td>Aston-Jones, Gary</td>
<td>Principal Investigator</td>
<td>Control of Dopamine Neuron Firing Patter by Pi-Coupled Receptors</td>
<td>Univ. of Texas</td>
<td>09/01/01 - 08/31/09</td>
<td>06/01/09 - 05/31/10</td>
</tr>
<tr>
<td>Athar, Saima</td>
<td>Co-Investigator</td>
<td>Alterations in Reward Processing During Drug Abstinence</td>
<td>NIH/NIDA</td>
<td>09/01/01 - 08/31/09</td>
<td>07/01/06 - 08/31/10</td>
</tr>
<tr>
<td>Bailey, Byron</td>
<td>Principal Investigator</td>
<td>Implementation of ThinkFirst Injury Prevention Programs in the Lowcountry</td>
<td>SC Dept. of Disabilities and Spec. Needs</td>
<td>100,499 - 02/28/10</td>
<td>07/01/08 - 06/30/09</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Prospective Study of Actifuse TM Synthetic Bone Graft in Patients</td>
<td>Apatech, Inc.</td>
<td>09/01/01 - 08/31/09</td>
<td>06/01/09 - 05/31/09</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Requiring Posteriorateral Instrumented Lumbar Fusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Establishing ThinkFirst Regional Chapters in SC: State Training</td>
<td>SC Dept. of Disabilities and Spec. Needs</td>
<td>100,499 - 02/28/10</td>
<td>07/21/08 - 07/20/11</td>
</tr>
<tr>
<td>Banik, Naren</td>
<td>Principal Investigator</td>
<td>Attenuation of Axonal Damage and Neuronal Death in EAE</td>
<td>NIH/NINDS</td>
<td>09/01/01 - 08/31/09</td>
<td>02/01/09 - 01/31/10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Calpain Activation of T Cells in Demyelinating Disease</td>
<td>NIH/NINDS</td>
<td>09/01/01 - 08/31/09</td>
<td>08/15/06 - 01/31/11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role of Proteinase in Spinal Cord Injury</td>
<td>NIH/NINDS</td>
<td>09/01/01 - 08/31/09</td>
<td>06/01/09 - 05/31/10</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Description</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct $</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------</td>
<td>---------</td>
<td>--------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Banik, Naren</td>
<td>Melatonin as a Therapy for Spinal Cord Injury</td>
<td>Sponsor: SC Spinal Cord Injury Fund</td>
<td>05/15/09 - 04/30/10</td>
<td>79,793</td>
<td></td>
</tr>
<tr>
<td>Bhat, Narayan</td>
<td>Atherogenic Induction of Neuroinflammation</td>
<td>Sponsor: NIH/NINDS</td>
<td>09/15/08 - 09/14/09</td>
<td>45,964</td>
<td></td>
</tr>
<tr>
<td>Buffalari, Deanne</td>
<td>Beta-Noradrenergic Receptor Blockage of Cocaine Withdrawal-Induced Anxiety</td>
<td>Sponsor: NIH/NIDA</td>
<td>02/01/09 - 01/31/10</td>
<td>50,054</td>
<td></td>
</tr>
<tr>
<td>Buhusi, Catalin</td>
<td>CHL1 Deficits and Schizophrenia: Pharmacology and Behavior</td>
<td>Sponsor: NARSAD</td>
<td>09/17/08 - 04/30/09</td>
<td>32,780</td>
<td></td>
</tr>
<tr>
<td>Cason, Angie</td>
<td>Drugs of Abuse, Gender Differences, and Protection by Sweets</td>
<td>Sponsor: NIH/NIDA</td>
<td>07/01/08 - 06/30/09</td>
<td>46,826</td>
<td></td>
</tr>
<tr>
<td>Chandler, L.</td>
<td>Ethanol and ERK/PKB Signaling in Brain</td>
<td>Sponsor: NIH/NIAAA</td>
<td>05/01/08 - 11/13/09</td>
<td>313,510</td>
<td></td>
</tr>
<tr>
<td>Chimowitz, Marc</td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 4</td>
<td>Sponsor: NIH/NIAAA</td>
<td>04/01/80 - 06/30/12</td>
<td>5,300,000</td>
<td></td>
</tr>
<tr>
<td>Cook, James</td>
<td>Role of PPARgamma and PPARgamma Agonists in Septic Shock</td>
<td>Sponsor: Childrens Hospital Research Fdn.</td>
<td>07/01/08 - 06/30/09</td>
<td>47,512</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Role of Eicosanoids in Shock</td>
<td>Sponsor: NIH/NIGMS</td>
<td>04/01/80 - 06/30/12</td>
<td>108,342</td>
<td></td>
</tr>
<tr>
<td>Research Faculty Activity</td>
<td>PI:</td>
<td>Sponsor:</td>
<td>Direct $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-----</td>
<td>----------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cook, James</strong></td>
<td>Lina Obeid</td>
<td>NIH/NIGMS</td>
<td>180,154</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Das, Arabinda</strong></td>
<td>Naren Banik</td>
<td>NIH/NINDS</td>
<td>218,475</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ellegala, Dilantha</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fan, Hongkuan</strong></td>
<td>James Cook</td>
<td>NIH/NIGMS</td>
<td>239,933</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Flynn Longmire, C.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Frankel, Bruce</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Giglio, Pierre</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Granholm, A.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Cook, James

**Sphingosine Phosphate Role in Inflammation**
- PI: Lina Obeid
- Sponsor: NIH/NIGMS
- Direct: $180,154
- Dept: Medicine

**Das, Arabinda**

**Calpain Activation of T Cells in Demyelinating Disease**
- PI: Naren Banik
- Sponsor: NIH/NINDS
- Direct: $218,475
- Dept: Neurosciences

**Ellegala, Dilantha**

**ICH Removal: Minimally Invasive + rt-PA (MISTIE)**
- Sponsor: Johns Hopkins Univ.
- Direct: $88,065
- Project Dates: 03/01/08 - 02/28/10
- Award: 200010363/5 R01 NS046309 08111705

**CLEAR IVH III-Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III**
- Sponsor: Johns Hopkins Univ.
- Direct: $3,216
- Project Dates: 12/01/08 - 04/30/10
- Award: Clear III Start Up 09062978

**Fan, Hongkuan**

**The Role of Eicosanoids in Shock**
- PI: James Cook
- Sponsor: NIH/NIGMS
- Direct: $239,933
- Dept: Neurosciences

**Flynn Longmire, C.**

**A Longitudinal Study of Cognitive and Functional Abilities of Subjects with Either Mild to Moderate Alzheimer's Disease, Mild Cognitive Impairment, or Normal Cognition Using a Neuropsychological Test Battery (NTB)**
- Sponsor: ELN-AIP-901
- Direct: $99,432
- Project Dates: 02/21/06 - 03/31/10
- Award: ELN-AIP-901 06050924

**Observational Study of Long-Term (18 Month) Cognitive Outcomes in Healthy Volunteers, Patients with Mild Cognitive Impairment (MCI) and Patients with Alzheimer’s Disease (AD) Who have Previously had PET Imaging with Florpirimine F 18 (F-AV-45) Injection**
- Sponsor: Avid Radiopharmaceuticals, Inc.
- Direct: $45,020
- Project Dates: 12/01/08 - 04/30/10
- Award: AV-45-A11 09031887

**Frankel, Bruce**

**Clinical Trial Comparing the Blackstone Advent TM Cervical Disc to Anterior Cervical Discectomy and Fusion (SCDF) for the Treatment of One Level Degenerative Disc Disease**
- Sponsor: Blackstone Medical, Inc.
- Direct: $366,456
- Project Dates: 11/10/08 - 11/09/11
- Award: CP-01003B 08080684

**Giglio, Pierre**

**A Randomized, Factorial Design, Phase II Trial of Temozolomide Alone and in Combination with Possible Permutations of Thalidomide, Isotretinoin, and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme**
- Sponsor: Univ. of Texas MD Anderson Cancer Center
- Direct: $9,600
- Project Dates: 09/08/08 - 11/01/13
- Award: 2004-0662 08090873

**Granholm, A.**

**Aminergic Function in Brain Aging and Alzheimer's Disease**
- Sponsor: Univ. of South Florida
- Direct: $130,463
- Project Dates: 07/01/08 - 06/30/09
- Award: 6155-1016-00-A 08041754

**An Animal Model for Age-Related Degeneration**
- Sponsor: NIH/NIA
- Direct: $175,567
- Project Dates: 07/01/08 - 06/30/09
- Award: 5 R01 AG012122-13 08052313

**Dual-Hit Hypothesis of Aging-Related DA Dysfunction**
- Sponsor: NIH/NIA
- Direct: $718,889
- Project Dates: 07/01/08 - 06/30/09
- Award: 5 P01 AG023630-04 08052314

**Palmetto State Geriatric Education Centers**
- Sponsor: Univ. of South Carolina
- Direct: $39,815
- Project Dates: 09/01/07 - 06/30/10
- Award: 09-1611/18190-FJ07/D31HP0 08070862

**Kumar Sambamurti**

**Regulation and Cell Biology of Beta-Secretase**
- PI: Kumar Sambamurti
- Sponsor: NIH/NIA
- Direct: $152,392
- Dept: Neurosciences

---

88 Annual Report for Research FY2009
Gudz, Tatyana

Co-PI or Project Leader
COBRE in Lipidomics - Pilot 2
Pl: Lina Obeid
Dept: Biochemistry and Molecular Biology
Sponsor: NIH/NICRR
Award: 5 P20 RR017677-07 (08070866-8)
Direct $ 50,000

Halford, Jonathan

Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects with Partial Onset Seizures Followed by an Open-Label Extension Study
Sponsor: Johnson and Johnson
Budget Dates: 10/04/06 - 03/15/11
Direct $ 3,553
F & A: 888

A Randomized, Double-Blind, Parallel-Group, Multi-Center Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamite, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures
Sponsor: Quintiles Pacific, Inc.
Budget Dates: 11/30/07 - 12/31/09
Direct $ 17,968
F & A: 4,492

Sponsor: PPD Development
Budget Dates: 05/07/08 - 10/31/09
Direct $ 53,836
F & A: 13,459

Hinson, Vanessa

Principal Investigator
Resident and Fellow Educational Grant
Sponsor: Allergan, Inc.
Budget Dates: 07/01/06 - 12/31/08
Direct $ 8,000
F & A: 0

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment, Sequential, Dose-Escalation, Safety, Tolerability and Preliminary, Efficacy Study of MYOBLOC for the Treatment of Troublesome Sialorrhea in Parkinson’s Disease Patients
Sponsor: Solstice Neurosciences, Inc.
Budget Dates: 09/06/07 - 03/05/09
Direct $ 6,400
F & A: 1,600

Parkinson’s Disease Neuroprotection Clinical Trial Center
Sponsor: NIH/NINDS
Budget Dates: 12/01/07 - 11/30/08
Direct $ 140
F & A: 64

A Multi-Site, Double-Blind, Randomized, Placebo-Controlled Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor
Sponsor: Univ. of South Florida
Budget Dates: 08/19/08 - 11/30/10
Direct $ 11,188
F & A: 2,747

A Pilot Trial of Lithium in Subjects with Progressive Supranuclear Palsy or Corticobasal Degeneration
Sponsor: Westat
Budget Dates: 07/01/08 - 09/29/09
Direct $ 84,808
F & A: 37,612

PARKINSONS DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
Sponsor: NIH/NINDS
Budget Dates: 12/01/08 - 11/30/09
Direct $ 38,900
F & A: 17,894

CD Probe - Cervical Dystonia - Patient Registry for Observation of BOTOX Efficacy
Sponsor: Allergan, Inc.
Budget Dates: 04/01/09 - 03/31/11
Direct $ 55,016
F & A: 13,004

Jayantithi, Lankupalle

Principal Investigator
Norepinephrine Transport Regulation by Phosphorylation
Sponsor: NIH/NIGMS
Budget Dates: 02/01/09 - 01/31/10
Direct $ 151,000
F & A: 69,460

Co-Investigator
Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Project 4
Pl: Ann-Charlotte Granholm
Dept: Neurosciences
Sponsor: NIH/NIA
Award: 5 P01 AG023630-04 (08052314-8)
Direct $ 105,504
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Title</th>
<th>Sponsor/Center</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayanthi, Lankupalle</td>
<td>Co-Investigator</td>
<td>Serotonin Transporter Phosphorylation</td>
<td>NIH/NIMH</td>
<td>09/01/08 - 08/31/09</td>
<td>$212,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 R01 MH062612-07 (09030410-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnson, Kevin</td>
<td>Co-Investigator</td>
<td>Using Neuroimaging, Quantitative EEG and Genetics to Diagnose Depression</td>
<td>Hope for Depression Research</td>
<td>05/01/08 - 04/30/09</td>
<td>$50,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 9-008 (08082838-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalivas, Peter</td>
<td>Principal Investigator</td>
<td>NAC-1, A Cocaine Regulated mRNA in the Rat Brain</td>
<td>Univ. of Pennsylvania</td>
<td>09/01/08 - 08/31/09</td>
<td>$65,426</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 548905/5 R01 DA011809-09 (08062075)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Postdoctoral Academic Career Development Scholar</td>
<td>Glutamate and Craving for Cocaine</td>
<td>NIH/NIDA</td>
<td>08/01/08 - 07/31/09</td>
<td>$233,585</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 R37 DA003906-25 (08072234)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurobiology of Addiction Research Center (NARC)</td>
<td>NIH/NIDA</td>
<td>05/01/09 - 04/30/10</td>
<td>$870,368</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 P50 DA015369-07 (09042729)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurobiology of Addiction Research Center (NARC)</td>
<td>NIH/NIDA</td>
<td>05/01/09 - 04/30/13</td>
<td>$399,533</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 3 P50 DA015369-07S2 (09043062)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>Translational Research in Addiction Center: Project 1</td>
<td>NIH/NIDA</td>
<td>08/01/08 - 07/31/10</td>
<td>$76,056</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 P20 DA022658-03 (08062601-3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 2</td>
<td>Development and Plasticity of Functional Micro-Organization of the Visual Cortex</td>
<td>NIH/NEI</td>
<td>06/01/09 - 05/31/10</td>
<td>$250,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 R01 EY017925-03 (0904248)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>depth Perception Coding in Complete Cortical Microcircuits</td>
<td>Whitehall Foundation</td>
<td>08/01/08 - 07/31/09</td>
<td>$70,070</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 2007-08-107 (08082844)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development and Plasticity of Functional Micro-Organization of the Visual Cortex</td>
<td>NIH/NEI</td>
<td>08/01/07 - 07/31/10</td>
<td>$4,918</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 8062410</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enhancement of Neurosciences Research: Endowed Professorships</td>
<td>SC Research Centers of Economic Excellence</td>
<td>03/30/08 - 05/29/09</td>
<td>$600,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 0602902</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapeutic Intervention in Cervical Spinal Cord Injury</td>
<td>VAMC</td>
<td>10/01/08 - 09/30/11</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 07063037</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>An In Vitro Model of Stem Cell Innervation of Myotubes</td>
<td>Univ. of Central Florida</td>
<td>07/01/08 - 06/30/09</td>
<td>$36,986</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 63016005 (08111494)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>COBRE in Lipidomics - Core C: Animal Core</td>
<td>NIH/NICRR</td>
<td>03/30/01 - 03/31/10</td>
<td>$92,941</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 P20 RR017677-07 (08070866-13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neprilysin and Amyloid-Beta Degradation in Alzheimer's Disease</td>
<td>VAMC</td>
<td>04/01/09 - 03/31/10</td>
<td>$113,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 0602410</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enhancement of Neurosciences Research: Endowed Professorships</td>
<td>SC Research Centers of Economic Excellence</td>
<td>04/01/06 - 03/31/10</td>
<td>$600,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 0602902</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Therapeutic Intervention in Cervical Spinal Cord Injury</td>
<td>VAMC</td>
<td>10/01/07 - 09/30/11</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 07063037</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>An In Vitro Model of Stem Cell Innervation of Myotubes</td>
<td>Univ. of Central Florida</td>
<td>07/01/08 - 06/30/09</td>
<td>$36,986</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 63016005 (08111494)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>COBRE in Lipidomics - Core C: Animal Core</td>
<td>NIH/NICRR</td>
<td>04/01/09 - 03/31/10</td>
<td>$92,941</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Award: 5 P20 RR017677-07 (08070866-13)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Kindy, Mark
**Co-Investigator**

**Controlling Complement in Cerebral Ischemic Injury**

- **PI:** Stephen Tomlinson
- **Sponsor:** NIH/NHLBI
- **Dept.:** Microbiology and Immunology
- **Award:** 5 R01 HL082485-04 (08092531-1)
- **Direct:** $218,475

## Knackstedt, Lori
**Principal Investigator**

**Striatal Glutamate Homeostasis and Cocaine Relapse**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 09/15/08 - 06/30/09
- **Award:** 1 R21 DA026801-01 (08031074)
- **Direct:** $150,000

## Kroener, Sven
**Co-Investigator**

**Alcohol Research Center - Treatment and Implications: Research Component 4**

- **PI:** Carrie Randall
- **Sponsor:** NIH/NIAAA
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** 1 R21 DA026801-01 (08031074)
- **Direct:** $131,501

## LaLumiere, Ryan
**Principal Investigator**

**Infralimbic Cortex Regulation of Memory Consolidation of Extinction of Cocaine Self-Administration**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 06/01/09 - 05/31/10
- **Award:** 1 R21 DA026801-01 (09030935)
- **Direct:** $125,000

## LaPointe, Marc
**Co-Investigator**

**Interventional Management of Stroke Study III (IMS III)**

- **PI:** Nikolaos Papamitsakis
- **Sponsor:** Univ. of Cincinnati
- **Dept:** Neurosciences
- **Award:** 003525/5 U01 NS052220-03 (08101646-1)
- **Direct:** $22,523

## Lavin, Antonieta
**Principal Investigator**

**Neuropsychiatric Phenomics**

- **Sponsor:** Univ. of California, Los Angeles
- **Budget Dates:** 07/01/08 - 06/30/09
- **Award:** 2000 G JM202/5 RL1 MH0832 (08070755)
- **Direct:** $31,747

## Lazaridis, Christos
**Principal Investigator**

**The ACCELERATE Trial: The Evaluation of Patients with Acute Hypertension and Intracerebral Hemorrhage with Intravenous Clevidipine Treatment**

- **Sponsor:** The Medicines Co.
- **Budget Dates:** 03/30/09 - 09/30/10
- **Award:** TMC-CLV-07-02 (09032303)
- **Direct:** $71,800

## McGinty, Jacqueline
**Principal Investigator**

**Drug Abuse Training Program**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 09/30/91 - 06/30/12
- **Award:** 5 T32 DA007288-17 (08022621)
- **Direct:** $302,587

## McLaughlin, Peter
**Co-Investigator**

**Hypothalamic Thyroid Hormone Receptors and Dopamine Hypothesis**

- **Sponsor:** NIH/NIDDK
- **Budget Dates:** 09/30/09 - 09/30/12
- **Award:** 5 R01 DK080462-04 (09021726)
- **Direct:** $164,640

## NAC1 and Proteasome Involvement in Cocaine Use
**Sponsor:** NIH/NIDA

- **Budget Dates:** 03/02/09 - 05/31/09
- **Direct:** $51,710

## NAC2 and Proteasome Involvement in Cocaine Use
**Sponsor:** NIH/NIDA

- **Budget Dates:** 03/02/09 - 05/31/09
- **Direct:** $0

## Co-Investigator

**Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Project 2**

- **PI:** Ann-Charlotte Granholm
- **Sponsor:** NIH/NIA
- **Dept.:** Neurosciences
- **Award:** 5 P01 AG023630-04 (08052314-6)
- **Direct:** $106,040

## Neurobiology of Addiction Research Center (NARC): Project 1 - Neuroplasticity Associated with Cocaine Seeking

- **PI:** Peter Kalivas
- **Sponsor:** NIH/NIDA
- **Dept:** Neurosciences
- **Award:** 5 P50 DA015369-07 (09042729-5)
- **Direct:** $128,586

## Neurobiology of Addiction Research Center (NARC): Pilot - Core C

- **PI:** Peter Kalivas
- **Sponsor:** NIH/NIDA
- **Dept:** Neurosciences
- **Award:** 5 P50 DA015369-07 (09042729-4)
- **Direct:** $0

## Neurally Influenced Addiction Research Center (NRC): Project 2 - BDNF Prevents Cocaine Abstinence-Induced Neuroadaptations

- **PI:** Peter Kalivas
- **Sponsor:** NIH/NIDA
- **Dept:** Neurosciences
- **Award:** 5 P50 DA015369-07 (09042729-6)
- **Direct:** $123,200

## Co-Investigator

**Interdisciplinary Women's Health Research at MUSC**

- **PI:** Kathleen Brady
- **Sponsor:** NIH/NICHD
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** 5 K12 HD055885-02 (08053046-1)
- **Direct:** $459,990
### Principals Investigator

#### Mintzer, Jacobo

**Alzheimer’s Disease Neuroimaging Initiative**

- **Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol**
  - **PI:** Howard Becker
  - **Sponsor:** NIH/NIAAA
  - **Dept.:** Psychiatry and Behavioral Sciences
  - **Award:** 1R01 AA018036-01 (08032137-1)
  - **Direct $**: 225,000

**Citalopram Treatment of Agitation in Alzheimer’s Disease (CITAD)**

- **Sponsor:** Johns Hopkins Univ.
  - **Award:** 1R01 AG031348-01A1 (07100167)

**A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease Who are Apolipoprotein E 4 Non-Carriers (Protocol ELN115727-301)**

- **Sponsor:** Elan Pharmaceuticals
  - **Award:** ELN115727-301 (08011462)

**A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease Who are Apolipoprotein E 4 Carriers (Protocol ELN115727-302)**

- **Sponsor:** Elan Pharmaceuticals
  - **Award:** ELN115727-302 (08011463)

**Antipsychotic Discontinuation in Alzheimer’s Disease**

- **Sponsor:** Research Fdn. for Mental Hygiene
  - **Award:** 5R01 AH021488-05 (08040402)

**Effect of Gamma Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo**

- **Sponsor:** Quintiles Pacific, Inc.
  - **Award:** HEL-MC-LFAN (08071186)

**A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Add-On Study of the Effectiveness of Immune Globulin Intravenous (Human) (IVIG, 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease**

- **Sponsor:** Univ. of California, San Diego
  - **Award:** 68-MUSC (IgIV) M-00 ADCS (08112539)

**A Phase-4, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multi-Dose, Parallel-Treatment Stage in Patients with Mild to Moderate Alzheimer’s Disease**

- **Sponsor:** Genentech, Inc.
  - **Award:** ABE4427g (09011522)

**Immunoglobulin Intravenous (IgIV) for Treatment of Alzheimer’s Disease**

- **Sponsor:** Univ. of California, San Diego
  - **Award:** ADC-031 (09021934)

**A Randomized, Controlled, Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer’s Disease Using Alzheimer’s Disease Medication**

- **Sponsor:** Premier Research
  - **Award:** Alz.1.C/C (09040265)

**A phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of dimebon (PF-01913539) for up to 26-weeks in patients with mild to moderate Alzheimer’s disease**

- **Sponsor:** INC Research, Inc.
  - **Award:** A1451027 (09052871)

### Principal Investigator

#### Muntz-Pope, Bonnie

**Establishing ThinkFirst Regional Chapters in SC: State Training and Mentoring Project**

- **Sponsor:** SC Dept. of Disabilities and Spec. Needs
  - **Award:** SG 2009-60 (08060586)

**Establishment of ThinkFirst Injury Prevention Programs in the Lowcountry Using ThinkFirst for Youth Curriculum, ThinkFirst for Teens and Training of VIP’s (Voices for Injury Prevention) to Assist in the Programming**

- **PI:** Byron Bailey
  - **Dept.:** Neurosciences
  - **Award:** SG 2009-59 (08060584-1)

**Direct $**: 2,315
<table>
<thead>
<tr>
<th>Research Faculty Activity</th>
<th>College of Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papamitsakis, N.</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Interventional Management of Stroke Study III (IMS III)</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Univ. of Cincinnati</td>
<td>Budget Dates: 12/01/07 - 11/30/09</td>
</tr>
<tr>
<td>Award: 003525/5 U01 NS052220-03 (08101646)</td>
<td>Project Dates: 12/01/07 - 11/30/09</td>
</tr>
<tr>
<td><strong>Interventional Management of Stroke (IMS III)</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Univ. of Cincinnati</td>
<td>Budget Dates: 12/01/08 - 11/30/09</td>
</tr>
<tr>
<td>Award: Coeus#003525/5U01NS052220 (09042958)</td>
<td>Project Dates: 12/01/08 - 11/30/10</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2)-TIMI 50</td>
<td></td>
</tr>
<tr>
<td>PI: James Thomas</td>
<td>Sponsor: Schering-Plough Research In Direct $180,000</td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: P04737/P05183 (07112882-2)</td>
</tr>
<tr>
<td>Ramamoorthy, S.</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Serotonin Transporter Phosphorylation</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIMH</td>
<td>Budget Dates: 04/01/09 - 03/31/10</td>
</tr>
<tr>
<td>Award: 5 R01 MH062612-07 (09030410)</td>
<td>Project Dates: 12/01/00 - 03/31/12</td>
</tr>
<tr>
<td><strong>Co-PI or Project Leader</strong></td>
<td></td>
</tr>
<tr>
<td>Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Project 4</td>
<td></td>
</tr>
<tr>
<td>PI: Ann-Charlotte Granholm</td>
<td>Sponsor: NIH/NIA</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 P01 AG023630-04 (08052314-8)</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td>Norepinephrine Transport Regulation by Phosphorylation</td>
<td></td>
</tr>
<tr>
<td>PI: Lankupalle Jayanthi</td>
<td>Sponsor: NIH/NIGMS</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 R01 GM081054-03 (08121719-2)</td>
</tr>
<tr>
<td>Ray, Swapan</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td>Attenuation of Axonal Damage and Neuronal Death in EAE</td>
<td></td>
</tr>
<tr>
<td>PI: Naren Banik</td>
<td>Sponsor: NIH/NINDS</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 R01 NS056176-04 (08120252-2)</td>
</tr>
<tr>
<td>Reissner, Kathrynn</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cytoskeletal Mechanisms of Cocaine-Induced Neuropasticity</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIDA</td>
<td>Budget Dates: 01/01/09 - 12/31/09</td>
</tr>
<tr>
<td>Award: 1 F32 DA026254-01 (08120360)</td>
<td>Project Dates: 01/01/09 - 03/31/12</td>
</tr>
<tr>
<td>Riegel, Jr., Arthur</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cellular Mechanisms Regulating VTA Dopamine Neurons</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIDA</td>
<td>Budget Dates: 09/01/08 - 08/31/09</td>
</tr>
<tr>
<td>Award: 5 K01 DA020751-04 (08090254)</td>
<td>Project Dates: 09/01/00 - 08/31/11</td>
</tr>
<tr>
<td>Rohrer, Baerbel</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Retinal Ganglion Cell Apoptosis in Experimental Glaucoma</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Duke Univ.</td>
<td>Budget Dates: 07/01/08 - 06/30/09</td>
</tr>
<tr>
<td>Award: 155454/148127/140558 303- (08052941)</td>
<td>Project Dates: 08/01/05 - 06/30/09</td>
</tr>
<tr>
<td><strong>Co-PI or Project Leader</strong></td>
<td></td>
</tr>
<tr>
<td>Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Core B</td>
<td></td>
</tr>
<tr>
<td>PI: Ann-Charlotte Granholm</td>
<td>Sponsor: NIH/NIA</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 P01 AG023630-04 (08052314-3)</td>
</tr>
<tr>
<td>Salak, Vicky</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td>Parkinson's Disease Neuroprotection Clinical Trial Center</td>
<td></td>
</tr>
<tr>
<td>PI: Vanessa Hisson</td>
<td>Sponsor: NIH/NINDS</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 U10 NS053372-03 (07092437-2)</td>
</tr>
<tr>
<td>Parkinsons Disease Neuroprotection Clinical Trial Center</td>
<td></td>
</tr>
<tr>
<td>PI: Vanessa Hisson</td>
<td>Sponsor: NIH/NINDS</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 U10 NS053372-04 (09012363-1)</td>
</tr>
<tr>
<td>CD Probe - Cervical Dystonia - Patient Registry for Observation of BOTOX Efficacy</td>
<td></td>
</tr>
<tr>
<td>PI: Vanessa Hisson</td>
<td>Sponsor: Allergan, Inc.</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: MedAff BTX-0718 (09030936-1)</td>
</tr>
<tr>
<td>Sambamurti, Kumar</td>
<td>Neurosciences</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Regulation and Cell Biology of Beta-Secretase</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NIA</td>
<td>Budget Dates: 07/01/08 - 06/30/10</td>
</tr>
<tr>
<td>Award: 5 R01 AG023055-05 (08051457)</td>
<td>Project Dates: 09/30/04 - 06/30/10</td>
</tr>
</tbody>
</table>
### Sambamurti, Kumar

**Co-Investigator**

**Title:** An Animal Model for Age-Related Degeneration  
**PI:** Ann-Charlotte Granholm  
**Sponsor:** NIH/NIA  
**Dept:** Neurosciences  
**Award:** 5 R01 AG012122-13 (08052313-1)  
**Direct $** 175,567

### Schochet, Terri

**Principal Investigator**

**Title:** Neuroadaptive Changes in Dendritically Targeted mRNAs in Cocaine Abstinence  
**Sponsor:** NIH/NIDA  
**Budget Dates:** 09/15/08 - 07/10/09  
**Direct $** 49,646  
**Project Dates:** 09/15/07 - 07/10/09  
**F & A:** 0

### See, Ronald

**Principal Investigator**

**Title:** Interdisciplinary Medication Development for Multiple Risk Factors in Relapse  
**Sponsor:** NIH/NIDA  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct $** 249,411  
**Project Dates:** 09/30/07 - 06/30/12  
**F & A:** 0

### Smith, Amena

**Principal Investigator**

**Title:** Role of Calpain in the Pathogenesis of Experimental Optic Neuritis  
**Sponsor:** NIH/NEI  
**Budget Dates:** 12/01/08 - 11/30/09  
**Direct $** 31,725  
**Project Dates:** 12/01/08 - 11/30/11  
**F & A:** 0

### Trantham, Heather

**Principal Investigator**

**Title:** Serotonin Modulation of Orbital Cortex GABA Interneurons  
**Sponsor:** NIH/NIMH  
**Budget Dates:** 08/01/08 - 07/31/09  
**Direct $** 153,000  
**Project Dates:** 08/01/08 - 07/31/10  
**F & A:** 0

### Turan, Tanya

**Principal Investigator**

**Title:** Atherogenic Components of Metabolic Syndrome in Intracranial Stenosis  
**Sponsor:** Amer. Acad. of Neurology  
**Budget Dates:** 03/01/08 - 03/31/10  
**Direct $** 89,290  
**Project Dates:** 03/01/08 - 03/31/10  
**F & A:** 0

### Tyor, William

**Principal Investigator**

**Title:** Novel Treatments for HIV Encephalitis in Mice  
**Sponsor:** VAMC  
**Budget Dates:** 10/01/08 - 09/30/09  
**Direct $** 122,900  
**Project Dates:** 10/01/07 - 09/30/11  
**F & A:** 0

### Varma, Abhay

**Principal Investigator**

**Title:** Melatonin as a Therapy for Spinal Cord Injury  
**Sponsor:** SC Spinal Cord Injury Fund  
**Budget Dates:** 07/01/07 - 06/30/10  
**Direct $** 79,793  
**Project Dates:** 07/01/07 - 06/30/10  
**F & A:** 0
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walker, Aljoeson</td>
<td>Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment</td>
<td>Aga Medical Corp.</td>
<td>09/22/04 - 12/31/09</td>
<td>1,157</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer's Disease Neuroimaging Initiative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Jacobo Mintzer</td>
<td>Sponsor: Univ. of California, San Diego</td>
<td>Direct: $ 1,157</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Neurosciences</td>
<td>Award: ADNI-024 (05081757-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whitfield, T.</td>
<td>Site and Mechanism of Action of BDNF-Induced Suppression of Cocaine-Seeking</td>
<td>NIH/NIDA</td>
<td>07/01/08 - 06/30/09</td>
<td>35,887</td>
<td></td>
</tr>
<tr>
<td>Wiggins, Armina</td>
<td>The Role of Beta Integrins in Cocaine Induced Neuroadaptations and Relapse</td>
<td>NIH/NIDA</td>
<td>07/01/08 - 06/30/09</td>
<td>35,887</td>
<td></td>
</tr>
<tr>
<td>Woodward, John</td>
<td>Neural Actions of Toluene</td>
<td>NIH/NIDA</td>
<td>03/01/09 - 12/31/09</td>
<td>228,573</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 4</td>
<td>Direct: $ 131,501</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Carrie Randall</td>
<td>Sponsor: NIH/NIAAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 P50 AA10761-14 (08111809-16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Actin Dynamics and Spine Remodeling in Ethanol-Induced Plasticity</td>
<td>NIH/NIAAA</td>
<td>04/01/09 - 03/31/10</td>
<td>318,633</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Sponsor: NIH/NIAAA</td>
<td>Direct: $ 237,500</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Actin Dynamics and Spine Remodeling in Ethanol-Induced Plasticity</td>
<td>NIH/NIAAA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Neurosciences</td>
<td>Award: 2 R01 AA10983-12A1 (08042169-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhu, Haojie</td>
<td>Experimental and Clinical Studies of Presbyacusis - Project 2</td>
<td>NIH/NIDCD</td>
<td>07/01/08 - 06/30/09</td>
<td>256,732</td>
<td></td>
</tr>
<tr>
<td>Obstetrics and Gynecology</td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carter, James</td>
<td>A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Doses of DR-3001 Versus Placebo in Women with Overactive Bladder</td>
<td>Duramed Research, Inc.</td>
<td>Direct: $ 66,737</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chang, Eugene</td>
<td>Safety of N-Acetylcysteine in Maternal Chorioamnionitis</td>
<td>NIH/NINDS</td>
<td>Direct: $ 275,737</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer</td>
<td>Morphotech, Inc.</td>
<td>Budget Dates: 06/29/09 - 07/31/14 Direct: $ 184,863</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Darnell, Christopher  
**Using Telemedicine to Improve Perinatal Care in South Carolina**  
Sponsor: March of Dimes/SC Chapter  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $1,500  
Dept: Obstetrics and Gynecology  
Award: (08090360)  

Dempsey-Fanning, A.  
**Post Fellowship Salary Support**  
Sponsor: Susan Thompson Buffet Fdn.  
Budget Dates: 08/11/08 - 08/10/09  
Direct: $38,130  
Dept: Obstetrics and Gynecology  
Award: 792 (08081918)  

Fylstra, Donald  
**A Randomized, International, Double-Blinded (with In-House Blinding), Controlled with GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women**  
Sponsor: Merck  
Budget Dates: 02/20/09 - 02/19/10  
Direct: $507,096  
Dept: Obstetrics and Gynecology  
Award: V503-001 (09011301-1)  

Johnson, Donna  
**Soluble FMS-Like Tyrosine Kinase 1 (SFLT-1), Placental Growth Factor (PLGF) Levels as Predictors of Preeclampsia Prior to Onset of Symptoms in Pregnant Women, as an Aid in Diagnosis in Symptomatic Women and for Risk Stratification**  
Sponsor: Ortho-Clinical Diagnostics  
Budget Dates: 06/07-02/14/07 - 12/31/09  
Direct: $137,376  
Dept: Obstetrics and Gynecology  
Award: 06-007 (07042310)  

Newman, Roger  
**The National Standard for Normal Fetal Growth**  
Sponsor: NIH/NICHD  
Budget Dates: 09/26/08 - 09/30/09  
Direct: $77,270  
Dept: Obstetrics and Gynecology  
Award: HHSN275200800014C (08030559)  

Rittenberg, Charles  
**Progesterone Outreach Program (POP)**  
Sponsor: March of Dimes/SC Chapter  
Budget Dates: 03/01/09 - 02/28/10  
Direct: $52,172  
Dept: Obstetrics and Gynecology  
Award: (08082230)  

Robinson, C.  
**Establishing the Utility of Cervilenz as an Inexpensive Device to Detect Short Cervical Length in the Mid-Second Trimester of Pregnancy**  
Sponsor: CerviLenz, Inc.  
Budget Dates: 02/20/09 - 02/19/10  
Direct: $22,900  
Dept: Obstetrics and Gynecology  
Award: HUB/K0725143.1 (09012674)  

Savage, Ashlyn  
**Using Telemedicine to Improve Perinatal Care in South Carolina**  
Sponsor: March of Dimes/SC Chapter  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $25,000  
Dept: Obstetrics and Gynecology  
Award: (08092945-1)  

Savage, Ashlyn

Co-Investigator

A Randomized, International, Double-Blinded (with In-House Blinding), Controlled with GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women

PI: David Soper  
Sponsor: Merck  
Dept: Obstetrics and Gynecology  
Award: V503-001 (09011301)  
Direct $507,096

The oncoFISH Cervical Test for Detection of 3q26 Region Gain

PI: Scott Sullivan  
Sponsor: Ikonisys, Inc.  
Dept: Obstetrics and Gynecology  
Award: IKON0801 (09042852-1)  
Direct $166,000

Soper, David

Principal Investigator

A Randomized, International, Double-Blinded (with In-House Blinding), Controlled with GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women

Sponsor: Merck  
Budget Dates: 01/16/09 - 12/31/13  
Direct: $507,096

PI: David Soper  
Sponsor: Merck  
Dept: Obstetrics and Gynecology  
Award: V503-001 (09011301)  
Project Dates: 01/16/09 - 12/31/13  
F & A: $125,524

The oncoFISH Cervical Test for Detection of 3q26 Region Gain

PI: Scott Sullivan  
Sponsor: Ikonisys, Inc.  
Dept: Obstetrics and Gynecology  
Award: IKON0801 (09042852-1)  
Direct $166,000

Sullivan, Scott

Principal Investigator

The oncoFISH Cervical Test for Detection of 3q26 Region Gain

Sponsor: Ikonisys, Inc.  
Budget Dates: 05/01/09 - 04/30/10  
Direct: $166,000

Award: IKON0801 (09042852)  
Project Dates: 05/01/09 - 04/30/10  
F & A: $40,750

Swift, Steven

Principal Investigator

A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Doses of DR-3001 Versus Placebo in Women with Overactive Bladder

Sponsor: Duramed Research, Inc.  
Budget Dates: 07/16/08 - 07/15/10  
Direct: $66,737

PI: David Soper  
Sponsor: Merck  
Dept: Obstetrics and Gynecology  
Award: V503-001 (09011301)  
Project Dates: 07/16/08 - 07/15/10  
F & A: $16,059

Vandorsten, J.

Co-Investigator

The National Standard for Normal Fetal Growth

PI: Roger Newman  
Sponsor: NIH/NICHD  
Dept: Obstetrics and Gynecology  
Award: HHSN275200800014C (08030559-1)  
Direct $77,270

Villers, Margaret

Co-Investigator

A Randomized, International, Double-Blinded (with In-House Blinding), Controlled with GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26-Year-Old Women

PI: David Soper  
Sponsor: Merck  
Dept: Obstetrics and Gynecology  
Award: V503-001 (09011301)  
Direct $507,096

Ophthalmology

Black, Robert

Co-Investigator

Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential Trigger Factor for Acute Naion

PI: Pamela Chavis  
Sponsor: Icon Clinical Research, Inc.  
Dept: Ophthalmology  
Award: A1481259 (08080894-1)  
Direct $35,300

Bowie, Esther

Principal Investigator

Trial to Assess the Ocular Safety of SCH 530348 in Patients with Atherosclerosis (Study P05183AM1)

PI: Pamela Chavis  
Sponsor: EMD Serono, Inc.  
Dept: Ophthalmology  
Award: 28156 (09030293-1)  
Direct $83,510

Chavis, Pamela

Principal Investigator

Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential Trigger Factor for Acute Naion

Sponsor: Icon Clinical Research, Inc.  
Budget Dates: 10/01/08 - 10/01/11  
Direct: $35,300

Award: A1481259 (08080894)  
Project Dates: 10/01/08 - 10/01/11  
F & A: $7,950
Chavis, Pamela

**Principal Investigator**

A Two-Arm, Randomised, Double Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects with Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) over a 36 Week Treatment Course

**Sponsor:** EMD Serono, Inc.
**Award:** 28156 (09030293)
**Budget Dates:** 05/26/09 - 05/25/10
**Direct:** $83,510

**Co-Investigator**

**Nasolacrimal Duct Obstruction Study (NLD3): A Randomized Trial Comparing Immediate Probing in an Office Setting with Deferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old**

**Pl:** Ronald Teed
**Dept:** Ophthalmology

**Sponsor:** Jaeb Center for Health Research
**Direct:** $6,098

**Amblyopia Treatment Study (A11): A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia**

**Pl:** Ronald Teed
**Dept:** Ophthalmology

**Sponsor:** Jaeb Center for Health Research
**Direct:** $3,325

**Amblyopia Treatment Study (ATS13): An Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old**

**Pl:** Ronald Teed
**Dept:** Ophthalmology

**Sponsor:** Jaeb Center for Health Research
**Direct:** $700

**Central Corneal Thickness in a Normal Pediatric Population (CCTS): A Prospective Study of Central Corneal Thickness in Children Less Than 18 Years Old**

**Pl:** Ronald Teed
**Dept:** Ophthalmology

**Sponsor:** Jaeb Center for Health Research
**Direct:** $47,370

**Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated with Latanoprost 0.005%**

**Pl:** Ronald Teed
**Dept:** Ophthalmology

**Sponsor:** Pfizer, Inc.
**Direct:** $19,935

**Phase 3, Prospective, Randomized, Double-Masked, 12-Week, Parallel-Group Study Evaluating the Efficacy and Safety of Latanoprost and Timolol in Pediatric Subjects with Glaucoma (A6111137)**

**Pl:** Ronald Teed
**Dept:** Ophthalmology

**Sponsor:** Pfizer, Inc.
**Direct:** $47,370

**Crosson, Craig**

**Principal Investigator**

**Ocular Hypotensive Activity of Acorn Compounds**

**Sponsor:** Acorn Biomedical, Inc.
**Award:** (08080171)
**Budget Dates:** 08/15/08 - 12/31/08
**Direct:** $9,899
**F & A:** $4,701

**Reversal of RPE Dysfunction Alimera Compounds**

**Sponsor:** Alimera Sciences
**Award:** A8111139 (08111287-1)
**Budget Dates:** 07/28/08 - 07/28/09
**Direct:** $23,756
**F & A:** $11,284

**INO-8875: Mechanism of Action**

**Sponsor:** Inotek Pharmaceuticals
**Award:** 5 R01 EY014653-05 (09040705-1)
**Budget Dates:** 12/30/08 - 08/31/09
**Direct:** $72,700
**F & A:** $34,533

**Adenosine Agonists: Potential Antiglaucoma Agents**

**Sponsor:** NIH/NEI
**Award:** 5 R01 EY009741-17 (09011418)
**Budget Dates:** 03/01/09 - 02/28/10
**Direct:** $250,662
**F & A:** $115,305

**Crouch, Rosalie**

**Principal Investigator**

**The Role of Aquaporin-0 in Lens Development and Aging**

**Sponsor:** Vanderbilt Univ.
**Award:** VUMC35317/7 R01 EY013462- (08090255)
**Budget Dates:** 08/03/08 - 07/31/09
**Direct:** $50,922
**F & A:** $22,666

**Synthetic Retinal Pigments and Binding Proteins**

**Sponsor:** NIH/NEI
**Award:** 5 R01 EY004939-26 (09012671)
**Budget Dates:** 08/01/08 - 03/31/11
**Direct:** $242,750
**F & A:** $111,665
Crouch, Rosalie

**Principal Investigator**

**Supplement to R01 EY004939**

**Sponsor:** NIH/NEI  
**Budget Dates:** 04/01/09 - 03/31/10  
**Direct:** $156,526  
**Award:** 5 R01 EY004939-26S1 (09021295)  
**Project Dates:** 08/01/83 - 03/31/11  
**F & A:** $51,152

**Husain, Shahid**

**Principal Investigator**

**Effects of Some Alcon’s Compounds on IOP in Ocular Hypertensive Rat Models**

**Sponsor:** Alcon, Inc.  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct:** $63,492  
**Award:** (08061232)  
**Project Dates:** 07/01/08 - 06/30/09  
**F & A:** $16,508

**Kono, Masahiro**

**Co-Investigator**

**Synthetic Retinal Pigments and Binding Proteins**  
**PI:** Rosalie Crouch  
**Sponsor:** NIH/NEI  
**Project Dates:** 08/01/08 - 03/31/11  
**F & A:** $51,152

**Koutalos, Yiannis**

**Principal Investigator**

**Transport Processes in Photoreceptors**

**Sponsor:** NIH/NEI  
**Budget Dates:** 03/01/09 - 02/28/10  
**Direct:** $225,000  
**Award:** 5 R01 EY014850-05 (09011302)  
**Project Dates:** 07/01/03 - 02/28/13  
**F & A:** $103,500

**Rohrer, Baerbel**

**Principal Investigator**

**Complement Activation in Retinal Degeneration**

**Sponsor:** Taligen  
**Budget Dates:** 08/18/08 - 08/17/10  
**Direct:** $219,178  
**Award:** Taligen (08062607)  
**Project Dates:** 08/18/08 - 08/17/10  
**F & A:** $100,822

**Nicotinic Receptor Activation and Oxidative Stress in Retinal Pigmented Epithelium**

**Sponsor:** Targacept, Inc.  
**Budget Dates:** 08-030-0299 (08100913)  
**Direct:** $10,808  
**Award:** 08-030-0299 (08100913)  
**Project Dates:** 08-030-0299 (08100913)  
**F & A:** $5,134

**High Content Metabolic Screens for Anti-Degenerative Agents in the Retina**

**Sponsor:** Fdn. Fighting Blindness  
**Budget Dates:** TA-NP-0607-0446-MUSC-WG (09061605)  
**Direct:** $200,000  
**Award:** TA-NP-0607-0446-MUSC-WG (09061605)  
**Project Dates:** TA-NP-0607-0446-MUSC-WG (09061605)  
**F & A:** $0

**Blocking Alternative Complement Activation in Animal Models of AMD**

**Sponsor:** Fdn. Fighting Blindness  
**Budget Dates:** TA-NP-0507-0387-USC (09070224)  
**Direct:** $84,551  
**Award:** TA-NP-0507-0387-USC (09070224)  
**Project Dates:** TA-NP-0507-0387-USC (09070224)  
**F & A:** $0

**Sandoval, Helga**

**Principal Investigator**

**Evaluation of JNJ-17166864 in the Prevention of Anterior Segment Inflammation after Phacoemulsification in an Animal Model**

**Sponsor:** Vistakon Pharmaceuticals, LLC  
**Budget Dates:** 11/01/08 - 12/30/09  
**Direct:** $12,138  
**Award:** JNJ-17166864 (Phaco) (08110664)  
**Project Dates:** 11/01/08 - 12/30/09  
**F & A:** $5,766

**Saunders, Richard**

**Principal Investigator**

**Early Treatment of Retinopathy of Prematurity, Phase II**

**Sponsor:** Univ. of Texas Health Science Center at Houston  
**Budget Dates:** 09/30/08 - 09/29/09  
**Direct:** $5,615  
**Award:** 0004359-Center 23/5U10EY0 (08091603)  
**Project Dates:** 09/30/08 - 09/29/09  
**F & A:** $2,583

**Solomon, Kerry**

**Principal Investigator**

**Device Evaluation Study to Assess the Physical and Clinical Performance of Prototype Punctal Plug Design Iterations**

**Sponsor:** QLT, Inc.  
**Budget Dates:** 12/01/08 - 12/31/09  
**Direct:** $159,860  
**Award:** PP DEV01 (08121096)  
**Project Dates:** 12/01/08 - 12/31/09  
**F & A:** $39,340

**US Clinical Study of the ACRYSOF II Natural IQ IOL**

**Sponsor:** Alcon, Inc.  
**Budget Dates:** 03/02/09- 03/19/10  
**Direct:** $85,780  
**Award:** Acrysof II - C07-45 (09021185)  
**Project Dates:** 03/02/09- 03/19/10  
**F & A:** $20,820

**A Clinical Safety and Efficacy Comparison of Nevanac 0.1% to Vehicle following Cataract Surgery in Diabetic Retinopathy Patients**

**Sponsor:** Alcon, Inc.  
**Budget Dates:** 03/23/09 - 03/22/10  
**Direct:** $86,500  
**Award:** NEVANAC C-07-43 (09021941)  
**Project Dates:** 03/23/09 - 03/22/10  
**F & A:** $21,000
Teed, Ronald

**Principal Investigator**

**Nasolacrimal Duct Obstruction Study (NLD3): A Randomized Trial Comparing Immediate Probing in an Office Setting withDeferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old**

Sponsor: Jaeb Center for Health Research, Inc.

Award: A6111137 (08102369)

Budget Dates: 11/01/08 - 12/31/09 F & A: 6,098

**Amblyopia Treatment Study (A11): A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia**

Sponsor: Jaeb Center for Health Research, Inc.

Award: A6111139 (08110333)

Budget Dates: 11/01/08 - 12/31/09 F & A: 3,325

**Amblyopia Treatment Study (ATS13): An Observational Study of Optical Correction for Strabismic Amblyopia inChildren 3 to <7 Years Old**

Sponsor: Jaeb Center for Health Research, Inc.

Award: A6111139 (08110333)

Budget Dates: 11/01/08 - 12/31/09 F & A: 1,543

**Central Corneal Thickness in a Normal Pediatric Population (CCTS): A Prospective Study of Central Corneal Thickness inChildren Less Than 18 Years Old**

Sponsor: Jaeb Center for Health Research, Inc.

Award: A6111139 (08110333)

Budget Dates: 11/01/08 - 12/31/09 F & A: 1,710

**Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated withLatanoprost 0.005%**

Sponsor: Pfizer, Inc.

Award: A6111139 (08110333)

Budget Dates: 10/27/08 - 11/01/09 F & A: 19,935

**Phase 3, Prospective, Randomized, Double-Masked, 12-Week, Parallel-Group Study Evaluating the Efficacy and Safety of Latanoprost and Timolol in Pediatric Subjects with Glaucoma (A6111139)**

Sponsor: Pfizer, Inc.

Award: a6111137 (09013003)

Budget Dates: 01/14/09 - 02/01/10 F & A: 47,370

**Reto Unrestricted Grant**

Sponsor: Research to Prevent Blindness

Project Dates: 01/01/09 - 12/31/09 F & A: 0

Wilson, M.

**Principal Investigator**

**Infant Aphakia Treatment Study**

Sponsor: Emory Univ.

Award: 5-26794/5U01EY013272-05 (08112540)

Budget Dates: 08/01/08 - 05/31/09 F & A: 19,208

**RPB Unrestricted Grant**

Sponsor: Research to Prevent Blindness

Project Dates: 01/01/09 - 12/31/09 F & A: 110,000

Orthopaedic Surgery

An, Y.

**Principal Investigator**

**The Osteointegration of Porous Materials Using a Rabbit Femoral Defect Model**

Sponsor: Stryker Orthopaedics

Award: NCS04-009 (04113024)

Project Dates: 11/23/04 - 12/31/09 F & A: 5,342

Hartsock, Langdon

**Principal Investigator**

**Clemson MUSC Orthopaedic Research Training Program**

Sponsor: Clemson Univ.

Award: 1133-7558-246-2006025 (07071072)

Budget Dates: 04/01/08 - 03/31/09 F & A: 22,000

**The Effect of Xybrex on Sternal Healing in Rabbit Sternotomy Model**

Sponsor: Clemson Univ.

Award: 1161-7559-245-2006311 (07090464)

Budget Dates: 07/30/07 - 06/01/09 F & A: 26,168

**Synthes Spine Educational Grant**

Sponsor: Synthes (USA)

Award: Educational Grant (08103031)

Project Dates: 01/01/09 - 12/31/09 F & A: 55,000

Kang, Qian

**Co-Investigator**

**Clemson MUSC Orthopaedic Research Training Program**

Pl: Langdon Hartsock

Dept: Orthopaedic Surgery

Sponsor: Clemson Univ.

Award: 1133-7558-246-2006025 (07071072-2)

Budget Dates: 04/01/07 - 03/31/09 F & A: 0

**The Effect of Xybrex on Sternal Healing in Rabbit Sternotomy Model**

Pl: Langdon Hartsock

Dept: Orthopaedic Surgery

Sponsor: Clemson Univ.

Award: 1161-7559-245-2006311 (07090464-4)

Budget Dates: 07/30/06 - 06/01/09 F & A: 55,219

Schutte, Del

**Principal Investigator**

**Stryker "Practice Solutions for an Impractical Time"**

Sponsor: Stryker Orthopaedics

Award: Educational Grant (09060186)

Project Dates: 05/01/09 - 12/31/09 F & A: 0
### Otolaryngology

**Ahlmstrom, Jayne**

**Co-Investigator**

**Experimental and Clinical Studies of Presbyacusis - Project 1**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $234,090
- **Project Dates:** 07/01/97 - 07/31/13
- **F & A:** $576,580

**Experimental and Clinical Studies of Presbyacusis - Project 2**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $256,732
- **Project Dates:** 07/01/08 - 07/31/10
- **F & A:** $93,682

**Auditory Analysis and Speech Recognition**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $203,656
- **Project Dates:** 09/01/08 - 08/31/09
- **F & A:** $9,043

---

**Day, Terry**

**Co-Investigator**

**Sphingolipids in Cancer Biology and Therapy: Project 4**

- **PI:** Yusuf Hannun
- **Sponsor:** NIH/NCI
- **Dept:** Biochemistry and Molecular Biology
- **Budget:** $103,997
- **Project Dates:** 07/01/08 - 06/30/11
- **F & A:** $0

**Other**

**Immunotherapy to Prevent Oral Permalignant Lesion Recurrence and Oral Cancer**

- **PI:** M. Young
- **Sponsor:** NIH/NCI
- **Dept:** Otolaryngology
- **Budget:** $207,500
- **Project Dates:** 09/01/08 - 06/30/10
- **F & A:** $3,987

---

**Dubno, Judy**

**Principal Investigator**

**Experimental and Clinical Studies of Presbyacusis**

- **Sponsor:** NIH/NIDCD
- **Budget:** $1,213,853
- **Project Dates:** 07/01/97 - 07/31/13
- **F & A:** $576,580

**Auditory Analysis and Speech Recognition**

- **Sponsor:** NIH/NIDCD
- **Budget:** $203,656
- **Project Dates:** 12/01/81 - 06/30/11
- **F & A:** $93,682

---

**Eckert, Mark**

**Co-PI or Project Leader**

**Experimental and Clinical Studies of Presbyacusis - Project 2**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $256,732
- **Project Dates:** 07/01/08 - 07/31/09
- **F & A:** $576,580

**Experimental and Clinical Studies of Presbyacusis - Project 1**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $234,090
- **Project Dates:** 07/01/08 - 07/31/10
- **F & A:** $9,043

---

**Gillespie, M.**

**Principal Investigator**

**Second Hand Smoke Exacerbates Allergic Rhinitis**

- **Sponsor:** Charleston Research Institute
- **Budget:** $300,000
- **Project Dates:** 07/01/08 - 06/30/11
- **F & A:** $0

**Cetuximab for Treatment of High-Risk Pre-Malignant Upper Aerodigestive Lesions**

- **Sponsor:** Johns Hopkins Univ.
- **Budget:** $11,013
- **Project Dates:** 12/01/07 - 01/31/09
- **F & A:** $3,987

**Other**

**Immunotherapy to Prevent Oral Permalignant Lesion Recurrence and Oral Cancer**

- **PI:** M. Young
- **Sponsor:** NIH/NCI
- **Dept:** Otolaryngology
- **Budget:** $207,500
- **Project Dates:** 09/20/07 - 08/31/12
- **F & A:** $9,043

---

**Harris, Kelly**

**Principal Investigator**

**Auditory Temporal Processing in the Aging Ear and Brain**

- **Sponsor:** NIH/NIDCD
- **Budget:** $113,041
- **Project Dates:** 09/01/08 - 08/31/09
- **F & A:** $9,043

---

**Horwitz, Amy**

**Co-Investigator**

**Experimental and Clinical Studies of Presbyacusis - Project 1**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $234,090

**Auditory Analysis and Speech Recognition**

- **PI:** Judy Dubno
- **Sponsor:** NIH/NIDCD
- **Dept:** Otolaryngology
- **Budget:** $203,656
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Direct $</th>
<th>F &amp; A $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lambert, Paul</td>
<td>Co-Investigator</td>
<td>Judy Dubno</td>
<td>NIH/NIDCD</td>
<td>394,377</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Core B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lathers, Deanne</td>
<td>Other</td>
<td>M. Gillespie</td>
<td>Charleston Research Institute</td>
<td>300,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Second Hand Smoke Exacerbates Allergic Rhinitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee, Fu-Shing</td>
<td>Co-Investigator</td>
<td>Judy Dubno</td>
<td>NIH/NIDCD</td>
<td>394,377</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Core B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schmiedt, Richard</td>
<td>Co-Investigator</td>
<td>M. Gillespie</td>
<td>Charleston Research Institute</td>
<td>300,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Second Hand Smoke Exacerbates Allergic Rhinitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Young, M.</td>
<td>Principal Investigator</td>
<td>Rodney Schlosser</td>
<td>Antigen Laboratories, Inc.</td>
<td>20,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of Palatability of Two Sublingual Diluents in Allergic Patients: A Prospective Pilot Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schlosser, Rodney</td>
<td>Principal Investigator</td>
<td>Rodney Schlosser</td>
<td>Antigen Laboratories, Inc.</td>
<td>20,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of Palatability of Two Sublingual Diluents in Allergic Patients: A Prospective Pilot Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schlosser, Rodney</td>
<td>Co-Investigator</td>
<td>Rodney Schlosser</td>
<td>Antigen Laboratories, Inc.</td>
<td>20,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of Palatability of Two Sublingual Diluents in Allergic Patients: A Prospective Pilot Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthews, Lois</td>
<td>Co-Investigator</td>
<td>Judy Dubno</td>
<td>NIH/NIDCD</td>
<td>394,377</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Core B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mills, John</td>
<td>Co-PI or Project Leader</td>
<td>Judy Dubno</td>
<td>NIH/NIDCD</td>
<td>394,377</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Core B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nguyen, Shaun</td>
<td>Co-PI or Project Leader</td>
<td>Rodney Schlosser</td>
<td>Antigen Laboratories, Inc.</td>
<td>20,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of Palatability of Two Sublingual Diluents in Allergic Patients: A Prospective Pilot Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schlosser, Rodney</td>
<td>Principal Investigator</td>
<td>Rodney Schlosser</td>
<td>Antigen Laboratories, Inc.</td>
<td>20,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assessment of Palatability of Two Sublingual Diluents in Allergic Patients: A Prospective Pilot Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schmiedt, Richard</td>
<td>Co-Investigator</td>
<td>M. Gillespie</td>
<td>Charleston Research Institute</td>
<td>300,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Second Hand Smoke Exacerbates Allergic Rhinitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Young, M.</td>
<td>Principal Investigator</td>
<td>VAMC</td>
<td>NIH/NIDCD</td>
<td>148,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vitamin D Therapy to Enhance Intratumoral Anti-Cancer Immune Reactivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Otolaryngology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Direct $ represents direct funding and F & A $ represents fringe & admin costs.
Young, M.  
**Principal Investigator**

**Defining and Interrupting the Pathways that Lead to HNSCC Invasiveness**
- **Sponsor:** VAMC  
- **Budget Dates:** 10/01/08 - 09/30/09  
- **Direct:** $125,000

**Macrophage-Driven Progression of Premalignant Oral Lesions Toward Invasiveness**
- **Sponsor:** NIH/NIDCR  
- **Budget Dates:** 08/01/08 - 06/30/09  
- **Direct:** $250,000

**Immunotherapy to Prevent Oral Premalignant Lesion Recurrence and Oral Cancer**
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 08/01/08 - 06/30/09  
- **Direct:** $207,500

**Other**
- **Second Hand Smoke Exacerbates Allergic Rhinitis**
  - **Sponsor:** Charleston Research Institute  
  - **Budget Dates:** 08/01/08 - 06/30/09

**Pathology and Laboratory Medicine**

Bilic, Masha  
**Co-Investigator**

**Role of Ets Genes in Transformation and Differentiation - Core A**
- **PI:** Dennis Watson  
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 10/01/08 - 09/30/09  
- **Direct:** $47,309

**Cunningham, Lisa**  
**Principal Investigator**

**Mechanisms of Sensory Hair Cell Death and Survival**
- **Sponsor:** NIH/NIDCD  
- **Budget Dates:** 07/01/08 - 06/30/09  
- **Direct:** $233,963

**Dammaj, Vincent**  
**Principal Investigator**

**Cellular Factors Promoting Renal Cell Carcinoma**
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 02/01/09 - 01/31/10  
- **Direct:** $190,000

**Findlay, Victoria**  
**Co-Investigator**

**Role of Ets Genes in Transformation and Differentiation - Project 2**
- **PI:** Dennis Watson  
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 04/01/09 - 03/31/12  
- **Direct:** $133,845

**Francis, Shimon**  
**Significant Contributor**

**Mechanisms of Sensory Hair Cell Death and Survival: Minority Supplement**
- **PI:** Lisa Cunningham  
- **Sponsor:** NIH/NIDCD  
- **Budget Dates:** 08/01/08 - 06/30/09  
- **Direct:** $28,887

**Gong, Yong-Zhong**  
**Co-Investigator**

**Role of Ets Genes in Transformation and Differentiation - Project 3**
- **PI:** Dennis Watson  
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 04/01/09 - 03/31/12  
- **Direct:** $182,546

**Hsu, Tien**  
**Co-PI or Project Leader**

**Role of Ets Genes in Transformation and Differentiation - Project 2**
- **PI:** Dennis Watson  
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 04/01/09 - 03/31/12  
- **Direct:** $133,845

**Role of Ets Genes in Transformation and Differentiation - Core C**
- **PI:** Dennis Watson  
- **Sponsor:** NIH/NCI  
- **Budget Dates:** 04/01/09 - 03/31/12  
- **Direct:** $17,599

---

**Other**
- **Second Hand Smoke Exacerbates Allergic Rhinitis**
  - **PI:** M. Gillespie  
  - **Sponsor:** Charleston Research Institute  
  - **Budget Dates:** 08/01/08 - 06/30/09  
  - **Direct:** $300,000

---

**Notes:**
- Award numbers are provided where applicable.
- Department affiliations are listed for clarity.
- Project dates and funding details are included for each research project.
Hsu, Tien

**Co-Investigator**

**Role of Ets Genes in Transformation and Differentiation - Project 1**

Pl: Dennis Watson  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NCI  
Award: 5 P01 CA078582-10 (09022680-2)  
Direct $278,738

**Cellular Factors Promoting Renal Cell Carcinoma**

Pl: Vincent Dammai  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NCI  
Award: 5 R01 CA128002-03 (08121105-2)  
Direct $190,000

Kawamori, Toshihiko

**Principal Investigator**

**The Sphingolipid Pathway in Colon Cancer Chemoprevention**

Pl: Yusuf Hannun  
Dept: Biochemistry and Molecular Biology  
Sponsor: NIH/NCI  
Budget Dates: 01/01/09 - 12/31/09  
Award: 1 R01 CA124687-01A1 (08030341)  
Project Dates: 01/01/09 - 12/31/13  
Direct $207,500

**Sphingolipids in Cancer Biology and Therapy - Project 1**

Pl: Yusuf Hannun  
Dept: Biochemistry and Molecular Biology  
Sponsor: NIH/NCI  
Award: 2 P01 CA097132-06 (07101010-4)  
Direct $124,398

**COBRE in Lipidomics - Core C: Animal Core**

Pl: Lina Obeid  
Dept: Biochemistry and Molecular Biology  
Sponsor: NIH/NCRR  
Award: 5 P20 RR017677-07 (08070866-13)  
Direct $92,941

LaRue, Amanda

**Principal Investigator**

**Fracture Repair by Mouse and Human Hematopoietic Stem Cells**

Pl: Judy Dubno  
Dept: Otolaryngology  
Sponsor: VAMC  
Direct $303,800

Lang, Hainan

**Co-PI or Project Leader**

**Experimental and Clinical Studies of Presbyacusis - Project 3**

Pl: Judy Dubno  
Dept: Otolaryngology  
Sponsor: NIH/NIDCD  
Award: 2 P50 DC000422-21A1 (07091918-4)  
Direct $253,994

**Hematopoietic Origin of Mesenchymal/Stromal Cells**

Pl: Makio Ogawa  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NIDDK  
Award: 5 R01 DK077821-02 (09010563-2)  
Direct $212,500

**HSC-Derived Fibroblasts in Normal and Diseased Valves**

Pl: Christopher Drake  
Dept: Cell Biology and Anatomy  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL080168-03 (09041614-1)  
Direct $250,000

Lewin, David

**Co-Investigator**

**Radiofrequency Tumor Ablation at Low Frequencies**

Pl: Dieter Haemmerich  
Dept: Pediatrics  
Sponsor: NIH/NCI  
Award: 1 R21 CA135519-01 (07101113-1)  
Direct $112,500

Moussa, Omar

**Principal Investigator**

**The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer**

Pl: Omar Moussa  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NCI  
Budget Dates: 05/01/09 - 03/31/10  
Award: 1 R01 CA127905-01A1 (08030449)  
Project Dates: 05/01/09 - 03/31/14  
Direct $207,500

F & A: $98,563
Moussa, Omar

**Co-PI or Project Leader**

American Cancer Society Institutional Research Grant (ACSI RG)

Pl: Carolyn Reed  
Dept: Surgery  
Sponsor: Amer. Cancer Soc.  
Award: IRG-97-219-08 (06033010-19)  
Direct $24,000

Ogawa, Makio

**Principal Investigator**

**Hematopoietic Origin of Mesenchymal/Stromal Cells**

Sponsor: NIH/NIDDK  
Award: 5 R01 DK077821-02 (09010563)

**Co-Investigator**

Experimental and Clinical Studies of Presbyacusis - Project 3

Pl: Judy Dubno  
Dept: Otolaryngology  
Sponsor: NIH/NIDCD  
Award: 2 P05 DC000422-21A1 (07091918-4)  
Direct $253,994

Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury

Pl: Daohong Zhou  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NIAID  
Award: 1 R01 AI080421-01 (08010836-1)  
Direct $250,000

HSC-Derived Fibroblasts in Normal and Diseased Valves

Pl: Christopher Drake  
Dept: Cell Biology and Anatomy  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL080168-03 (09041614-1)  
Direct $250,000

Re, Gian

**Co-Investigator**

Evaluations of the Cepheid HemosIL Xpert Factor II and V Assay According to the Clinical Protocol, Clinical Evaluation of the HemosIL Xpert Factor II and V Assay

Pl: Daynna Wolff  
Dept: Pathology and Laboratory Medicine  
Sponsor: Cepheid  
Award: (07102980-4)  
Direct $33,834

Schulte, Bradley

**Principal Investigator**

**Inner Ear Ion Transport Mechanisms**

Sponsor: NIH/NIDCD  
Award: 5 R01 DC000713-17 (08061225)

**Co-Investigator**

Experimental and Clinical Studies of Presbyacusis - Project 3

Pl: Judy Dubno  
Dept: Otolaryngology  
Sponsor: NIH/NIDCD  
Award: 2 P05 DC000422-21A1 (07091918-4)  
Direct $253,994

Singh, Avtar

**Principal Investigator**

**AMP Kinase Activity in Stroke Injury**

Sponsor: VAMC  
Award: (08042165)

**Smith, Michael**

**Co-Investigator**

The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer

Pl: Omar Moussa  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NCI  
Award: 1 R01 CA127905-01A1 (08030449-1)  
Direct $207,500

Spyropoulos, Demetri

**Principal Investigator**

Developmental Transcription Factors in Prostate Cancer

Sponsor: Emory Univ.  
Award: 5-24346-G1/2R01CA106826-0 (08020174)

**Co-Investigator**

American Cancer Society Institutional Research Grant (ACSI RG)

Pl: Carolyn Reed  
Dept: Surgery  
Sponsor: Amer. Cancer Soc.  
Award: IRG-97-219-08 (06033010-17)  
Direct $24,000

Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury

Pl: Daohong Zhou  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NIAID  
Award: 1 R01 AI080421-01 (08010836-1)  
Direct $250,000

Mechanisms and Significance of Cubilin-Mediated HDL Uptake

Pl: W. Argraves  
Dept: Cell Biology and Anatomy  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL061873-07 (08071822-1)  
Direct $242,750

SC Cobre for Developmentally Based Cardiovascular Diseases: Core D - Molecular Tool Kit

Pl: Roger Markwald  
Dept: Cell Biology and Anatomy  
Sponsor: NIH/NCCRR  
Award: 5 P20 RR016434-08 (08081298-12)  
Direct $180,160

Expression and Function of Hemoglobin in Alveolar Epithelial Cells

Pl: John Baatz  
Dept: Pediatrics  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL085738-02 (08120253-1)  
Direct $225,000
Spyropoulos, Demetri

Co-Investigator
Role of Ets Genes in Transformation and Differentiation - Core B
Pl: Dennis Watson
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 5 P01 CA078582-10 (09022680-6)
Direct $ 137,589

Macrophage-Driven Progression of Premalignant Oral Lesions Toward Invasiveness
Pl: M. Young
Dept: Otolaryngology
Sponsor: NIH/NIDCR
Award: 1 R01 DE018168-01A2 (07102462-1)
Direct $ 250,000

Steed, Lisa

Principal Investigator
BBL CHROMagar VRE Evaluation for Detection of Vancomycin Resistance in Enterococci
Pl: Becton Dickinson
Sponsor: NIH/NIDCR
Budget Dates: 05/01/07 - 04/30/10
Direct: $ 36,100
Award: 06C1-020-CVRE-MUSC (07042731)
Project Dates: 05/01/07 - 04/30/10
F & A: $ 8,900

Co-Principal Investigator
Clinical Evaluation of the Charles River Laboratories LAL Test for the Presence of (1,3)-Beta-D-Glucan Present in Human Serum
Pl: Michael Schmidt
Dept: Microbiology and Immunology
Sponsor: Charles River Laboratories
Award: (08101017-1)
Direct $ 1,003,994

Co-Investigator
Copper Antimicrobial Research Program (CAP)
Pl: Michael Schmidt
Dept: Microbiology and Immunology
Sponsor: Advanced Technology Institut
Award: 2007-614/Mod. No. 4 (08052315-1)
Direct $ 304,037

Copper Air Quality Program
Pl: Michael Schmidt
Dept: Microbiology and Immunology
Sponsor: Advanced Technology Institut
Award: 2007-617 (08052833-1)
Direct $ 9,745

Turner, David

Co-Investigator
Role of Ets Genes in Transformation and Differentiation - Project 1
Pl: Dennis Watson
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 5 P01 CA078582-10 (09022680-2)
Direct $ 278,738

Wang, Yong

Co-Investigator
American Cancer Society Institutional Research Grant (ACSIRG)
Pl: Carolyn Reed
Dept: Surgery
Sponsor: Amer. Cancer Soc.
Award: IRG-97-219-08 (06033010-17)
Direct $ 24,000

Co-Investigator
Radiation-Induced Lymphoid and Hematopoietic Toxicity
Pl: Daohong Zhou
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 5 R01 CA086860-06 (07113095-2)
Direct $ 1,044

Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury
Pl: Daohong Zhou
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NIAID
Award: 1 R01 AI080421-01 (08010836-1)
Direct $ 250,000

Radiation-Induced Lymphoid and Hematopoietic Toxicity
Pl: Daohong Zhou
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 5 R01 CA086860-07 (08122949-2)
Direct $ 101,255

Cancer Therapy-Induced Long-Term Bone Marrow Injury
Pl: Daohong Zhou
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 5 R01 CA122023-03 (09040808-1)
Direct $ 190,000

Watson, Dennis

Principal Investigator
Role of Ets Genes in Transformation and Differentiation
Pl: NIH/NCI
Sponsor: NIH/NCI
Award: 5 P01 CA078582-10 (09022680)
Budget Dates: 05/01/09 - 04/30/10
Project Dates: 09/30/98 - 04/30/10
Direct: $ 797,626
F & A: $ 366,111

Co-PI or Project Leader
MUSC Cancer Center Support Grant: Program 2: Cancer Genes and Molecular Regulation
Pl: Andrew Kraft
Dept: Medicine
Sponsor: NIH/NCI
Award: 1 P30 CA138313-01 (08042262-5)
Direct $ 22,954

Co-Investigator
The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer
Pl: Omar Moussa
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 1 R01 CA127905-01A1 (08030449-1)
Direct $ 207,500

COBRE in Lipidomics - Core C: Animal Core
Pl: Lina Obeid
Dept: Biochemistry and Molecular Biology
Sponsor: NIH/NICRR
Award: 5 P20 RR017677-07 (08070866-13)
Direct $ 92,941
### Watson, Dennis

**Mentor**  
South Carolina COBRE for Oral Health Grant - Core A: Administrative  
Pl: Keith Kirkwood  
Sponsor: NIH/NCRR  
Dept: Craniofacial Biology  
Award: 5 P20 RR017696-08 (09033151-2)  
Direct $ 408,237

### Wei, Ling

**Principal Investigator**  
Novel Strategy for Neurovascular Repair after Neonatal Ischemic Stroke  
Sponsor: Amer. Heart Assoc.  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $ 90,909

### Wolff, Daynna

**Principal Investigator**  
Evaluations of the Cepheid HemosIL Xpert Factor II and V Assay According to the Clinical Protocol,  
Clinical Evaluation of the HemosIL Xpert Factor II and V Assay  
Sponsor: Cepheid  
Budget Dates: 10/10/07 - 10/10/08  
Direct: $ 33,834

### Won, Je-Seong

**Co-Investigator**  
Cytokines in Glial Cells and EAE Brain  
Pl: Inderjit Singh  
Dept: Pediatrics  
Award: 5 R01 NS037766-10 (08072235-1)  
Direct $ 219,267

### Yang, Jack

**Principal Investigator**  
Sponsor: Cytyc Corp.  
Budget Dates: 10/15/09 - 01/14/10  
Direct: $ 36,300

### Zhou, Daohong

**Principal Investigator**  
Radiation-Induced Lymphoid and Hematopoietic Toxicity  
Sponsor: NIH/NCI  
Budget Dates: 03/01/09 - 01/31/10  
Direct: $ 101,255

**Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury**  
Sponsor: NIH/NIAID  
Budget Dates: 09/05/09 - 09/30/10  
Direct: $ 20,760

### Abel, Anne

**Principal Investigator**  
South Carolina Child Abuse and Neglect Medical Response System Contract  
Sponsor: Univ. of South Carolina  
Budget Dates: 07/01/08 - 12/31/08  
Direct: $ 204,587

### Atz, Andrew

**Co-Investigator**  
Randomized Clinical Trials for Pediatric Heart Disease  
Pl: J. Saul  
Dept: Pediatrics  
Award: 5 U01 HL068281-08 (08072339-1)  
Direct $ 194,200

### Baatz, John

**Principal Investigator**  
Expression and Function of Hemoglobin in Alveolar Epithelial Cells  
Sponsor: NIH/NHLBI  
Budget Dates: 02/01/09 - 01/31/10  
Direct: $ 225,000

Baatz, John

**Principal Investigator**

**Comparison of Gene Expression and Image Data in Marine Mammal Cells: Baseline Data for Assessing Marine Mammal Health**

**Sponsor:** Natl. Inst. of Standards and Technology  
**Budget Dates:** 03/01/09 - 02/28/10  
**Direct:** $73,958

**Award:** 70ANB6H6212 (09022472)  
**Project Dates:** 09/01/06 - 02/28/10  
**F & A:** $19,229

Co-Investigator

**Cellular Factors Promoting Renal Cell Carcinoma**

**PI:** Vincent Dammai  
**Sponsor:** NIH/NCI  
**Budget Dates:** 03/01/09 - 02/28/10  
**Direct:** $190,000

**Dept:** Pathology and Laboratory Medicine  
**Award:** 5 R01 CA128002-03 (0812105-2)

Baker, George

**Principal Investigator**

**Preload Recruitable Stroke Work Derived from Three Dimensional Echocardiographic Pressure: Volume Loop Analysis in Congenital and Pediatric Heart Disease**

**Sponsor:** American Society of Echocardiography  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct:** $45,455

**Award:** 13 (08011787)  
**Project Dates:** 07/01/08 - 06/30/09  
**F & A:** $4,545

Bandisode, Varsha

**Principal Investigator**

**Closure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder**

**Sponsor:** Aga Medical Corp.  
**Budget Dates:** 01/10/08 - 01/09/13  
**Direct:** $3,634

**Award:** AGA 016 (08020709)  
**Project Dates:** 01/10/08 - 01/09/13  
**F & A:** $909

**The AMPLATZER Duct Occluder II in Patients with a Patent Ductus Arteriosus (ADO II Trail)**

**Sponsor:** Aga Medical Corp.  
**Budget Dates:** 02/28/08 - 09/30/13  
**Direct:** $48,132

**Award:** ADO II Trial (08092537)  
**Project Dates:** 02/28/08 - 09/30/13  
**F & A:** $11,158

Basco, William

**Principal Investigator**

**Academic Administrative Units in Primary Care**

**Sponsor:** HRSA  
**Budget Dates:** 09/01/08 - 08/31/09  
**Direct:** $185,185

**Award:** 2 D54P05448-04-01 (07121036)  
**Project Dates:** 09/01/08 - 08/31/09  
**F & A:** $14,815

**NRSA for Primary Medical Care: Developing Primary Care Researchers Using Research Networks**

**Sponsor:** HRSA  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct:** $127,371

**Award:** 1 T32 HP10255-01-00 (08022939)  
**Project Dates:** 07/01/08 - 06/30/09  
**F & A:** $8,375

**Prescribing Errors in Ambulatory Pediatric Care**

**Sponsor:** AHRQ  
**Budget Dates:** 06/01/06 - 05/31/10  
**Direct:** $113,410

**Award:** 5 K08 HS015679-04 (09020207)  
**Project Dates:** 06/01/06 - 05/31/10  
**F & A:** $9,073

Bowlby, Deborah

**Principal Investigator**

**Increlex Growth Forum Database - IGFD Registry: A Patient Registry for Monitoring Long-Term Safety and Efficacy of Increlex**

**Sponsor:** Tercica, Inc.  
**Budget Dates:** 12/04/06 - 12/03/09  
**Direct:** $876

**Award:** MS 305 (07012514)  
**Project Dates:** 12/04/06 - 12/03/09  
**F & A:** $220

**A Multi-center, Open-Label, Single-Arm Study Assessing DYAD Perception of Convenience and Preference of the Newly Developed Genotropin Mark VII Pen**

**Sponsor:** Icon Clinical Research, Inc.  
**Budget Dates:** 06/16/09 - 06/15/10  
**Direct:** $16,540

**Award:** A6281291 (09070755)  
**Project Dates:** 06/16/09 - 06/15/10  
**F & A:** $3,510

Carpenter, Laura

**Principal Investigator**

**A Randomized, Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acid Supplementation in Autism**

**Sponsor:** Autism Speaks  
**Budget Dates:** 07/01/08 - 06/30/09  
**Direct:** $123,571

**Award:** 2934 (08021555)  
**Project Dates:** 07/01/08 - 06/30/10  
**F & A:** $12,357

Charles, Jane

**Principal Investigator**

**Personnel Development Collaboration IDEA**

**Sponsor:** SC Dept. of Education  
**Budget Dates:** 09/08-09-01 (08092319)  
**Direct:** $1,000

**Award:** 09-CO-306-01 (08092319)  
**Project Dates:** 09/08-09-01 (08092319)  
**F & A:** $0

**SC Autism and Developmental Disabilities Monitoring Project (ADDM)**

**Sponsor:** CDC  
**Budget Dates:** 06/01/09 - 05/31/10  
**Direct:** $392,803

**Award:** 5 UR3 DD000083-04 (09022354)  
**Project Dates:** 06/01/06 - 05/31/10  
**F & A:** $117,840

Co-Investigator

**A Randomized, Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acid Supplementation in Autism**

**PI:** Laura Carpenter  
**Sponsor:** Autism Speaks  
**Direct:** $123,571

**Award:** 2934 (08021555-1)
<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Academic Administrative Units in Primary Care</th>
<th>Sponsor: HRSA</th>
<th>Direct $</th>
<th>185,185</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darden, Paul</td>
<td>Pl: William Basco</td>
<td>Award: 2 D54P05448-04-01 (07121036-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Pediatrics</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Randomized Clinical Trials for Pediatric Heart Disease</th>
<th>Sponsor: NIH/NHLBI</th>
<th>Direct $</th>
<th>194,200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forbus, Geoffrey</td>
<td>Pl: J. Saul</td>
<td>Award: 5 U01 HL068281-08 (08072339-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Pediatrics</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Clinical Trials for Antiviral Therapies</th>
<th>Sponsor: Univ. of Alabama</th>
<th>Budget Dates: 07/01/07 - 07/31/10</th>
<th>Direct: $</th>
<th>65,400</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fowler, Sandra</td>
<td>Award: N01-A1-30025 (07091498)</td>
<td>Project Dates: 07/01/07 - 07/31/10</td>
<td>F &amp; A:</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>SC Children's AIDS Care System</th>
<th>Sponsor: SC DHEC</th>
<th>Budget Dates: 08/01/08 - 07/31/09</th>
<th>Direct: $</th>
<th>116,482</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Investigator</td>
<td>Academic Administrative Units in Primary Care</td>
<td>Sponsor: HRSA</td>
<td>Direct $</td>
<td>185,185</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 2 D54P05448-04-01 (07121036-1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass</th>
<th>Sponsor: Amer. College of Cardiology</th>
<th>Budget Dates: 07/01/08 - 06/30/09</th>
<th>Direct: $</th>
<th>65,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graham, Eric</td>
<td>Award: (07042521)</td>
<td>Project Dates: 07/01/07 - 06/30/10</td>
<td>F &amp; A:</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Provider Reminders: Improving Vaccine Delivery in Office Practice</th>
<th>Sponsor: CDC</th>
<th>Direct $</th>
<th>136,986</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gustafson, Kristina</td>
<td>Award: 5 U01 IP000146-02 (08053048-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Radiofrequency Tumor Ablation at Low Frequencies</th>
<th>Sponsor: NIH/NCI</th>
<th>Budget Dates: 08/01/08 - 07/31/09</th>
<th>Direct: $</th>
<th>112,500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemmerich, Dieter</td>
<td>Award: 1 R21 CA135519-01 (07101113)</td>
<td>Project Dates: 08/01/08 - 07/31/10</td>
<td>F &amp; A:</td>
<td>53,438</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Development of Multi-Probe Radiofrequency Ablation</th>
<th>Sponsor: Univ. of Wisconsin</th>
<th>Budget Dates: 05/01/08 - 03/31/09</th>
<th>Direct: $</th>
<th>37,566</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Award: 280H604/R01CA108869-03 (08092218)</td>
<td>Project Dates: 05/02/06 - 04/30/10</td>
<td>F &amp; A:</td>
<td>17,281</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Prevention of Grounding Pad Skin Burns During Radiofrequency Tumor Ablation</th>
<th>Sponsor: NIH/NCI</th>
<th>Budget Dates: 06/01/09 - 05/31/10</th>
<th>Direct: $</th>
<th>168,971</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Award: 5 R01 CA118990-03 (09041591)</td>
<td>Project Dates: 07/01/07 - 05/31/11</td>
<td>F &amp; A:</td>
<td>53,557</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Experimental and Clinical Studies of Presbyacusis - Core B</th>
<th>Sponsor: NIH/NIDCD</th>
<th>Direct $</th>
<th>394,377</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hammond, Lyn</td>
<td>Award: 2 P50 DC000422-21A1 (07091918-6)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Randomized Trial of Maternal Vitamin D Supplementation to Prevent Childhood Asthma</th>
<th>Sponsor: Brigham and Womens Hospital</th>
<th>Budget Dates: 03/01/09 - 02/28/10</th>
<th>Direct: $</th>
<th>74,486</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hollis, Bruce</td>
<td>Award: 104228 (08012941)</td>
<td>Project Dates: 03/01/09 - 02/28/14</td>
<td>F &amp; A:</td>
<td>35,380</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Establishing the Vitamin D Requirements During Lactation</th>
<th>Sponsor: NIH/NICHD</th>
<th>Budget Dates: 08/01/08 - 07/31/09</th>
<th>Direct: $</th>
<th>409,086</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Award: 5 R01 HD047511-03 (08053050)</td>
<td>Project Dates: 09/28/06 - 07/31/11</td>
<td>F &amp; A:</td>
<td>127,886</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Vitamin D Insufficiency and Cardiovascular Risk in Type 2 Diabetes</th>
<th>Sponsor: Amer. Heart Assoc./Mid-Atlant</th>
<th>Direct $</th>
<th>60,000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Award: 0755466U (07010511-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Clofarabine in Combination with Cytarabine and Total Body Irradiation Followed by Allogeneic Hematopoietic Progenitor Cell Transplantation in Children with Acute Lymphoblastic Leukemia in Third Complete Remission</th>
<th>Sponsor: Columbia Univ.</th>
<th>Budget Dates: 05/01/09 - 04/30/10</th>
<th>Direct: $</th>
<th>8,500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hudspeth, Michelle</td>
<td>Award: CHNY=06532/ici0062 (09040272)</td>
<td>Project Dates: 05/01/09 - 04/30/10</td>
<td>F &amp; A:</td>
<td>1,500</td>
<td></td>
</tr>
</tbody>
</table>
Hudspeth, Michelle  
**Principal Investigator**  
**Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) of the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD**  
Sponsor: Osiris Therapeutics, Inc.  
Budget Dates: 05/30/09 - 05/30/11  
Award: 275, BB-IND 7939 (09060418)  
Project Dates: 05/30/09 - 05/30/11  
Direct: $3,246

Hulsey, Thomas  
**Co-PI or Project Leader**  
**Southeastern Predoctoral Training in Clinical Research (RMI): Administrative Core**  
PI: Barbara Tilley  
Sponsor: NIH/NCRR  
Budget Dates: 05/30/09 - 05/30/11  
Direct: $72,090

**Southeastern Predoctoral Training in Clinical Research (RMI): Curriculum Core**  
PI: Barbara Tilley  
Sponsor: NIH/NCRR  
Budget Dates: 05/30/09 - 05/30/11  
Direct: $56,743

**Co-Investigator**  
**Provider Reminders: Improving Vaccine Delivery in Office Practice**  
PI: James Roberts  
Sponsor: CDC  
Budget Dates: 05/30/09 - 05/30/11  
Direct: $136,986

Jackson, Sherron  
**Principal Investigator**  
**Stroke with Transfusions Changing to Hydroxyurea (SWITCH)**  
Sponsor: St. Jude Childrens Hospital  
Budget Dates: 08/01/08 - 07/31/09  
Award: 111270040-7302977/5U01HL0 (08112541)  
Project Dates: 08/01/08 - 07/31/09  
Direct: $87,863

Jenkins, Dorothea  
**Principal Investigator**  
**Safety of N-Acetylcysteine in Maternal Chorioamnionitis**  
Sponsor: NIH/NINDS  
Budget Dates: 02/01/09 - 01/31/10  
Award: 5 R01 NS052448-03 (08121613)  
Project Dates: 02/01/09 - 01/31/10  
Direct: $275,737

Kalpatthi, R.  
**Principal Investigator**  
**Pediatric Hydroxyurea Phase III Clinical Trial (Baby Hug)**  
Sponsor: NIH/NHLBI  
Budget Dates: 07/01/08 - 06/30/09  
Award: N01-HB-07154 (08050841)  
Project Dates: 06/01/00 - 06/30/12  
Direct: $171,965

**A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of AMG 531 in Thrombocytopenic Pediatric Subjects with Chronic Immune (Idiopathic) Thrombocytopenic Purpura**  
Sponsor: Amgen  
Budget Dates: 07/29/08 - 07/28/09  
Award: (08071715)  
Project Dates: 07/29/08 - 07/28/09  
Direct: $35,310

Katikaneni, Lakshmi  
**Principal Investigator**  
**Ophthalmologic Follow-Up Care and Early Intervention Enrollment for Children Born Very-Low-Birth-Weight**  
Sponsor: Boston Medical Center  
Budget Dates: 11/01/08 - 10/31/09  
Award: (08120469)  
Project Dates: 11/01/08 - 10/31/09  
Direct: $1,000

Key, Janice  
**Principal Investigator**  
**Sea Island Teen Opportunity for Prevention Programs**  
Sponsor: New Morning Fdn.  
Budget Dates: 07/01/08 - 06/30/09  
Award: (08060993)  
Project Dates: 07/01/04 - 06/30/09  
Direct: $181,188

**SC Institute for Childhood Obesity and Related Disorders (SCICORD)**  
Sponsor: Univ. of South Carolina  
Budget Dates: 06/02/08 - 06/30/10  
Award: 07 1381/18140-KL02 (08102882)  
Project Dates: 01/01/06 - 06/30/10  
Direct: $31,041

**Co-Investigator**  
**Charleston County Teen and Family EMPOWER (Ethnic Minority Outreach and Web-Based Education for Risk Reduction) Program**  
PI: Carla Danielson  
Sponsor: SAMHSA  
Budget Dates: 07/01/08 - 06/30/10  
Award: 1795SP015156-01 (08032861-1)  
Project Dates: 07/01/08 - 06/30/10  
Direct: $255,006
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key, L.</td>
<td>SEARCH for Diabetes in Youth 2: South Carolina Center</td>
<td>Univ. of North Carolina</td>
<td>02/01/08 - 09/29/09</td>
<td>47,920</td>
<td>22,043</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Safety and Efficacy of Atorvastatin in Newly Diagnosed Type I Diabetes</td>
<td>Sponsor: Childrens Hosp. of Philadelphia</td>
<td>02/01/08 - 09/29/10</td>
<td>65,671</td>
<td></td>
</tr>
<tr>
<td>Khan, Mush</td>
<td>Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy</td>
<td>NIH/NINDS</td>
<td>02/01/08 - 09/29/10</td>
<td>309,821</td>
<td></td>
</tr>
<tr>
<td>Kolb, Robert</td>
<td>The Role of the Primary Cilium in Glomerular Podocyte Cells</td>
<td>Sponsor: NIH/NIDDK</td>
<td>06/01/09 - 05/31/10</td>
<td>120,625</td>
<td></td>
</tr>
<tr>
<td>Kraveka, Jacqueline</td>
<td>COG Per Case and Specimen Reimbursement</td>
<td>National Childhood Cancer Fdn.</td>
<td>03/01/09 - 02/28/10</td>
<td>50,000</td>
<td></td>
</tr>
<tr>
<td>Metabolomic Profiling of Bioactive Sphingolipids in Neuroblastoma</td>
<td>Sponsor: St. Baldricks Fdn.</td>
<td>07/01/08 - 10/01/09</td>
<td>5,498</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lemon, Henry</td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Project 1</td>
<td>Sponsor: NIH/NCRR</td>
<td>07/01/08 - 10/01/09</td>
<td>139,160</td>
<td></td>
</tr>
<tr>
<td>Macias, Michelle</td>
<td>Training CED/COR Pediatric and Child Psychiatry</td>
<td>Sponsor: HRSA</td>
<td>07/01/08 - 10/01/09</td>
<td>13,889</td>
<td></td>
</tr>
<tr>
<td>Madyastha, Prema</td>
<td>Safety and Efficacy of Atorvastatin in Newly Diagnosed Type I Diabetes</td>
<td>Sponsor: Childrens Hosp. of Philadelphia</td>
<td>07/01/08 - 10/01/09</td>
<td>65,671</td>
<td></td>
</tr>
<tr>
<td>Lee, Kyu-Ho</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct: $</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>----------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Maria, Bernard</td>
<td>Principal Investigator</td>
<td>Neurobiology of Disease in Children Conferences</td>
<td>NIH/NINDS</td>
<td>04/01/09 - 06/30/09</td>
<td>60,000</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Perturbation of Hyaluronan Function in Cancer</td>
<td>NIH/NCI</td>
<td>04/15/01 - 06/30/09</td>
<td>172,000</td>
</tr>
<tr>
<td>Marsh, Linda</td>
<td>Co-Investigator</td>
<td>Sea Island Teen Opportunity for Prevention Programs</td>
<td>New Morning Fdn.</td>
<td>04/15/09 - 06/30/09</td>
<td>181,818</td>
</tr>
<tr>
<td>McQuinn, Tim</td>
<td>Principal Investigator</td>
<td>Research Training in Pediatric Cardiology</td>
<td>NIH/NHLBI</td>
<td>07/01/09 - 06/30/09</td>
<td>243,374</td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Core A1 - Business Management</td>
<td>NIH/NCRR</td>
<td>07/01/09 - 06/30/09</td>
<td>181,141</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Core A3 - Program Development</td>
<td>NIH/NCRR</td>
<td>07/01/09 - 06/30/09</td>
<td>43,174</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Core B - Imaging</td>
<td>NIH/NCRR</td>
<td>07/01/09 - 06/30/09</td>
<td>157,026</td>
</tr>
<tr>
<td></td>
<td>Mentor</td>
<td>SC Cobre for Developmentally Based Cardiovascular Diseases: Core A2 - Mentoring</td>
<td>NIH/NCRR</td>
<td>07/01/09 - 06/30/09</td>
<td>73,695</td>
</tr>
<tr>
<td>Peden-Adams, Margie</td>
<td>Principal Investigator</td>
<td>Perfluorooctane Sulfonate (PFOS) Affects IgM Production via IL-2</td>
<td>NIH/NIEHS</td>
<td>06/01/09 - 05/31/10</td>
<td>50,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mixture Effect of PCB's and PBDE's on Immunosuppression</td>
<td>NOAA</td>
<td>08/22/08 - 06/30/09</td>
<td>4,941</td>
</tr>
<tr>
<td>Pittard, William</td>
<td>Principal Investigator</td>
<td>Infant Well Child Care: Association with Readiness for 1st Grade Learning by Low Income Children</td>
<td>Commonwealth Fund</td>
<td>01/01/09 - 12/31/09</td>
<td>15,917</td>
</tr>
<tr>
<td>Purohit, Dilip</td>
<td>Principal Investigator</td>
<td>Perinatal Regional Systems Development</td>
<td>SC DHEC</td>
<td>07/01/08 - 06/30/09</td>
<td>236,080</td>
</tr>
<tr>
<td>Randazzo, William</td>
<td>Principal Investigator</td>
<td>Stay in School: School-Based Pediatrics</td>
<td>Amer. Acad. of Pediatrics</td>
<td>07/01/08 - 04/30/09</td>
<td>6,400</td>
</tr>
<tr>
<td>Reddy, Sakamuri</td>
<td>Principal Investigator</td>
<td>Inhibition of Osteoclast Activity by OIP-1/HSCAL</td>
<td>NIH/NIDCR</td>
<td>07/01/08 - 06/30/09</td>
<td>133,313</td>
</tr>
<tr>
<td>Reigart, II, John</td>
<td>Co-PI or Project Leader</td>
<td>Academic Administrative Units in Primary Care</td>
<td>HRSA</td>
<td>07/01/08 - 04/30/09</td>
<td>185,185</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct $</td>
<td>F &amp; A $</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>Ringewald, Jeremy</td>
<td>Closure of Atrial Septal Defects with the AMPLATZER Septal Occluder Post Market Study (ASD PMS II)</td>
<td>Aga Medical Corp.</td>
<td>05/16/08 - 05/15/11</td>
<td>324</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Provider Reminders: Improving Vaccine Delivery in Office Practice</td>
<td>CDC</td>
<td>09/01/08 - 08/31/10</td>
<td>136,986</td>
<td>63,014</td>
</tr>
<tr>
<td></td>
<td>Integrating Environment Management of Pediatric Asthma into Health Care: Creating Faculty Champions at Medical Schools and Outreach to the Health Care Community and Developing a Powerpoint Presentation</td>
<td>National Environmental Educ. and Training Fdn.</td>
<td>10/01/08 - 09/30/09</td>
<td>8,333</td>
<td>1,667</td>
</tr>
<tr>
<td></td>
<td>A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered with Routine Infant Vaccinations to Healthy Infants</td>
<td>i3 Research</td>
<td>04/22/09 - 06/30/11</td>
<td>113,670</td>
<td>27,668</td>
</tr>
<tr>
<td>Saul, J.</td>
<td>NERI/NIH Site Service Agreements</td>
<td>New England Research Institutes</td>
<td>06/01/08 - 12/31/08</td>
<td>35,548</td>
<td>9,952</td>
</tr>
<tr>
<td></td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>NIH/NHLBI</td>
<td>09/01/08 - 08/31/09</td>
<td>194,200</td>
<td>89,332</td>
</tr>
<tr>
<td>Shatat, Ibrahim</td>
<td>24 Hour Ambulatory Blood Pressure Measurements and Patterns in Children and Adolescents with Sickle Cell Disease</td>
<td>Dialysis Clinics, Inc.</td>
<td>06/25/09 - 06/24/10</td>
<td>12,058</td>
<td>0</td>
</tr>
<tr>
<td>Shirali, Girish</td>
<td>COMPASSION Study - Echocardiography Core Laboratory</td>
<td>Edwards Lifesciences</td>
<td>08/01/08 - 12/31/14</td>
<td>157,300</td>
<td>38,700</td>
</tr>
<tr>
<td></td>
<td>iE33 System and Investigational microTEE Transesophageal and X5-1 Engineering Clinical Evaluation</td>
<td>Philips Medical Systems, NA</td>
<td>03/03/09 - 03/31/10</td>
<td>4,100</td>
<td>400</td>
</tr>
<tr>
<td>Singh, Inderjit</td>
<td>Cytokines in Glial Cells and EAE Brain</td>
<td>NIH/NINDS</td>
<td>09/01/08 - 08/31/09</td>
<td>219,267</td>
<td>100,863</td>
</tr>
<tr>
<td></td>
<td>Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy</td>
<td>NIH/NINDS</td>
<td>02/01/09 - 01/31/10</td>
<td>309,821</td>
<td>142,518</td>
</tr>
</tbody>
</table>
### Pediatrics

**Singh, Inderjit**
- **Co-Investigator**
- **Safety and Efficacy of Atorvastatin in Newly Diagnosed Type I Diabetes**
  - **PI:** Valerie Durkalski
  - **Sponsor:** Children's Hosp. of Philadelphia
  - **Direct:** $65,671
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
  - **Award:** 950297RSUB (06031457-1)

**Spratt, Eve**
- **Principal Investigator**
- **Training CED/COR Pediatric and Child Psychiatry**
  - **Sponsor:** HRSA
  - **Budget Dates:** 07/01/08 - 06/30/09
  - **Direct:** $13,889
  - **F & A:** $1,111
- **Project Dates:** 07/01/06 - 06/30/11
  - **Award:** 5 T20 MC07467-03-00 (08041029)

**Taylor, Sarah**
- **Principal Investigator**
- **Identifying Vit D Deficiency and Effects in VLBW Infants**
  - **Sponsor:** NIH/NCRR
  - **Budget Dates:** 07/01/08 - 06/30/09
  - **Direct:** $140,108
  - **F & A:** $11,209
- **Project Dates:** 07/01/07 - 06/30/12
  - **Award:** 5 K23 RR021891-02 (08042498)

**Virella-Lowell, I.**
- **Principal Investigator**
- **Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease**
  - **Sponsor:** Inspire Pharmaceuticals, Inc.
  - **Budget Dates:** 05/22/08 - 05/21/11
  - **Direct:** $64,696
  - **F & A:** $16,174
- **Project Dates:** 05/22/08 - 05/21/11
  - **Award:** 08-110 (08041030)

### Psychiatry and Behavioral Sciences

**Acierno, Ron**
- **Principal Investigator**
- **Sexual Assault and Domestic Violence Intervention: Training Program for Students in Health Professions**
  - **Sponsor:** SC Dept. of Public Safety
  - **Budget Dates:** 10/01/08 - 09/30/09
  - **Direct:** $62,758
  - **F & A:** $0
- **Award:** 1K08026 (08050533)

**Wagner, Carol**
- **Co-Investigator**
- **Establishing the Vitamin D Requirements During Lactation**
  - **Sponsor:** NIH/NICHD
  - **Budget Dates:** 07/01/08 - 06/30/10
  - **Direct:** $409,086
- **Award:** 5 R01 HD047511-03 (08053050-1)

**Decision Support in the Care of Preterm Newborns - Tool Development**
- **Sponsor:** NIH/NHLBI
  - **Budget Dates:** 09/01/07 - 06/30/10
  - **Direct:** $171,889
  - **F & A:** $0
- **Award:** 1 R21 HL090598-01A1 (08071184-1)

**General Clinical Research Center**
- **Sponsor:** NIH/NCRR
  - **Budget Dates:** 09/01/07 - 06/30/10
  - **Direct:** $121,588
  - **F & A:** $25,682
- **Award:** 5 R21 AG030667-02 (08051676)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Award Details</th>
<th>Budget Dates</th>
<th>Direct $</th>
<th>F &amp; A</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acienro, Ron</td>
<td>Co-PI or Project Leader</td>
<td>Innovative Service Delivery for Secondary Prevention of PTSD in at-Risk OIF-OEF Service Men and Women</td>
<td>Charleston Research Institute</td>
<td>Award: W81XWH-08-00477 (08052722-1)</td>
<td>07/01/07 - 05/09/10</td>
<td>157,662</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Prevention of Postrape Drug Abuse: Replication Study</td>
<td>NIH/NIDA</td>
<td>Budget Dates: 08/01/09 - 06/30/09</td>
<td>Direct: $</td>
<td>505,705</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Heidi Resnick</td>
<td>Evidence-Based Provider Training Tool for PTSD Patients in Support of Psychological Health</td>
<td>US Navy Bureau of Medicine</td>
<td>Award: N00189-08-P-ZA85 (08100166-1)</td>
<td>05/10/09 - 05/09/10</td>
<td>370,370</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Development and Evaluation of a Web-Based Intervention for Disaster Victims</td>
<td>NIH/NIMH</td>
<td>Award: 5 R34 MH077149-03 (09050175-1)</td>
<td>05/10/09 - 05/09/10</td>
<td>71,250</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Kenneth Ruggiero</td>
<td>GxE: Monoamine Transporter Genotypes and Risk of Trauma-Related Psychopathology</td>
<td>NIH/NIMH</td>
<td>Award: 1 F32 MH083469-01 (07073166-1)</td>
<td>06/01/09 - 05/31/10</td>
<td>44,846</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amstadter, Ananda</td>
<td>Principal Investigator</td>
<td>GxE: Monoamine Transporter Genotypes and Risk of Trauma-Related Psychopathology</td>
<td>NIH/NIMH</td>
<td>Award: 1 F32 MH083469-01 (07073166)</td>
<td>Project Dates: 08/01/08 - 06/30/09</td>
<td>44,846</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anderson, Berry</td>
<td>Other</td>
<td>A Prospective, Multi-Center, Double-Blind, Randomized, Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects with Major Depression Disorder (MDD)</td>
<td>Brainsway</td>
<td>Award: CTP-0001-11 (08120984-1)</td>
<td></td>
<td>281,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anton, Jr., Raymond</td>
<td>Principal Investigator</td>
<td>A Phase 2 Study of LY2196044 Compared with Naltrexone and Placebo in the Treatment of Alcohol Dependence</td>
<td>Eli Lilly</td>
<td>Budget Dates: 09/17/07 - 09/30/10</td>
<td>Direct: $</td>
<td>81,374</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Mark George</td>
<td>Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism</td>
<td>NIH/NIAAA</td>
<td>Budget Dates: 05/15/09 - 04/30/14</td>
<td>Direct: $</td>
<td>368,736</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>A Phase II, Multi-Center, Randomized, Double-Blind, Two-Stage, Clinical Trial to Evaluate the Efficacy and Safety of MK-0594 in Patients with Alcohol Dependence</td>
<td>NIH/NIAAA</td>
<td>Budget Dates: 05/15/09 - 04/30/14</td>
<td>Direct: $</td>
<td>140,218</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Backe, Sudie</td>
<td>Principal Investigator</td>
<td>An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence</td>
<td>NIH/NIAAA</td>
<td>Budget Dates: 04/01/09 - 03/31/10</td>
<td>Direct: $</td>
<td>119,071</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Carrie Randall</td>
<td>Career Development and Mentoring in Clinical/Translational Alcohol Research</td>
<td>NIH/NIAAA</td>
<td>Budget Dates: 06/01/09 - 05/31/13</td>
<td>Direct: $</td>
<td>207,877</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Website Maintenance for Naltrexone/Acamprosate and CBT/MET Light for Alcoholism</td>
<td>N00189-08-P-ZA85</td>
<td>Award: HHSN275200900373P (09062549)</td>
<td>Project Dates: 07/01/07 - 05/09/10</td>
<td>5,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>Alcohol Research Center - Treatment and Implications: Pilot</td>
<td>NIH/NIAAA</td>
<td>Award: 5 P50 AA010761-14 (08111809-18)</td>
<td>Direct: $</td>
<td>53,931</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 1</td>
<td>NIH/NIAAA</td>
<td>Award: 5 P50 AA010761-14 (08111809-13)</td>
<td>Direct: $</td>
<td>154,563</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI: Carrie Randall</td>
<td>Alcohol Research Center - Treatment and Implications: Pilot</td>
<td>NIH/NIAAA</td>
<td>Award: 5 P50 AA010761-14 (08111809-18)</td>
<td>Direct: $</td>
<td>154,563</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 1</td>
<td>NIH/NIAAA</td>
<td>Award: 5 P50 AA010761-14 (08111809-13)</td>
<td>Direct: $</td>
<td>154,563</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- Direct $ indicates direct costs.
- F & A indicates indirect costs.

---

**Annual Report for Research FY2009**

115
### Back, Sudie

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence</td>
<td>Sponsor: City College of New York Award: 41654A (07020264-1)</td>
<td>23,387</td>
</tr>
<tr>
<td></td>
<td>The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues</td>
<td>Sponsor: NIH/NIDA Award: 1 R21 DA026085-01 (08031313-1)</td>
<td>178,500</td>
</tr>
<tr>
<td></td>
<td>Drug Abuse Research Training (DART) Program</td>
<td>Sponsor: NIH/NIDA Award: 5 R25 DA020537-04 (09031144-1)</td>
<td>256,253</td>
</tr>
</tbody>
</table>

### Becker, Howard

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preclinical Medications Screening in Alcohol Dependence and Anxiety Models</td>
<td>Sponsor: NIH/NIDDK Award: HHSN267200700038C (07050139)</td>
<td>222,816</td>
</tr>
<tr>
<td></td>
<td>Repeated Ethanols: Subjective Effects and Ethanol Drinking</td>
<td>Sponsor: VAMC Award: (07063034) Project Dates: 09/29/08 - 09/29/14</td>
<td>124,900</td>
</tr>
<tr>
<td></td>
<td>Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol</td>
<td>Sponsor: NIH/NIAAA Award: 1 R01 AA018036-01 (08032137)</td>
<td>225,000</td>
</tr>
<tr>
<td></td>
<td>Ethanol Dependence and Stress Effects on Ethanol Drinking: CRF and Neurosteroids</td>
<td>Sponsor: NIH/NIAAA Award: 5 U01 AA014095-07 (08120462)</td>
<td>279,054</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-PI or Project Leader</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 2</td>
<td>Sponsor: NIH/NIAAA Award: 5 P50 AA010761-14 (0811809-14)</td>
<td>131,373</td>
</tr>
<tr>
<td></td>
<td>Actin Dynamics and Spine Remodeling in Ethanol-Induced Plasticity</td>
<td>Sponsor: NIH/NIAAA Award: 2 R01 AA010983-12A1 (08042169-1)</td>
<td>237,500</td>
</tr>
</tbody>
</table>

### Bernstein, Hilary

<table>
<thead>
<tr>
<th>Other</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Methylphenidate-Ethanol Interactions in ADHD and Co-Abuse</td>
<td>Sponsor: NIH/NIAAA Award: 5 R01 AA016707-05 (08062069-1)</td>
<td>218,475</td>
</tr>
</tbody>
</table>

### Best, Connie

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Evidence-Based Provider Training Tool for PTSD Patients in Support of Psychological Health</td>
<td>Sponsor: US Navy Bureau of Medicine and Surgery Award: N00188-05-P-ZA85 (08100166) Project Dates: 09/30/08 - 09/29/10</td>
<td>370,370</td>
</tr>
</tbody>
</table>

### Book, Sarah

<table>
<thead>
<tr>
<th>Co-PI or Project Leader</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phased Treatment for Social Anxiety and Hazardous Drinking</td>
<td>Sponsor: NIH/NIAAA Award: 2 R01 AA013379-05A1 (07102673-1)</td>
<td>374,710</td>
</tr>
<tr>
<td></td>
<td>Stress and Subsequent Drinking in Individuals with Different Drinking Motives</td>
<td>Sponsor: NIH/NIAAA Award: 5 R21 AA016289-02 (08051672-1)</td>
<td>118,750</td>
</tr>
</tbody>
</table>

### Borckardt, Jeffrey

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor/Grant Details</th>
<th>Direct Funds $</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TMS in the Management of Postoperative Pain</td>
<td>Sponsor: NIH/NINR Award: 1 R21 NR010635-01A2 (08031832)</td>
<td>125,000</td>
</tr>
<tr>
<td></td>
<td>Data Analysis and Inference Issues in Continuous Quality Improvement</td>
<td>Sponsor: Robert Wood Johnson Fdn. Award: 65188 (08060479)</td>
<td>47,079</td>
</tr>
<tr>
<td></td>
<td>TMS Effects on Pain Perception</td>
<td>Sponsor: NIH/NINDS Award: 5 K23 NS050485-04 (09020210)</td>
<td>137,341</td>
</tr>
</tbody>
</table>
Brawman-Mintzer, O.

**Principal Investigator**

**A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults with Generalized Anxiety Disorder**

**PI:** Therese Killeen

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** Takeda Pharmaceuticals

**Award:** LuAA21004_309 (08062591)

**Budget Dates:** 06/25/08 - 11/30/09

**Direct:** $3,200

---

**Borckardt, Jeffrey**

**Co-Investigator**

**The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 1 R21 DA026085-01 (08031313-1)

**Budget Dates:** 09/15/08 - 06/30/09

**Direct:** $178,500

---

**Brady, Kathleen**

**Principal Investigator**

**The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 5 R01 DA023188-02 (09040924)

**Budget Dates:** 05/01/06 - 04/30/11

**Direct:** $591,436

---

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health**

**PI:** Jeffrey Borckardt

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NICHHD

**Award:** 5 K12 HD055885-02 (08053046)

**Budget Dates:** 09/28/07 - 07/31/12

**Direct:** $459,990

---

**D-Cycloserine Facilitation of Cocaine-Cue Extinction**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 3 U10 DA013727-09S2 (09012676)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $64,107

---

**Clinical Investigation of Drug Abuse Disorders**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 5 K24 DA000435-10 (08061006)

**Budget Dates:** 09/15/09 - 07/31/09

**Direct:** $1,407,762

---

**South Carolina Consortium of the Clinical Trials Network**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 5 U10 DA013727-09 (08070134)

**Budget Dates:** 09/01/08 - 08/31/09

**Direct:** $989,921

---

**South Carolina Consortium of the Clinical Trials Network**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 3 U10 DA013727-09S1 (08112125)

**Budget Dates:** 09/30/00 - 08/31/10

**Direct:** $670,508

---

**DCCU: Clinical Research Core**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 5 R01 DA23188-82 (09040924)

**Budget Dates:** 06/01/08 - 05/31/10

**Direct:** $251,745

---

**Translational Research in Addiction Center: Project 4**

**PI:** Ronald See

**Dept:** Neurosciences

**Sponsor:** NIH/NIDA

**Award:** 5 P20 DA022658-03 (08062601-6)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $113,255

---

**General Clinical Research Center**

**PI:** Joseph Reves

**Dept:** Anesthesia and Perioperative Medicine

**Sponsor:** NIH/NCRR

**Award:** 5 M01 RR001070-32 (09042955-1)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $118,585

---

**Drug Abuse Research Training (DART) Program**

**PI:** Carrie Randall

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 5 R25 DA020537-04 (09031144)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $30,451

---

**D-Cycloserine Facilitation of Cocaine-Cue Extinction**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 3 U10 DA013727-09S2 (09012676)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $251,745

---

**Co-PI or Project Leader**

**Translational Research in Addiction Center: Project 4**

**PI:** Ronald See

**Dept:** Neurosciences

**Sponsor:** NIH/NIDA

**Award:** 5 P20 DA022658-03 (08062601-6)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $113,255

---

**General Clinical Research Center**

**PI:** Joseph Reves

**Dept:** Anesthesia and Perioperative Medicine

**Sponsor:** NIH/NCRR

**Award:** 5 M01 RR001070-32 (09042955-1)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $118,585

---

**Drug Abuse Research Training (DART) Program**

**PI:** Carrie Randall

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NIDA

**Award:** 5 P50 AA010761-14 (08111809-17)

**Budget Dates:** 09/01/08 - 08/31/10

**Direct:** $74,185

---

**Significant Contributor**

**A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence**

**PI:** Therese Killeen

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** City College of New York

**Award:** 41654A (07020264-1)

**Budget Dates:** 09/01/09 - 02/10/10

**Direct:** $23,387

---

**Brawman-Mintzer, O.**

**Principal Investigator**

**A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults with Generalized Anxiety Disorder**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** Takeda Pharmaceuticals

**Award:** LuAA21004_309 (08062591)

**Budget Dates:** 06/25/08 - 11/30/09

**Direct:** $3,200

---

**A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase II Study of 2 Oral Dose Groups of AZD7325, with a Lorazepam Arm, in Subjects with Generalized Anxiety Disorder (GAD)**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** Quintiles Pacific, Inc.

**Award:** D114OC00014 (09020961)

**Budget Dates:** 02/11/09 - 02/10/10

**Direct:** $151,646

---

**Dose Groups of AZD7325, with a Lorazepam Arm, in Subjects with Generalized Anxiety Disorder (GAD)**

**PI:** Kathleen Brady

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** Quintiles Pacific, Inc.

**Award:** D114OC00014 (09020961)

**Budget Dates:** 02/11/09 - 02/10/10

**Direct:** $37,286
Brawman-Mintzer, O.  
**Co-PI or Project Leader**
Pilot Study of the Efficacy and Tolerability of Duloxetine in Patients with Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction - SOD)  
Pl: Christopher Lawrence  
Dept: Medicine  
Sponsor: Lilly Research Laboratories  
Award: F1J-MC-X038 (06053118-2)  
**F & A:** Direct $19,500

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD)  
Pl: Peter Cotton  
Dept: Medicine  
Sponsor: NIH/NIDDK  
Award: 5 U01 DK074739-02 (08042495-1)  
**F & A:** Direct $866,102

Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) - Data  
Pl: Peter Cotton  
Dept: Medicine  
Sponsor: NIH/NIDDK  
Award: 5 U01 DK074739-02 (08042495-2)  
**F & A:** Direct $120,521

Carpenter, Matthew  
**Principal Investigator**

**Stimulus Control and Trajectories of Adolescent Smoking**  
Sponsor: NIH/NIDA  
Award: 5 K23 DA020482-02 (08070869)  
**Project Dates:** 09/01/05 - 03/31/10  
**Budget Dates:** 09/30/05 - 03/31/12  
**F & A:** Direct $164,128

**A Pilot RCT to Examine a Potentially Reduced Exposure Tobacco Product**  
Sponsor: Prevent Cancer Foundation  
Award: (08091083)  
**Project Dates:** 09/15/09 - 01/14/10  
**Budget Dates:** 09/15/09 - 01/14/11  
**F & A:** Direct $40,000

**A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers**  
Sponsor: NIH/NIDA  
Award: 5 R01 DA021619-03 (09032096)  
**Project Dates:** 09/30/07 - 05/31/11  
**Budget Dates:** 09/30/07 - 05/31/12  
**F & A:** Direct $202,757

Chapman, Jason  
**Co-Investigator**

Adapting MST to Address Transmission Risk Behaviors in HIV+ Young People  
Pl: Elizabeth Letourneau  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 R34 MH077500-03 (08121612-2)  
**Project Dates:** 07/01/08 - 06/30/09  
**Budget Dates:** 09/01/08 - 06/30/10  
**F & A:** Direct $80,987

Differential Response to Evidenced-Based Treatment  
Pl: Philippe Cunningham  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 R01 MH068813-05 (09021287-1)  
**Project Dates:** 07/01/08 - 06/30/09  
**Budget Dates:** 09/01/08 - 06/30/10  
**F & A:** Direct $419,973

Cunningham, P.  
**Principal Investigator**

Multisystemic Therapy to Reduce Health Disparities in Adolescents with Asthma  
Pl: Wayne State Univ.  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 R01 MH068813-05 (09021287-1)  
**Project Dates:** 07/01/08 - 03/31/10  
**Budget Dates:** 09/01/08 - 03/31/10  
**F & A:** Direct $21,773

Adherence to IDDM Regimen in Urban Youth  
Pl: Wayne State Univ.  
Dept: Psychiatry and Behavioral Sciences  
Sponsor:  
Award: R01 DK059067/WSU06059-A2 (08071501)  
**Project Dates:** 09/01/06 - 08/31/11  
**Budget Dates:** 09/01/06 - 06/30/09  
**F & A:** Direct $13,144

Differential Response to Evidenced-Based Treatment  
Pl: Wayne State Univ.  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 R01 MH068813-05 (09021287-1)  
**Project Dates:** 07/01/08 - 03/31/10  
**Budget Dates:** 09/01/08 - 03/31/10  
**F & A:** Direct $419,973

Danielson, Carla  
**Principal Investigator**

Charleston County Teen and Family EMPOWER (Ethnic Minority Outreach and Web-Based Education for Risk Reduction) Program  
Pl: SAMHSA  
Dept: Psychiatry and Behavioral Sciences  
Sponsor:  
Award: 1R01DA023099-01A2 (07110194-1)  
**Project Dates:** 07/01/08 - 03/31/10  
**Budget Dates:** 09/01/08 - 03/31/10  
**F & A:** Direct $505,705

Risk Reduction for Drug Use and Sexual Revictimization  
Pl: Wayne State Univ.  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5 K23 DA018686-03 (08051675)  
**Project Dates:** 07/01/08 - 03/31/10  
**Budget Dates:** 09/01/08 - 03/31/10  
**F & A:** Direct $12,142

Co-Investigator

Prevention of Postrape Drug Abuse: Replication Study  
Pl: Heidi Resnick  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 1 R01 DA023099-01A2 (07110194-1)  
**Project Dates:** 07/01/08 - 03/31/10  
**Budget Dates:** 09/01/08 - 03/31/10  
**F & A:** Direct $505,705

Web-Based Intervention for Disaster-Affected Adolescents and Families  
Pl: Kenneth Ruggiero  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 U01 DK074739-02 (08042495-1)  
**Project Dates:** 07/01/08 - 03/31/10  
**Budget Dates:** 09/01/08 - 03/31/10  
**F & A:** Direct $244,615

**Direct:** $244,615

**Annual Report for Research FY2009**
### De Arellano, Michael

**Principal Investigator**

**National Crime Victim Center Outreach Vehicle**  
Sponsor: SC Dept. of Public Safety  
Budget Dates: 07/01/08 - 06/30/09  
Direct: $30,400  
F & A: $0

**The Violence against Hispanic Women Network**  
Sponsor: SC Dept. of Public Safety  
Budget Dates: 10/01/08 - 09/30/09  
Direct: $76,807  
F & A: $0

**Co-Investigator**

**Charleston County Teen and Family EMPOWERR (Ethnic Minority Outreach and Web-Based Education for Risk Reduction) Program**  
Pl: Carla Danielson  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: SAMHSA  
Direct: $255,006

**CSA Prevention Training for Child Care Professionals: Stewards of Children**  
Pl: Alyssa Rheingold  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: CDC  
Direct: $200,635

**Project BEST: Bringing Empirically Supported Treatments to South Carolina’s Children and Families**  
Pl: Benjamin Saunders  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Dee Norton Lowcountry Childr  
Direct: $366,498

### Devane, C.

**Principal Investigator**

**Bipolar Disorder in Pregnancy: Predictors of Morbidity**  
Sponsor: Emory Univ.  
Budget Dates: 08/01/08 - 07/31/09  
Direct: $48,223  
F & A: $22,183

**Reduction in Fetal Drug Exposure from Paliperidone Compared with Risperidone**  
Sponsor: Ortho-McNeil-Janssen Pharmaceuticals, Inc.  
Budget Dates: 12/26/08 - 12/31/09  
Direct: $48,683  
F & A: $23,125

**Aripiprazole Intramuscular Depot Program in Schizophrenia**  
Sponsor: Covance, Inc.  
Budget Dates: 01/15/09 - 01/31/12  
Direct: $356,200  
F & A: $88,425

**Co-PI or Project Leader**

**South Carolina Consortium of the Clinical Trials Network**  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Direct: $64,107  
F & A: $8,425

**Co-Investigator**

**CBT and Modafinil for Cocaine Addiction**  
Pl: Robert Malcolm, Jr.  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Direct: $250,000

**A Randomized, Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acid Supplementation in Autism**  
Pl: Laura Carpenter  
Dept: Pediatrics  
Sponsor: Autism Speaks  
Direct: $123,571

**Drug Transporters and the Disposition of ADHD Therapeutic Agents**  
Pl: John Markowitz  
Dept: Pharmaceutical and Biomedical Science  
Sponsor: NIH/NIDA  
Direct: $220,500

**South Carolina Consortium of the Clinical Trials Network**  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Direct: $989,921

### Donovan, Jennifer

**Principal Investigator**

**Prevention of Weight Gain and Dyslipidemia by Green Tea Therapy in Patients Initiating Therapy with Zyprexa**  
Sponsor: Eli Lilly  
Budget Dates: 09/08/08 - 09/07/10  
Direct: $232,036  
F & A: $57,384

**Co-Investigator**

**A Randomized, Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acid Supplementation in Autism**  
Pl: Laura Carpenter  
Dept: Pediatrics  
Sponsor: Autism Speaks  
Direct: $123,571  
F & A: $2934 (08021555-1)
<table>
<thead>
<tr>
<th><strong>Donovan, Jennifer</strong></th>
<th><strong>Co-Investigator</strong></th>
</tr>
</thead>
</table>
| **Drug Transporters and the Disposition of ADHD Therapeutic Agents** | PI: John Markowitz  
Dept: Pharmaceutical and Biomedical Science  
Sponsor: NIH/NIDA  
Award: 5 R01 DA022475-02 (08061645-1)  
F & A: 220,500 |
| **Bipolar Disorder in Pregnancy: Predictors of Morbidity** | PI: C. Devane  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Emory Univ.  
Award: 5 R01 MH07153-04/5-27505- (08080172-1)  
F & A: 48,223 |
| **Reduction in Fetal Drug Exposure from Paliperidone Compared with Risperidone** | PI: C. Devane  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Ortho-McNeil-Janssen Pharm  
Award: ICD 161655 (08112020-1)  
F & A: 48,683 |
| **Aripiprazole Intramuscular Depot Program in Schizophrenia** | PI: C. Devane  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Covance, Inc.  
Award: 31-07-247 (09010874-1)  
F & A: 356,200 |
| **South Carolina Consortium of the Clinical Trials Network** | PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 3 U10 DA013737-09S2 (09012676-1)  
F & A: 64,107 |

<table>
<thead>
<tr>
<th><strong>Fitzgerald, Monica</strong></th>
<th><strong>Co-Investigator</strong></th>
</tr>
</thead>
</table>
| **Project BEST: Bringing Empirically Supported Treatments to South Carolina’s Children and Families** | PI: Benjamin Saunders  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Dee Norton Lowcountry Childr  
Award: 1582-SP (08072856-1)  
F & A: 366,498 |
| **Trauma Learning Collaborative for DC (TLC for DC)** | PI: Benjamin Saunders  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: DC Office of Victim Services  
Award: 09-MUSC-02 (08082839-1)  
F & A: 150,000 |

<table>
<thead>
<tr>
<th><strong>George, Mark</strong></th>
<th><strong>Principal Investigator</strong></th>
</tr>
</thead>
</table>
| **PTSD/TBI Clinical Consortium Coordinating Center and Clinical Site** | Sponsor: SC Research Authority  
Award: 2009-114/PT074968-W81XWH- (08100691)  
Budget Dates: 09/15/09 - 01/15/09  
F & A: 13,071 |
| **PTSD/TBI Neuroimaging Core Proposal** | Sponsor: SC Research Authority  
Award: 2009-114 (08111496)  
Budget Dates: 09/15/09 - 09/14/13  
F & A: 39,212 |
| **A Prospective, Multi-Center, Double-Blind, Randomized, Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H- Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects with Major Depression Disorder (MDD)** | Sponsor: Brainsway  
Award: CTP-0001-11 (08120984)  
Budget Dates: 03/16/09 - 09/15/10  
F & A: 281,000 |
| **A Unified Neuroanatomical Model of Speech Production and Perception: Implications for Apraxia of Speech and Conduction Aphasia** | Sponsor: Univ. of South Carolina  
Award: 09-1649/1 R01 DC 00957-01 (08122239)  
Budget Dates: 02/25/09 - 01/31/14  
F & A: 13,036 |
| **Co-Investigator** | **The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues** | PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 1 R21 DA026085-01 (08031313-1)  
F & A: 178,500 |
| **TMS in the Management of Postoperative Pain** | PI: Jeffrey Borckardt  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NINR  
Award: 1 R21 NR010635-01A2 (08031824-1)  
F & A: 125,000 |
| **Translational Research in Addiction Center: Project 2** | PI: Ronald See  
Dept: Neurosciences  
Sponsor: NIH/NIDA  
Award: 5 P20 DA022658-03 (08062601-4)  
F & A: 137,136 |

<table>
<thead>
<tr>
<th><strong>Gray, Kevin</strong></th>
<th><strong>Principal Investigator</strong></th>
</tr>
</thead>
</table>
| **Training in Craving and Treatment in Adolescent Marijuana Use Disorders (AACAP Physician Scientist Program in Substance Abuse K12 Award)** | Sponsor: Amer. Acad. of Child Psychiatry  
Award: 5 K12 DA000357-10 (05042644)  
Budget Dates: 09/01/08 - 08/31/09  
F & A: 151,500 |
| **Co-PI or Project Leader** | **ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health: Component #4** | PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5 P30 DA016511-07 (08042808-4)  
F & A: 137,566 |
| **Co-Investigator** | **A Pilot RCT to Examine a Potentially Reduced Exposure Tobacco Product** | PI: Matthew Carpenter  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Prevent Cancer Foundation  
Award: (08091083-1)  
F & A: 40,000 |
Gray, Kevin

Co-Investigator
A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers
Pl: Matthew Carpenter
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Award: 5 R01 DA021619-03 (09032096-1)
Direct: 202,757

Griffin, W.

Co-Investigator
Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol
Pl: Howard Becker
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIAAA
Award: 1 R01 AA018036-01 (08032137-1)

Co-Investigator
Methylphenidate-Ethanol Interactions in ADHD and Co-Abuse
Pl: Kennerly Patrick
Dept: Pharmaceutical and Biomedical Science
Sponsor: NIH/NIAAA
Award: 5 R01 AA016707-05 (08062069-1)

Grubaugh, Anouk

Principal Investigator
Improving Mental Health Services for Diverse Veterans with PTSD and SMI
Sponsor: VAMC
Budget Dates: 01/01/09 - 12/31/09
Direct: 150,600

Hamner, Mark

Principal Investigator
A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD
Sponsor: Astrazeneca
Budget Dates: 11/01/09 - 12/31/09
Direct: 12,821

A 38-Week, Multi-Center, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment (Aripiprazole Intramuscular Depot Program in Schizophrenia)
Sponsor: Covance, Inc.
Budget Dates: 01/01/09 - 12/31/09
Direct: 344,400

Hanson, Rochelle

Co-PI or Project Leader
Trauma Learning Collaborative for DC (TLC for DC)
Pl: Benjamin Saunders
Dept: Psychiatry and Behavioral Sciences
Sponsor: DC Office of Victim Services
Direct: 150,000

Co-Investigator
Project BEST: Bringing Empirically Supported Treatments to South Carolina’s Children and Families
Pl: Benjamin Saunders
Dept: Psychiatry and Behavioral Sciences
Sponsor: Dee Norton Lowcountry Childr
Direct: 366,498

Hardesty, Susan

Co-Investigator
Aripiprazole Intramuscular Depot Program in Schizophrenia
Pl: C. Devane
Dept: Psychiatry and Behavioral Sciences
Sponsor: Covance, Inc.
Direct: 356,200

Hartwell, Karen

Principal Investigator
Impact of Varenicline on BOLD fMRI Activation During Smoking Cue-Induced Craving in Nicotine-Dependent Individuals
Sponsor: Pfizer, Inc.
Budget Dates: 09/17/08 - 10/01/10
Direct: 40,500

Co-Investigator
The Impact of Real-Time fMRI Feedback on Response to Nicotine Cues
Pl: Kathleen Brady
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Direct: 178,500

Haynes, Louise

Co-Investigator
South Carolina Consortium of the Clinical Trials Network
Pl: Kathleen Brady
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Direct: 989,921

South Carolina Consortium of the Clinical Trials Network
Pl: Kathleen Brady
Dept: Psychiatry and Behavioral Sciences
Direct: 670,508
Henggeler, Scott

**Principal Investigator**

**Substance Abusing Delinquents: 5-Year Outcomes of RCT**

Sponsor: NIH/NIDA  
Award: 5 R01 DA013066-10 (08071716)  
Budget Dates: 09/01/08 - 08/31/10  
Direct: $288,245  
F & A: $132,593

**Enhancing Juvenile Drug Court Outcomes with EBPs**

Sponsor: NIH/NIDA  
Award: 5 R01 DA01992-02 (08071717)  
Budget Dates: 09/01/08 - 08/31/09  
Direct: $451,075  
F & A: $191,138

**BlueSky and Building Stronger Families**

Sponsor: Annie E. Casey Fdn.  
Award: 96.2013 (09021069)  
Budget Dates: 03/01/09 - 02/28/10  
Direct: $286,023  
F & A: $0

**Testing Therapist Training Intervention to Implement an EBT for Adolescents**

Sponsor: NIH/NIDA  
Award: 5 R01 DA017487-06 (09021828)  
Budget Dates: 09/01/08 - 03/31/12  
Direct: $458,805  
F & A: $185,275

**Vocational Outcomes for Youth with Substance Abuse Problems and High HIV Risk**

Sponsor: NIH/NIDA  
Award: 5 R01 DA019708-04 (09041597)  
Budget Dates: 09/01/08 - 05/31/11  
Direct: $472,384  
F & A: $77,287

**Co-Investigator**

**Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth**

Pl: Elizabeth Letourneau  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 1 R01 DA025880-01 (08022292-1)  
Budget Dates: 09/01/08 - 08/31/10  
Direct: $214,404

**Adapting MST to Address Transmission Risk Behaviors in HIV+ Young People**

Pl: Elizabeth Letourneau  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 R34 MH077500-03 (08121612-2)  
Budget Dates: 09/01/08 - 08/31/10  
Direct: $80,987

**Differential Response to Evidenced-Based Treatment**

Pl: Phillippin Cunningham  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 5 R01 MH068813-05 (09021287-1)  
Budget Dates: 09/01/08 - 08/31/10  
Direct: $419,973

Killeen, Therese

**Principal Investigator**

**A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence**

Sponsor: City College of New York  
Award: 41654A (07020264)  
Budget Dates: 09/01/08 - 06/30/09  
Direct: $23,387  
F & A: $11,108

**Co-Investigator**

**South Carolina Consortium of the Clinical Trials Network**

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5 U10 DA013727-09 (08070134-1)  
Budget Dates: 09/01/08 - 06/30/09  
Direct: $989,921

**South Carolina Consortium of the Clinical Trials Network**

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5 U10 DA013727-09S1 (08112125-1)  
Budget Dates: 09/01/08 - 06/30/09  
Direct: $670,508

**D-Cycloserine Facilitation of Cocaine-Cue Extinction**

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5 R01 DA023188-02 (09040924-1)  
Budget Dates: 09/01/08 - 06/30/09  
Direct: $251,745

Kilpatrick, Dean

**Principal Investigator**

**National Center for Disaster Mental Health Research - Phase II**

Sponsor: Dartmouth Coll.  
Award: 496/5P60MH082598-02 (07032710)  
Budget Dates: 09/23/08 - 08/31/09  
Direct: $62,276  
F & A: $29,581

**Traumatic Stress Across the Lifespan: A Biopsychosocial Training Program**

Sponsor: NIH/NIMH  
Award: 2 T32 MH018689-21 (07052955)  
Budget Dates: 09/01/08 - 06/30/13  
Direct: $269,789  
F & A: $20,844

**The Psychobiology of Trauma and Resilience Across the Lifespan**

Sponsor: NIH/NIMH  
Award: 5 R13 MH078814-03 (08070351)  
Budget Dates: 09/01/08 - 07/31/10  
Direct: $49,686  
F & A: $0

**Self-Assessment and Self-Help for Teen Violence Victims**

Sponsor: DC Office of Victim Services  
Award: 09-MUSC-01 (08082842)  
Budget Dates: 10/01/08 - 03/31/10  
Direct: $278,940  
F & A: $0

**National Center for Disaster Mental Health Research - Phase I**

Sponsor: Dartmouth Coll.  
Award: 365/5P60MH082598-2 (08102778)  
Budget Dates: 09/01/08 - 08/31/09  
Direct: $16,688  
F & A: $7,676

**Co-Investigator**

**Web-Based Intervention for Disaster-affected Adolescents and Families**

Pl: Kenneth Ruggiero  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIMH  
Award: 1 R01 MH081056-01A1 (07110202-1)  
Budget Dates: 09/01/08 - 08/31/09  
Direct: $244,615
Kilpatrick, Dean

**Co-Investigator**

**Elder Mistreatment**

- **PI:** Ron Aciero
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIA
- **Award:** 5 R21 AG030667-02 (08051676-1)
- **Direct:** $121,588

**CSA Prevention Training for Child Care Professionals: Stewards of Children**

- **PI:** Alyssa Rheingold
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** CDC
- **Award:** 5 R49 CE000890-03 (08071087-1)
- **Direct:** $200,635

**Evidence-Based Provider Training Tool for PTSD Patients in Support of Psychological Health**

- **PI:** Connie Best
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** US Navy Bureau of Medicine
- **Award:** N00189-08-P-ZA85 (08100166-1)
- **Direct:** $370,370

Larowe, Steven

**Co-Investigator**

**CBT and Modafinil for Cocaine Addiction**

- **PI:** Robert Malcolm, Jr.
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Award:** 2 R01 DA016368-05 (07062927-1)
- **Direct:** $250,000

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health: Component #4**

- **PI:** Kathleen Brady
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Award:** 5 P50 DA016511-07 (08042808-4)
- **Direct:** $137,566

**A Controlled Trial of NAC for Cocaine Dependence**

- **PI:** Robert Malcolm, Jr.
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Award:** 5 R01 DA019903-04 (08093054-2)
- **Direct:** $263,066

Letourneau, E.

**Principal Investigator**

**Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 09/25/08 - 06/30/09
- **Direct:** $214,404

**Adapting MST to Address Transmission Risk Behaviors in HIV+ Young People**

- **Sponsor:** NIH/NIMH
- **Budget Dates:** 02/01/07 - 01/31/10
- **Direct:** $80,987

Li, Xingbao

**Co-Investigator**

**Translational Research in Addiction Center: Project 2**

- **PI:** Ronald See
- **Dept:** Neurosciences
- **Sponsor:** NIH/NIDA
- **Award:** 5 P20 DA022658-03 (08062601-4)
- **Direct:** $137,136

**Alcohol Research Center - Treatment and Implications: Research Component 1**

- **PI:** Carrie Randall
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 5 P50 AA010761-14 (08111089-3)
- **Direct:** $154,563

**Alcohol Research Center - Treatment and Implications: Research Component 3**

- **PI:** Carrie Randall
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 5 R01 AA018036-01 (08032137-1)
- **Direct:** $86,774

Lopez, Marcelo

**Co-Investigator**

**Preclinical Medications Screening in Alcohol Dependence and Anxiety Models**

- **PI:** Howard Becker
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDDK
- **Award:** HHSN2672007000038C (07051039-2)
- **Direct:** $222,816

**Role of Amygdala Glutamate in Tolerance to the Aversive Effects of Ethanol**

- **PI:** Howard Becker
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 1 R01 AA018036-01 (08032137-1)
- **Direct:** $225,000

Madan, Alok

**Co-PI or Project Leader**

**Data Analysis and Inference Issues in Continuous Quality Improvement**

- **PI:** Jeffrey Borckardt
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** Robert Wood Johnson Fdn.
- **Award:** 65188 (08060479-1)
- **Direct:** $47,079

Magruder, Kathryn

**Principal Investigator**

**Depression, Pain, and Diabetic Neuropathy, Secondary Analysis**

- **Sponsor:** Eli Lilly
- **Budget Dates:** 07/19/05 - 06/30/08
- **Direct:** $37,542

**Randomized Trial of an Online Early Intervention for Combat PTSD in Primary Care**

- **Sponsor:** Henry M. Jackson Fdn.
- **Budget Dates:** 07/16/07 - 06/30/09
- **Direct:** $33,166

**Oral Health in People with Systemic Sclerosis**

- **PI:** Hon Yuen
- **Dept:** Health Professions
- **Sponsor:** NIH/NIDCR
- **Award:** 5 R21 DE017360-02 (08052830-1)
- **Direct:** $148,350
Magruder, Kathryn

Co-Investigator
South Carolina Consortium of the Clinical Trials Network
Pl: Kathleen Brady
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Award: 5 U10 DA013727-09 (08070134-1)

Malcolm, Jr., Robert

Principal Investigator
CBT and Modafinil for Cocaine Addiction
Sponsor: NIH/NIDA
Award: 2 R01 DA016368-05 (07062927)

Medication Development for Stimulant Dependence (MDS)
Sponsor: Univ. of California, Los Angeles
Award: 2000-S-JD-914/N01DA-3-882 (08060687)

ESRC343 - A Timeline Study of Alcohol Use in Alcohol Dependent Patients with Insomnia
Sponsor: Sepracor, Inc.
Budget Dates: 09/01/08 - 08/31/09
Direct: $21,992
Award: ESRC343 (08090359)

McCart, Michael

Principal Investigator
Augmentation of Exposure Therapy with D-Cycloserine for Pediatric PTSD
Sponsor: NARSAD
Award: (07042623)

Co-Investigator
Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth
Pl: Elizabeth Letourneau
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Award: 1 R01 DA025880-01 (08022292-1)

McRae, Aimee

Principal Investigator
Stress and Marijuana Cue-Elicited Craving and Reactivity
Sponsor: NIH/NIDA
Award: 5 R21 DA022424-02 (08070971)

ORWH: SCOR on Sex and Gender Factors Affecting Women's Health: Component #2
Pl: Kathleen Brady
Dept: Psychiatry and Behavioral Sciences
Sponsor: NIH/NIDA
Award: 5 P50 DA16515-07 (08042808-3)

Co-Investigator
Treatment Implications of Beta-Blockade Effects on Memory for Cocaine Craving
Pl: Michael Saladin
Dept: Health Sciences and Research
Sponsor: NIH/NIDA
Award: 1 R21 DA025155-01 (07101223-1)

Translational Research in Addiction Center: Project 4
Pl: Ronald See
Dept: Neurosciences
Sponsor: NIH/NIDA
Award: 5 P20 DA022658-03 (08062601-6)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>McRae, Aimee</td>
<td>Co-Investigator</td>
<td>D-Cycloserine Facilitation of Cocaine-Cue Extinction</td>
<td>NIH/NIDA</td>
<td>09/040924-1</td>
<td>251,745</td>
<td></td>
</tr>
<tr>
<td>Middaugh, Lawrence</td>
<td>Co-PI or Project Leader</td>
<td>Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Core A</td>
<td>NIH/NIA</td>
<td>08052314-2</td>
<td>64,596</td>
<td></td>
</tr>
<tr>
<td>Miller, Peter</td>
<td>Principal Investigator</td>
<td>Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care</td>
<td>NIH/NIAAA</td>
<td>09/20/08 - 08/31/09</td>
<td>337,197</td>
<td>160,169</td>
</tr>
<tr>
<td>Myrick, Donald</td>
<td>Co-PI or Project Leader</td>
<td>Alcohol Research Center - Treatment and Implications: Research Component 3</td>
<td>NIH/NIAAA</td>
<td>08111809-15</td>
<td>86,774</td>
<td></td>
</tr>
<tr>
<td>Nahas, Ziad</td>
<td>Principal Investigator</td>
<td>Oxytocin for Treating Depression: A Double-Blind, Placebo-Controlled Neuroimaging Study</td>
<td>NIH/NIMH</td>
<td>08062601-4</td>
<td>137,136</td>
<td></td>
</tr>
</tbody>
</table>

**McRae, Aimee**

D-Cycloserine Facilitation of Cocaine-Cue Extinction
PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Direct: $251,745

**Middaugh, Lawrence**

Dual-Hit Hypothesis of Aging-Related DA Dysfunction - Core A
PI: Ann-Charlotte Granholm  
Dept: Neurosciences  
Sponsor: NIH/NIA  
Direct: $64,596

**Miller, Peter**

Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care
Sponsor: NIH/NIAAA  
Budget Dates: 09/20/08 - 08/31/09  
Project Dates: 09/20/08 - 08/31/12  
Direct: $337,197  
F & A: $160,169

**Myrick, Donald**

Alcohol Research Center - Treatment and Implications: Research Component 3
PI: Carrie Randall  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIAAA  
Direct: $86,774

**Nahas, Ziad**

Oxytocin for Treating Depression: A Double-Blind, Placebo-Controlled Neuroimaging Study
Sponsor: Hope for Depression Research Fdn.  
Budget Dates: 01/01/07 - 06/30/09  
Direct: $26,182  
F & A: $2,618

DBS and Rodent Antidepressant-Screen Models
Sponsor: NIH/NIMH  
Budget Dates: 07/01/08 - 06/30/10  
Direct: $163,940  
F & A: $12,539

Using Neuroimaging, Quantitative EEG and Genetics to Diagnose Depression
Sponsor: Hope for Depression Research Fdn.  
Budget Dates: 01/01/09 - 12/31/09  
Direct: $50,000  
F & A: $5,000
## O'Neil, Patrick

**Principal Investigator**

**A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients with Type 2 Diabetes Mellitus Managed with Oral**

Sponsor: Arena Pharmaceuticals, Inc.
Award: APD356-010 (07121467)
Budget Dates: 12/06/07 - 12/05/10
Direct: $4,175
F & A: $1,044

**A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format**

Sponsor: Weight Watchers International, Inc.
Award: 08101118
Budget Dates: 10/04/08 - 10/31/09
Direct: $420,500
F & A: $104,500

## Olive, Michael

**Principal Investigator**

**Examining the Effects of the Novel ALDH2 Inhibitor CVT-10216 on Basal and Ethanol-Stimulated Release in the Nucleus Accumbens**

Sponsor: CV Therapeutics, Inc.
Award: CVT-10216 (07051177)
Budget Dates: 05/01/07 - 12/31/09
Direct: $7,446
F & A: $3,424

**Metabotropic Glutamate Receptor Signaling and Extinction Learning**

Sponsor: NIH/NIDA
Award: 5 R01 DA024355-02 (08051564)
Budget Dates: 09/09/07 - 07/30/09
Direct: $196,000
F & A: $90,160

## Payne, Rebecca

**Principal Investigator**

**Pain and Craving among Cocaine Dependent Individuals**

Sponsor: APIRE
Award: (08072552)
Budget Dates: 08/01/08 - 07/31/10
Direct: $2,500
F & A: $0

## Randall, Carrie

**Principal Investigator**

**Phased Treatment for Social Anxiety and Hazardous Drinking**

Sponsor: NIH/NIAAA
Award: 2 R01 AA013379-05A1 (07102673)
Budget Dates: 09/01/08 - 08/31/09
Direct: $374,710
F & A: $113,403

**Mentoring and Career Development in Alcohol Research**

Sponsor: NIH/NIAAA
Award: 5 K24 AA013314-08 (08071494)
Budget Dates: 09/01/08 - 08/31/09
Direct: $140,972
F & A: $11,278

**Alcohol Research Center - Treatment and Implications**

Sponsor: NIH/NIAAA
Award: 5 P50 AA010761-14 (0811809)
Budget Dates: 12/10/09 - 12/31/10
Direct: $1,181,647
F & A: $531,197

**Co-Investigator**

**Stress and Subsequent Drinking in Individuals with Different Drinking Motives**

Sponsor: NIH/NIAAA
Budget Dates: 09/01/08 - 08/31/09
Direct: $118,750
F & A: $0
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Research Title</th>
<th>Sponsor</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randall, Jeff</td>
<td>Co-Investigator</td>
<td>Adapting MST to Address Transmission Risk Behaviors in HIV+ Young People</td>
<td>Sponsor: NIH/NIMH</td>
<td>$80,987</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 R34 MH077500-03 (08121612-2)</td>
<td></td>
</tr>
<tr>
<td>Randall, Patrick</td>
<td>Co-Investigator</td>
<td>Phased Treatment for Social Anxiety and Hazardous Drinking</td>
<td>Sponsor: NIH/NIAAA</td>
<td>$374,710</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 2 R01 AA013379-05A1 (07102673-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Stress and Subsequent Drinking in Individuals with Different Drinking Motives</td>
<td>Sponsor: NIH/NIAAA</td>
<td>$118,750</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 R21 AA016289-02 (08051672-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism</td>
<td>Sponsor: NIH/NIAAA</td>
<td>$368,736</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 1 R01 AA017633-01A1 (08061646-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Alcohol Research Center - Treatment and Implications: Pilot</td>
<td>Sponsor: NIH/NIAAA</td>
<td>$53,931</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 P50 AA010761-14 (08111809-18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Alcohol Research Center - Treatment and Implications: Components 1-3</td>
<td>Sponsor: NIH/NIAAA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 P50 AA010761-14 (08111809-13)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Alcohol Research Center - Treatment and Implications: Components 4-5</td>
<td>Sponsor: NIH/NIAAA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 P50 AA010761-14 (08111809-14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Stress and Subsequent Drinking in Individuals with Different Drinking Motives</td>
<td>Sponsor: NIH/NIAAA</td>
<td>$118,750</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 R21 AA016289-02 (08051672-1)</td>
<td></td>
</tr>
<tr>
<td>Stresnick, Heidi</td>
<td>Principal Investigator</td>
<td>Prevention of Postrape Drug Abuse: Replication Study</td>
<td>Sponsor: NIH/NIDA</td>
<td>$505,705</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 1 R01 DA023099-01A2 (07110194)</td>
<td>Budget Dates: 09/15/08 - 06/30/09</td>
<td>Direct: $505,705</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Web-Based Intervention for Disaster-Affected Adolescents and Families</td>
<td>Sponsor: NIH/NIMH</td>
<td>$244,615</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 1 R01 MH081056-01A1 (07110202-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Elder Mistreatment</td>
<td>Sponsor: NIH/NIAA</td>
<td>$121,588</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 R21 AG030667-02 (08051676-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Development and Evaluation of a Web-Based Intervention for Disaster Victims</td>
<td>Sponsor: NIH/NIMH</td>
<td>$71,250</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 5 R34 MH077149-03 (09050175-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Self-Assessment and Self-Help for Teen Violence Victims</td>
<td>Sponsor: DC Office of Victim Services</td>
<td>$278,940</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 09-MUSC-01 (08082842-1)</td>
<td></td>
</tr>
<tr>
<td>Rheingold, Alyssa</td>
<td>Principal Investigator</td>
<td>Specialized Services for Survivors of Homicide</td>
<td>Sponsor: SC Dept. of Public Safety</td>
<td>$48,967</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 1V06105 (08020592)</td>
<td>Budget Dates: 07/01/08 - 06/30/09</td>
<td>Direct: $48,967</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>CSA Prevention Training for Child Care Professionals: Stewards of Children</td>
<td>Sponsor: CDC</td>
<td>$200,635</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 5 R49 CE000890-03 (08071078)</td>
<td>Budget Dates: 09/01/08 - 08/31/09</td>
<td>Direct: $200,635</td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>National Crime Victim Center Outreach Vehicle</td>
<td>Sponsor: SC Dept. of Public Safety</td>
<td>$30,400</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: 1W09017 (08022185-1)</td>
<td></td>
</tr>
</tbody>
</table>

Annual Report for Research FY2009
Rheingold, Alyssa  
Co-PI or Project Leader  
The Violence against Hispanic Women Network  
Pl: Michael De Arellano  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: SC Dept. of Public Safety  
Award: 1K08017 (08102268-1)  
Direct: $76,807  

Co-Investigator  
Charleston County Teen and Family EMPOWER (Ethnic Minority Outreach and Web-Based Education for Risk Reduction) Program  
Pl: Carla Danielson  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: SAMHSA  
Award: 1U79SP015156-01 (08032861-1)  
Direct: $255,006  

Ruggiero, Kenneth  
Principal Investigator  
Web-Based Intervention for Disaster-Affected Adolescents and Families  
Pl: Dean Kilpatrick  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Dartmouth Coll.  
Award: 496/5P60MH082598-02 (07032710-1)  
Direct: $62,276

Co-Investigator  
Prevention of Posttrape Drug Abuse: Replication Study  
Pl: Heidi Resnick  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 1 R01 DA023099-01A2 (07110194-1)  
Direct: $505,705  

Development and Evaluation of a Web-Based Intervention for Disaster Victims  
Pl: Carla Danielson  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: SAMHSA  
Award: 1U79SP015156-01 (08032861-1)  
Direct: $255,006  

National Center for Disaster Mental Health Research - Phase II  
Pl: Dean Kilpatrick  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Dartmouth Coll.  
Award: 365/5P60MH082598-2 (08102778-1)  
Direct: $16,688  

Other  
Self-Assessment and Self-Help for Teen Violence Victims  
Pl: Dean Kilpatrick  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: DC Office of Victim Services  
Award: 09-MUSC-01 (08082842-1)  
Direct: $278,940

Sampson, Royce  
Co-Investigator  
General Clinical Research Center  
Pl: Joseph Reves  
Dept: Anesthesia and Perioperative Medicine  
Sponsor: NIH/NCRR  
Award: 5 M01 RR001070-32 (09042955-1)  
Direct: $1,579,043

Santos, Alberto  
Co-Investigator  
Drug Abuse Research Training (DART) Program  
Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: NIH/NIDA  
Award: 5 R25 DA020537-04 (09031144-1)  
Direct: $256,253

Saunders, Benjamin  
Principal Investigator  
Disseminating Trauma-Focused CBT to Child Welfare Therapists: Web-Based Model  
Pl: Allegheny-Singer Research Inst.  
Sponsor: SC Dept. of Public Safety  
Award: 208.0327 (08022078)  
Budget Dates: 09/01/08 - 12/31/08  
Direct: $20,785  

Project BEST: Bringing Empirically Supported Treatments to South Carolina’s Children and Families  
Pl: Dee Norton Lowcountry Childrens Center  
Sponsor: SC Dept. of Public Safety  
Award: 1552-SP (08072856)  
Budget Dates: 07/01/07 - 06/30/09  
Direct: $366,498  

Trauma Learning Collaborative for DC (TLC for DC)  
Pl: DC Office of Victim Services  
Sponsor: SC Dept. of Public Safety  
Award: 09-MUSC-02 (08082839)  
Budget Dates: 01/01/08 - 09/30/09  
Direct: $150,000
Saunders, Benjamin

**Co-PI or Project Leader**

**Self-Assessment and Self-Help for Teen Violence Victims**
- PI: Dean Kilpatrick
- Dept: Psychiatry and Behavioral Sciences
- Co-Investigator
- Sponsor: DC Office of Victim Services
- Award: 09-MUSC-01 (08082842-1)
- Direct: $278,940

**Web-Based Intervention for Disaster-Affected Adolescents and Families**
- PI: Kenneth Ruggiero
- Dept: Psychiatry and Behavioral Sciences
- Award: 1 R01 MH081056-01A1 (07110202-1)
- Direct: $244,615

**Charleston County Teen and Family EMPOWER (Ethnic Minority Outreach and Web-Based Education for Risk Reduction) Program**
- PI: Carla Danielson
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: SAMHSA
- Award: 1U79SP015156-01 (08032861-1)
- Direct: $255,006

**Elder Mistreatment**
- PI: Ron Acierno
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: NIH/NIA
- Award: 5 R21 AG030667-02 (08051676-1)
- Direct: $121,588

**CSA Prevention Training for Child Care Professionals: Stewards of Children**
- PI: Alyssa Rheingold
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: CDC
- Award: 5 R49 CE000890-03 (08071078-1)
- Direct: $200,635

**Evidence-Based Provider Training Tool for PTSD Patients in Support of Psychological Health**
- PI: Connie Best
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: US Navy Bureau of Medicine
- Award: N00189-08-P-ZA85 (08100166-1)
- Direct: $370,370

---

Schoenwald, Sonja

**Principal Investigator**

**Advanced Center to Improve Pediatric Mental Health Care**
- Sponsor: Rady Childrens Hospital San Diego
- Award: (07050241)
- Project Dates: 05/06/08 - 03/31/13
- Direct: $25,612
  - F & A: 11,782

**Center to Promote Schools as the Context for Urban Children's Mental Health**
- Sponsor: Univ. of Illinois, Chicago
- Award: PAF#2007-06003/1P20MH0784 (07051592)
- Project Dates: 06/01/08 - 03/31/09
- Direct: $56,136
  - F & A: 26,664

**Mental Health Services and Predictors of Learning in Urban Schools**
- Sponsor: Univ. of Illinois, Chicago
- Award: 494685 E6842 (07101533)
- Project Dates: 06/01/08 - 03/31/09
- Direct: $13,343
  - F & A: 6,338

**Mental Health Services and Predictors of Learning in Urban Schools**
- Sponsor: Univ. of Illinois, Chicago
- Award: 494685 E6842 (08062535)
- Project Dates: 06/01/08 - 03/31/09
- Direct: $13,343
  - F & A: 6,338

**Advanced Center to Improve Pediatric Mental Health Care (ACIPMHC)**
- Sponsor: Rady Childrens Hospital San Diego
- Award: S000305/662-91193560/P30M (09051914)
- Project Dates: 05/06/08 - 04/30/09
- Direct: $35,174
  - F & A: 16,180

**Co-Investigator**

**Differential Response to Evidenced-Based Treatment**
- PI: Philippe Cunningham
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: NIH/NIMH
- Award: S R01 MH066813-05 (09021287-1)
- Direct: $419,973

Sheidow, Ashli

**Principal Investigator**

**Adaptation of Multisystemic Therapy in Transition Age Youth**
- Sponsor: Univ. of Massachusetts
- Award: 6084147/RFS800056/R34-MH0 (08081509)
- Project Dates: 09/01/07 - 07/31/10
- Direct: $54,110
  - F & A: 24,890

**Co-Investigator**

**Center to Promote Schools as the Context for Urban Children's Mental Health**
- PI: Sonja Schoenwald
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: Univ. of Illinois, Chicago
- Award: PAF#2007-06003/1P20MH0784 (07051592-1)
- Direct: $56,136

**Targeting HIV Risks Behaviors in Juvenile Drug Court-Involved Youth**
- PI: Elizabeth Letourneau
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: NIH/NIDA
- Award: 1 R01 DA025880-01 (08022292-1)
- Direct: $214,404

Smith, Daniel

**Co-Investigator**

**Disseminating Trauma-Focused CBT to Child Welfare Therapists: Web-Based Model**
- PI: Benjamin Saunders
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: Allegheny-Singer Research In
- Award: 208.0327 (08022078-1)
- Direct: $20,785

**Increasing Minority Participation in Clinical Research**
- PI: Arch Mainous
- Dept: Family Medicine
- Sponsor: Duke Endowment
- Award: 6098-SP (08091605-2)
- Direct: $324,767

**Evidence-Based Provider Training Tool for PTSD Patients in Support of Psychological Health**
- PI: Connie Best
- Dept: Psychiatry and Behavioral Sciences
- Sponsor: US Navy Bureau of Medicine
- Award: N00189-08-P-ZA85 (08100166-1)
- Direct: $370,370
<table>
<thead>
<tr>
<th>Name</th>
<th>PI/Co-Investigator</th>
<th>Sponsor</th>
<th>Dept</th>
<th>Direct/Indirect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith, Daniel</td>
<td>Self-Assessment and Self-Help for Teen Violence Victims</td>
<td>DC Office of Victim Services</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$278,940</td>
</tr>
<tr>
<td>Sonne, Susan</td>
<td>South Carolina Consortium of the Clinical Trials Network</td>
<td>NIH/NIDA</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$989,921</td>
</tr>
<tr>
<td>Stewart, Scott</td>
<td>CBT and Modafinil for Cocaine Addiction</td>
<td>NIH/NIDA</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$250,000</td>
</tr>
<tr>
<td>Sweat, Michael</td>
<td>Community-Based VCT Tanzania</td>
<td>NIH/NIMH</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$1,506,334</td>
</tr>
<tr>
<td></td>
<td>Efficacy of HIV Posttest Support for ANC in South Africa</td>
<td>NIH/NIAAA</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$199,519</td>
</tr>
<tr>
<td>Swenson, Cynthia</td>
<td>MST Model with Child Maltreatment</td>
<td>MST Group, LLC</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$136,058</td>
</tr>
<tr>
<td>Thomas, Suzanne</td>
<td>Stress and Subsequent Drinking in Individuals with Different Drinking Motives</td>
<td>NIH/NIAAA</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>$74,185</td>
</tr>
<tr>
<td>Research Faculty Activity</td>
<td>Psychiatry and Behavioral Sciences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Thomas, Suzanne

**Co-Investigator**

**Phased Treatment for Social Anxiety and Hazardous Drinking**
- **PI:** Carrie Randall
- **Sponsor:** NIH/NIAAA
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** 2 R01 AA013379-05A1 (07102673-1)
- **Direct $** 374,710

### Tolliver, Bryan

**Principal Investigator**

**Treatment of Alcohol Dependence and Comorbid Bipolar Disorder**
- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 05/20/09 - 04/30/10
- **Direct $** 193,438
- **Project Dates:** 05/20/09 - 04/30/14
- **F & A:** 15,014

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health: Component #2**
- **PI:** Kathleen Brady
- **Sponsor:** NIH/NIDA
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** 5 P50 DA016511-07 (08042808-3)
- **Direct $** 147,149

### Uhde, Thomas

**Principal Investigator**

**Innovative Service Delivery for Secondary Prevention of PTSD in at-Risk OIF-OEF Service Men and Women**
- **Sponsor:** Charleston Research Institute
- **Budget Dates:** 04/01/08 - 03/31/09
- **Direct $** 157,662
- **Project Dates:** 04/01/08 - 03/31/12
- **F & A:** 40,992

### Veatch, Lynn

**Co-Investigator**

**ESRC343 - A Timeline Study of Alcohol Use in Alcohol Dependent Patients with Insomnia**
- **PI:** Robert Malcolm, Jr.
- **Sponsor:** Sepracor, Inc.
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** ESRC343 (08090359-1)
- **Direct $** 21,992

### Voronin, Konstantin

**Co-Investigator**

**Alcohol Research Center - Treatment and Implications: Research Component 1**
- **PI:** Carrie Randall
- **Sponsor:** NIH/NIAAA
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** 5 P50 AA010761-14 (08111809-1)
- **Direct $** 154,563

### Wagner, Mark

**Co-Investigator**

**Translational Research in Addiction Center: Project 4**
- **PI:** Ronald See
- **Sponsor:** NIH/NIDA
- **Dept:** Neurosciences
- **Award:** 5 P20 DA022658-03 (08062601-6)
- **Direct $** 118,585

### Wang, Zhewu

**Principal Investigator**

**Monoamine Transporter Genes: PTSD with Substance Dependence Risk Factors**
- **Sponsor:** VAMC
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct $** 146,500
- **Project Dates:** 10/01/08 - 09/30/10
- **F & A:** 0

### Weinstein, Benjamin

**Co-Investigator**

**Aripiprazole Intramuscular Depot Program in Schizophrenia**
- **PI:** C. Devane
- **Sponsor:** Covance, Inc.
- **Dept:** Psychiatry and Behavioral Sciences
- **Award:** 31-07-247 (09051586-1)
- **Direct $** 356,200

### Radiation Oncology

### Gattoni-Celli, S.

**Principal Investigator**

**Vitamin D in Prostate Cancer**
- **Sponsor:** Gateway for Cancer Research
- **Budget Dates:** 10/01/08 - 09/30/09
- **Direct $** 160,164
- **Project Dates:** 10/01/08 - 09/30/09
- **F & A:** 39,853

### Radiology

### Bilgen, Mehmet

**Principal Investigator**

**MRI Evaluation of Altered Inflammatory Response in SCI**
- **Sponsor:** SC Spinal Cord Injury Fund
- **Budget Dates:** 07/01/08 - 06/30/09
- **Direct $** 25,000
- **Project Dates:** 07/01/08 - 06/30/09
- **F & A:** 0

### Guimaraes, Marcelo

**Co-PI or Project Leader**

**Use of Hydrogel Filaments for the Embolization of Arteries, Veins and Vascular Injuries: Pilot Study in a Swine Animal Model**
- **PI:** Renan Uflacker
- **Sponsor:** Terumo Medical Corp.
- **Dept:** Radiology
- **Award:** Terumo Pig (09051586-1)
- **Direct $** 26,824
Morgan, Paul

**Principal Investigator**

**BiCoEE/Endowed Chair Funding, Dr. Paul Morgan**

Sponsor: USC Research Foundation  
Award: (09012034)  
Budget Dates: 01/01/09 - 06/30/10  
Direct: $ 191,400

**Co-Investigator**

**PTSD/TBI Neuroimaging Core Proposal**

Pl: Mark George  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: SC Research Authority  
Award: 2009-114 (08111496-1)  
Direct: $ 39,212

Rumboldt, Zoran

**Principal Investigator**

**CT Evaluation of patients with clinically and radiologically suspected stroke**

Sponsor: Siemens Medical Solutions USA  
Project Dates: 06/01/09 - 07/01/11  
Budget Dates: 09/01/08 - 12/31/09  
Direct: $ 30,106

**Co-PI or Project Leader**

**A Prospective, Multi-Center, Registry Study for Clinical Outcome in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Registry Study)**

Sponsor: General Electric  
Award: GE-012-096 (08092530)  
Project Dates: 09/01/08 - 12/31/09  
F & A: $ 23,175

**A Post-Marketing Safety Study in Patients with Moderate Renal Insufficiency who receive OMNISCAN (Gadodiamide Injection) for Contrast-Enhanced Magnetic Resonance Imaging (MRI)**

Sponsor: General Electric  
Award: GE-041-075 (09052985)  
Project Dates: 06/01/09 - 03/31/12  
F & A: $ 17,175

Schoepf, Uwe

**Principal Investigator**

**Patient-Based Optimization of Contrast Material Delivery at CT Coronary Angiography (CardiacFlow)**

Sponsor: Medrad, Inc.  
Award: CardiacFlow (07121466)  
Project Dates: 12/01/07 - 03/31/09  
F & A: $ 2,192

**A Prospective, Multi-Center, Registry Study for Clinical Outcome in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Registry Study)**

Sponsor: General Electric  
Award: GE-012-096 (08092530)  
Project Dates: 09/01/08 - 12/31/09  
F & A: $ 95,700

**A Post-Marketing Safety Study in Patients with Moderate Renal Insufficiency who receive OMNISCAN (Gadodiamide Injection) for Contrast-Enhanced Magnetic Resonance Imaging (MRI)**

Sponsor: General Electric  
Award: GE-041-075 (09052985)  
Project Dates: 06/01/09 - 03/31/12  
F & A: $ 72,200

Schonholz, Claudio

**Principal Investigator**

**The Embolic Protection with Reverse Flow (EMPiRE) Study of the Gore Neuro Protection System in Carotid Stenting of Patients at High Risk for Carotid Endarterectomy**

Sponsor: W.L. Gore and Associates, Inc.  
Award: EMPiRE (06060545)  
Project Dates: 06/13/06 - 12/31/09  
F & A: $ 52,400

**Evaluation of Gore Flow Reversal (GFR) Vs. Distal Filter Embolic Protection Device(s) (EPD), During Carotid Artery Stenting (CAS) as a Means of Reducing Potential Procedural Thromboembolic and/or Atheroembolic Events, as Measured by High Intensity Transitory Signals (HITS) or Micro-Embolic Signals (MES) Via Intra-Procedural Transcranial Doppler (TCD)**

Sponsor: W.L. Gore and Associates, Inc.  
Award: Gore Empire TCD (08101644)  
Project Dates: 08/06/08 - 12/31/09  
F & A: $ 24,000

**GORE EMBOLic Filter in Carotid Stenting for High Risk Surgical Subjects (GORE EMBOLDEN)**

Sponsor: W.L. Gore and Associates, Inc.  
Award: GEF 06-08 (08112229)  
Project Dates: 12/18/08 - 06/30/10  
F & A: $ 16,813

Spampinato, Maria

**Principal Investigator**

**A Multi-Center, Randomized, Double-Blind, Crossover, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadovist) in Patients Referred for Contrast-Enhanced MRI of the Central Nervous System (CNS)**

Sponsor: Bayer Pharmaceuticals  
Award: 310123 (08100376)  
Project Dates: 10/09/08 - 10/08/09  
Direct: $ 122,500

**Co-Investigator**

**CT Evaluation of patients with clinically and radiologically suspected stroke**

Pl: Zoran Rumboldt  
Dept: Radiology  
Sponsor: Siemens Medical Solutions USA  
Award: MUSC-2009-CT-10-Rumboldt (09062550-1)  
Direct: $ 30,106

Spicer, Kenneth

**Principal Investigator**

**A Two-Part, Front-Running, Phase II/III Study of the Correspondence between 18F-AV-45 PET Imaging and Post-Mortem Amyloid Plaque Pathology**

Sponsor: Avid Radiopharmaceuticals, Inc.  
Award: 18F-AV-45-A07 (09022349)  
Project Dates: 01/09/08 - 12/01/09  
F & A: $ 26,224
Turk, III, Aquilla

**Principal Investigator**

MAPS Trial: Matrix and Platinum Science a Prospective, Randomized, Multi-Center Trial Investigating Matrix2 and GDC Coils for the Treatment of Intracranial Saccular Aneurysms

* Sponsor: Boston Scientific Corp.  
  * Award: MAPS (07112676)  
  * Project Dates: 11/08/07 - 06/30/15  
  * Budget Dates: 11/08/07 - 06/30/15  
  * Direct: $111,888  
  * F & A: $27,972

**Patients Prone to Recurrence after Endovascular Treatment: A Randomized Trial Comparing Platinum and Hydrogel-Coated Coils**

* Sponsor: Center Hospital - University of Montreal  
  * Award: NCT00626912 (08041443)  
  * Project Dates: 08/18/08 - 04/30/09  
  * Budget Dates: 08/18/08 - 01/02/13  
  * Direct: $10,822  
  * F & A: $2,706

**Aneurysm and Parent Vessel Occlusion**

* Sponsor: Nfocus Neuromedical, Inc.  
  * Award: Nfocus Canine (08052719)  
  * Project Dates: 05/01/08 - 12/31/08  
  * Budget Dates: 05/01/08 - 12/31/08  
  * Direct: $231,537  
  * F & A: $106,507

**Safety and Efficacy of Endovascular Treatment of Unruptured Intracranial Aneurysms in the Prevention of Aneurysmal Haemorrhages: A Randomized Comparison with Indefinite Deferral of Treatment in 2002 Patients Followed for 10 Years**

* Sponsor: Center Hospital - University of Montreal  
  * Award: ISRCTN62758344 (08052720)  
  * Project Dates: 08/18/08 - 11/02/20  
  * Budget Dates: 08/18/08 - 11/02/20  
  * Direct: $29,720  
  * F & A: $7,430

**Temporary Aneurysm Neck Bridge**

* Sponsor: MindFrame, Inc.  
  * Award: IP-0162 (08061122)  
  * Project Dates: 07/01/08 - 09/30/09  
  * Budget Dates: 07/01/08 - 09/30/09  
  * Direct: $51,173  
  * F & A: $24,307

**ev3 Researching AXIUM(tm) Coiling Experience and Recanalization (RACER)**

* Sponsor: ev3 Neurovascular  
  * Award: Micro Racer (08070352)  
  * Project Dates: 07/08/08 - 06/30/10  
  * Budget Dates: 07/08/08 - 06/30/10  
  * Direct: $20,500  
  * F & A: $4,500

**Penumbra Imaging Collaborative Study (PICS): A Multi-Center Trial to Assess Outcome of Patients Revascularized by the Penumbra(tm) System**

* Sponsor: Penumbra, Inc.  
  * Award: PICS - CLP 1953.A (08112128)  
  * Project Dates: 11/03/08 - 11/02/09  
  * Budget Dates: 11/03/08 - 11/02/09  
  * Direct: $43,700  
  * F & A: $10,300

**Fellows Regional Technology Training Course**

* Sponsor: Boston Scientific Corp.  
  * Award: Training Grant (09022043)  
  * Project Dates: 02/10/09 - 06/15/10  
  * Budget Dates: 02/10/09 - 06/15/10  
  * Direct: $6,221  
  * F & A: $2,955

**Co-Investigator**

Interventional Management of Stroke Study III (IMS III)

* PI: Nikolaos Papamitsakis  
  * Sponsor: Univ. of Cincinnati  
  * Award: 003525/5 U01 NS052220-03 (08101646-1)  
  * Direct: $22,523  
  * Dept: Neurosciences

Uflacker, Renan

**Principal Investigator**

SIR-Spheres Registry to Generate and Enable Compilation of Data on the Safety and Efficacy of Treatment with SIR-Spheres

* Sponsor: Sirtex Medical  
  * Award: (08052210)  
  * Project Dates: 06/26/08 - 12/31/09  
  * Budget Dates: 06/26/08 - 12/31/12  
  * Direct: $10,600  
  * F & A: $1,900

CABANA: A Carotid Stenting Boston Scientific Surveillance Program

* Sponsor: Boston Scientific Corp.  
  * Award: CABANA (09030932)  
  * Project Dates: 02/12/09 - 02/28/10  
  * Budget Dates: 02/12/09 - 02/28/10  
  * Direct: $13,300  
  * F & A: $2,700

Use of Hydrogel Filaments for the Embolization of Arteries, Veins and Vascular Injuries: Pilot Study in a Swine Animal Model

* Sponsor: Terumo Medical Corp.  
  * Award: Terumo Pig (09051586)  
  * Project Dates: 05/12/09 - 12/31/09  
  * Budget Dates: 05/12/09 - 12/31/09  
  * Direct: $26,824  
  * F & A: $12,742

**Co-PI or Project Leader**

The Embolic Protection with Reverse Flow (EMPIRE) Study of the Gore Neuro Protection System in Carotid Stenting of Patients at High Risk for Carotid Endarterectomy

* PI: Claudio Schonholz  
  * Sponsor: W.L. Gore and Associates, Inc.  
  * Award: EMPIRE (06060545-4)  
  * Direct: $52,400

Vincent, Diana

**Co-Investigator**

Alzheimer’s Disease Neuroimaging Initiative

* PI: Jacobo Mintzer  
  * Sponsor: Univ. of California, San Diego  
  * Award: ADNI-024 (05081757-2)  
  * Direct: $66,220

Surgery

Baliga, Prabhakar

**Principal Investigator**

A Phase IIb, Randomized, Multi-Center, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients

* Sponsor: Isotechnika, Inc.  
  * Award: ISA05-01 (06092233)  
  * Project Dates: 08/21/06 - 12/31/09  
  * Budget Dates: 08/21/06 - 12/31/09  
  * Direct: $15,463  
  * F & A: $3,866
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Co-Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baliga, Prabhakar</td>
<td>Bradley, Scott</td>
<td>Bratton, Charles</td>
<td>Camp, Ernest</td>
<td>Chavin, Kenneth</td>
<td></td>
<td>Cole, David</td>
<td></td>
<td>Hsia, Tain-Yen</td>
<td>Hughes, Michael</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td>A Program to Increase Living Donations in African Americans</td>
<td>Co-Investigator</td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>A Pilot Study Comparing Two different Sirolimus-Based Transition Regimens in African-American Renal Transplant Recipients</td>
<td>The Hepatic Research Registry</td>
<td>Targeting the CaSm Oncogene as a Novel Therapy for Pancreatic Cancer</td>
<td>Epistatic Effects of FcgammaR and Fc (GM) Genes in Breast Cancer</td>
<td>Transatlantic Network of Excellence in Multi-Scale Modeling</td>
<td>A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-TACRO Tablets Once Daily and Prograf Capsules Twice Daily in Adult De Novo Liver Transplant Patients</td>
</tr>
<tr>
<td>Award: 5 R01 DK062596-07 (08062489)</td>
<td>Award: 5 U01 HL068281-08 (08072339-1)</td>
<td>Award: 04687E5-4543 (09051567)</td>
<td>Award: 5 R01 DK069369-03 (08051463)</td>
<td>Award: (04092001)</td>
<td>Award: 1 T32 DK083262-01 (08080687-1)</td>
<td>Award: 5 R01 CA123159-02 (08051354)</td>
<td>Award: W81XWH-08-1-0373 (07052112-2)</td>
<td>Award: 20030549/1T0.0045 (08112019)</td>
<td>Award: LCP-TACRO 2018 (08111914)</td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
<td><strong>Objectives</strong></td>
</tr>
<tr>
<td>A Program to Increase Living Donations in African Americans</td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>A Pilot Study Comparing Two different Sirolimus-Based Transition Regimens in African-American Renal Transplant Recipients</td>
<td>The Hepatic Research Registry</td>
<td>Targeting the CaSm Oncogene as a Novel Therapy for Pancreatic Cancer</td>
<td>Epistatic Effects of FcgammaR and Fc (GM) Genes in Breast Cancer</td>
<td>Transatlantic Network of Excellence in Multi-Scale Modeling</td>
<td>A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-TACRO Tablets Once Daily and Prograf Capsules Twice Daily in Adult De Novo Liver Transplant Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
<td><strong>Budget Dates</strong></td>
</tr>
<tr>
<td>08/01/08 - 07/31/09</td>
<td>08/01/08 - 07/31/09</td>
<td>08/01/08 - 07/31/09</td>
<td>08/01/08 - 07/31/09</td>
<td>10/01/04 - 12/31/08</td>
<td>10/01/04 - 12/31/08</td>
<td>08/01/08 - 07/31/09</td>
<td>08/01/08 - 07/31/09</td>
<td>11/25/08 - 05/31/09</td>
<td>12/09/08 - 12/08/10</td>
</tr>
<tr>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
<td><strong>Direct</strong></td>
</tr>
<tr>
<td>$139,650</td>
<td>$194,200</td>
<td>$223,244</td>
<td>$37,022</td>
<td>$152,782</td>
<td>$196,074</td>
<td>$624,700</td>
<td>$100,000</td>
<td>$10,000</td>
<td>$145,788</td>
</tr>
<tr>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
<td><strong>F &amp; A</strong></td>
</tr>
<tr>
<td>$64,239</td>
<td>$9,256</td>
<td>$54,936</td>
<td>$9,526</td>
<td>$38,195</td>
<td>$90,209</td>
<td>$155,300</td>
<td>$0</td>
<td>$0</td>
<td>$35,822</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Project Dates</td>
<td>Direct: $</td>
<td>F &amp; A: $</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------</td>
<td>-----------------------------------</td>
<td>-----------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ikonomidis, John</td>
<td><strong>3F Aortic Bioprosthesis, Model 1000</strong></td>
<td>3F Therapeutics</td>
<td>06/01/02 - 12/31/10</td>
<td>06/01/02 - 12/31/10</td>
<td>32,400</td>
<td>8,100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Intracellular Signaling in Thoracic Aortic Aneurysms</strong></td>
<td>NIH/NHLBI</td>
<td>08/01/08 - 07/31/09</td>
<td>08/01/08 - 07/31/09</td>
<td>150,000</td>
<td>66,500</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Evaluation of the GORE TAG Thoracic Endoprosthesis 45 mm for the Primary Treatment of Aneurysms of the Descending Thoracic Aorta</strong></td>
<td>W.L. Gore and Associates, Inc.</td>
<td>02/01/09 - 01/09/10</td>
<td>02/01/09 - 01/09/10</td>
<td>22,249</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Advanced Glycation End-Products in Human Myocardium</strong></td>
<td>Univ. of Vermont</td>
<td>08/01/08 - 02/28/09</td>
<td>08/01/08 - 02/28/09</td>
<td>150,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Intracellular Signaling in Thoracic Aortic Aneurysms</strong></td>
<td>NIH/NHLBI</td>
<td>07/21/08 - 06/30/09</td>
<td>07/21/08 - 06/30/09</td>
<td>110,045</td>
<td>27,511</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)</strong></td>
<td>Bristol Myers Squibb</td>
<td>12/01/08 - 11/30/09</td>
<td>12/01/08 - 11/30/09</td>
<td>9,200</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants</strong></td>
<td>Viropharma, Inc.</td>
<td>12/01/08 - 11/30/09</td>
<td>12/01/08 - 11/30/09</td>
<td>24,826</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>A Phase 2, Multi-Center, Open-Label, Active, Comparator-Controlled, Extension Trial to Evaluate the Long Term Safety and Efficacy of CP690,550 in Renal Allograft Recipients</strong></td>
<td>Icon Clinical Research, Inc.</td>
<td>02/21/09 - 01/20/10</td>
<td>02/21/09 - 01/20/10</td>
<td>88,600</td>
<td>21,525</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Controlled, Randomized, Prospective, Double-Blind, Multi-Center, Phase III, Dose-Escalation Study of the Safety, PK, and Clinical Activity of ISNP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation</strong></td>
<td>CTI Clinical Trial and Consulting Services, Inc.</td>
<td>02/21/09 - 01/20/10</td>
<td>02/21/09 - 01/20/10</td>
<td>135,000</td>
<td>64,125</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Development and Characterization of Tyrosinase Epitope Specific TCR Transgenic Mice</strong></td>
<td>NIH/NIAMS</td>
<td>04/18/08 - 03/31/10</td>
<td>04/18/08 - 03/31/10</td>
<td>68,182</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Isolation and Characterization of Prostate Antigen Specific High Affinity TCR</strong></td>
<td>Charlotte Geyer Fdn.</td>
<td>09/01/08 - 02/28/09</td>
<td>09/01/08 - 02/28/09</td>
<td>110,000</td>
<td>52,250</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer SPORE</strong></td>
<td>Mayo Clinic</td>
<td>07/01/08 - 12/31/09</td>
<td>07/01/08 - 12/31/09</td>
<td>8,116</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Annual Report for Research FY2009
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitas, Michael</td>
<td>Peripheral Blood Molecular Staging of Breast Cancer</td>
<td>Washington Univ.</td>
<td>08/01/08 - 07/31/09</td>
<td>$21,798</td>
<td>$10,027</td>
</tr>
<tr>
<td>Mukherjee, Rupak</td>
<td>Donation of Pacemakers and Pacemaker Supplies</td>
<td>Medtronic, Inc.</td>
<td>03/05/09 - 12/31/09</td>
<td>$27,600</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Donation of Pacemaker Repair Supplies</td>
<td>Medtronic, Inc.</td>
<td>03/23/09 - 12/31/09</td>
<td>$300</td>
<td>$0</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Endothelin Receptors and Progression to Heart Failure</td>
<td>NIH/NHLBI</td>
<td>09/12/06 - 07/31/11</td>
<td>$250,000</td>
<td>$402,977</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>HeartNet-3 Pre-Clinical Acute Evaluation of Cardiac Hemodynamics in a Heart Failure Animal Model</td>
<td>Paracor Medical, Inc.</td>
<td>09/12/06 - 07/31/11</td>
<td>$50,258</td>
<td>$0</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Collagenase Inhibition in Heart Failure</td>
<td>NIH/NHLBI</td>
<td>09/12/06 - 07/31/11</td>
<td>$272,167</td>
<td>$0</td>
</tr>
<tr>
<td>Nishimura, Michael</td>
<td>TCR Affinity and Therapeutic Efficacy of T Cells</td>
<td>NIH/NCI</td>
<td>06/01/09 - 04/30/10</td>
<td>$231,659</td>
<td>$61,294</td>
</tr>
<tr>
<td></td>
<td>MUSC Cancer Center Support Grant: Program 3: Cancer Immunology and Immunotherapy</td>
<td>NIH/NCI</td>
<td>07/01/07 - 04/30/12</td>
<td>$24,391</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Development and Characterization of Tyrosinase Epitope Specific TCR Transgenic Mice</td>
<td>NIH/NIAMS</td>
<td>01/01/01 - 12/31/09</td>
<td>$135,000</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Isolation and Characterization of Prostate Antigen Specific High Affinity TCR</td>
<td>Charlotte Geyer Fdn.</td>
<td>03/13/06 - 06/30/11</td>
<td>$110,000</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>South Carolina COBRE for Oral Health Grant - Core A: Administrative</td>
<td>NIH/NCRR</td>
<td>09/01/08 - 07/31/09</td>
<td>$408,237</td>
<td>$0</td>
</tr>
<tr>
<td>Reed, Carolyn</td>
<td>American Cancer Society Institutional Research Grant (ACSIRG)</td>
<td>Amer. Cancer Soc.</td>
<td>01/01/01 - 12/31/09</td>
<td>$120,000</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal Malignancy: Endowed Professorships</td>
<td>SC Research Centers of Economic Excellence</td>
<td>07/01/08 - 06/30/09</td>
<td>$992,198</td>
<td>$0</td>
</tr>
<tr>
<td>Robison, Jacob</td>
<td>MUSC Cancer Center Support Grant: Senior Leadership</td>
<td>NIH/NHLBI</td>
<td>03/13/06 - 06/30/11</td>
<td>$229,094</td>
<td>$0</td>
</tr>
<tr>
<td></td>
<td>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2)-TIMI 50</td>
<td>Schering-Plough Research</td>
<td>09/01/08 - 07/31/09</td>
<td>$180,000</td>
<td>$0</td>
</tr>
<tr>
<td>Name</td>
<td>Department</td>
<td>Project Name</td>
<td>Sponsor</td>
<td>Direct Funds</td>
<td>Indirect Funds</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Robison, Jacob</td>
<td>Medicine</td>
<td>A Phase IIa, Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication</td>
<td>Colorado Prevention Center</td>
<td>132,198</td>
<td></td>
</tr>
<tr>
<td>Smith, Charles</td>
<td>Medicine</td>
<td>Drug Discovery in Cancer: COEE Endowment 2008</td>
<td>MUSC Fdn.</td>
<td>110,691</td>
<td></td>
</tr>
<tr>
<td>Spinale, Francis</td>
<td>Medicine</td>
<td>Maladaptive Remodeling in Aging Myocardium</td>
<td>VAMC</td>
<td>195,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>Endothelin Receptors and Progression to Heart Failure</td>
<td>NIH/NHLBI</td>
<td>250,000</td>
<td>118,750</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>Protection of Ischemic Myocardium</td>
<td>Univ. of Louisville</td>
<td>33,503</td>
<td>15,411</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>Proteolytic Enzyme Induction within the Human Myocardial Interstitium</td>
<td>VAMC</td>
<td>208,585</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>Peptide Profiling for Biomarker Discovery within the SMART AV Study</td>
<td>SMART AV study</td>
<td>502,627</td>
<td>125,656</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>HeartNet-3 Pre-Clinical Acute Evaluation of Cardiac Hemodynamics in a Heart Failure Animal Model</td>
<td>Paracor Medical, Inc.</td>
<td>50,258</td>
<td>23,873</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>Endothelin Receptors and Progression to Heart Failure</td>
<td>NIH/NHLBI</td>
<td>250,000</td>
<td>79,529</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>Collagenase Inhibition in Heart Failure</td>
<td>NIH/NHLBI</td>
<td>272,167</td>
<td>118,750</td>
</tr>
<tr>
<td>Keane, Thomas</td>
<td>Medicine</td>
<td>Advanced Glycation End-Products in Human Myocardium</td>
<td>Univ. of Vermont</td>
<td>148,785</td>
<td></td>
</tr>
<tr>
<td>Rovner, Eric</td>
<td>Medicine</td>
<td>A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 10mg ZD 4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-Resistant Prostate Cancer</td>
<td>Astrazeneca</td>
<td>119,100</td>
<td>29,150</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>A Phase III, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Daily, Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients</td>
<td>Astrazeneca</td>
<td>100,428</td>
<td>24,032</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>The Role of Thromboxane A2 (TP) Receptor Beta in Bladder Cancer</td>
<td>NIH/NCI</td>
<td>207,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>A Phase 2, 12 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study Evaluating the Efficacy and Safety of PD 0296885 for the Treatment of Symptoms Associated with Interstitial Cystitis/Painful Bladder Syndrome</td>
<td>Pfizer, Inc.</td>
<td>70,758</td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Award</td>
<td>Project Dates</td>
<td>F &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-------</td>
<td>---------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rovner, Eric</td>
<td>A4291043 (08111810)</td>
<td>11/18/08 - 11/17/09</td>
<td>17,065</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Savage, Stephen</td>
<td>SPI-612 (09021302)</td>
<td>02/26/09 - 12/31/12</td>
<td>13,282</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Eoquin as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Project Dates</th>
<th>Direct</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spectrum Pharmaceutical Research</td>
<td>SPI-612 (09021302)</td>
<td>02/26/09 - 12/31/12</td>
<td>$56,128</td>
</tr>
<tr>
<td>Researcher Name</td>
<td>Role/Institution</td>
<td>Research Title</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------</td>
<td>----------------</td>
<td>---------</td>
</tr>
<tr>
<td>Amella, Elaine</td>
<td>Co-PI or Project Leader</td>
<td>Feeding in Elderly Late-Stage Dementia: the FIELD Trial</td>
<td>Sponsor: NIH/NIA</td>
</tr>
<tr>
<td>Andrews, Jeannette</td>
<td>Principal Investigator</td>
<td>Partnership Readiness for Community Based Participatory Research</td>
<td>Sponsor: NIH/NINR</td>
</tr>
<tr>
<td>Barbosa, Gail</td>
<td>Principal Investigator</td>
<td>Advance Education Nursing Grants</td>
<td>Sponsor: HRSA</td>
</tr>
<tr>
<td>Bond, Sharon</td>
<td>Principal Investigator</td>
<td>Translating an Efficacious HPV Vaccine into the Control of Cervical Cancer</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Bryant, Deborah</td>
<td>Principal Investigator</td>
<td>Mobile Mammography Screening for Underinsured Communities</td>
<td>Sponsor: Susan G. Komen Fdn.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC Tobacco Collaborative at HCC MHU</td>
<td>Sponsor: SC Tobacco Collaborative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Early Detection for Breast Cancer Using Outreach Navigators and Mobile Mammography Screening</td>
<td>Sponsor: Komen for the Cure/Lowcountry Affiliate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Southeastern US Collaborative CEED</td>
<td>Sponsor: Morehouse School of Medicine</td>
</tr>
<tr>
<td>Edlund, Barbara</td>
<td>Co-Investigator</td>
<td>Developing Caring Professionals: Infusing Compassion and Humanism in Health Professions Education</td>
<td>Sponsor: Arthur Vining Davis Fdn.</td>
</tr>
<tr>
<td>Grossman, Janet</td>
<td>Co-Investigator</td>
<td>Early Intervention to Reduce Domestic Violence</td>
<td>Sponsor: MUSC Fdn.</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Sponsor</td>
<td>Direct $</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------</td>
<td>--------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Grossman, Janet</td>
<td>Co-Investigator Basic Nurse Education and Practice Program</td>
<td>HRSA</td>
<td>323,590</td>
</tr>
<tr>
<td></td>
<td>Pl: Marilyn Laken</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Nursing</td>
<td>Award: 5 D11HP00285-08-02 (08070347-1)</td>
<td></td>
</tr>
<tr>
<td>Inman, Dianna</td>
<td>Co-Investigator Early Intervention to Reduce Domestic Violence</td>
<td>MUSC Fdn.</td>
<td>246,903</td>
</tr>
<tr>
<td></td>
<td>Pl: Deborah Williamson</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Nursing</td>
<td>Award: 6111-SP (07120733-1)</td>
<td></td>
</tr>
<tr>
<td>Jenkins, Carolyn</td>
<td>Principal Investigator Racial and Ethnic Approaches to Community Health US</td>
<td>CDC</td>
<td>684,008</td>
</tr>
<tr>
<td></td>
<td>Sponsor: CDC</td>
<td>Budget Dates: 09/30/08 - 09/29/09</td>
<td></td>
</tr>
<tr>
<td>Kelechi, Teresea</td>
<td>Principal Investigator Safety and Wound Healing Efficacy of the TalidermR Wound Dressing a Poly-N-Acetyl Glucosamine-Derived Membrane Material in Humans with Venous Stasis Ulcers: A Pilot Study</td>
<td>Marine Polymer Technologies</td>
<td>1,962</td>
</tr>
<tr>
<td></td>
<td>Pl: Leonard Egede</td>
<td>Project Dates: 09/30/07 - 09/29/12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NIDDK</td>
<td>Direct $ 343,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Medicine</td>
<td>Award: 1 R01 DK081121-01A1 (07111552-1)</td>
<td></td>
</tr>
<tr>
<td>Laken, Marilyn</td>
<td>Principal Investigator Partnerships with Title One Schools to Reduce Health Disparities</td>
<td>Duke Endowment</td>
<td>100,838</td>
</tr>
<tr>
<td></td>
<td>Sponsor: Duke Endowment</td>
<td>Budget Dates: 01/01/09 - 12/31/09</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pl: Catherine Ling</td>
<td>Project Dates: 01/01/08 - 12/01/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: HRSA</td>
<td>Direct $ 3,241</td>
<td></td>
</tr>
<tr>
<td>Magwood, Gayenelle</td>
<td>Co-Investigator Feeding in Elderly Late-Stage Dementia: the FIELD Trial</td>
<td>NIH/NIA</td>
<td>122,941</td>
</tr>
<tr>
<td></td>
<td>Pl: Mark Delegge</td>
<td>Direct $ 684,008</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Medicine</td>
<td>Award: 1 R21 AG032083-01A1 (08031073-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Racial and Ethnic Approaches to Community Health US</td>
<td>CDC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pl: Carolyn Jenkins</td>
<td>Direct $ 62,331</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Nursing</td>
<td>Award: 5 U58 DP001015-02 (08051565)</td>
<td></td>
</tr>
<tr>
<td>Mueller, Martina</td>
<td>Principal Investigator Decision Support in the Care of Preterm Newborns - Tool Development</td>
<td>NIH/NHLBI</td>
<td>171,889</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NHLBI</td>
<td>Direct $ 828,258</td>
<td>62,331</td>
</tr>
<tr>
<td></td>
<td>Pl: Peter Miller</td>
<td>Award: 1 R01 HL090598-01A1 (080711194)</td>
<td></td>
</tr>
<tr>
<td>Nemeth, Lynne</td>
<td>Co-Investigator Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care</td>
<td>NIH/NIAAA</td>
<td>337,197</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Direct $ 278,258</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pl: Psychiatry and Behavioral Sciences</td>
<td>Award: 1 R01 AA016768-01A2 (07102672-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pl: Steven Ornstein</td>
<td>Sponsor: AHRQ</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Family Medicine</td>
<td>Direct $ 278,258</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Title</td>
<td>Sponsor</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Nickerson, Brenda</td>
<td>Principal Investigator</td>
<td>Mobile Mammography Screening for Underinsured Communities</td>
<td>Susan G. Komen Fdn.</td>
</tr>
<tr>
<td>Pope, Charlene</td>
<td>Co-Investigator</td>
<td>Carolina Conversations: A Multiethnic Digital Corpus of Speech for Older Persons</td>
<td>NIH/NLM</td>
</tr>
<tr>
<td>Smith, Gigi</td>
<td>Co-Investigator</td>
<td>Depression Screening in Youth with Epilepsy</td>
<td>Epilepsy Fdn.</td>
</tr>
<tr>
<td>Smith, Sheila</td>
<td>Co-Investigator</td>
<td>Nurse Education Practice and Retention</td>
<td>HRSA</td>
</tr>
<tr>
<td>Stroud, Sally</td>
<td>Principal Investigator</td>
<td>Advanced Education Nursing Traineeship</td>
<td>HRSA</td>
</tr>
<tr>
<td>Stuart, Gail</td>
<td>Principal Investigator</td>
<td>Simulation in Nursing Education</td>
<td>Health Sciences SC</td>
</tr>
<tr>
<td>Vandemark, Lisa</td>
<td>Co-PI or Project Leader</td>
<td>Early Intervention to Reduce Domestic Violence</td>
<td>MUSC Fdn.</td>
</tr>
<tr>
<td>Wagner, Janelle</td>
<td>Principal Investigator</td>
<td>Depression Screening in Youth with Epilepsy</td>
<td>Epilepsy Fdn.</td>
</tr>
<tr>
<td>Williamson, Deborah</td>
<td>Principal Investigator</td>
<td>Early Intervention to Reduce Domestic Violence</td>
<td>MUSC Fdn.</td>
</tr>
</tbody>
</table>

Annual Report for Research FY2009 141
Williamson, Deborah  Co-Investigator
Southeastern US Collaborative CEED
PI: Marvella Ford  Sponsor: Morehouse School of Medicine  Direct $ 47,945
Dept: Biostatistics, Bioinformatics and Epidemiology  Award: 1-U58-DP-000984-01 (09012891-1)
Pharmaceutical and Biomedical Sciences

Beeson, Craig
Principal Investigator
Argolyn-MUSC Contract
Sponsor: Argolyn Bioscience, Inc.
Budget Dates: 08/01/08 - 12/31/08
Direct: $102,300
F & A: $47,058

Co-PI or Project Leader
High Content Metabolic Screens for Anti-Degenerative Agents in the Retina
PI: Baerbel Rohrer
Sponsor: Fdn. Fighting Blindness
Budget Dates: 08/01/08 - 12/31/08
Direct: $200,000

Co-Investigator
Hsp90 Regulates EphA2 Signaling and Cell Migration in Glioblastoma
PI: Jennifer Isaacs
Sponsor: NIH/NCI
Budget Dates: 08/01/07 - 12/31/08
Direct: $207,500

Blum, Jason
Principal Investigator
Role of iPLA2-Gamma in Renal Function Following Oxidative Stress
Sponsor: NIH/NIDDK
Budget Dates: 03/01/08 - 02/28/10
Direct: $49,646

Eaddy, Andre
Principal Investigator
Role of IFLA2gamma in Oxidant-Induced Cell Death and Renal Failure
Sponsor: NIH/NIEHS
Budget Dates: 09/01/08 - 08/31/09
Direct: $31,711

Hall, Philip
Co-PI or Project Leader
MUSC Cancer Center Support Grant: Protocol Review and Monitoring System
PI: Andrew Kraft
Sponsor: NIH/NCI
Budget Dates: 09/01/08 - 08/31/09
Direct: $48,531

Lemasters, John
Co-PI or Project Leader
Drug Discovery in Cancer: COEE Endowment
PI: Rick Schnellmann
Sponsor: MUSC Fdn.
Budget Dates: 07/01/08 - 02/28/09
Direct: $90,000

MUSC Cancer Center Support Grant: Cell and Molecular Imaging
PI: Andrew Kraft
Sponsor: NIH/NCI
Budget Dates: 09/01/08 - 08/31/10
Direct: $55,859

Markowitz, John
Principal Investigator
Organic Anion Transporters 2 and 3 in Renal and CNS Toxicity
Sponsor: Virginia Commonwealth Univ.
Budget Dates: 07/01/08 - 02/28/09
Direct: $14,266
F & A: $6,281

Drug Transporters and the Disposition of ADHD Therapeutic Agents
Sponsor: NIH/NIDA
Budget Dates: 08/01/08 - 07/31/09
Direct: $220,500
F & A: $101,430

Methylphenidate-Ethanol Interactions in ADHD and Co-Abuse
PI: Kennerly Patrick
Sponsor: NIH/NIAAA
Direct: $218,475
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nieminen, Anna-Liisa</td>
<td>Mechanisms of Cell Death after Photodynamic Therapy</td>
<td>NIH/NCI</td>
<td>$176,202</td>
<td>$74,536</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NCI</td>
<td>Budget Dates: 08/01/08 - 07/31/09</td>
<td>Project Dates: 09/14/07 - 07/31/11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 CA119079-02 (08052837)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrick, Kennerly</td>
<td>Methylenphenidate-Ethanol Interactions in ADHD and Co-Abuse</td>
<td>NIH/NIAAA</td>
<td>$218,475</td>
<td>$100,499</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NIAAA</td>
<td>Budget Dates: 09/01/08 - 08/31/09</td>
<td>Project Dates: 09/30/02 - 08/31/11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 AA016707-05 (08062069)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schnellmann, Rick</td>
<td>Center for Drug Discovery in Cancer: Endowed Professorships</td>
<td>SC Research Centers of Economic Excellence</td>
<td>$276,532</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Sponsor: SC Research Centers of Economic Excellence</td>
<td>Budget Dates: 07/01/08 - 06/30/09</td>
<td>Project Dates: 09/15/05 - 06/30/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: (06062510)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mitochondrial Biogenesis Promotes Recovery from Oxidant Injury</td>
<td>NIH/NIGMS</td>
<td>$200,000</td>
<td>$95,000</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NIGMS</td>
<td>Budget Dates: 09/01/08 - 06/30/09</td>
<td>Project Dates: 09/01/08 - 06/30/12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 1 R01 GM084147-01 (07604844)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug Discovery in Cancer: COEE Endowment</td>
<td>MUSC Fdn.</td>
<td>$290,691</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Sponsor: MUSC Fdn.</td>
<td>Budget Dates: 07/01/07 - 06/30/10</td>
<td>Project Dates: 07/01/07 - 06/30/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: (07072337)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Training Program in Environmental Stress Signaling</td>
<td>NIH/NIHES</td>
<td>$128,876</td>
<td>7,527</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NIHES</td>
<td>Budget Dates: 07/01/08 - 06/30/09</td>
<td>Project Dates: 07/01/05 - 06/30/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 T32 ES012878-04 (07120730)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel Phospholipase A2 in Oxidant-Induced Cell Injury</td>
<td>NIH/NIDDK</td>
<td>$264,728</td>
<td>$16,282</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NIDDK</td>
<td>Budget Dates: 12/01/08 - 11/30/09</td>
<td>Project Dates: 03/15/02 - 11/30/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 KD062028-06 (08101750)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dedifferentiation Following Renal Cell Injury</td>
<td>Rhode Island Hospitals</td>
<td>$35,397</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: Rhode Island Hospitals</td>
<td>Budget Dates: 04/01/09 - 03/31/10</td>
<td>Project Dates: 09/01/06 - 03/31/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: RIH701-9697/5 R01 DK07199 (09011417)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mentor</td>
<td>NIH/NCRR</td>
<td>$220,470</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NCRR</td>
<td>Budget Dates: 07/01/08 - 06/30/09</td>
<td>Project Dates: 07/01/08 - 06/30/09</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 P20 RR017677-07 (08070866-2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith, Charles</td>
<td>Spingosine Kinase as a Target for Cancer Therapy</td>
<td>NIH/NCI</td>
<td>$38,000</td>
<td>$17,480</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NCI</td>
<td>Budget Dates: 02/01/08 - 01/31/09</td>
<td>Project Dates: 04/01/07 - 01/31/12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 CA122226-02 (07121470)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cell Cycle Specific CDK Inhibitors as Potential Anti-Tumor Therapeutics Through Replace</td>
<td>Univ. of South Carolina</td>
<td>$12,186</td>
<td>$5,788</td>
</tr>
<tr>
<td></td>
<td>Sponsor: Univ. of South Carolina</td>
<td>Budget Dates: 09/25/08 - 07/31/09</td>
<td>Project Dates: 09/25/08 - 07/31/13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 09-1634/11110 FA31 (08121833)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Spingosine Kinase as a Target for Cancer Therapy</td>
<td>NIH/NCI</td>
<td>$190,473</td>
<td>$86,927</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NCI</td>
<td>Budget Dates: 02/01/09 - 01/31/10</td>
<td>Project Dates: 04/01/07 - 01/31/12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 CA122226-03 (08123052)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acyltransferase Inhibitors as Anti Ras Agents</td>
<td>NIH/NCI</td>
<td>$169,819</td>
<td>$65,520</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NCI</td>
<td>Budget Dates: 02/01/09 - 01/31/10</td>
<td>Project Dates: 09/10/07 - 01/31/10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 CA075248-14 (08123053)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>MUSC Fdn.</td>
<td>$90,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: MUSC Fdn.</td>
<td>Direct $</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Pharmaceutical and Biomedical Science</td>
<td>Award: (07072337)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Mechanism of Action of Unique Small Molecules That Inhibit the Pim Protein Kinase Blocking Prostate Cancer Cell Growth</td>
<td>DOD</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: DOD</td>
<td>Direct $</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dept: Medicine</td>
<td>Award: W81XWH-09-1-0300 (08060478-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Faculty Activity</td>
<td>Pharmacy and Biomedical Sciences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Townsend, Danyelle</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pharmacology of NOV-002</strong></td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Kenneth Tew</td>
<td>Sponsor: Novos Therapeutics, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Cell and Molecular Pharmacology</td>
<td>Award: Novos Year 4 (08072963-1)</td>
<td>Direct $ 210,650</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Glutathione S-Transferases in Drug and Stress Response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Kenneth Tew</td>
<td>Sponsor: NIH/NCI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Cell and Molecular Pharmacology</td>
<td>Award: 5 R01 CA085660-11 (09011304-2)</td>
<td>Direct $ 213,341</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Wright, Gary</strong></td>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Role of Prolyl Hydroxylase Oxygen-Sensor in Cardioprotection</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Kenneth Tew</td>
<td>Sponsor: NIH/NHLBI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Cell and Molecular Pharmacology</td>
<td>Award: 5 R01 HL084302-02 (08071823)</td>
<td>Direct $ 225,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>A Novel VEGF Signaling Pathway Leading to Mitochondrial Biogenesis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Robin Muise-Helmericks</td>
<td>Sponsor: NIH/NHLBI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Cell Biology and Anatomy</td>
<td>Award: 5 R01 HL084565-03 (08102993-1)</td>
<td>Direct $ 200,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Yu, Shan</strong></td>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Novel Strategy for Neurovascular Repair after Neonatal Ischemic Stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Ling Wei</td>
<td>Sponsor: Amer. Heart Assoc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Pathology and Laboratory Medicine</td>
<td>Award: 0840110N (07071077-2)</td>
<td>Direct $ 90,909</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Zhong, Zhi</strong></td>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Transplantation of Reduced-Size Fatty Livers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Ling Wei</td>
<td>Sponsor: NIH/NIDDK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Pathology and Laboratory Medicine</td>
<td>Award: 5 R01 DK070844-04 (09040816)</td>
<td>Direct $ 175,567</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pharmacy and Clinical Sciences</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bosso, John</strong></td>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Safety of High-Concentration Vancomycin for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Pfizer, Inc.</td>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: GA5951TH (08101747)</td>
<td>Budget Dates: 10/15/08 - 06/30/10</td>
<td>Project Dates: 10/15/08 - 06/30/10</td>
<td>Direct $ 115,934</td>
<td></td>
</tr>
<tr>
<td><strong>Drayton, Shannon</strong></td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SCCP Medicaid Academic Detailing Project</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Patrick Mauldin</td>
<td>Sponsor: Univ. of South Carolina</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Pharmacy and Clinical Sciences</td>
<td>Award: 08-1470 (09050172-1)</td>
<td>Direct $ 93,793</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mauldin, Patrick</strong></td>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ethnic Differences in Medication Adherence and Cost for Elderly Veterans with DM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: (08102373)</td>
<td>Sponsor: (08102373)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: 08-1470 (09050172)</td>
<td>Budget Dates: 05/01/09 - 12/31/09</td>
<td>Project Dates: 05/01/09 - 12/31/09</td>
<td>Direct $ 93,793</td>
<td></td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Telephone Delivered Behavioral Skills Intervention for Blacks with T2DM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Leonard Egede</td>
<td>Sponsor: NIH/NIDDK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: 1 R01 DK081121-01A1 (07111552-1)</td>
<td>Direct $ 343,500</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Peter Cotton</td>
<td>Sponsor: NIH/NIDDK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: 5 U01 DK074739-02 (08042495-1)</td>
<td>Direct $ 866,102</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) - Data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Peter Cotton</td>
<td>Sponsor: NIH/NIDDK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Medicine</td>
<td>Award: 5 U01 DK074739-02 (08042495-2)</td>
<td>Direct $ 120,521</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Innovative Service Delivery for Secondary Prevention of PTSD in at-Risk OIF-OEF Service Men and Women</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Thomas Uhde</td>
<td>Sponsor: Charleston Research Institute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Award: W81XWH-08-2-0047 (08052722-1)</td>
<td>Direct $ 157,662</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Statistical and Data Coordinating Center for ALIAS and IMS III Trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Yuko Palesch</td>
<td>Sponsor: NIH/NINDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dept: Biostatistics, Bioinformatics and Epidemiology</td>
<td>Award: 5 U01 NS054630-05 (09032626-1)</td>
<td>Direct $ 955,523</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Nappi, Jean

**Principal Investigator**

**Spaulding Pharmacokinetic Analysis**

**Sponsor:** Spaulding Clinical  
**Award:** Spaulding (08070975)  
**Budget Dates:** 08/18/08 - 12/31/08  
**Direct:** $8,000  
**F & A:** $2,000

**Co-Investigator**

**Safety of High-Concentration Vancomycin for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections**

**PI:** John Bosso  
**Dept:** Pharmacy and Clinical Sciences  
**Sponsor:** Pfizer, Inc.  
**Award:** GA951TH (08101747-1)

**SCCP Medicaid Academic Detailing Project**

**PI:** Patrick Mauldin  
**Dept:** Pharmacy and Clinical Sciences  
**Sponsor:** Univ. of South Carolina  
**Award:** 08-1470 (09050172-1)

---

Ragucci, Dominic

**Principal Investigator**

**MUSC Medical Center and College of Pharmacy - Postgraduate 1 Residency**

**Sponsor:** Amgen  
**Award:** PGY1 Residency (09022891)  
**Budget Dates:** 07/01/09 - 06/30/10  
**Direct:** $40,000  
**F & A:** $0

---

Shrader, Sarah

**Principal Investigator**

**Comparison of South Carolina Family Practice Physicians and Community Pharmacists’ Knowledge and Attitudes Regarding Emergency Contraception**

**Sponsor:** Advocates for Youth  
**Award:** (08111812)  
**Budget Dates:** 11/24/08 - 11/23/09  
**Direct:** $5,000  
**F & A:** $0

---

Taber, David

**Co-Investigator**

**A Pilot Study Comparing Two different Sirolimus-Based Transition Regimens in African-American Renal Transplant Recipients**

**PI:** Charles Bratton  
**Dept:** Surgery  
**Sponsor:** Wyeth, Inc.  
**Award:** 04687E5-4543 (09051567-1)

**Pre-Doctoral Training in Primary Care: Motivate for Health**

**PI:** Alexander Chessman  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Award:** 1 R01 AA016768-01A2 (07102672-1)

**Medication Safety in Primary Care Practice - Translating Research into Practice (MS-TRIP)**

**PI:** Steven Ornstein  
**Dept:** Family Medicine  
**Sponsor:** AHRQ  
**Award:** 5 R18 HS017037-02 (08061965-1)

**Residency Training in Primary Care**

**PI:** Peter Carek  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Award:** 5 D58HP03371-05-00 (08062484-1)

**Effect on Boxed Warnings and Public Information on Pharmaceutical Use**

**PI:** Ruth Jenkins  
**Dept:** Family Medicine  
**Sponsor:** Univ. of Georgia  
**Award:** RR579-050/3503578 (08071496-1)

---

Wessell, Andrea

**Co-Investigator**

**Implementation of Alcohol Screening, Intervention, and Treatment in Primary Care**

**PI:** Peter Miller  
**Dept:** Psychiatry and Behavioral Sciences  
**Sponsor:** NIH/NIAAA  
**Award:** 1 R01 AA016768-01A2 (07102672-1)

**Pre-Doctoral Training in Primary Care: Motivate for Health**

**PI:** Alexander Chessman  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Award:** 1 D56HP10309-01-00 (07120623-1)

**Medication Safety in Primary Care Practice - Translating Research into Practice (MS-TRIP)**

**PI:** Steven Ornstein  
**Dept:** Family Medicine  
**Sponsor:** AHRQ  
**Award:** 5 R18 HS017037-02 (08061965-1)

**Residency Training in Primary Care**

**PI:** Peter Carek  
**Dept:** Family Medicine  
**Sponsor:** HRSA  
**Award:** 5 D58HP03371-05-00 (08062484-1)

**Effect on Boxed Warnings and Public Information on Pharmaceutical Use**

**PI:** Ruth Jenkins  
**Dept:** Family Medicine  
**Sponsor:** Univ. of Georgia  
**Award:** RR579-050/3503578 (08071496-1)